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TANDEM REACTION SEQUENCES ON A ZIRCONOCENE TEMPLATE 
By Józef Stec 
 
The novel research work described in this thesis covers three areas of organozirconium 
chemistry. 
The  first  area  concerns  the  synthesis  of  rigid  core  structures  containing  the  cis-
bicyclo[3.3.0]oct-2-ene  skeleton.  Zirconocene  mediated  co-cyclisation  of  1,6-enynes 
provides unsaturated 5-membered zirconacycles which are homologated to 6-membered 
zirconacycles by insertion of 1,1-dihalo-1-lithio species (dihalogenocarbenoids). Further 
rearrangement  to  a  novel  zirconium-alkenylidene  complex  driven  by  acetylides 
provided a powerful method for a rapid construction of novel bicyclic compounds with 
the potential for functionalization at multiple sites. Such obtained analogues provided 
an  attractive  template  for  structure-activity  studies  with  respect  to  investigating  the 
biological function of the human orphan nuclear receptors: LRH-1 and SF-1. Equivalent 
tandem  insertion  of  1,1-dihalo-1-lithio  species  and  lithium  acetylides  into  saturated 
zirconacycles resulted in the synthesis of novel bicyclo[3.3.0]octanes, though in many 
cases limited by a ￿-H elimination process. 
In the second area is presented research work relating to acyclic organozirconocene 
systems. Insertion of allenyl and propargyl carbenoids into organochlorozirconocenes 
and bisalkyl/-alkynyl zirconocenes led to 1,2-zirconate rearrangement with expulsion of 
the  corresponding  leaving  group.  Lewis  acid  promoted  insertion  of  aldehydes  and 
ketones  into  the  resulting  allenyl/propargyl  zirconocene  intermediate  gave  after 
hydrolysis a series of propargylic alcohols. Insertion of carbenoids derived from chiral 
propargyl  tosylates  into  organochlorozirconocenes  and  further  1,2-metallate 
rearrangement gave the final alcohols as enantiomerically enriched products. 
   3 
The third area was an attempted total synthesis of the natural product mucosin, whose 
structure  contains  a  bicyclo[4.3.0]nonane  unit  with  four  contiguous  stereocentres. 
Zirconocene mediated co-cyclisation of the appropriate precursor provided four possible 
diastereoisomers. It was proved that thermodynamic equilibration of the zirconacycle 
gives the desired bicyclic product as a major isomer. Although the target molecule was 
not realised, thorough work on Zr-based total synthesis of mucosin has been achieved 
and a viable route for successful completion of the synthesis has also been proposed. 
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Chapter 1.  Introduction 
1.1.  Overview 
At the outset, the aim of the PhD research project was to develop highly convergent, 
zirconocene-mediated, synthetic routes to rigid core structures for use in pharmaceutical 
discovery, which have the potential to be implemented in high throughput automated 
synthesis  facilities.  This  involved  optimisation  of  reaction  conditions  and  substrate-
scoping  studies for  the  existing  method for  one-pot  three-component coupling  on  a 
zirconocene template, originally discovered by previous members of the Whitby group. 
Application of this method with optimised conditions to a wide range of enynes resulted 
in synthesis of a series of novel compounds containing the rigid cis-bicyclo[3.3.0]oct-2-
ene skeleton. Such analogues were used for structure-activity studies with respect to 
investigating  the  biological  function  of  the  human  orphan  nuclear  receptors:  Liver 
Receptor Homolog-1 (LRH-1) and Steroidogenic Factor-1 (SF-1). 
The aim was also to explore novel methodology for synthetically attractive carbon-
carbon bond forming reactions by using stoichiometric zirconium chemistry. Discussed 
in this thesis are examples of current methodology for further elaboration of cyclic and 
acyclic zirconocene systems via carbenoid insertion and a novel 1,3-Zr alkenylidene 
rearrangement.  
Chapter 1 presents a brief description of biological background for a part of this project 
before  the  subject  of  zirconacycle  formation  and  carbenoid  insertion  into 
organozirconium bonds is explained. The subsequent chapters then describe the results 
obtained. Firstly, the insertion of dihalogenocarbenoids into unsaturated and saturated 
zirconacycles  and  subsequent  rearrangement  to  a  novel  zirconium-alkenylidene 
complex are discussed. Elaboration of acyclic zirconocene complexes through allenyl 
and  propargyl  carbenoids  insertion  with  the  potential  for  asymmetric  synthesis  is 
presented. Finally, attempted first total synthesis of the natural product mucosin based 
on zirconocene mediated co-cyclisation of the appropriate triene is described. 
 
1.2.  Orphan Nuclear Receptors (ONRs) 
The nuclear hormone (NRs) superfamily in mammals comprises a highly conserved 
group of 49 receptors which act as transcription factors to regulate genetic networks 
involved in cell growth and differentiation and metabolism.
1 Most are ligand regulated 
responding to dietary or endocrine signals such as steroid hormones, retinoids, vitamin   20 
D, fatty acids and thyroid hormone. NRs are attractive targets for drug discovery
2,3 and 
small molecules  that regulate them comprise around 13% of  current FDA-approved 
drugs.
4  Originally  around  half  of  the  NRs  had  no  known  natural  ligands  and  were 
termed Orphan Nuclear Receptors (ONRs).
5 Since most have a ligand binding pocket 
they provide great potential as novel targets for pharmaceuticals.
6 A key step is to find 
natural  or  synthetic  regulatory  ligands  to  probe  their  biology
7,8,9-a  process  termed 
‘reverse endocrinology’.
10  Several have been ‘adopted’ (or deorphanized) recently, for 
example NR1H4 (FXR) by bile acids
11 and peroxisome proliferators-activated receptor 
family  (PPAR’s,  NR1C’s.),
12  leading  to  great  advances  in  understanding  and 
application. We have a particular interest in the Liver Receptor Homolog-1 (LRH-1, 
NR5A2)
13 and Steroidogenic Factor-1 (SF-1, NR5A1),
14  members of the subfamily V 
nuclear receptors (NR5A). 
 
1.2.1.  Structural features of NRs 
NRs  typically  have  a  conserved  domain  structure  (Figure  1.1)  that  includes  the  N-
terminus A/B domain [often containing a ligand-independent activation function-1 (AF-
1)];  also  N-terminus,  highly  conserved  DNA-binding  domain  (DBD  or  C  domain), 
which is composed of two zinc fingers; the C-terminus ligand-binding domain (LBD or 
E domain), which contains an equally conserved ligand-dependent activation function-2 
(AF-2) motif that mediates coactivator interaction; and the D domain, which serves as a 
flexible hinge between the DBD and LBD.
13,15 
 
 
 
 
 
Figure 1.1 Canonical structure of generic nuclear receptor (NR). 
 
The DBD is responsible for DNA response element recognition and dimerization, and 
the conserved LBD is involved in many overlapping functions including ligand binding, 
nuclear  localization,  dimerization,  silencing  and  transactivation.
15  When  bound  by 
hormone (or other small lipophilic ligands, including metabolites and certain synthetic 
ligands), these receptors function as ligand-dependent transcription factors by binding to 
unique response elements in the promoter of specific target genes.
13,16 
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1.2.2.  Structural features of the NR5 subfamily in the NRs superfamily  
Members  of  the  NR5  family  are  orphan  receptors  that  belong  to  one  of  the  four 
subclasses of the Ftz-F1 subfamily (named for their homology with Drosophila fushi 
tarazu factor-1, the first cloned member of this group). Steroidogenic factor-1 (SF-1, 
NR5A1) and its closest homolog, liver receptor-homolog-1 (LRH-1, NR5A2) are the 
only human proteins that belong to  this class.
17   These  and other NR5A subfamily 
members are unique in the NR superfamily; however, because they contain a distinctive 
26-amino acid motif, called the Fushi Tarazu-Factor1 domain (A box). The A box is 
located just C-terminal to the conserved zinc finger DNA-binding domain and contact 
the upstream motif in the binding site, thereby it is thought to be a key protein-protein 
interaction module (Figure 1.2).
18,19 
 
 
 
 
 
Figure 1.2 Specific structure of NR5A subfamily members. 
 
Although SF-1 and LRH-1 are derived from two different genes, they share a highly 
conserved DBD (over 95% identity) and moderately conserved LBD (56%). Thus, both 
receptors can recognize the same DNA sequence and several reports demonstrate that 
genes expressed in the adrenal, in adipocytes, and in the ovary previously shown to be 
regulated by SF-1 can also be transactivated by LRH-1.
20-24 On the other hand, their 
different biological activities are contributed in part by distinct structural features in 
their LBDs, which recruit specific cofactors to regulate transcription.
25 
 
1.2.3.  Biological  functions  of  ONRs:  Liver  Receptor  Homolog-1  (LRH-1)  and 
Steroidogenic Factor-1 (SF-1) 
LRH-1 plays a critical role in embryonic development of the endoderm.
26  In adults it is 
expressed in the intestine, liver, exocrine pancreas and ovary. It is extensively expressed 
in the mouse brain.
27 LRH-1 regulates the expression of genes involved in hepatic bile 
acid biosynthesis,
28 the bile salt export pump
29 and cholesterol homeostasis.
13  Thus, the 
receptor may be a target for the treatment of cardiovascular disease
30 and cholinostatic 
liver diease.
31 It is a key controller in the hepatic acute-phase response.
32  
LBD 
AF2 
Hinge  DBD 
Ftz-F1 
A box 
   22 
Its  regulation  of  aromatase  expression
33  also  suggests  a  possible  utility  in  cancer 
therapy, particularly human breast carcinomas.
34, 35, 36-39 LRH-1 is expressed in human 
intestinal  crypt  cells  where  it  controls  cell  proliferation  and  differentiation.
40  Its 
potential role in gastric cancer has been reviewed.
41 Expression of LRH-1 is found to be 
substantially raised in human gastric cancer cells,
42 and it influences tumor formation 
through effects on cell cycle and inflammation.
43 LRH-1 is a key regulator of Mouse 
Embryonic Stem cell pluripotency and differentiation.
44 It has been shown to be a key 
regulator of oct-4 expression,
26 and oct-4 is important in the maintenance of adult neural 
stem cell pluripotency,
45 so there may be applications in neurodegenerative disorders. 
LRH-1 probably has a key role in ovulation and female fertility, and is a possible target 
for contraception.
46  
Nuclear receptor SF-1 (NR5A1) plays multiple roles in endocrine development
47,48,49 
including  sex  determination,  for  example  SF-1  knock-out  mice  were  phenotypically 
female independent of genetic sex,
50 and lack adrenals, gonads and the ventromedial 
hypothalamic nucleus.
51,50  
SF-1  is  an  important  regulator  of  mouse  ES  pluripotence  and  differentiation.
44  In 
particular it promotes steroidogenesis demonstrating that is a dominant regulator of the 
steroidogenic  cell  phenotype.  Forced  expression  of  SF-1  transforms  human  bone 
marrow mesenchymal cells into steroidogenic cells.
52, 53, 54,55 Like LRH-1 SF-1 has been 
shown  to  regulate  oct-4  expression  with  implications  for  control  of  stem  cell 
pluripotence.
56 
SF-1  has an  important  role  in  steroid  regulation  throughout  life,  particularly  via its 
control  of  the  expression  of  the  steroidogenic cytochrome  P450  genes  in  endocrine 
tissues,  such  as  the  adrenal  cortex,  testes,  and  ovary.
57, 
58  Mutation  of  the  gene  in 
humans correlates with disorders of testes development.
59 It is overexpressed in most 
cases of childhood adrenocortical tumors, and reverse agonists inhibit proliferation.
60  
SF-1  is  closely  involved  in  the  development  of  endometriosis  and  endometrial 
cancers.
61, 62, 63 It is also expressed in the hypothalamus and has been implicated in the 
regulation of feeding behaviour.
64,  65 A CNS selective knockout of SF-1 in mice has 
demonstrated strong effects on anxiety, energy homeostasis and appetite.
66, 67 
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1.2.4.  Mode of action of LRH-1 and SF-1 with suggested regulation of activity 
Unlike most NRs, LRH-1 and SF-1 bind to DNA as monomers and show constitutive 
activation  of  transcription  when  expressed  in  cells.
13,14    Receptor  activity  can  be 
regulated by phosphorylation,
68 sumoylation
69 or through interaction with the atypical 
orphan receptors SHP (NR0B1)
70,71 and DAX-1 (NR0B2)
72,73 that lack their own DNA-
binding domains.   
Although  originally  defined  as  ONRs  X-ray  crystallography  coupled  with  mass 
spectroscopy (MS) has recently revealed the presence of E. coli derived phospholipids 
phosphatidylethanolamines 1.1 and phosphatidylglycerides 1.2a in the ligand binding 
pockets of human LRH-1 and SF-1 (Figure 1.3).
74,75,76,77 The phospholipids identified in 
the crystals had C16 or 18 acyl groups, some of which were identified as having a cis 
alkene  in  the  D9  position,  but  MS  studies  showed  that  a  wide  range  of  related 
phospholipids (C12-C18 acyl groups with various unsaturation) were also bound to the 
receptors.  The  binding  of  phospholipids  in  SF-1  was  shown  to  strongly  activate 
recruitment  of  co-activator  peptide.
76    Mutation  experiments  on  hLRH-1  showed  a 
correlation between  binding of  phospholipid and LRH-1 induced activation of gene 
expression.
77  Exchange of bacterially derived phosphatidyl glyceride 1.1 (Figure 1.3) 
with  inosityl  phospholipids  (particularly  the  triphosphate  derivative  1.3)
75  and  
phosphatidylcholine  1.2b
78  has  been  demonstrated  for  SF-1.  In  the  latter  case  the 
exchange had  little effect  on binding of coactivator  peptides.
78 Recently Moore  has 
reported that diundecanoyl (1.2b, R
1 = R
2 = n-C9H19) and dilauroyl (1.2b, R
1 = R
2 = n-
C11H23) phosphatidylcholine (PC) act as agonists of the LRH-1 receptor and has shown 
that administration of these lipids to diabetic mice reduces blood glucose levels.
79  
Indirect  activation  of  SF-1  through  increased  levels  of  phosphatidylinositol  (3,4,5) 
triphosphate 1.3 induced by a tamoxifen analogue has been suggested as relevant in 
endometrial cell proliferation.
63 Sphingosine 1.4 has also been reported to bind to SF-1 
and suppresses expression of cytochrome P450 17 (CYP17) gene (which is regulated by 
SF-1) suggesting that it may be an antagonist of SF-1.
80,81,82 Derivatives of 1.4 such as 
sphingosylphosphorylcholine and N-Acyl-1.4 (ceramides) may also be natural ligands.   24 
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Figure 1.3 Agonists and antagonists for LRH–1 and SF–1. 
 
Recently,  Whitby  et  al.  reported  the  first  synthetic  small  molecule,  GSK8470  1.5 
(Figure 1.4), as a potent agonist for LRH-1 (EC50 = 430 nM) and SF-1 (EC50 = 54 nM). 
A SAR study on series 1.6 led to the more active analogue 1.7 with EC50 = 34 nM for 
LRH-1 and EC50 = 43 nM for SF-1.
83  
Subsequently  the  herbicide atrazine  has  also  been  reported
84-86  to  bind to  SF-1  and 
induce aromatase expression at relatively low concentrations (0.1 mM), but as mutations 
of the LBD of SF-1 have no effect the interaction must be other than with the ligand 
binding pocket. 
Recently p-heptyoxyphenol 1.8 was reported as a potent (IC50 = 7.2 mM) inverse agonist 
for SF-1, but with no activity against LRH-1.
87 Expression of several reported SF-1 
target genes was suppressed by 1.8 in cell based assays. Although 1.8 was reported to 
inhibit proliferation of adrenocortial carcinoma cell line H295R, it had the same effect 
with an SF-1 negative cell line (SW-13).
60  
Several  isoquinoline  based  inverse  agonists  of  SF-1  were  discovered  through  high 
throughput screening and further SAR studies, of which 1.9 was the most active (IC50 = 
200  nM).
88,  89  At  high  levels  (10  mM)  1.9  modestly  suppressed  doxycycline  (Dox) 
induced proliferation of H295R cell line with little effect on the SF-1 negative SW-13 
cell line.    25 
Closely related isoquinolines affected both cell lines in a similar way suggesting a non-
SF-1 mechanism. The SAR for these series seems complex, for example replacing the 
methoxy group in 1.9 with ethoxy gave a compound highly active against a range of 
other  receptors,  and  exhibiting  strong  cell  toxicity  suggesting  transactivation  assay 
artefacts (e.g. promiscuous inhibition of the reporter system).  
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Figure 1.4 Discovery of small molecule agonist and inverse agonists for LRH-1 and SF-1. 
 
Although  GSK8470  1.5  and  related  compounds  1.6  have  proven  to  be  excellent 
biological probes for LRH-1 and SF-1 they have a number of drawbacks.  
Most important is that they are very unstable to acid making handling difficult and 
raising doubts about stability during biological application. The series also shows little 
discrimination between LRH-1 and SF-1.  
 
1.3.  Organozirconium chemistry 
1.3.1.  Formation of carbon-zirconium bonds 
The  origin  of  organozirconium  chemistry  is  dated  by  the  preparation  of  the  first  
organozirconium  compounds,  zirconocene  dibromide  (ZrCp2Br2)  and  soon  after 
zirconocene dichloride (ZrCp2Cl2) by Wilkinson and Birmingham in 1954.
90 The use of 
organozirconium chemistry in organic chemistry originated in the early 1970’s with the 
preparation of HZrCp2Cl,
91 and the observation by Wailes et al. of its addition across 
carbon-carbon  double  bonds.
92  Extensive  studies  including  synthetic  utility  of 
HZrCp2Cl were  started by  Schwartz in  1974,
93 whose name  has been given to this 
reagent. Formation of acyclic organozirconium species 1.11 and 1.12 is achieved via 
hydrozirconation of alkanes or alkynes with the Schwartz reagent (Scheme 1.1).   26 
Cp2ZrHCl
1.10
ZrCp2Cl
R
H
1.11
ZrCp2Cl
R
H
H
1.12
(i) (ii)
Reagents and Conditions: (i) 1.0 eq alkene, RT; (ii) 1.0 eq alkyne, RT.  
Scheme 1.1 Hydrozirconation of alkenes and alkynes. 
 
Products of hydrozirconation can be efficiently converted into organic compounds by 
reacting with electrophiles (halogens, acid chlorides) as well as with carbenoids (e.g. 
carbon monoxide).
93,94 
 
The original method for preparation of zirconacycles from alkenes and alkynes was 
based on formation of the 14-electron species zirconocene (Cp2Zr), generated in situ by 
reducing zirconocene dichloride with Mg/Hg amalgams (Scheme 1.2).
95,96 
Reagents and Conditions: (i) 0.25 eq Cp2ZrCl2, 0.25 eq HgCl2, 1.25 eq Mg, THF; 
(ii) 1.0 eq Cp2ZrCl2, 1.0 eq HgCl2, 10 eq Mg.
R R ZrCp2
R
R
R
R
(i) SiMe3 (ii)
ZrCp2
SiMe3
1.13
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Scheme 1.2 Formation of zirconacycles. 
 
Initially this method was satisfactory for performing co-cyclisations, however, a more 
experimentally convenient process avoiding the toxicity of mercury was developed,
97 
which still remains the most versatile and commonly used today (Scheme 1.3). 
Treatment of a cold solution of zirconocene dichloride in THF with 2 equivalents of n-
BuLi  gives dibutyl zirconocene 1.17 also known as the Negishi reagent. Warming to 
room temperature leads to loss of butane through ￿-hydrogen abstraction to form the 
active zirconocene(1-butene) 1.18. Zirconocene(1-butene) 1.18 can either be considered 
as Cp2Zr(IV) 1.18a or a Cp2Zr(II) 1.18b species. The weakly bound butene ligand is 
readily displaced by alkene or alkyne from the co-cyclisation substrate, followed by 
carbometallation  type  reaction  to  expand  the  ring  to  a  zirconacycle,  such  as  1.20 
(Scheme 1.3).   27 
Cp2ZrCl2 ZrCp2
R1
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Cp2Zr H
Cp2Zr Cp2Zr
R1
R2
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Cp2 R1
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1.18a 1.18b
1.19
1.20
Reagents and Conditions: (i) n-BuLi (2.0 eq), THF, -78 oC, 15 min; 
(ii) 1,n-diene,-diyne, -enyne; (iii) -78 oC to RT.
(i), (ii), (iii)
 
Scheme 1.3 Mechanism for co-cyclisation of unsaturated organic molecules with Negishi reagent. 
 
The  development  of  zirconocene(1-butene)  and  its  wide  applicability  to  reductive 
couplings of unsaturated organic molecules such as 1,n-dienes, -diynes and -enynes has 
led  to  rapid  expansion  of  organozirconium  chemistry.  This  method  has  also  been 
successfully applied in the total synthesis of many natural products.
98-100 
 
The methodology for formation of monocyclic zirconacycles has also been developed 
(Scheme 1.4). Synthesis of zirconacyclopentanes 1.22, 1.23, zirconacyclopentenes 1.24 
and zirconacyclopentadienes 1.27 is achieved by trapping zirconocene ethylene 1.21 
with alkenes and alkynes.
101 The complex 1.21 is generated by either treating ZrCp2Cl2 
with two equivalents of EtMgBr
102 or by synthesising zirconocene(1-butene) 1.18 under 
an atmosphere of ethylene gas.
103 One ethene molecule remains bound to the Zr atom 
when reaction with alkenes or alkynes occurs, thus leading to the observed selective 
cross-coupling reactions, so that specific monocycles 1.22, 1.23 or 1.24 can be formed. 
Heating the resulting monocycle in the presence of aldehydes, nitriles or other alkynes 
results  in  the  loss  of  ethane  allowing  the  formation  of  unsymmetrical 
zirconamonocycles,
104 such as 1.25, 1.26 and 1.27.   28 
Cp2Zr Cp2Zr
(iii) (iv)
Reagents and Conditions: (i) 2.0 eq n-BuLi, -78 oC to RT, under an atmosphere of
ethene; (ii) 2.0 eq EtMgBr, -78 oC to RT, 1 h; (iii) H2CCHAr, 0 oC; (iv) H2CCHR,
0 oC; (v) R1CCR1, 0 oC; (vi) R3CN, 25 oC; (vii) R2CHO, 50 oC; (viii) R4CCR4,  50 oC.
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Scheme 1.4 Access to monocycles by trapping zirconocene ethylene complex. 
 
1.3.2.  Carbocycle formation by zirconocene mediated co-cyclisation of enynes 
Both  1,6-  and  1,7-enynes  1.28  are  excellent  substrates  for  zirconocene(1-butene) 
mediated co-cyclisation to afford the corresponding bicyclic zirconacycles usually in 
high yields.
105,106 Although preparation of bicyclic zirconacyclopentenes is limited by 
the ring size, a wide variety of substituents on both the ring and the alkyne are tolerated 
(Scheme  1.5).
105,107  Furthermore,  substitution  on  the  alkyne  is  required  as  terminal 
alkynes  fail  to  cyclise  under  these  conditions.  Enynes  with  an  a-substituent  to  the 
alkene show a high level of diastereoselectivity through control of the ring junction 
formed in the cyclisation step.
107-110  
 
Examples carrying ring substitutions such as alkyl, protected alcohol, amine and amide 
are also reported in the literature. Cyclisation of precursors possessing substitution on 
the double bond are known, including unusual examples such as allene 1.34.
105   29 
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Scheme 1.5 Variability of substituents on enynes. 
 
1.4.  Elaboration of unsaturated zirconacycles 
Although  a  broad  spectrum  of  unsaturated  organic  molecules  can  be  co-cyclised  in 
intra- and/or inter-molecular fashion to give a variety of metallacycles, the potential of 
organozirconium chemistry is significantly increased by the ability to functionalise the 
C-Zr bond. Over the past two decades many sophisticated methods for elaboration of 
the C-Zr bond have been developed which allow access to a great deal of useful organic 
products. The selected methods will be concisely overviewed throughout the following 
section. 
 
1.4.1.  Protonation and halogenation 
The simplest functionalisation of zirconacycles is protonation to give the corresponding 
hydrocarbon, which can be done under acidic or basic conditions. The widely used 
quenches are: MeOH, aqueous solution of NaHCO3, aq HCl or aq H2SO4. Choice of the 
quenching conditions is dictated by the acid/base stability of the products.  
The  analogous  reaction  with  MeOD,  D2O,  DCl  or  D2SO4  can  be  used  to  perform 
deuterolysis. Incorporation of deuterium atom into products is very often a valuable tool 
for the determination of mechanisms.    30 
Methodology  for  selective  monohalogenation  of  zirconacyclopentenes  has  been 
explored  by  Takahashi  (Scheme  1.6).
111  Depending  on  the  reagent  used  and  the 
substituents present on the double bond, halogenation can be regiospecific to give either 
vinyl halides 1.38, 1.40 or the alkyl halides 1.39, 1.41 in yields ranging from 78 to 
94%.
112,113 With aryl substituents present on the double bond, vinyl halide is formed by 
method b. Selective methanolysis of the zirconium-alkyl bond was observed to form the 
alkoxy-zirconocene intermediate 1.37, subsequent treatment of such obtained species 
with iodine resulted in alkenyl iodide 1.38 in excellent yield.
114 Direct halogenation of 
the  zirconacyclopentene  1.36  with  iodine,  followed  by  acidic  protonolysis  gave  the 
alkyl iodide with high selectivity. With alkyl substituents present on the double bond, 
the regioselectivity can be controlled by use of either I2 or CBr4. 
Reagents and Conditions: method a: 1.2 eq I2, then HCl; method b: 1.5 eq MeOH, then 
1.2 eq I2; method c: CBr4 or CCl3Br.
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Scheme 1.6 Selective halogenation of zirconacyclopentenes. 
 
1.4.2.  Carbonylation and isocyanide insertion 
One of the earliest and most widely used methods for elaboration of zirconacycles is 
carbonylation.
96,115 The availability of the d-orbital on the zirconium atom and carbene-
like nature of carbon monoxide are essential for the reaction to occur. Carbon monoxide 
donates a lone pair of electrons into the vacant d-orbital of the Zr atom to give the 
complex 1.43 (Scheme 1.7). Subsequent migration of the sp
3 carbon-zirconium bond 
gives the zirconocene acyl complex 1.44 and allows the zirconium atom to return to its 
favourable 16-electron state. Rearrangement to the zirconocene ￿
2-ketone complex 1.45 
then follows, which can be converted to cyclopentanol 1.46 or cyclopentanone 1.47 on 
protonolysis,  or  oxidative  work-up  with  iodine  (prolonged  exposure  to  CO  is  an 
alternative method), respectively.
116,117   31 
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Reagents and Conditions: (i) CO, -78 oC; (ii) 3 M HCl; (iii) RT, I2.  
Scheme 1.7 Carbonylation of zirconacycles. 
 
Insertion of isocyanides into zirconacycles is the analogous reaction to carbonylation, 
since isocyanides are isoelectronic with carbon monoxide (Scheme 1.8). 
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Reagents and Conditions: (i) PhNC, THF, -35 oC; (ii) Alkyne, reflux; (iii) MeOH; (iv) SiO2 
or spontaneous.
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Scheme 1.8 Isocyanide insertion into zirconacyclopentenes. 
 
Insertion of  phenyl  isocyanide into zirconacyclopentanes affords iminoacyl complex 
1.50, which slowly rearranges to give ￿
2-imine complex 1.51 (Scheme 1.8).
118  
Trapping the complex 1.51 with alkyne gives the expanded a,￿-unsaturated ￿
2-imine 
complex 1.52. Subsequent methanolysis provides diallylic amine 1.53, which undergoes 
an unusual anti-1,3 allylic shift of amine
119 either on silica or spontaneously to give the 
tertiary amine product 1.54.  
Insertion of t-butyl isocyanide occurs specifically into the alkyl-zirconium bond to give 
the  iminoacyl  intermediate  1.55,  which  does  not  rearrange  to  ￿
2-imine  complex 
(Scheme 1.9). Protonolysis with HCl gave aldehyde 1.56.   32 
ZrCp2
Nt-Bu
1.55 Bu
(i)
Bu
O
1.56
Reagents and Conditions: (i) 2 M HCl, RT.  
Scheme 1.9 t-Butyl isocyanide insertion into zirconacyclopentaene complex. 
 
More recently copper-mediated insertion of isocyanides into zirconacyclopentadienes 
has been reported.
120 
 
1.4.3.  Metathesis to main group elements 
Elaboration of both C-Zr bonds present in zirconacycles via exchange of the zirconium 
atom for a main group element provides a range of highly functionalized, often unusual, 
heterocycles (Scheme 1.10).  
Reagents and Conditions: (i) for P, As: PhECl2, 25 oC; (ii) for Sb, Bi: ECl3, 25 oC;
(iii) PhLi; (iv) a. for Si: SiBr4 (neat), 150 oC, 2 d; b. for Ge: GeCl4, 25 oC, 2 min;
(v) GaCl3, 25 oC, 5 min, then (Et)4N+Cl; (vi) PhBCl2,  25 oC, 1 h; (vii) a. for S, Se: 
Z2X2, 25 oC, 1 h; b. Me2SnBr2, 25 oC, 2 d; (viii) S2Cl2, 25 oC, 1 h.
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1.61, 68 % 1.62, 73 %
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Scheme 1.10 Heterocycle synthesis via metathesis with main group elements.   33 
Nugent, who extensively developed this area, demonstrated the facile preparation of 
main group heterocycles 1.58, 1.60 – 1.62, 1.64, 1.66 from zirconacyclopentanes, -enes 
and -dienes (Scheme 1.10).
108,121-123 The group 15 phenyl derivatives 1.58.1-4, can be 
prepared by reaction of a zirconacycle with the element dichloride or trichloride. The 
latter case requires treatment of the cyclic monochloride 1.59 with PhLi. Group 14 and 
16 compounds can also be prepared. For group 13 elements, borole 1.61 and gallole salt 
1.62 can be synthesised, and the latter compounds are stable and do not undergo Diels-
Alder reactions. 
 
1.4.4.  Carbenoid insertion 
Organic species which exhibit reaction qualitatively similar to those of carbenes are 
referred  to  as  carbenoids.  Lithium  carbenoids  show  the  greatest  utility  in  organic 
synthesis,  although  carbenoids  with  metals  such  as  potassium,  sodium  and  tin  are 
known.
124 Insertion of lithium carbenoids into organozirconocenes has been extensively 
explored by Whitby
118 and a great deal of this thesis is related to this theme. 
 
1.4.4.1.  Synthesis and reactivity of lithium carbenoids 
Lithium halocarbenoids are thermolabile molecules in which a single carbon atom is 
substituted with a halogen and lithium atom. These species are formed at temperatures 
usually below –78 °C by either deprotonation or halogen-lithium exchange.  
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Scheme 1.11 Formation of lithium carbenoids. 
 
Deprotonation  of  an  organohalide  with  an  organolithium  or  lithium  amide  base 
generates the carbenoid molecule (equation a, Scheme 1.11)
125,126 A limitation of this 
method is the low acidity of the proton, which makes deprotonation at low temperatures 
difficult. Alternatively, halogen-lithium exchange of a gem-dihalo-compound leads to 
the same type of structure (equation b, Scheme 1.11)
127 however the main drawback 
related to this method is a-metallation.
128   34 
Carbenoids  are  usually  unstable  at  temperatures  higher  than  –70  °C  and  undergo 
decomposition through various reactions (Scheme 1.12). a-Elimination,  which yields 
the  highly  reactive  carbene  species  1.72  is  the  main  decomposition  reaction.
129  For 
certain carbenoids ￿-elimination is an alternative route for decomposition and can result 
in formation of alkenes 1.74 (Scheme 1.12).
129 
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Scheme 1.12 Decomposition routes for carbenoids. 
 
Carbenoids show amphiphilic nature therefore they can react as both nucleophiles and 
as electrophiles.
124 Carbenoids generally undergo three main types of reaction:
126,130,131  
a.  Nucleophilic reactions such as alkylations and acylations with retention of 
the configuration at the carbenoid centre. 
b.  Electrophilic behaviour includes reactions with strong nucleophiles with 
inversion of the configuration at the carbenoid centre. 
c.  Combined nucleophilic and electrophilic  properties allow carbenoids to 
insert into single and double bonds. 
 
1.4.4.2.  Allyl and alkyl carbenoid insertion into zirconacycles 
Selective means of elaborating carbon-zirconium bonds through regioselective insertion 
of alkyl and allyl carbenoids into unsymmetrical zirconacycles have been reported.
132,133 
Distinct substitution patterns of zirconacycles and different electronic properties of the 
carbenoids  account  for  complete  selectivity  observed  in  most  of  the  investigated 
examples where a single product is isolated. 
 
1.4.4.2.1.  Allyl carbenoid insertion into zirconacyclopentenes 
The first report on carbon-carbon bond forming reactions via insertion of carbenoids 
into organotransition metal complexes was by Negishi et al.
134 The authors describe the 
insertion of ￿- and ￿-haloorganolithiums into acyclic organozirconocene derivates to 
give a good yield of alkenes and allenes on acid quench.   35 
Whitby extended this methodology to the insertion of a wide range of carbenoids into 
zirconacycles. Initial nucleophilic attack of allyl carbenoid (lithium chloroallylide) 1.76 
onto the Zr atom in zirconacyclopentene 1.75 generates an 18-electron ‘ate’ complex 
1.77 (Scheme 1.13).
135 A 1,2-metallate rearrangement
136 with loss of the leaving group 
affords  zirconocene  ￿
3-complex  1.78.  Methanolysis  of  the  allyl  zirconium  complex 
affords an 85 : 15 mixture of alkene products 1.79a and 1.79b in 71% yield. Further 
elaboration  of  the  allyl  zirconium  complex  by  benzaldehyde  insertion  provides  the 
alcohol 1.80 in excellent yield.  
Extensive  elaborations  of  this  methodology  include  insertions  of  various  allyl 
carbenoids into a wide range of saturated and unsaturated zirconacycles and trapping the 
resulting zirconocene ￿
3-complex with different electrophiles such as ketones, iminium 
and thienium ions and through the Lewis acid promoted addition of aldehydes, acetals 
and orthoesters.
137-139 
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Scheme 1.13 Insertion of lithium chloroallylide into unsaturated zirconacycle. 
 
1.4.4.2.2.  Allyl and alkyl carbenoid insertion into a-substituted zirconacyclopentenes 
A study of lithium chloroallylide and chloromethylallylide insertion into a wide range 
of unsymmetrical zirconacyclopentenes resulted in a very good regioselectivity. In all 
cases  the  final  product  was  obtained  as  a  single  regioisomer  (Scheme  1.14).
132,135 
Complete selectivity for the alkyl zirconium bond was observed when the vinyl carbon 
￿- to the zirconium centre was substituted (R’ = Ph, SiMe3, n-Bu) in both monocyclic 
1.81 and bicyclic zirconacycles 1.83a, b, c to provide the corresponding products 1.82 
and 1.84a,b, c. Zirconacyclopentene 1.85 with substitution at the alkyl carbon ￿- to   36 
zirconium showed complete regioselectivity for the alkenyl zirconium bond. Further 
studies however, revealed that the nature of substitution at the alkyl carbon adjacent to 
Zr was also important, and exclusive insertions into the most hindered alkyl zirconium 
bond were observed (zirconacycles 1.88, 1.90). 
Reagents and Conditions: (i) 1.1 eq CH2CHCH2Cl, LiTMP, -78 to -60  oC, 1 h;
(ii) 1.5 eq PhCHO, 1.5 eq BF3·Et2O, -60  oC to RT, 2 h; (iii)  MeOH, aq NaHCO3, 
RT, 16 h; (iv) CH2C(CH3)CH2Cl, LDA, -78  oC to RT, 2 h; (v) AcOH, RT, 24 h;
(vi) 5 eq LiTMP, -78 to -30  oC, 2 h; (vii) 5 eq PhCHO, 5 eq BF3·Et2O, -78  oC
to RT, 5 h; (viii) MeOH, aq NaHCO3, RT, 1 h; (ix) CH2C(CH3)CH2Cl, LDA,
-100  oC to -60  oC, 2 h.
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Scheme 1.14 Regiochemistry of allyl carbenoid insertion into zirconacyclopentenes. 
 
Insertion of alkyl carbenoids: lithiated chloroacetonitrile 1.92 and lithiated chloromethyl 
phenyl sulfone 1.95 into monocyclic zirconacyclopentene 1.81 afforded products 1.93 
and 1.96 in good and very good yield, respectively (Scheme 1.15).
140 A double insertion 
was observed for lithiated chloroacetonitrile when used in excess to provide the double 
insertion product 1.94 in low yield.    37 
Also elimination of the sulfone group from the zirconacycle 1.100 upon warming to RT 
is observed to give product 1.102 in moderate yield. This process can be explained by a 
novel  endocyclic  cyclometallation  process
141  to  afford  the  zirconocene  ￿
2-alkene 
complex 1.100, which allows the sulfone group to be eliminated 1.101. 
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Scheme 1.15 Regiochemistry of alkyl carbenoid insertion into monocyclic zirconacyclopentenes. 
 
The  insertion  of  electron  rich  and  electron  poor  alkyl  carbenoids  into  bicyclic 
zirconacycles 1.83c, 1.103 and 1.110 has been examined (Scheme 1.16).
133,140 Insertion 
of  lithiated  chloroacetonitrile  1.92  and  lithiated  chloromethyl  phenyl  sulfone  1.95 
(electron poor carbenoids), into zirconacyclopentenes 1.103 and 1.110 was successful 
and  afforded  products  1.104,  1.106  and  1.111  in  reasonable  yields,  and  observed 
regioselectivity for the alkyl zirconium bond in all examples.    38 
Treatment  of  zirconacycle  1.103  with five  equivalents  of lithiated  chloroacetonitrile 
1.92 resulted in double carbenoid insertion product 1.105, isolated in low yield as a 
separable 2.2 : 1 mixture of diastereoisomers (Scheme 1.16).  
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Scheme 1.16 Regiochemistry of alkyl carbenoid insertion into bicyclic zirconacyclopentenes. 
 
Different  conditions  were  required  for  efficient  insertion  of  lithiated  chloromethyl 
phenyl sulfone 1.95 into zirconacycles 1.103 and 1.110. In the less constrained system 
1.110 insertion occurred at –78 °C to afford sulfone 1.111, however, for insertion into 
the more constrained system 1.103, warming to 0 °C was required to afford sulfone 
1.106. Additionally when the reaction with zirconacyclopentene 1.110 was warmed to 
room temperature before quenching, the product of sulfone elimination, diene 1.112 
was isolated (Scheme 1.16). 
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The electron rich silicon substituted carbenoid Me3SiCHLiCl 1.107 inserts efficiently 
into 1.83c to give, on aqueous work-up, mostly the expected product 1.108, but also a 
significant amount of the regioisomer 1.109 derived from insertion into the zirconium-
alkenyl bond (Scheme 1.16).
133 Although other electron rich carbenoids such as lithiated 
chloromethyl methyl ether, 2-methoxyethoxymethyl chloride and chloromethyl phenyl 
sulfide insert into zirconacyclopentenes, the yields are low and the products too messy 
to properly characterise. 
Different models can be used to explain the regiochemistry of carbenoid insertion into 
zirconacycles.
118,132 Favoured direction of lateral attack is used to explain the selectivity 
of  carbenoid  insertion  for  zirconacycles  1.81,  1.83,  1.103,  1.110.  Considering  a 
carbenoid  as  an  electrophilic  species  provides  an  explanation  for  the  selectivity  of 
carbenoid insertion into the more hindered and electron rich C-Zr bond in zirconacycles 
1.88 and 1.90. In the third model, regioselectivity may be determined by the favoured 
1,2-metallate rearrangement of a fluxional ‘ate’ complex created by initial nucleophilic 
attack of the carbenoid on Zr atom. 
 
1.4.4.2.3.  Allyl  and  alkyl  carbenoid  insertion  into  a-unsubstituted 
zirconacyclopentenes 
Cyclisation of terminal alkynes with the zirconocene(1-butene) fails
105,142 but reaction 
of hept-1-en-6-yne with zirconocene(ethylene), followed by heating
104,143 gives the a-
unsubstituted zirconacyclopentene 1.113 (Scheme 1.17).  
Alternative conditions using a combination of activated magnesium and zirconocene 
dichloride also allowed co-cyclisation of the terminally unsubstituted enyne but was 
found to be unreliable and accounts for the poor yields often observed in the series 
based on zirconacycle 1.113.
140 Insertion of one allyl and three alkyl carbenoids into 
zirconacyclopentenes 1.113 and 1.116 gave mixed results (Scheme 1.17). Insertion of 
lithium  chloroallylide  1.76  followed  by  benzaldehyde  gave  a  2.2  :  1  mixture  of 
regioisomeric  insertion  products  1.114  and  1.115.
132  Insertion  of  lithiated 
chloromethylphosphonate  1.117  and  lithiated  chloroacetonitrile  1.92  (electron  poor 
carbenoids) resulted in insertion with complete regioselectivity for the alkyl zirconium 
bond to give products 1.118 and 1.120, respectively. Whereas, the electron rich lithiated 
chloromethyl trimethylsilane 1.107 displayed moderate 3 : 1 selectivity for the alkenyl 
zirconium  bond,  affording  an  inseparable  mixture  of  compounds  1.121  and  1.122 
(Scheme 1.17).
140   40 
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Scheme 1.17 Allyl and alkyl carbenoid insertion into zirconacyclopentenes. 
 
Results from the phosphonate and nitrile carbenoids appear to indicate initial carbenoid 
insertion occurs on the side of the alkyl zirconium bond. This could be explained by the 
alkenyl  proton  being  positioned  in  the  direction  of  lateral  attack,  preventing  initial 
attack on the alkenyl side of the zirconacycle 1.113. Thomas also gives the explanation 
for the results from lithiated chloromethyl trimethylsilane insertion. The ￿-silicon atom 
stabilises  the  ‘ate’  complex,  formed  from  silyl  carbenoid  and  zirconacycle  1.116, 
slowing rearrangement and allowing the more electron rich carbon zirconium bond to 
migrate.
140  
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Chapter 2.  Three-component  coupling  of  zirconacyclo-
pentenes,  dihalocarbenoids  and  acetylides  via 
rearrangement to a novel zirconium-alkenylidene 
complex 
This chapter presents a sophisticated method for elaboration of zirconacyclopentenes. 
Sequential  addition  of  1,1-dihalo-1-lithioalkanes  and  lithium  acetylides  to 
zirconacyclopentenes  results  in  highly  convergent,  three-component  coupling  on  a 
zirconocene template. This process is thought to proceed through the rearrangement to a 
novel zirconium-alkenylidene complex.  
 
2.1.  Introduction to research area 
Addition of lithium 2,2,6,6-tetramethylpiperidide (LiTMP) to a mixture of zirconacycle 
1.103, formed by co-cyclisation of enyne 2.1,
105 and dichloromethane (1.5 eq) at –78 °C  
followed by addition of lithium phenyl acetylide (1.1 eq) and quenching with MeOH 
and  aq  NaHCO3  gave  the  bicyclic  compound  2.2  in  52%  yield  (Scheme  2.1).
140,144 
Work-up with MeOD/D2O gave predominantly the bis-deuterated compound 2.3 (77% 
bis-deuterated,  residue  mono-deuterated)  suggesting  a  zirconium-alkenylidene  or  1-
metallo(Zr  or  Li)-1-zircono-alkene  intermediate.  When  BuCHBr2  was  used  as  the 
carbenoid  precursor  compound  2.4  was  obtained  in  42%  yield.  An  important 
observation, with implications for the mechanism, was that the use of 2.2 equivalents of 
lithium phenyl acetylide substantially increased the yield of 2.4 to 86%. Examination of 
the reaction mixture after 1.1 equivalents of lithium phenyl acetylide had been added, 
showed around 50% conversion into 2.4, with the residue being a product of carbenoid 
insertion (Scheme 2.1). 
ZrCp2
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(ii), (iii), (iv)
Ph
Pr
H
2.2 R1 = R2 = H
2.3 R1 = H, R2 = D
2.4 R1 = n-Bu, R2 = H
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2.1
R2
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(i)
Reagents and Conditions:(i) Cp2ZrCl2, 2 eq n-BuLi, -78 oC to RT, 3 h; (ii) CHR1X2,
LDA, -78 oC, 0.5 h; (iii) PhCCLi, -78 oC, 0.5 h; (iv) H2O or D2O, -78 oC to RT, 16 h.
Scheme 2.1 Insertion of alkyl lithium carbenoids in the presence of lithium phenyl acetylide. 
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2.2.  Precedent and elucidation of the mechanism 
The first proposed step is insertion of 1,1-dihalo-1-lithio species into 1.103 to form the 
expanded six-membered zirconacycle 2.6 via 1,2-metallate rearrangement (Scheme 2.2). 
After addition of lithiated phenyl acetylide 2.7 to afford the ‘ate’ complex 2.8 ring 
closure occurs via 1,2-bond migration to give intermediate 2.9. It has been found from 
the previous work
145 that the 1,2-rearrangement of the neutral intermediate 2.6 to be 
slow at –78 °C hence the requirement for the formation of 2.8 before rearrangement 
(Scheme 2.2).  
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Scheme 2.2 Initial stages of the three-component coupling on zirconocene. 
 
Initially a 3,3-sigmatropic Cope-type rearrangement of 2.9 to the Zr-alkenylidenate 2.13 
was suspected (Scheme 2.3), but theoretical calculations indicated it to have a very high 
activation energy, inconsistent with the low temperature at which the reaction occurs.
140 
Successive 1,3-migration of the zirconium to the ring junction to give 2.10 followed by 
a 1,3-alkyl shift from the metal to the beta-position of the alkyne 2.11 is an alternative 
(Scheme 2.3).  
The  failure  to  trap  the  supposed  alkenylidene  intermediate  2.11  with  alkynes  or 
carbonyl  compounds
144 indicated  that  even  if formed  it must  be  rapidly  trapped  by 
lithiated alkyne as the ate complex 2.13. Indeed calculations indicate this to be a very 
favourable process and could account for the need for two equivalents of the acetylide. 
It is not expected for complex 2.13 to show normal metal carbene reactivity as it lacks 
the empty orbital on the metal required for concerted [2+2] additions to be allowed.   43 
Surprisingly, attempts to trap the intermediate 2.13 with electrophiles such as methyl 
iodide, NBS and benzaldehyde also failed. 
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Scheme 2.3 Possible 3,3-sigmatropic rearrangement of 2.9 to give 2.13. 
 
There is also precedent for the second migration in the ring contraction of zirconacycle 
2.14 to afford a zirconium alkenylidene complex 2.15 (Scheme 2.4),
146 and  similar 
transformations are known for mid-/late-transition-metal complexes.
147,148 
Bu Bu
ZrCp2
ZrCp2
2.14 2.15  
Scheme 2.4 Zirconocene-alkyne to -alkylidene rearrangement. 
 
We would not expect the ‘ate’ complex 2.12 to make a 1,3-alkyl shift as it lacks the 
empty orbital on the metal which makes this a symmetry allowed process. Therefore it 
is  believed  that  addition  of  the  second  equivalent  of  lithiated  alkyne  occurs  before 
rearrangement to give the intermediate 2.16 (Scheme 2.5).    44 
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Scheme 2.5 Final stages of the three-component coupling on zirconocene. 
 
A new mechanism (Scheme 2.5) was therefore proposed based on a fragmentation of 
the  zirconate  species  2.16  via  elimination  of  the  allylic  carbanion  2.17  and  its 
subsequent re-addition to the ￿-carbon of the bisphenylethynyl zirconium complex 2.18 
to afford the novel zirconocene-alkenylidenate complex 2.13. There is a driving force 
for the rearrangement in release of strain energy in going from a bicyclo[3.3.0]oct-1-ene 
to  bicyclo[3.3.0]oct-2-ene  system,  as  it  was  previously  observed  for  a  1,3-amine 
rearrangement (Scheme 1.8).
119 
It is also possible that the fragments 2.17 and 2.18 are formed from 2.12 (Scheme 2.3). 
Rapid loss/re-addition of anions for zirconate complexes is known.
149-151 Although beta-
addition to a metal alkyne is unknown for early transition metals, it is an established 
route for the formation of mid-/late-transition-metal alkenylidene complexes.
147,148 
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Further  work  to  elucidate  the  mechanism  of  the  multi-component  coupling  on 
zirconocene was done by the author. The normal test for a fragmentation/recombination 
mechanism would be a crossover experiment with a different bisalkynyl zirconocene 
added (Scheme 2.6). 
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Scheme 2.6 Crossover experiment. 
 
To  the  intermediate  2.19  (Scheme  2.7)  was  added  at  –78  °C  previously  prepared 
bisphenylethynyl zirconocene 2.18 followed by sequential addition of p-t-BuPhCCLi 
2.7a. The progress of the reaction was monitored by GC which showed no reaction after 
addition of the first equivalent of 2.7a. A second equivalent of p-t-BuPhCCLi caused 
incorporation of both alkynes and the final compounds 2.20 and 2.4 were created, in an 
approximate ratio 1.9 : 1 respectively, with the residue being a product of carbenoid 
insertion. The third equivalent of the acetylide forced the remaining intermediate 2.19 to 
convert quickly into the final products in the ratio of 6.4 : 1. Addition to the reaction 
mixture  of  bis(p-tert-butylphenylethynyl)  zirconocene  2.18a  in  the  first  instance, 
followed by sequential addition of PhCCLi 2.7, provided the final compounds 2.20 and 
2.4 in the ratio of 1 : 9.7, respectively.   46 
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Scheme 2.7 Possible explanation of the results from crossover experiment. 
 
Observation of no reaction during first addition of acetylide 2.7a shows that it is all 
trapped  by  the  bis-alkynyl  zirconocene  2.18 to  give  the  tris-alkynyl-zirconate  2.21a 
which might further exchange to give 2.18a and 2.7 species. We would expect trapping 
by bromide 2.19 to be slow as the zirconium is sterically hindered. If the formation of 
2.21a was fast and reversible it would lead to an equilbrium concentration of Ar
1CCLi 
and Ar
2CCLi in a ratio of 1 : 2. If this concentration was either significant, or the 
equilibrium fast, then we would expect the free acetylide to attack bromide 2.19 in an 
irreversible  sequence  leading  to  the  cyclised  product  2.22/2.22a  (and  hence  final 
rearranged products) – presumably as a 1 : 2 ratio of Ar
1 and Ar
2 substituted cases. This 
does not happen so the formation of 2.18/2.18a + 2.7/2.7a from 2.21a/2.21b is either 
slow or very strongly in favour of 2.21a/2.21b.   47 
If formation of trisacetylide zirconate was a slow equilibrium, or effectively irreversible 
(i.e. minimal back reaction) then we would not expect any crossover product. 
As soon as the second equivalent of acetylide 2.7a starts to be added it can only react 
with bromide 2.19 leading to 2.22, but this is much more reactive towards acetylide 
2.7a  leading  to  the  alkynate  complex  2.23a  which  does  break  down  to  bis-alkyne 
complex 2.18a and allyl anion 2.24. 
2.22a would be expected to be more reactive towards addition of the acetylide 2.7a than 
complex 2.19 as the zirconium is much less hindered. 
There is now a competition between the allyl anion 2.24 and any acetylide present in 
solution for the bis-alkynyl complex 2.18a. Since the reaction normally works well with 
2 equivalents of acetylide the allyl anion 2.24 must react faster (indeed the reaction may 
take place through rapid recombination in the solvent cage). The prediction would be 
that  the  crossover  products  should  not  be  seen  and  sole  product  2.25a  should  be 
obtained,  but  this  is  not  in  accord  with  the  observations.  The  crossover  product, 
however, could arise in two possible ways:  
1. from the presence of 2.7 in solution competing with 2.7a for 2.22a (or 2.19), or  
2. from the presence of 2.18 (or 2.18b) competing with 2.18a for 2.24.  
If  the  equilibrium  between  2.21a/2.21b  and  2.18/2.18a  +  2.7/2.7a  was  strongly  in 
favour of 2.21a/2.21b, but fast, then the excess 2.7a might exchange to give 2.7.  
The statistical ratio (i.e. would predict 2 : 1 2.25 : 2.25a initially moving to 2 : 3 at end 
of addition of third equivalent of 2.7a) is not observed which may signify that this 
equilibriation is not occurring at a similar rate to the addition of 2.7a  and/or reaction of 
2.7a  with 2.19 but a slow equilibriation could explain the results. 
The observation of a great amount of the crossover product formed as the first part of 
the second equivalent of 2.7a is added, but much less as the third equivalent is added 
could be a  reflection  of the greater  amount of 2.7a  present,  but the ratios are not 
statistical indicating that this is at best a partial answer.  
The two extreme cases can be considered: if formation of trisacetylide zirconates was a 
fast  equilibrium,  and  gave  a  significant  concentration  of  [acetylide  + 
bisalkynylzirconium] we would expect substantial ‘crossover’ product (~2 : 1 in favour 
of crossover at start of addition of the second equivalent of acetylide moving to 3 : 2 in 
favour of non-crossover as last part of third equivalent of acetylide was added).  
If the equilibrium of 2.18 + 2.7a to 2.18a + 2.7 was slow, the prediction would be that if 
the three equivalents of acetylide 2.7a were added rapidly no crossover products should   48 
be observed. The experiment was carried out and the results showed that both products 
2.20 and 2.4 were created in the ratio of 5 : 1, respectively. This result is inconsistent 
with  the  above  assumption  and  may  indicate  that  the  fragmentation/recombination 
process occurs not entirely in an intramolecular fashion. Additionally, the crossover 
product may arise either from the attack of acetylide 2.7 onto bromide 2.19 or from 
trapping the bisalkynyl Zr complex 2.18a (or 2.18b) by the allylic anion 2.24. 
 
An indication that the proposed mechanism is reasonable is that addition of t-BuLi to 
bis(phenylethynyl)zirconocene  2.18  (Scheme  2.8)  at  –78  °C  with  immediate  protic 
quench afforded the alkene 2.27 (88% isolated yield), probably via the alkenylidene-ate 
complex  2.26.  Addition  of  n-BuLi  to  bis(phenylethynyl)zirconocene  gave  (Z)-1-
phenylhexene 2.30 (73%) only on warming to room temperature before protonolysis, 
presumably by initial addition to the metal to afford 2.28 followed by the type of 1,2-
migration previously reported by Negishi,
152 to afford 2.29. The result indicates that a 
bulky nucleophile is important for successful beta addition to the alkyne to inhibit direct 
attack on the metal.  
Accordingly,  attempts  were  made  to  add  PhLi  and  s-BuLi  to  2.18;  however,  GC 
analysis of those reactions showed no conversion to such products even after warming 
the reaction mixture to RT.   
(i)
Cp2Zr
Ph
t-Bu
Ph
t-Bu
Ph Li+
(ii)
2.26 2.27
Cp2Zr
Ph
Ph
Cp2Zr
Ph
Ph
(iii)
n-Bu
Cp2Zr
Ph
n-Bu n-Bu
Ph
Li+ Li+
(iv)
2.28 2.29 2.30
Ph
2.18
Reagents and Conditions:(i) t-BuLi, -78 oC; (ii) H2O,
-78 oC, 0.5 h; (iii) n-BuLi, -78 oC to RT; (iv) H2O, RT.  
 Scheme 2.8 Alternative route to alkenylidene zirconate complexes. 
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2.3.  Substrate-scoping studies 
The scope of the three-component coupling was investigated through variation of the 
co-cyclisation,  carbenoid  and  acetylide  precursors.  It  was  essential  to  prepare  a 
reasonable number of the bicyclic compounds with a wide range of various substituents 
for biological testing. It was hoped that high-throughput screening would lead to the 
identification of an active and selective agonist/antagonist for the human orphan nuclear 
receptors: LRH-1 and SF-1. 
 
2.3.1.  Synthesis of starting materials 
2.3.1.1.  Synthesis of substituted acetylenes 
1-Ethynyl-3-methoxybenzene  2.31  (Figure  2.1)  was  prepared  from  commercially 
available starting materials using literature methods.
153,154 Other acetylenes used in the 
reactions were either purchased from suppliers or prepared by previous members of the 
Whitby group. 
OMe
2.31
 
Figure 2.1 1-Ethynyl-3-methoxybenzene. 
 
2.3.1.2.  Synthesis of gem-dibromides 
Dibromides  2.33a,b,c  (Scheme  2.9)  were  synthesised  according  to  literature 
precedent
155 from the corresponding aldehydes 2.32. Other 1,1-dihalides used in the 
reactions were either purchased from suppliers or prepared by previous members of the 
group. 
Reagents and Conditions:(i) (PhO)3P, Br2,CH2Cl2, -20 oC to  0 oC over 1 h.
R H
O R
a. n-Hex,   72%
b. c-Hex,   9%
c. n-Oct,    77%
R Br
Br (i)
'(PhO)3PBr2' 2.32 2.33
 
Scheme 2.9 Conversion of aldehydes into 1,1–dibromoalkanes. 
 
2.3.1.3.  Synthesis of co-cyclisation precursors 
The  following  1,6-enynes  (Scheme  2.10)  were  prepared  by  alkylation  of  the 
corresponding lithiated alkynes with 5-bromo-1-pentene.    50 
R
R     R
a. Ph,       88%
b. n-Bu,    61%
c. n-Hex,  55%
(i), (ii), (iii)
Reagents and Conditions:(i)  n-BuLi, THF, -78 oC, 0.5 h; (ii) HMPA, -78 oC
to -50 oC; (iii) 5-bromo-1-pentene, -50 oC to RT, 4-12 h, then aq NH4Cl.
2.34
2.35
 
Scheme 2.10 Preparation of enynes. 
 
Enynes carrying hydroxyl group have also been prepared. (7-Phenylhept-1-en-6-yn-3-
yloxy)(tert-butyl)dimethylsilane 2.41 was synthesised as in Scheme 2.11. Ethanol and 
in  situ  generated  Me3SiI  converted  acrolein  2.36  into  1,1-diethoxy-3-iodopropane 
2.37,
156, 
157 which after rapid purification by chromatography on basic alumina (grade 
III)  was  reacted  with  lithium  phenyl  acetylide  to  give  (5,5-diethoxypent-1-yn-1-
yl)benzene 2.38. Hydrolysis of the acetal to give an aldehyde 2.39 was followed by 
reaction with vinyl magnesium bromide to afford the alcohol 2.40. Protection of the 
hydroxyl group with t-BuMe2SiOTf gave the desired cyclisation precursor 2.41. 
O
I
OEt
OEt
Ph
OEt
OEt
Ph
O
HO
Ph
(i) (ii) (iii)
(iv) (v)
OH
Ph
O
Ph
O
+
(R)-2.40
(vi)
90% e.e.
Reagents and conditions: (i) 1. NaI, Me3SiCl, MeCN; 2. EtOH, 0 oC to RT, 2 h, 47%;
(ii) 1.5 eq PhCCLi, 1.5 eq HMPA, THF, -78 oC, 1 h then RT, 14 h, 81%;
(iii) THF : H2O (4 :1), HCl (2M), RT, 3 h, 100%; (iv) 1. CH2CHMgBr, -78oC to
-65 oC, 1 h; 2. aq NH4Cl, 65%; (v) Me2t-BuSiOTf, imidazole, DMAP, THF, RT, 18 h, 
99%; (vi) (E)-vinyl crotonate, Novozyme 435, 42 oC, 72 h, 96%; (vii) Me2t-BuSiOTf,
Et3N, DCM, 0 oC to RT, 0.5 h, 67%.
TBDMSO
Ph
2.36 2.37 2.38
2.40 2.39
2.41
(S)-2.42
(vii)
TBDMSO
Ph
(R)-2.41
Scheme 2.11 Synthesis of (7-phenylhept-1-en-6-yn-3-yloxy)(tert-butyl)dimethylsilane. 
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The  (R)-enantiomer  of  the  alcohol  2.40  was  obtained  by  crotylation  reaction  using 
Novozyme  435  as  the  catalyst,  an  immobilised  Candida  antartica  lipase  which  is 
known to be selective for the (S)-enantiomer of alcohols with a similar structure.
158 
Reaction was stopped at around 50%  conversion  and the recovered enantioenriched 
alcohol  (R)-2.40  (90%  e.e.)  converted  through  to  (R)-2.41  by  the  known  procedure 
(Scheme 2.11).
159 
 
Synthesis  of  (1-phenylhept-6-en-1-yn-4-yloxy)(tert-butyl)dimethylsilane  2.48  was 
achieved in five steps (Scheme 2.12). Protection of the hydroxyl group in (±)-glycidol 
2.43 as the tetrahydropyranyl ether 2.44
160 followed by reaction of the crude product 
with vinylmagnesium bromide catalysed by CuBr gave the THP protected pent-4-ene-
1,2-diol  2.45.
161  Removal  of  the  THP  protecting  group
162  gave  pent-4-ene-1,2-diol 
2.46.
163 A one-pot ring closure/ring opening procedure was used to convert pent-4-ene-
1,2-diol into  7-phenylhept-1-en-6-yn-4-ol 2.47.
164,165 Thus selective tosylation  of the 
primary alcohol was followed by in situ ring closure to an epoxide, and ring opening 
with lithium phenylacetylide to afford the alcohol 2.47. 
The overall yield was poor despite considerable optimization. TBDMS protection of  
alcohol 2.47 gave the desired compound 2.48. 
O OH OH
OTHP
(ii)
Ph
HO
O OTHP (i)
(iv)
Reagents and conditions: (i) 1. DHP, CH2Cl2, TsOH, 0 oC, 15 min; 2. RT, 1 h, 100%; 
(ii) 1. CH2CHMgBr, cat. CuBr, THF, -10 oC, 4 h; 2. aq NH4Cl, 86%; (iii) MeOH,
Amberlyst-15, 50 oC, 1 h, 60%; (iv) 1. NaH, THF, -10 oC; 2. N-Tosyl imidazole,
-10 oC, 1 h; 3. 2.0 eq PhCCLi, THF, HMPA, -10 to 0 oC 1h. 4. RT, 40 h, then
aq NaHCO3, 28%; (v) Me2t-BuSiOTf, imidazole, DMAP, THF, RT, 15 h, 82%.
Ph
TBDMSO
(v)
2.43
OH
OH
(iii)
2.44 2.46 2.45
2.48 2.47
 
Scheme 2.12 Synthesis of (1-phenylhept-6-en-1-yn-4-yloxy)(tert-butyl)dimethylsilane. 
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(1-Phenylhept-6-en-1-yn-3-yloxy)(tert-butyl)dimethylsilane  2.52  (Scheme  2.13)  was 
synthesised from 4-penten-1-ol 2.49 through Swern oxidation to give the corresponding 
aldehyde 2.50, and subsequent nucleophilic addition of phenyl acetylide to the carbonyl 
group to provide the alcohol 2.51.
159 The poor yield over the two steps is explained by 
troublesome volatility of the aldehyde 2.50. TBDMS protection of the hydroxyl group 
gave the co-cyclisation precursor 2.52. 
OH O
(i) (ii) Ph
2.51
HO
Ph
2.52
TBDMSO
(iii)
2.49 2.50
Reagents and conditions: (i) 1. DMSO, (COCl)2, DCM, -78 oC, 1 h; 2. Et3N,
-78 oC to RT; 3. H2O/brine; (ii) 1.5 eq PhCCLi, THF, HMPA, -78 oC to -55 oC, 
1.5 h then aq NH4Cl, 27% (over two steps); (iii) Me2t-BuSiOTf, Et3N, DCM,
0 oC to RT, 0.5 h, 74%.  
Scheme 2.13 Preparation of (1-phenylhept-6-en-1-yn-3-yloxy)(tert-butyl)dimethylsilane. 
 
Reaction  of  lithiated  tert-butyldimethyl(pent-4-ynyloxy)silane  2.53  with  5-bromo-1-
pentene gave an inseparable mixture of two compounds 2.54 and 2.55 in the ratio of 2 : 
1 respectively and 63% combined yield (Scheme 2.14). The undesired product 2.55 
resulted from the nucleophilic attack of the lithiated alkyne onto silyl group. Use of 5-
iodo-1-pentene instead provided the desired compound 2.54
166 and the by-product 2.55 
with improved ratio (5.7 : 1) and yield (75%). Subsequent zirconocene mediated co-
cyclisation turned out to be selective for the enyne 2.54 and the by-product 2.55 present 
in the reaction mixture has been shown to have no effect on the reaction.  
(i) or (ii)
Reagents and Conditions: method (i) 1. n-BuLi, THF, -78 oC, 0.5 h; 2. HMPA,
-78 oC to -50 oC; 3. 5-bromo-1-pentene, -50 oC to RT, 24 h, then aq NH4Cl, 63%; 
method (ii) 1. n-BuLi, THF, -78 oC, 0.5 h; 2. HMPA, -78 oC to -50 oC; 3.
5-iodo-1-pentene, -50 oC to RT, 24 h, then aq NH4Cl, 75%.
2.53 2.54
OTBDMS
+
2.55
TBDMSO
Si
OTBDMS
 
Scheme 2.14 Synthesis of 10-(tert-butyldimethylsiloxy)-l-decen-6-yn.   53 
Enynes containing a nitrogen atom have been prepared (Scheme 2.15). N-methyl-N-
(phenylprop-2-ynyl)prop-2-en-1-amine 2.57 and N-benzyl-N-(phenylprop-2-ynyl)prop-
2-en-1-amine 2.60 (Scheme 2.15) were prepared from N-allyl-N-methylamine 2.56, and 
N-allyl-N-benzylamine  2.59,  which  was  synthesised  from  allyl  amine  2.58  in  78% 
yield,
167 respectively in copper-catalysed Mannich reaction.
168 
Reagents and Conditions: (i) PhCCH, CH2O, DMSO, cat. CuI, 30 oC, 
24 h, 41%; (ii) BnBr, 0 oC to RT, 16 h then aq NaHCO3, 78%;
(iii) PhCCH, CH2O, DMSO, cat. CuI, 30 oC, 15 h, 89%.
H2N BnHN
MeHN
BnN
Ph
2.58 2.59
2.56
2.60
MeN
Ph
2.57
(ii) (iii)
(i)
 
Scheme 2.15 Synthesis of nitrogen containing substrates. 
 
2.3.2.  Synthesis of cis-bicyclo[3.3.0]oct-2-enes by using stoichiometric zirconium 
chemistry 
Extension of the multi component reaction to the use of a wide range of starting enynes, 
dihalocarbenoids,  and  lithiated  alkynes  resulted  in  synthesis  of  a  number  of 
bicyclo[3.3.0]octanes (Scheme 2.16, Table 2.1). 
2.62
R3 R1
H
R2 ZrCp2
R1
2.61
2.20, 2.63 a-aa
ZrCp2
R1
R2
X
Reagents and conditions: (i) R2CHX2 [X= Br for R2 = n-Hex, n-Bu, n-Oct.
X = Cl for R2 = H, SiMe2Ph], LDA or LiTMP, -78 oC, 15 min; (ii) 3 eq R3CCLi, 
-78 oC to -60 oC over 0.5 h; (iii) MeOH, aq NaHCO3, RT, 12-16 h.
(i) (ii), (iii)
 
Scheme 2.16 One-pot tandem reaction sequence on zirconocene. 
 
The synthetic route introduced above (Scheme 2.16) provides an efficient method for 
construction and functionalisation at multiple sites rigid core structures containing cis-
bicyclo[3.3.0]oct-2-ene skeleton. Yields range from good to very good (Table 2.1).   54 
Use of a wide range of acetylides (2.63a-l) (Table 2.1) provided the final compounds in 
very  good  yields.  Diminished  yields  were  however  observed  for  alkyl-substituted 
acetylides (2.63i,k,l) in comparison with acetylides carrying aromatic substituent. These 
results seem to imply that alkyl-substituted acetylides for some reasons are less reactive 
towards the zirconium-alkenylidene rearrangement than aryl-substituted acetylides.  
 
Compound   R
1  R
2  R
3  Yield / %
a 
2.20  n-Pr  n-Bu  4-t-BuPh  66 
2.63a  Ph  n-Hex  Ph  86 
2.63b  Ph  n-Hex  3-MeOPh  78 
2.63c  Ph  n-Hex  4-MeOPh  72 
2.63d  Ph  n-Hex  4-MePh  62 
2.63e  Ph  n-Hex  4-EtPh  70 
2.63f  Ph  n-Hex  4-n-BuPh  78 
2.63g  Ph  n-Hex  4-t-BuPh  51 
2.63h  Ph  n-Hex  4-PhPh  60 
2.63i  Ph  n-Hex  n-Pr  54 
2.63j  Ph  n-Hex  n-Bu  75 
2.63k  Ph  n-Hex  n-Hex  65 
2.63l  Ph  n-Hex  n-Oct  56 
2.63m  3-MeOPh  n-Hex  Ph  75 
2.63n  4-EtPh  n-Hex  Ph  70 
2.63o  n-Pr  n-Hex  Ph  82 
2.63p  n-Bu  n-Hex  Ph  88 
2.63q  n-Hex  n-Hex  Ph  86 
2.63r  c-Hex  n-Hex  Ph  80 
2.63s  (CH2)3OH  n-Hex  Ph  61 
2.63t  Ph  H  Ph  58 
2.63u  Ph  n-Bu  Ph  71 
2.63v  Ph  n-Oct  Ph  73 
2.63w  Ph  SiMe2Ph  Ph  45 
2.63x  n-Bu  SiMe2Ph  Ph  69 
2.63y  n-Hex  c-Hex  Ph  10 
2.63z  n-Hex  n-Hex  n-Bu  68 
2.63aa  n-Pr  n-Hex  4-t-BuPh  86 
Table 2.1 Variation of 1-(2-alkenyl)-bicyclo[3.3.0]oct-2-enes 2.63. 
a isolated yield of >95% pure material.   55 
The bicyclic compounds 2.63m-r (Table 2.1) were obtained in very good yields for both 
R
1 = alkyl and R
1 = aryl. A slightly lower yield is observed for compound 2.63s, but the 
yield  was  given  for  two  steps:  the  reaction  sequence  on  zirconocene  and  TBAF 
deprotection step. 
Insertion of lithiated dichloromethane followed by insertion of phenyl acetylide gave 
the product 2.63t in 58% isolated yield. In this particular case the yield is lower due to 
multiple insertion of this carbenoid into the zirconacycle, therefore the purification was 
made  difficult.  Silyl  substituted  carbenoids  were  also  examined,  and  the  final 
compounds 2.63w, x with incorporated SiMe2Ph group were obtained in 45% and 69% 
yield respectively. The final yield of product 2.63w is significantly diminished by the 
undesired  de-silylation  which  occurred  under  the  reaction  conditions.  The  same  de-
silylation process was observed by Thomas,
140 who has also noted that different quench 
conditions may have prevented this de-silylation process from occurring, however these 
were not tried. Incorporation of a carbenoid carrying an alpha-branch occurred very 
poorly and provided the desired compound 2.63y only in 10% isolated yield. The poor 
yield  is  due  to  deprotonation  of  the  a-branched  1,1-dihalo  species  2.33b  being 
immediately  followed  by  1,2-H  shift  (even  at  –78  °C)  with  loss  of  LiBr,  to  give 
relatively unreactive alkenylhalide species 2.66 (Scheme 2.17). This process is thought 
to be occurring due to metal assisted ionisation as in 2.65.
124,169-171 
Br Br
(i)
Br Li
Br
H
Br
2.33b 2.66
-LiBr
Reagents and conditions: (i) LDA or LiTMP, THF, -78 °C.
2.64 2.65
Br Li
Br
H
d-
d+
 
Scheme 2.17 Decomposition of a a a a-branched carbenoids. 
 
The tandem reaction sequence also worked well for the formation of pyrrolidine fused 
systems 2.67a, b (Scheme 2.18).   56 
RN
Ph
Ph
n-Hex
H
RN
Ph (i), (ii)
(iii), (iv)
2.67a, R = Me, 62%
2.67b, R = Bn, 74%
Reagents and conditions: (i) Cp2ZrBu2, THF, -78 °C to RT, 2 h;
(ii) n-HexCHBr2, LDA, -78 °C, 15 min; (iii) 3.0 eq PhCCLi, -78 °C 
to -60 °C over 0.5 h; (iv) MeOH, aq NaHCO3, RT, 12-16 h.
2.57, R = Me
2.60, R = Bn
 
Scheme 2.18 Formation of pyrrolidine fused systems. 
 
Co-cyclisation of precursor 2.41, and further carbenoid and acetylide insertion resulted 
in synthesis of compounds with oxygen-substitution on the saturated cyclopentane ring. 
The synthesis of the 6-oxygenated compounds is shown in Scheme 2.19. 
Ph
Ph
n-Hex
H TBDMSO
Ph
Ph
n-Hex
H TBDMSO
H
H
exo : endo, 1.6:1, 88%
+
2.68-exo
2.68-endo
TBDMSO
Ph
Reagents and conditions: (i) Cp2ZrBu2, THF -78 oC, 0.5 h, then 2 h at RT; (ii)
n-HexCHBr2, LDA, -78 oC, 15 min; (iii) 3.0 eq PhCCLi, -78 oC to -60 oC over
45 min; (iv) MeOH, aq NaHCO3, RT, 5 h; (v) 5.0 eq TBAF, THF, RT, 20 h, then 
H2O; (vi) Pyridine, 73 eq Ac2O, 0.58 eq DMAP, RT, 13 h.
Ph
Ph
n-Hex
H HO
Ph
Ph
n-Hex
H HO
H
H
+
Ph
Ph
n-Hex
H AcO
Ph
Ph
n-Hex
H AcO
H
H
+
(i), (ii)
(iii), (iv)
2.41
(v) (vi) 2.69-exo
2.69-endo
2.70-exo, 82%
2.70-endo, 95%
exo : endo, 1.6:1, 76%
 
Scheme 2.19 Synthesis of 6-oxygenated series. 
 
Precursor 2.41 underwent the zirconocene induced co-cyclisation, carbenoid insertion 
and phenyl acetylide addition to give a 1.6 : 1 mixture of the exo- and endo-isomers 
2.68 after protonolysis. TBAF cleavage of the silyl group furnished the desired bicyclic 
alcohols  2.69.  The  exo-  and  endo-  isomers  were  partly  separated  by  careful 
chromatography, the endo-isomer eluting first. The relative stereochemistries of the exo- 
and  endo-  isomers  were  clear  from  coupling  patterns  to  the  proton  adjacent  to  the 
hydroxyl group. In the endo-isomer it appears as a ddd, J = 9.1, 8.5, 5.5 Hz, in the exo-
isomer as a broad singlet, the patterns being in accord with expectations from molecular 
modelling and the Karplus relationship of couplings to dihedral angles.
172, 173    57 
The separated diastereoisomers of 2.69 were acylated to afford 2.70-exo and 2.70-endo. 
A crystal structure of 2.70-endo (attached in appendix) confirmed the stereochemical 
assignment.
174 
It  was  required  to  separate  enantiomers  of  2.69-exo  for  biological  testing  (Scheme 
2.20). The most convenient route to the enantiopure compounds proved to be separation 
by chiral HPLC on a Diacel OD-H column, the two enantiomers having remarkably 
different retention times (2.69-exo-ent-1 at 11.7 min, 2.69-exo-ent-2 after 18.5 min – 1 
mL/min 1% isopropanol in hexane on 4.6 x 250 mm column) allowing clean separation.  
Ph
Ph
n-Hex
H HO H
Ph
Ph
n-Hex
H HO H
2.69-exo-ent-1 2.69-exo-ent-2
+
Ph
Ph
n-Hex
H HO H
(i)
2.69-exo
Reagents and conditions: (i) HPLC on Diacel OD-H chiral column.  
Scheme 2.20 Chiral HPLC seperation of enantiomers of 2.69-exo. 
 
The  identity  of  the  enantiomers  was  proven  by  conversion  of  the  enantioenriched 
TBDMS  protected  alcohol  (R)-2.41  (90%  e.e.)  through  to  2.69-exo  (Scheme  2.21), 
which was found by chiral HPLC to be predominantly (20 : 1) the more slowly eluted 
enantiomer (2.69-exo-ent-2), thus identifying its absolute stereochemistry. 
TBDMSO
Ph
H
n-Hex
Ph Ph
TBDMSO
H
n-Hex
Ph Ph
TBDMSO
H
n-Hex
Ph Ph
HO
H
n-Hex
Ph Ph
HO
+ +
2.69-exo-ent-2
2.69-endo-ent-2
2.68-exo-ent-2
2.68-endo-ent-2
Reagents and conditions: (i) Cp2ZrBu2, THF -78 oC, 0.5 h then 2 h at RT;
(ii) n-HexCHBr2, LDA, -78 oC, 15 min; (iii) 3.0 eq PhCCLi, -78 oC to -60 oC 
over 45 min; (iv) MeOH, aq NaHCO3, RT, 12 h, 90%; (v) 20 eq TBAF, THF,
RT, 22 h, then H2O, 65%.
(i), (ii)
(iii), (iv)
(v)
(R)-2.41
 
Scheme 2.21 Asymmetric synthesis of alcohol 2.69-exo. 
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The 7-oxygenated series was synthesised as shown in Scheme 2.22. Enyne 2.48 was 
subjected to the zirconocene mediated co-cyclisation, dibromocarbenoid insertion and 
phenyl acetylide driven zirconate rearrangement to obtain a 1 : 1 mixture of the exo- and 
endo-isomers 2.71. After TBAF cleavage of the silyl group, the exo- and endo- isomers 
of 2.72 were partly separated by careful chromatography, the endo-isomer eluting first. 
Acylation  of  the  separated  diastereoisomers  gave  2.73-exo  and  2.73-endo  (Scheme 
2.22). 
Ph
Ph
n-Hex
H
Ph
Ph
n-Hex
H
exo : endo, 1:1, 78%
+
2.71-exo
2.71-endo
Ph
Reagents and conditions: (i) Cp2ZrBu2, THF -78 oC, 0.5 h, then 2 h at RT; (ii) n-HexCHBr2,
LDA, -78 oC, 15 min; (iii) 3.0 eq PhCCLi, -78 oC to -60 oC over 45 min; (iv) MeOH,
aq NaHCO3, RT, 5 h; (v) 2.0 eq TBAF, THF, RT, 20 h, then H2O; (vi) Pyridine, 73 eq
 Ac2O, 0.58 eq DMAP, RT, 17 h.
Ph
Ph
n-Hex
H
Ph
Ph
n-Hex
H
+
Ph
Ph
n-Hex
H
Ph
Ph
n-Hex
H
+
(i), (ii)
(iii), (iv)
2.48
(v) (vi) 2.72-exo
2.72-endo
2.73-exo, 80%
2.73-endo, 79%
exo : endo, 1:1, 70%
TBDMSO
H
TBDMSO
TBDMSO
H
HO
H H
AcO
HO
H H
AcO
 
Scheme 2.22 Synthesis of 7-oxygenated series. 
 
The relative stereochemistries of 2.72-exo and 2.72-endo (and hence 2.73-exo and 2.73-
endo) were established by NMR studies combined with molecular modelling (Table 
2.2)  using  the  MMFF94  force  field  as  implemented  in  Spartan  06  (Wavefunction 
Inc.).
175 The proton next to the hydroxyl group in one isomer appeared as a tt, J = 8.5, 
5.9 Hz (due to couplings of 8.5, 8.3, 6.3 and 5.5 Hz), consistent with 2.72-exo or the 
equatorial conformer of 2.72-endo (2.72-endo eq. conf.), but as a quintet (J = 5.5 Hz) in 
the  other  diastereoisomer  –  not  consistent  with  any  minimum  energy  structure. 
Molecular  modelling  showed  that  2.72-exo  had  a  well  defined  minimum  energy 
conformer, but for 2.72-endo the ‘equatorial’ and ‘axial’ hydroxy conformers (2.72-
endo eq. and 2.72-endo ax.) were <1 kJ/mol different in energy. The expected coupling 
patterns  for  each  conformer  of  2.72-endo  were  calculated  using  the  Altona 
modification
173  of  the  Karplus  relationship
172  between  dihedral  angle  and 
3J  as 
implemented  in  the  Mspin  program
176  from  Mestrec.  The  average  showed  a  good   59 
correlation to the observed coupling constants (Table 2.2). Final proof was hoped to 
come from low temperature 
1H NMR experiments, however, no splitting of all averaged 
signals for geminal protons into axial and equatorial signals was demonstrated even at 
the lowest temperature (–80 °C). NOE experiments of 2.72-endo also turned out not to 
bring any relevant insights. 
Ph
HO
H
H
H Ha
Hb
H
Hb
Ha
hex
Ph
6
5
7
8
Ph
H
H
H
H Ha
Hb
OH
Hb
Ha
hex
Ph
6
5
7
8 Ph
H
H
H
H Ha
Hb
HO Hb
Ha
hex
Ph
6
5
8
7
4 4
4
2.72-exo 2.72-endo ax. conf. 2.72-endo eq. conf.  
3J coupling 
  H
7-H
8b  H
7-H
8a  H
7-H
6b  H
7-H
6a  H
6b-H
5  H
6a-H
5 
2.72-exo             
Dihedral  164  47  154  37  14  104 
Calculated 
3J  10.2  6.1  8.9  7.6  9.7  1.9 
Observed 
3J  8.5  5.5  8.3  6.3  10  3.6 
2.72-endo ax. conf.             
Dihedral  38  80  33  87  18  101 
Calculated 
3J  5  1.3  5.9  1.3  9.4  1.6 
2.72-endo eq. conf.             
Dihedral  44  159  46  165  35  155 
Calculated 
3J  6.6  9.5  6.3  10.4  7.3  10.5 
Average 2.72-endo 
eq. and -ax. conf. 
3J  5.8  5.4  6.1  5.9  8.4  6.1 
Observed 
3J  6.2  4.6  5.6  5  9.5  6 
Table 2.2 Correlation between predicted and observed coupling constants for 2.72. 
 
2.3.3.  Insertion  of  alkyl  carbenoid  and  phenyl  acetylide  into  bicyclo[4.3.0]-
zirconacyclopentene and sterically hindered zirconacyclopentenes 
Variation in the ring size fused to the zirconacycles was sought in respect of the multi-
component coupling sequence. Co-cyclisation with Negishi reagent of the homologous 
enyne,  1-(oct-7-en-1-ynyl)benzene  2.74  resulted  in  six-five  fused  zirconacycle  2.75 
(Scheme 2.23). Subsequent insertion of lithiated dibromoheptane and lithium phenyl 
acetylide provided a mixture of compounds 2.78 and 2.79 in 52% combined yield and 
initial GC ratio of 4.7 : 1 respectively. Compounds 2.78 and 2.79 were partly separated 
by careful column chromatography to obtain the final products as single compounds in 
26% and 4% yield, respectively.   60 
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Ph
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ZrCp2
Ph
n-Hex
Br
Ph
2.18
2.78 : 2.79, 4.7 : 1, 52%
Reagents and conditions: (i) Cp2ZrBu2, THF -78 oC, 0.5 h, then 2 h at RT; 
(ii) n-HexCHBr2, LiTMP, -90 oC to -78 oC, 25 min; (iii) 3.0 eq PhCCLi,
 -78 oC to  -55 oC over 45 min; (iv) MeOH, aq NaHCO3, RT, 16 h.
(i) (ii) (iii)
(iv) H
H
 
Scheme 2.23 Extension of the method to six-five fused zirconacyclopentene. 
 
Other  unexpected  products  emerged  in  the  crude  reaction  mixture.  GC  and  GCMS 
analysis  revealed  the  molecular  mass  of  these  products  corresponded  to  the  ￿-H 
elimination products 2.82, 2.83 (Scheme 2.24). The presence of a few compounds with 
the same molecular mass strongly suggests the products of both exo- and endocyclic ￿-
H abstraction process, which occurs in the intermediate 2.80. 
Ph
ZrCp2
Ph
C5H11
H
2.80
C5H11
Ph
2.82
n-Hex
Ph
2.83
Ph
n-Hex
ZrCp2
Ph
280 H
+
- Cp2Zr(H)CCPh, 2.81
(+ tautomers for 1,5-H shift)
 
Scheme 2.24 ￿-H Elimination process in six-five fused zirconacycles after alkyl carbenoid insertion. 
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A conclusion can be drawn from these results, that release of strain energy via 1,3-Zr 
rearrangement  in  the  intermediate  2.77  is  impeded,  thus  making  the  undesired  ￿-H 
elimination  process  more  favourable  at  the  stage  of  the  intermediate  2.80  (Scheme 
2.24).  Additionally,  trapping  of  the  bisalkynyl  Zr  species  2.18  does  not  occur 
exclusively  in  the  bridgehead  position,  which  suggests  that  there  is  only  a  small 
difference in release of strain energy between these two resonance structures 2.77a and 
2.77b. Similar results were obtained when enyne 2.84 was subjected to the reaction 
sequence (Scheme 2.25). In the examined reaction coordination of two molecules of 
phenyl  acetylide  2.7  to  Zr  atom  to  give  the  corresponding  allylic  anion  2.85  and 
bis(phenylethynyl) zirconium complex 2.18 does seem to be more favourable process 
than  ￿-H  abstraction,  however  the  latter  process  is  still  competitive  and  results  in 
compounds 2.86 as minor products. Subsequent re-addition of the anion 2.85a to the ￿ 
carbon  of  the  Cp2Zr(CCPh)2  complex  occurs  very  slowly,  even  upon  warming  the 
reaction mixture to RT. As a result a mixture of compounds 2.87 (major product) and 
2.88 (minor product) is obtained. The final compound 2.87 was isolated in only 25% 
yield since the purification was very difficult due to by-products 2.86 and 2.88, all of 
which have similar polarity. It was assumed, but has not been proven, that the ring 
junction stereochemistry in the product 2.87 is cis. 
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Reagents and conditions: (i) Cp2ZrBu2, THF, -78 oC, 0.5 h then 2 h at RT;
(ii) n-HexCHBr2, LiTMP, -90 oC to -78 oC, 25 min; (iii) 3.0 eq PhCCLi, -78 oC 
to -55 oC over 45 min; (iv) -55 oC  to RT, then MeOH, aq NaHCO3, RT, 16 h.
(i), (ii), (iii)
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Scheme 2.25 Tandem reaction sequence on enyne 2.84.   62 
An  endocyclic  ￿-H  elimination  was  observed  in  the  case  of  insertion  of  lithiated 
(dichloromethyl)dimethyl(phenyl)silane into zirconacyclopentene 2.89 (Scheme 2.26). 
SiMe2Ph
3.26b
Li
X
X
SiMe3
SiMe2Ph
ZrCp2
Ph
H
SiMe3
SiMe2Ph
SiMe2Ph
SiMe3
1,5-H and 1,5-Si 
shifts
2.90
2.91 2.92, 52%
ZrCp2
2.89
SiMe3
1.83b
SiMe3 (i) (ii), (iii)
(iv)
Reagents and conditions: (i) Cp2ZrBu2, THF, -78 oC, 0.5 h then 3 h at
RT; (ii) 1.3 eq Cl2CHSiMe2Ph, n-BuLi, -95 oC to -20 oC; (iii) 3.0 eq
PhCCLi, -78 oC to -50 oC over 1 h; (iv)  MeOH, aq NaHCO3, RT, 12 h.  
Scheme 2.26 Insertion of (dichloromethyl)dimethyl(phenyl)-silane into zirconacycle 2.89. 
 
The steric encumbrance introduced by the silyl carbenoid favours the endocyclic ￿-H 
elimination process in intermediate 2.90, to provide compound 2.91 which after 1,5-H 
and 1,5-Si shifts gives the final diene 2.92 in moderate yield. 
 
2.3.4.  Competition  between  TBDMSO  group  elimination  and  1,3-zirconate 
rearrangement 
Co-cyclisation of TBDMS protected 7-phenylhept-1-en-6-yn-5-ol 2.52 gave a mixture 
of exo : endo unsaturated zirconacycles 2.93 in the ratio of 5 : 1, respectively (ratio 
estimated  by taking a sample of  the  reaction mixture and subsequent  GC analysis), 
(Scheme 2.27). Insertion of lithiated 1,1-dibromoheptane and phenyl acetylide resulted in 
partial elimination of the TBDMS protected hydroxyl function in the exo position from 
intermediate 2.95a to give the conjugated diene 2.96 as a major product. Also product 
2.99, which results from protonation of the remaining allylic anion 2.97, was detected in 
the  crude  reaction  mixture.  The  resulting  allylic  anion  did  not  react  with  the 
bisphenylalkynyl complex 2.18 as the bulky TBDMSO group blocks the exo face. The 
compound  2.100  was  obtained  as  a  minor  product  from  the  Zr-alkenylidene 
rearrangement to give the alkenylidenate species 2.98, as the TBDMSO group is endo 
directed,  therefore  prevents  the  elimination  process  from  occurring  in  intermediate 
2.95b.    63 
Products 2.96 and 2.100 were isolated as pure compounds in low yields (21% and 2%, 
respectively) as the purification on silica gel column was difficult; however, the yields 
of compounds 2.96, 2.99 and 2.100 estimated by GC in the crude reaction mixture are 
much higher. 
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Reagents and conditions: (i) Cp2ZrBu2, THF -78 oC, 0.5 h then 2 h at RT; (ii) n-HexCHBr2, 
LDA, -78 oC, 15 min; (iii) 3.0 eq PhCCLi, -78 oC to -55 oC over 45 min; (iv)  MeOH, 
aq NaHCO3, RT, 16 h.
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Scheme  2.27  Competition  between  elimination  of  TBDMSO  group  and  1,3  Zr-alkenylidene 
rearrangement. 
 
2.3.5.  Application of the existing method to monocyclic zirconacyclopentenes 
Insertion of lithium 1,1-dibromoheptane into zirconacyclopentene 1.24 (created in situ 
by  insertion  of  the  corresponding  alkyne  into  Zr-ethene  complex,  1.21)  gave  the 
expanded  six-membered  zirconacyle  2.101  (Scheme  2.28).  Further  Zr-alkenylidene 
rearrangement driven by phenyl acetylide to give intermediate 2.102 followed by endo- 
and exocyclic ￿-H elimination to provide after protonolysis an inseparable mixture of 
products  2.103  and  2.104  in  64%  and  45%  combined  yield  for  hexyl  and  phenyl 
substituent, respectively. Although the main limitation of the synthetic route presented 
below is the ￿-H abstraction, this method can be an alternative route for synthesis of 
substituted cyclopentadienes.   64 
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Scheme 2.28 Insertion of alkynes and carbenoids into Zr-ethene complex. 
 
2.4.  Synthesis of 1-alkoxy-cis-bicyclo[3.3.0]oct-2-enes 
The  results  from  testing  for  biological  activity  against  LRH-1  and  SF-1  of  alkoxy 
analogues  2.107  of  1.7 were  required  to  complete  a  series for  publication  (Scheme 
2.29). 
O
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n-Hex
H
Ph
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H
OH
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H
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2.105 2.106 2.107a-j
2.35a
Reagents and conditions: (i) Co2(CO)8, 10 eq DMSO, THF, reflux, 5 h, 80%; 
(ii) n-HexMgBr, CeCl3, -10 oC to RT, 1 h, 90%; (iii) 10 eq ROH, 0.1 eq
camphorsulfonic acid, RT, 3.5 h, then aq NaHCO3.
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Scheme 2.29 Synthesis of alkoxy analogues of 1.7. 
 
Tertiary alcohol 2.106 was synthesised as previously reported
83 from hept-6-en-1-yn-1-
ylbenzene 2.35a via Pauson-Khand cyclisation to give the cyclopentenone 2.105 and 
cerium  trichloride  assisted  1,2-addition  of  hexylmagnesium  bromide  (Scheme  2.29).   65 
Exposure  of  2.106  to  various  alcohols  in  the  presence  of  catalytic  amounts  of 
camphorsulphonic acid gave a series of analogues 2.107 of 1.7 in which an alkoxy 
group  replaced  the  aniline  substituent.  Yields  for  the  last  step  were  generally  good 
(Table 2.3), the exception being when the alcohol carried an alpha-branch. The products 
2.107 were unstable to silica, so were purified by column chromatography on basic 
grade III alumina. 
Compound  R  Yield / % 
2.107a  OMe  75 
2.107b  OEt  69 
2.107c  OPr  71 
2.107d  O-i-Pr  7 
2.107e  O-n-Bu  68 
2.107f  OCH2CH(Me)(Et)  64 
2.107g  O-n-Pent  62 
2.107h  O-n-Hex  65 
2.107i  O-c-Hex  12 
2.107j  OBn  63 
Table 2.3 Synthesis of 1-alkoxy-3-hexyl-2-phenyl-cis-bicyclo[3.3.0]oct-2-enes. 
 
2.5.  SAR  for  1-alkoxy-cis-bicyclo[3.3.0]oct-2-enes  and  ‘all  carbon’ 
analogues of GSK8470 
The  compounds  2.63a-w,  2.67a-b,  2.69,  2.70,  2.72,  2.73,  2.78  and  2.107a-j  were 
screened  for  activity  against  both  hLRH-1  and  hSF-1  using  FRET-based  peptide 
recruitment assay.
177 Purified bacterial expressed ligand binding domains
75 of human 
LRH-1  or  human  SF-1  were  labelled  with  biotin  and  incubated  with  APC  labelled 
streptavidin (Molecular Probes). Peptides derived from TIF2 amino acids 737-757 (B-
QEPVSPKKKENALLRYLLDKDDTKD-CONH2) for LRH-1, or from DAX-1 amino 
acids 1-23 (B-MAGENHQWQGSILYNMLMSAKQT-CONH2) for SF-1 were labelled 
with  biotin  and  incubated  with  europium  labelled  streptavidin  (Wallac  Inc.).  The 
labelled receptor and peptide were incubated in the presence of various concentrations 
of  test  compound  and  the  associated  complexes  quantified  by  time  resolved 
fluorescence  energy  transfer  (TR-FRET).  The  EC50’s  of  the  test  compounds,  which 
serve as a measure of the binding affinity for the receptor, was estimated from a plot 
using  the  ratio  of  fluorescence  values  collected  at  671  nM  to  fluorescence  values 
collected 618 nM versus concentration of test compound added.    66 
Typically 11 points over certain concentration range were used to construct each dose-
response curve and the EC50 was calculated using the appropriate software. For LRH-1 
6 repeats were carried out, for SF-1 3. Standard deviation (SD) serves as a measure of 
uncertainty of the results. Test compounds that increased the affinity of the receptors for 
the peptide yielded an increase in fluorescent signal which is reported as the relative 
efficacy (RE) at peptide recruitment, which in the absence of a known standard was 
normalized to racemic 2.69-exo for LRH-1 and 2.69-exo-ent-2 for SF-1. 
The data is presented in several tables. Table 2.4 shows the alkoxy-substituted series 
2.107a-j, Table 2.5, Table 2.6 and Table 2.7 show the series 2.63 compounds with 
emphasis of variation at the 1, 2 and 3 positions of the bicyclo[3.3.0]oct-2-ene skeleton 
respectively. Table 2.8 contains the alternative core structures of 2.67 and 2.78. Finally, 
Table  2.9  provides  results  from  compounds  2.69,  2.70,  2.72  and  2.73  with  oxygen 
substitution on the cyclopentane ring.
177  
O
H
2.107a-j
Ph R
 
LRH-1  SF-1 
Compound  R  pEC50 
(±SD) 
RE (±SD) 
pEC50 
(±SD) 
RE (±SD) 
1.5  –  6.2 (0.07)   0.89  6.8 (0.008)   0.35 
1.7  –  7.5 (0.003)   0.38  7.4 (0.008)   0.70 
2.107a  OMe  ia  ia  ia  ia 
2.107b  OEt  5.6 (0.05)   0.17 (0.02)  6.3 (0.06)   0.50 (0.02) 
2.107c  OPr  5.6 (0.10)   0.21 (0.04)  6.7 (0.04)   0.62 (0.02) 
2.107d  O-i-Pr  5.5 (0.04)   0.19 (0.03)  6.4 (0.04)   0.46 (0.04) 
2.107e  OBu  5.3 (0.05)   0.39 (0.03)  6.6 (0.07)  0.60 (0.03) 
2.107f  OCH2CH(Me)(Et)  5.6 (0.06)   0.18 (0.03)  6.7 (0.06)  0.52 (0.02) 
2.107g  OPent  ia  ia  6.4 (0.08)   0.40 (0.02) 
2.107h  O-n-Hex  ia  ia  ia  ia 
2.107i  O-c-Hex  6.1 (0.03)   0.16 (0.02)  7.1 (0.05)  0.63 (0.006) 
2.107j  OBn  ia  ia  ia  ia 
Table 2.4 LRH-1 and SF-1 binding and activation of alkoxy substituted series 2.107.   67 
Pleasingly,  it  was  found  that  many  of  the  alkoxy-substituted  analogues  were active 
against  both  LRH-1  and  SF-1  showing  that  the  nitrogen  in  the  aniline  series  1.6 
(exemplified by 1.5 and 1.7) was not necessary. All the compounds bound substantially 
less strongly to LRH-1 (pEC50 are ranging from 5.3 to 6.1), and induce less recruitment 
of peptide (RE from 0.16 to 0.39), than the aniline series (pEC50 = 7.5 and RE = 0.38 for 
1.7)  suggesting  that  an  aromatic  group  is  preferred  by  LRH-1  in  this  region. 
Unfortunately it was not possible to make the OPh substituted system – it was too 
unstable, both because phenoxide is a much better leaving group than alkoxides, but 
also because phenol will act as an acid catalyst for decomposition. The compounds 
showed reasonable selectivity for SF-1, with binding approaching (pEC50 = 6.3 ÷ 7.1), 
and efficacy exceeding (RE = 0.40 ÷ 0.63) that of the currently most used biological 
tool 1.5 (pEC50 = 6.8 and RE = 0.35). For both LRH-1 and SF-1 was found a clear SAR 
relating to the size of the R group with both small groups (Me) and large groups giving 
compounds which bound weakly (pEC50 < 5.0). The cut-off for large chains is sharp 
indicating a defined pocket being filled. For LRH-1 this is above four carbons long 
(cyclohexyl, CH2CH(Me)(Et), and n-butyl all fit, n-pentyl does not. For SF-1 the pocket 
appears slightly larger with n-pentyl fitting, but n-hexyl not. Similar trend was observed 
with aniline series 1.6, where compounds with NPh bound strongly (pEC50 > 6.0) and 
were active (RE = 0.50 ÷ 1.0), whereas compounds with 3- or 4-substitution on the NAr 
ring gave reduced binding (pEC50 < 5.0) or inactive compounds.
83  
Although the alkoxy-substituted series provided a candidate for one of the key-aims – 
the SF-1 selective compound 2.107g, the compounds proved as acid sensitive as the 
aniline series. For example they decomposed on attempted chromatography on silica, or 
if stored in glassware which had not been base washed.  
Due to acid instability of series 2.107, compound 2.63a was examined as it has similar 
cis-bicyclo[3.3.0]oct-2-ene  structure  but  lacking  the  cause  of  acid  instability  –  the 
bridgehead  leaving  group.  Delightfully  it  was  found  to  exhibit  good  binding  and 
activation of both LRH-1 and SF-1 (Table 2.5). 
 
 
 
 
 
   68 
R Ph
H
2.63a-l  
LRH1 (RE)  SF1 (RE)  Compound  R 
pEC50 (±SD)  RE (±SD)  pEC50 (±SD)  RE (±SD) 
2.63a  Ph  6.6 (0.06)  0.24 (0.05)  7.2 (0.02)  0.82 (0.06) 
2.63b  3-MeOPh  6.5 (0.05)  0.25 (0.04)  7.2 (0.1)  0.27 (0.008) 
2.63c  4-MeOPh  ia  ia  ia  ia 
2.63d  4-MePh  5.7 (0.12)  0.25 (0.02)  6.8 (0.05)  0.28 (0.004) 
2.63e  4-EtPh  ia  ia  ia  ia 
2.63f  4-n-BuPh  ia  ia  ia  ia 
2.63g  4-t-BuPh  ia  ia  ia  ia 
2.63h  4-PhPh  ia  ia  ia  ia 
2.63i  n-Pr  5.5 (0.17)  0.23 (0.04)  6.8 (0.02)  0.63 (0.02) 
2.63j  n-Bu  ia  ia  6.7 (0.07)  0.70 (0.03) 
2.63k  n-Hex  ia  ia  ia  ia 
2.63l  n-Oct  ia  ia  ia  ia 
Table 2.5 Variation of bridgehead substituent in series 2.63 compounds. 
 
Variation of the lithiated alkyne used in the multi-component synthesis of 2.63 allowed 
variation of the bridgehead substituent (Table 2.5). As with the series 2.107 compounds, 
a strict cut-off in the size of group R which can be accommodated is observed. Even 
addition of a para-methyl group to the preferred phenyl substituent decreased binding 
2.63d, and anything larger 2.63e-h gave inactive compounds. Interestingly a 3-MeO 
group was well tolerated perhaps indicating some stabilisation via dipolar interactions 
or weak H-bonding, whereas a 4-OMe substitution gave an inactive compound (2.63c). 
When R is an alkyl group 2.63i-l LRH-1 binds only the shortest tried 2.63i (R = n-Pr), 
and then with low pEC50 and efficacy. Even compound 2.63j with R = n-Bu is inactive, 
and since this is little longer that R = Ph indicates a strong preference for an aryl group. 
SF-1 bound the R= n-Bu compound 2.63j strongly and with good efficacy confirming 
the larger pocket noted in the SAR of series 2.107, and providing an excellent SF-1 
selective  analogue.  Compounds  with  the  longer  chain  R  =  n-Hex,  n-Oct;  2.63k,l 
respectively, were inactive.   69 
Ph R
H
2.63a, m-s  
LRH1 (RE)  SF1 (RE) 
Compound  R 
pEC50 (±SD)  RE (±SD)  pEC50 (±SD)  RE (±SD) 
2.63a  Ph  6.6 (0.06)  0.24 (0.05)  7.2 (0.02)  0.82 (0.06) 
2.63m  3-MeOPh  6.6 (0.02)  0.23  6.9 (0.02)  0.40 
2.63n  4-EtPh  ia  ia  ia  ia 
2.63o  n-Pr  ia  ia  6.4 (0.02)  0.52 (0.11) 
2.63p  n-Bu  ia  ia  6.6 (0.08)  0.57 (0.03) 
2.63q  n-Hex  ia  ia  ia  ia 
2.63r  c-Hex  ia  ia  6.7 (0.05)  0.56 (0.04) 
2.63s  (CH2)3OH  6.0 (0.04)  0.38 (0.05)  ia  ia 
Table 2.6 Variation of 2-substituent in series 2.63 compounds. 
 
Changing the 1,6-enyne starting material allowed the structure activity relationship due 
to variation of the substituent on position 2 of the bicyclo[3.3.0]oct-2-ene to be probed 
(Table 2.6). The tight constraints, and apparent preference for aryl groups of the LRH-1 
binding site are again apparent. Although a 3-methoxy-phenyl group 2.63m is tolerated, 
4-ethylphenyl 2.63n is not, and surprisingly none of R = n-Pr, n-Bu, or c-Hex 2.63o,p,r, 
all similar sizes to a phenyl group, gave active compounds. SF-1 proved much more 
accommodating, consistent with the larger ligand binding pocket, although compounds 
with 4-ethyl-phenyl 2.63n or n-Hex, 2.63q, substituents were not active. n-Pr, n-Bu and 
c-Hex substituted compounds 2.63o,p,r all gave similar binding and efficacy with SF-1, 
but distinctly poorer than compound 2.63a (R = Ph). Remarkably, the 3-hydroxypropyl 
subsistent in 2.63s gave good binding and activation of LRH-1, but is inactive against 
SF-1 providing the only example of a highly LRH-1 selective compound. It is believed 
that the hydroxyl group may be picking up binding to the polar area at the entrance to 
the ligand binding pocket where the phosphate portion of phospholipids is found in 
crystal structures of LRH-1. The inactivity of 2.63s indicates this to be a very non-polar 
area in SF-1.    70 
Ph
Ph
R
H
2.63a, t-w  
LRH1 (RE)  SF1 (RE) 
Compound  R 
pEC50 (±SD)  RE (±SD)  pEC50 (±SD)  RE (±SD) 
2.63a  Ph  6.6 (0.06)  0.24 (0.05)  7.2 (0.02)  0.82 (0.06) 
2.63t  H  ia  ia  ia  ia 
2.63u  n-Bu  6.7 (0.02)  0.54 (0.05)  7.4 (0.03)  0.85 (0.01) 
2.63v  n-Oct  5.8 (0.16)  0.15 (0.02)  6.8 (0.07)  0.65 (0.04) 
2.63w  SiMe2Ph  6.8 (0.05)  0.54 (0.05)  7.2 (0.04)  0.33 (0.002) 
Table 2.7 Variation of 3-substituent in series 2.63 compounds. 
 
Using alternative dihalocarbenoids in the formation of 2.63 allowed the biological effect 
of some variation in the 3-substituent (Table 2.7). Reducing it to a hydrogen, gave an 
inactive compound against both receptors indicating that the ligand binding pocket does 
need to be filled for binding/activity. Shortening the n-hexyl 2.63a substituent to n-butyl 
2.63u gave a substantial increase in efficacy for LRH-1 without affecting SF-1.  
The bulky SiMe2Ph substituent gave a substantial increase in efficacy for LRH-1, and a 
significant  decrease  in  efficacy  for  SF-1.  An  n-octyl  chain  gave  some  reduction  in 
binding and efficacy, particularly for LRH-1. 
RN
Ph Ph
H
Ph Ph
H
2.67a, R = Me
2.67b, R = Bn
2.78
 
LRH1 (RE)  SF1 (RE) 
Compound 
pEC50 (±SD)  RE (±SD)  pEC50 (±SD)  RE (±SD) 
2.63a  6.6 (0.06)  0.24 (0.05)  7.2 (0.02)  0.82 (0.06) 
2.78  6.6 (0.05)  0.24 (0.04)  7.2 (0.05)  0.40 (0.004) 
2.67a  5.9 (0.03)  0.20 (0.03)  6.5 (0.11)  0.49 (0.02) 
2.67b  ia  ia  ia  ia 
Table 2.8 Effect of variations in skeleton on biological activity. 
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Variation  in  the  core  skeleton  was  also  considered  (Table  2.8).  The  only  effect  of 
changing the fused saturated ring from cyclopentane (in 2.63a) to cyclohexane (in 2.78) 
was reduced efficacy against SF-1. The pyrrolidine fused systems 2.67a,b offered the 
potential of improved solubility. The N-methyl compound 2.67a was active against both 
receptors,  although  with  reduced  binding  and  efficacy,  particularly  against  LRH-1. 
Given the improved solubility characteristic of 2.67a c.f. the hydrocarbons 2.63 it is a 
useful SF-1 selective compound. 
Ph Ph
H
RO
2.72, R = H
2.73, R = OAc
Ph Ph
H RO
2.69, R = H
2.70, R = OAc  
Table 2.9 Effect of oxygen substitution on the cyclopentane ring. 
 
Finally  some  analogues  with  oxygen  substitution  of  the  cyclopentane  ring  were 
examined (Table 2.9). The choice was driven by the crystal structure of LRH-1
75 which 
indicated  a  polar  patch  (Arg-393  and  His-390)  in  the  generally  hydrophobic  ligand 
binding site. 
Pleasingly it was found that the compound with a 6-exo-hydroxy substituent (2.69-exo) 
was the most active of all the compounds tested – both in binding and efficacy against 
both LRH-1 and SF-1.  
LRH1 (RE)  SF1 (RE) 
Compound 
pEC50 (±SD)  RE (±SD)  pEC50 (±SD)  RE (±SD) 
2.63a  6.6 (0.06)  0.24 (0.05)  7.2 (0.02)  0.82 (0.06) 
2.69-exo (racemic)  6.6 (0.05)  1.0 (0.05)  7.5 (0.10)  0.94 (0.05) 
2.69-exo-ent-1  6.6 (0.02)  0.29 (0.04)  7.6 (0.04)  0.99 (0.03) 
2.69-exo-ent-2  6.7 (0.19)  0.88 (0.06)  7.5 (0.21)  1.0 (0.10) 
2.69-endo  6.4 (0.08)  0.68 (0.03)  7.2 (0.06)  0.74 (0.005) 
2.70-exo  6.4 (0.09)  0.18 (0.03)  6.4 (0.01)  0.18 (0.007) 
2.70-endo  6.6 (0.06)  0.18 (0.04)  7.0 (0.03)  0.25 (0.008) 
2.72-exo  6.0 (0.07)  0.53 (0.06)  6.6 (0.07)  0.45 (0.02) 
2.72-endo  5.8 (0.04)  0.32 (0.03)  6.5 (0.05)  0.87 (0.007) 
2.73-exo  ia  ia  ia  ia 
2.73-endo  6.3 (0.09)  0.13 (0.01)  6.7 (0.04)  0.32 (0.02)   72 
The strong activity provided an incentive to separately test the two enantiomers of 2.69-
exo, and surprisingly it turned out that both enantiomers have equal binding to both 
LRH-1 and SF-1. Indeed the only difference between them was the substantially greater 
efficacy  of  ent-2  c.f.  ent-1  with  LRH-1.  It  is  usual  for  only  one  enantiomer  of  a 
compound to be active against a particular receptor, and particularly surprising in this 
case  when  such  strong  SAR  effects  against  small  changes  in  structure  has  been 
observed. The endo-epimer of 2.69 showed very similar binding and efficacy against 
both receptors as compound 2.63a lacking the oxygen substitution. Acylation of the 
alcohol  had  little  effect  on  binding  (Table  2.9,  entries  6  vs  2  and  7  vs  5),  but 
substantially reduced efficacy, with the exception of 2.70-exo where binding to SF-1 
was  reduced,  incidentally  providing  one  of  the  most  ‘LRH-1  selective’  compounds 
produced.  
The 7-hydroxyl substituted systems 2.72-exo and 2.72-endo showed reduced binding 
compared  to  the  unsubstituted  analogue  2.63a,  though  efficacies  were  reasonable. 
Acylation of the exo-alcohol gave inactive compound 2.73-exo against both LRH-1 and 
SF-1 (entry 10) indicating a size limitation of this part of the binding pocket. Acylation 
of the endo alcohol to give 2.73-endo (entry 11) was well tolerated. 
 
Agonist/antagonist crossover 
For most compounds the biological results were clear – excellent agreement between 
the repeats, with nicely sigmoidal curves for active compounds (at least when EC50 >6) 
and inactive compounds showing no response. However, in a few cases variable results 
were obtained which might be attributed to agonist/antagonist crossover. For LRH-1 
this is best illustrated by the curves for the N-benzyl pyrrolidine 2.67b (Figure 2.2). In 
this case three runs showed agonist activity with a  pEC50 of 6.5,  but another  three 
showed what may be interpreted as antagonist activity, with around the same binding 
constant. Similar behaviour, but with 4 agonist and 2 antagonist lines were observed for 
2.63m and 2.72-endo (pEC50 6.6 and 5.8 respectively). Since the protein used for assay 
is known to contain phospholipids, and some of these are known agonists for LRH-1 it 
is possible that 2.67b has stronger binding, but lower efficacy than the natural ligand. If 
the amount or type of phospholipids varied between experiments it is possible to get the 
apparent  agonist/antagonist  crossover  behaviour  observed.  Against  SF-1  the 
agonist/antagonist behaviour was observed in two compounds – the exo-acetates 2.70-
exo and 2.73-exo. In the former case 2/3 curves showed agonist activity (as in Table   73 
2.9), the other antagonist (~same pEC50 and RE of –0.2); in the later 1/3 curves was 
agonist (pEC50 6.8, RE 0.2) and 2/3 antagonist (pEC50 6.8, RE –0.2). In addition two 
compounds (2.63n and 2.63s) showed quite convincing antagonist activity (sigmoidal 
curves showing negative response) with pEC50’s of ~6.5.    
 
Figure 2.2 Agonist/antagonist crossover for 2.67b. 
 
Comparison of efficacy and binding 
It is notable that with both receptors examined the maximum activation (RE) varied 
widely. Ploting the RE against the pEC50 for all the ‘all carbon’ systems for LRH-1 and 
SF-1 (Figure 2.3) demonstrates the modest correlation between the two, particularly for 
LRH-1.  In  particular  there  are  groups  of  compounds  with  strong  binding,  but  poor 
efficacy, providing indications of how agonists can be developed. 
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Figure 2.3 Comparison of efficacy and binding.   74 
Choice of compounds recommend as biological probes 
Compound  2.69-exo  provides  an  excellent  replacement  for  compound  1.5  as  a 
biological  tool. It  has excellent  stability, reasonable  solubility in polar  solvents and 
improved binding and efficacy against both LRH-1 and SF-1. Little is lost by using the 
1.6  :  1  mixture  of  2.69-exo  and  2.69-endo  produced  directly  from  the  zirconium 
mediated reaction thus avoiding a tricky separation. Compound 2.63j provides the best 
tool  for  selective  activation  of  SF-1  (with  2.63o,p,r  also  being  good).  Its  main 
disadvantage  is  its  non-polar  nature  which  may  cause  solubility  problems  in  polar 
solvents, in which case pyrrolidine 2.67a provides reasonable selectivity and may be 
preferred.  
 
2.6.  Conclusions for chapter 2 
Substrate  scoping  studies  for  the  one-pot  tandem  reaction  sequence  on  zirconocene 
template resulted in synthesis of a wide range of bicyclic compounds containing rigid 
cis-bicyclo[3.3.0]oct-2-ene  skeleton.  The  final  compounds  were  obtained  in  yields 
ranging  from  good  to  very  good.  For  sterically  encumbered  zirconacycles  (or 
carbenoids), the undesired ￿-hydride elimination process was observed. Nonetheless, 
the one-pot tandem reaction sequence provides an excellent method for construction of 
bicyclic compounds and potential for functionalisation at multiple sites. Such obtained 
compounds were tested for biological activity in search for active and selective agonists 
and  antagonists  for  orphan  nuclear  receptors:  hLRH-1  and  hSF-1.  Pleasantly, 
improvement in binding, efficacy, selectivity and acid stability in the case of certain 
compounds was observed in comparison with the previously reported 1-aryl amino cis-
bicyclo[3.3.0]oct-2-enes.  
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Chapter 3.  Dihalocarbenoid  and  acetylide  insertion  into 
saturated zirconacyclopentanes 
3.1.  Introduction to research area 
3.1.1.  Zirconocene mediated co-cyclisation of dienes 
A wide range of 1,n-dienes can be cyclised with the Negishi reagent to afford saturated 
zirconacycles. Extensive research in this area is well described in literature
122,116,178,179 
The great range of dienes containing heteroatoms, available for co-cyclisation has led to 
a  number  of  heterocycles  being  synthesised  by  this  method.
180  Also  zirconocene 
mediated  co-cyclisation of  dienes  has  been applied  to  the  total  synthesis  of  natural 
products.
181 
 
3.1.2.  Elaboration of zirconacyclopentanes 
There  are  several  well  established  methods  in  which  zirconacyclopentanes  can  be 
further  elaborated  to  give  useful  organic  products.  Similarly  to  unsaturated 
zirconacycles, zirconacyclopentanes can be protonated, halogenated,
111 transmetallated 
to Cu
182 and Mg.
102,183 They also undergo metathesis with main group elements,
121,123 
carbon  monoxide,
116,117  isonitrile
184  and  carbenoid
118  insertion.  The  latter  method  is 
more relevant to research described in this section and therefore will be reviewed in 
more detail. 
 
3.1.2.1.  Allyl and methylallyl carbenoid insertion into saturated zirconacycles 
Insertion of lithium chloroallylide and chloromethylallylide into zirconacyclopentanes 
has been extensively investigated by Whitby and co-workers. (Scheme 3.1).
138,185 
Insertion of lithiated allyl chloride 1.76 into saturated zirconacycle 3.0 affords the 18-
electron allyl-zirconocene complex 3.1. Protonolysis of this complex with acetic acid 
gives excellent control of the double bond geometry in product 3.2.  
The one-pot tandem reaction sequence on zirconocene allows a great deal of diversity in 
terms of diene, carbenoid and electrophile variability. The allyl-Zr complex 3.1 was 
found to react with a broad spectrum of electrophiles yielding the products shown in 
Scheme  3.1.
139  Lewis  acid  promoted  insertion  of  aldehydes,  acetals,  and  additional 
iminium  ions  provides  the  corresponding  alcohols  3.3,  ethers  3.4  and  amines  3.5, 
though without significant diastereoselectivity. For insertion of ketones longer reaction 
times and higher temperatures were required to obtain tertiary alcohols 3.7.   76 
ZrCp2
OH
H
H
H
3.3
3.1
3.2
(ii) (iii), (iv)
Reagents and Conditions: (i) CH2CHCH2Cl, LDA or LiTMP, -78 oC, 0.5 h; (ii) MeOH
or AcOH, 16 h; (iii) 1.1 eq RCHO, 1.1 eq BF3·Et2O, -40 oC to RT, 3 h; (iv)  MeOH, aq 
NaHCO3, RT, 12 h; (v) RCH(OEt)2, BF3·Et2O, -78 oC to RT, 2 h; (vi) for a: 1.3 eq
(CH2NR2)I, -78 oC to RT, 1.5 h; for b, c: 1.5 eq RCH(NR1
2)(OBu), 1.5 eq BF3·Et2O,
-78 oC to RT, 2 h; (vii) 2.0 eq 1,3-dithenium-tetrafluoroborate, -78 oC to RT, 1.5 h;
(viii) for a: Me2CO, benzene, 80 oC, 48 h; for b, c: Ph2CO, cyclohexanone, toluene,
110 oC, 48 h.
MeOH, E:Z, 70:30, 94%
AcOH, E:Z, >98:2, 75%
R
H
H H
NR1
2
H
3.5
H
OEt
H
3.4
H
OH
H
3.7
H
R
R
R1
R
3.3      R                      Yield, %   d.r.
a.       Ph                       90           2.9:1 
b.      2,4-(MeO)C6H3    60           3.1:1    
c.      CHMe2                 90           1.3:1
d.      (CH2)2Me             95           1.5:1
a. R = H, R1 = Me, 89%
b. R = Ph, R1 = -(CH2)5-, 95%
c. R = 4-Cl-C6H4, R1 = Me, 92%
a. R = Me, 73%
b. R = Et, 61%
c. R = CH=CH2, 64%
d. R = CH=CHPr, 76%
e. R = CH=CHCH=CHMe, 84%
f.  R = OEt, 71%
H
3.6, 70%
H
S
S
a. R = R1 = Me, 54%
b. R = R1 = Ph, 57%
c. R = R1 = -(CH2)5-, 56%
(v), (iv)
(vii), (iv)
(vi), (iv)
(viii), (iv)
H 3.0
H
ZrCp2
(i)
 
Scheme 3.1 Diversity of allyl zirconocene complexes elaboration. 
 
Variations of allyl carbenoid in terms of leaving group and substitution have also been 
investigated.
137 
 
3.1.2.2.  Insertion of 1-halo-1-lithioalkanes into zirconacyclopentanes 
Alkyl  carbenoid  insertion  into  a  wide  range  of  zirconacyclopentanes  has  also  been 
investigated.
133,186 
Carbenoids  with  electron-donating  and  electron-withdrawing  groups  were  found  to 
insert into bicyclic and monocyclic unsubstituted zirconacyclopentanes (Scheme 3.2).   77 
Reagents and Conditions: (i) LiTMP or LDA, -78 oC; 
(ii)  MeOH, aq NaHCO3, RT, 12 h.
ZrCp2
R
R
H
H
R
R
H
H
ZrCp2
R1
R
R
H
H
R1
(i)
(ii)
3.8 3.9 3.10
Cl R1
ZrCp2
ZrCp2
R1
(i)
(ii)
3.11 3.12
Cl R1 R1
3.13
 
Scheme 3.2 Insertion of  alkyl carbenoids into zirconacyclopentanes. 
 
Entry  Zirconacycle/ R, R  Carbenoid/ R
1  Yields of 3.10, 3.13/ % 
a  3.8a/ -CH2OCMe2OCH2-  1.107/ SiMe3,   78 
b  3.8a/ -CH2OCMe2OCH2-  3.14/ SiMe2Ph  77 
c  3.8b/ -CH2OMe, -CH2OMe  3.14/ SiMe2Ph  70 
d  3.8b/ -CH2OMe, -CH2OMe  3.15/ SnBu3  11 
e  3.8a/ -CH2OCMe2OCH2-  3.16/ SPh  77 
f  3.8a/ -CH2OCMe2OCH2-  3.17/ OEt  45 
g  3.8b/ -CH2OMe, -CH2OMe  1.117/ P(O)(OEt)2  74 
h  3.8b/ -CH2OMe, -CH2OMe  1.92/ CN  24 
i  3.8b/ -CH2OMe, -CH2OMe  1.95/ SO2Ph  67 
j  3.11  1.117/ P(O)(OEt)2  56 
Table 3.1 Yields of 3.10 and 3.13 from insertion o various carbenoids into zirconacycles 3.8a, b and  
3.11. 
 
Insertion of alkyl carbenoids into zirconacycles 3.8a,b and 3.11 occurred successfully in 
many cases to provide the corresponding products, apart from a few cases, in very good 
yields (Table 3.1). In all but one case products of monoinsertion were obtained. The low 
yields of products 3.10d,f and h are related to the peculiar reactivity of the carbenoids 
used  in  these  reactions.  The  a-stannyl  carbenoid  3.15  is  suspected  to  undergo 
tin/lithium exchange very quickly, the a-ethoxy carbenoid 3.17 is thermally unstable 
and  the  complex  3.9f  decomposes  above  –20 
oC,  whereas  insertion  of  lithiated 
chloroacetonitrile  1.92  resulted  in  bisinsertion  product  to  be  the  major  (45%)  and 
monoinsertion product 3.10h to be the minor (24%).
133  
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3.1.2.3.  Insertion of 1,1-dihalo-1-lithioalkanes into zirconacyclopentanes 
A special case of insertion of a dihalocarbenoid into an organozirconium system 3.8a 
was reported in 1999,
145 where the zirconacycle ring expansion was followed by a ring 
closure with loss of a second halide (Scheme 3.3). In this example, the 1,2-metallate 
rearrangement
134,136  to  afford  zirconacyclohexane  3.19  is  followed  by  dyotropic 
rearrangement
187-189  to  form  the  bicyclo-Zr  complex  3.20,  which  after  protonolysis 
provides the bicyclo[3.3.0]octane system 3.21. If the intermediate 3.20 with R = n-Pr 
was warmed to RT before quench, dehydrozirconation process occurred to give solely 
product  3.22  (Scheme  3.3).
145  Very  poor  yields  were  obtained  for  insertion  of 
dichloromethane, but reasonable in other cases. 
Reagents and Conditions: (i) Cp2ZrCl2, n-BuLi, THF, -78  oC to RT, 2 h; (ii) 1.5 eq
RCHX2, 1.7 eq LDA, -78  oC to -55  oC over 2 h; (iii)  MeOH, aq NaHCO3, -78  oC 
to RT, 16 h; (iv) -78  oC to RT, then MeOH, aq NaHCO3, 16 h.
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b.     n-Pr        
c.     OMe        
d.     SiMe2Ph 
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Li+
-LiCl
Yield (%)
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66
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71
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Scheme 3.3 Carbocycles synthesis via insertion of dihalocarbenoids into zirconacyclopentane. 
 
3.2.  Construction of bicyclo[3.3.0]octanes via insertion of 1,1-dihalo-
1-lithio species and lithium acetylides into zirconacyclopentanes 
The following section discusses further work in the area of dihalocarbenoid insertion 
into  zirconacyclopentanes.  Alkyl  carbenoid  and  acetylide  insertion  into  a  range  of 
zirconacyclopentanes has been investigated. The reaction sequence worked well in the 
case of unsubstituted dienes to provide the corresponding products of three-component 
coupling on a zirconocene template in reasonable yields. The main limitation of this 
method  has  arisen  from  the  ￿-hydride  elimination  process  observed  in  the  case  of 
sterically encumbered zirconacycles.    79 
3.2.1.  Preparation of cyclisation precursors 
4,4-Bis(methoxymethyl)hepta-1,6-diene  3.23,  (Z)-4,4-bis(methoxymethyl)nona-1,6-
diene  3.24  and  N-allyl-N-benzyl-2-methylprop-2-en-1-amine  3.25  (Figure  3.1)  were 
prepared from commercially available starting materials using literature methods and 
had spectral  properties consistent with those included in  the  thesis of former  group 
members or literature.
132 
O
O
3.23
O
O
3.24
BnN
3.25  
Figure 3.1 Dienes for Zr-mediated cyclisation and further elaboration. 
 
3.2.2.  Elaboration  of  zirconacyclopentanes  via  dihalocarbenoid  and  acetylide 
insertion 
 
3.2.2.1  Insertion  of  alkyl  carbenoids  and  acetylides  into  a-unsubstituted 
zirconacyclopentanes 
Extension  of  the  one-pot  three-component  coupling  of  saturated  zirconacycles, 
dihalocarbenoids and acetylides resulted in synthesis of a series of novel compounds 
containing a bicyclo[3.3.0]octane core (Scheme 3.4).  
Insertion of 1,1-dihalo-1-lithio species 3.26 into zirconacyclopentane 3.8b affords the 
‘ate’  complex  3.27  which  undergoes  1,2-metallate  rearrangement  to  provide  the 
expanded zirconacyclohexane 3.28. Nucleophilic attack of lithium acetylide onto the Zr 
atom  forces  the  second  C-Zr  bond  to  migrate,  thus  to  afford  the  carbobicyclo-Zr 
complex  3.30.  Insertion  of  a  second  equivalent  of  acetylide  affords  the  bisalkynyl-
zirconium species 2.18 (2.18c) through elimination of carbanion 3.32. Subsequent re-
addition of the anion to ￿-carbon of the bisalkynyl-zirconium intermediate 2.18 (2.18c) 
provides the novel zirconium-alkenylidenate complex  3.33 to give the carbobicyclic 
compounds 3.34a-c after quenching (Scheme 3.4).   80 
Y = C(CH2OMe)2
3.26/ R1               R2          Yield (%)
3.26a/ n-Hex       Ph           3.34a, 77
3.26a/ n-Hex       n-Hex      3.34b, 47
3.26b/ SiMe2Ph   Ph           3.34c, 35
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X
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3.31
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3.8b
3.23
3.34
3.33 3.32
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H
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Scheme 3.4 Insertion of dihalocarbenoids and acetylides into zirconacyclopentanes. 
 
Insertion of lithiated 1,1-dibromoheptane 3.26a and acetylide 2.7 into zirconacycle 3.8b 
provided the bicyclic compound 3.34a in good yield. The much lower yield for 3.34b is 
related to use of the acetylide with an aliphatic substituent 2.18b (R
2 = n-Hex) which 
turned  out  to  be  less  reactive  than  the  acetylide  with  an  aromatic  substituent 
(observation consistent with insertion of acetylides in zirconacyclopentenes), therefore 
four equivalents of this reagent were required to obtain the desired product 3.34b in an 
acceptable yield of 47%. Insertion of lithiated (dichloromethyl)dimethyl(phenyl)silane 
3.26b  into  zirconacycle  3.8b  occurred  efficiently,  however,  the  following  phenyl   81 
acetylide insertion turned out to be sluggish and gave the desired compound  3.34c in 
only  35%  yield,  provided  that  the  reaction  mixture  was  warmed  to  –20  °C  before 
quench.  In  this  case  a  higher  temperature  was  required  to  make  the  zirconium-
alkenylidene rearrangement occur (3.32c ￿ 3.33c) since the resulting anion 3.32c is 
stabilized by the adjacent silyl group, therefore the intermediate is less reactive towards 
the  rearrangement.  Additionally,  the  protonated  compounds  3.35a,b  (96  :  4 
respectively) were detected by GC in the crude reaction mixture in nearly equimolar 
amount.  
H
H
O
O
SiMe2Ph
3.35a
H
H
O
O
SiMe2Ph
3.35b  
Figure 3.2 Product of protonation 3.32c. 
 
When the procedure was modified by addition of phenylacetylide previously pre-mixed 
with HMPA to 3.28, and the whole reaction mixture was allowed to warm to –15 °C 
before quenching, the major product obtained in the reaction was compound 3.35a. 
 
Zirconocene mediated co-cyclisation of 1-allyl-2-vinylbenzene 3.36 provided a mixture 
of trans : cis ring junction zirconacycles 3.37a,b in GC ratio of protonated products 82 : 
18,  respectively  (Scheme  3.5).  The  stereochemistries  of  the  ring  junction  of  these 
compounds were assigned by correlation of 
1H NMR shifts of the methyl groups in 
products 3.38a and b with the reported spectra
190 of trans- and cis-1,2-dimethylindans. 
The proton
 NMR shifts of the methyl groups in cis-isomer were shifted upfield: 1.19 
and 1.03 ppm (lit. 1.14, 0.98 ppm) in comparison with the shifts of the methyl groups 
being in trans relationship: 1.36 and 1.26 ppm (lit. 1.28, 1.19 ppm). 
Further  insertion  of  lithiated  1,1-dibromoheptane  3.26a  and  phenyl  acetylide  2.7, 
however, occurred exclusively into the trans ring junction zirconacycle 3.37a to give 
compounds 3.39a,b as an inseparable mixture of two diastereoisomers in the ratio of 1.4 
: 1. The stereochemistry at the quaternary carbon centre has not been assigned. 
It is postulated that steric reasons of the cis ring junction zirconacycle 3.37b inhibited 
the carbenoid and acetylide insertion, therefore the yield of the final products 3.39 is 
diminished (48%).   82 
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(ii) 2M HCl, RT, 20 h; (iii) 1.05 eq n-HexCHBr2, 1.1 eq LDA, -78  oC, 15 min;
(iv) 3.0 eq PhCCLi, -78  oC to -30  oC, 1.5 h; (v)  MeOH, aq NaHCO3, RT, 12 h.
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Scheme 3.5 Insertion of lithiated 1,1-dibromoheptane and phenyl acetylide into zirconacycle 3.37a. 
 
Dienes containing a nitrogen atom were examined next (Scheme 3.6). Co-cyclisation of 
N-allyl-N-benzylprop-2-en-1-amine 3.40a provided a mixture of 3.2 : 1 trans : cis ring 
junction zirconacycles 3.41a (ratio and stereochemistry determined by GC analysis of 
the quenched zirconacycles and comparison with the literature precedent). Literature 
precedent  reports  a  zirconocene  mediated  co-cyclisation  of  this  diene  under  similar 
conditions to give an 4 : 1 mixture of trans : cis ring junction zirconacycles.
116 Further 
insertion of lithiated 1,1-dibromoheptane followed by acetylide addition gave the final 
compound 3.42a in 59% yield and the same ratio of 3.2 : 1, trans : cis ring junction 
diastereoisomers, which were separable by silica gel column chromatography.  
In turn, zirconocene mediated co-cyclisation of N,N-diallylbenzenamine 3.40b provided 
the final compounds 3.42b as a mixture of cis : trans ring junction isomers in the ratio 
of 1.27 : 1 and 70% yield (Scheme 3.6). Nugent and Taber obtained the cis : trans ring 
junction zirconacycles 3.41b in the ratio of 2 : 1.
122 Noteworthy is the fact that both cis 
diastereoisomers of the final product 3.42b were created in GC ratio of 13.75 : 1 with 
respect to the newly formed quarternary carbon centre. The cis, trans stereochemistry of 
the final compounds was determined on the basis of 
13C NMR analysis.  
   83 
For the cis isomer 
13C NMR symmetry was observed therefore the number of signals of 
the core carbons was twofold reduced whereas for the trans isomer all core carbon 
signals were observed. 
Reagents and Conditions: (i) Cp2ZrCl2, n-BuLi, THF, -78  oC to RT, 3 h;
(ii) 1.05 eq n-HexCHBr2, 1.5 eq LiTMP, -78  oC, 20 min; (iii) 3.0 eq PhCCLi, 
-78  oC to -45  oC, 1 h; (iv)  MeOH, aq NaHCO3, RT, 12 h.
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Scheme 3.6 Construction of pyrrolidine-fused carbocycles 3.42. 
 
3.2.2.2  Insertion  of  lithiated  1,1-dibromoheptane  and  phenyl  acetylide  into  a-
substituted zirconacyclopentanes 
In the case of terminally substituted dienes 3.24 and 3.43 the sole products obtained in 
the  one-pot  tandem  reaction  sequence  on  a  zirconocene  template  were  compounds 
resulting from the ￿-hydride elimination (dehydrozirconation) process 3.45a and 3.45b 
(Scheme 3.7). Product 3.45a was obtained as a single (E)-isomer from (Z)-Et substituted 
diene 3.24, whereas product 3.45b was obtained from (E)-Ph substituted diene 3.43 and 
consisted of two (E)- and (Z)-isomers in the ratio of  9 : 1, respectively (Figure 3.3).  
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3.45b. R = Ph, 85%
Reagents and Conditions: (i) Cp2ZrCl2, n-BuLi, THF, -78  oC to RT, 14-15 h; 
(ii) 1.3 eq n-HexCHBr2, 1.5 eq LiTMP, -78  oC, 0.5 h; (iii) 3.0 eq PhCCLi,
-78  oC to -35  oC, (to -15  oC for b); (iv)  MeOH, aq NaHCO3, RT, 16 h.
(i) (ii), (iii), (iv)
 
Scheme 3.7 Insertion of carbenoid and acetylide into a a a a-substituted zirconacyclopentanes 3.44a, b.   84 
The (E)- and (Z)-isomers of 3.45b were identified by means of 
13C NMR shifts of the 
crucial carbon 10 (Figure 3.3) which was shifted upfield in the (E)-isomer by steric 
compression (‘g-gauche effect’),
191 and this isomer appeared to be the major. 
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Figure 3.3 Difference in 
13C NMR shifts between E and Z isomers of 3.45b. 
 
The  ￿-hydride  elimination  was  revealed  to  be  a  very  fast  process  even  at  low 
temperature  (–78  °C  and  lower)  when  carbenoid  insertion  was  followed  by  phenyl 
acetylide addition to give the the intermediate 3.46 (Scheme 3.8). 
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Scheme 3.8 Dehydrozirconation process in complexes 3.46 and 3.48. 
 
The availability of an empty orbital on Zr atom and the steric encumbrance in complex 
3.46 (Figure 3.4) favour the undesired dehydrozirconation process before insertion of 
the  second  equivalent  of  phenyl  acetylide  and  subsequent  1,3-Zr  rearrangement. 
Therefore quick addition or increase in equivalents of the phenyl acetylide did not result 
in its incorporation into the final molecule.   85 
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Figure 3.4 Steric clash in complex 3.46 favours ￿-H elimination. 
 
The same process, however, was observed when the zirconacyclohexane complex 3.47 
was  allowed  to  warm  above  0  °C  (Scheme  3.8).  In  this  case  the  dyotropic 
rearrangement
187-189 to give carbocycle-Zr complex 3.48 is a temperature driven process 
and  the  resulting  species  3.49  is  postulated  to  be  expelled  from  intermediate  3.48 
through ￿-hydride elimination process. 
 
3.2.2.3.  Insertion  of  lithiated  1,1-dibromoheptane  and  phenyl  acetylide  into  ￿-
substituted zirconacyclopentanes 
Zirconocene mediated co-cyclisation of dienes with internally substituted double bonds,  
3.25 and 3.50 gave exclusively cis-fused zirconacycles 3.51a and 3.51b respectively 
(Scheme  3.9).
132  Subsequent  addition  of  carbenoid  3.26a  and  phenyl  acetylide  2.7 
resulted  in  obtaining  a  mixture  of  final  compounds  3.53a,b  and  both  exo-  and 
endocyclic ￿-H elimination products 3.54a,b and 3.55a,b. Product 3.53a was obtained 
in 35% yield and contained 3% by 
13C NMR of the other isomer (at the carbenoid C 
centre). It was assumed, but has not been proven, that the major isomer is the shown exo 
addition product. Simultaneously in this reaction were obtained other products, which 
are deemed to be 3.54a and 3.55a in 44% combined yield, as an inseparable mixture of 
four compounds. 
Product 3.53b was obtained in only 14% overall yield and contained 6% (by 
13C NMR) 
of the other isomer (at the carbenoid C centre). Simultaneously in this reaction were 
obtained products 3.54b and 3.55b in 23% combined yield, as an inseparable mixture of 
four compounds. The residue consisted of product 3.56, derived from protonation of 
zirconacycle  3.51b  (Scheme  3.9).  These  results  suggest  that  the  ￿-substituent  in 
zirconacycles 3.51a and 3.51b clearly has an effect on the reaction by facilitating the ￿-
H abstraction process as well as direction of the nucleophilic attack of the acetylide onto   86 
Zr  atom  in  intermediate  3.52.  It  is  believed  that  the  acetylide  attacks  the 
zirconacyclohexane 3.52 from its exo face, however, the bulky bridgehead substituent 
introduces a steric clash therefore the nucleophilic attack also occurs in small amounts 
from the endo face, to provide an inseparable mixture of diastereoisomers of the final 
products 3.53a,b. The size of the substituent is considered to play a role as for R = Me, 
there was found only 3% of the minor isomer, whereas for R = Ph, the amount was 
increased to 6%. 
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Scheme  3.9  Insertion  of  lithiated  1,1-dibromoheptane  and  phenyl  acetylide  into  ￿-substituted 
zirconacyclopentanes 3.51a and b. 
 
3.2.2.4  Insertion  of  lithiated  1,1-dibromoheptane  and  phenyl  acetylide  into  
zirconacyclopentanes fused to a six-membered ring 
Variation in the ring size of zirconacycles was sought in respect of the multi-component 
coupling  sequence.  Zirconocene  mediated  co-cyclisation  of  1,7-heptadiene  3.57 
provided  six-five fused zirconacycles as a mixture of cis : trans ring junction isomers, 
3.58 in the ratio of 82 : 18 respectively. These zirconacycles were subjected to insertion 
of  lithiated  1,1-dibromoheptane  3.26a  and  further  phenyl  acetylide  2.7  to  provide 
compounds 3.59 as an inseparable mixture of  cis : trans ring junction isomers in the 
ratio of 2 : 1 and 53% combined yield (Scheme 3.10).    87 
The cis, trans stereochemistry of the final compounds was determined on the basis of 
13C NMR analysis. For the cis isomer 
13C NMR symmetry was observed therefore the 
number of signals of the core carbons was twofold reduced whereas for the trans isomer 
splitting of the core carbon signals was observed. Also only one cis isomer was created 
in this reaction.  
An  exocyclic  ￿-H  elimination  was  observed  for  this  system  and  alkene  3.60  was 
obtained as a single cis ring junction isomer in 40% yield. 
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           2:1, 53%
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Reagents and Conditions: (i) Cp2ZrCl2, n-BuLi, THF, -78  oC to RT, 2 h; (ii) 1.3 eq
n-HexCHBr2, 1.5 eq  LDA, -78  oC, 15 min; (iii) 3.0 eq PhCCLi, -78  oC to -50  oC, 
0.5 h; (iv)  MeOH, aq NaHCO3, RT, 16 h.
Scheme 3.10 Coupling of zirconacycle 3.58, carbenoid and phenyl acetylide on zirconocene. 
  
Three component coupling of zirconacycle 3.62, derived from co-cyclisation of 1,2-
diallylbenzene 3.61, lithiated 1,1-dibromoheptane 3.26a and phenyl acetylide 2.7 gave a 
single cis ring-fused product 3.64 in 40% yield (Scheme 3.11). The stereochemistry of 
the product 3.64 was assigned by 
13C NMR analysis which showed 
13C NMR symmetry 
for the core carbons. However, during the co-cyclisation step cis : trans zirconacycles 
3.62  were  formed  in  the  ratio  of  57  :  43  respectively.  According  to  the  literature 
precedent the zirconocene mediated co-cyclisation of 3.61 provided a mixture of cis : 
trans zirconacycles in the ratio of  92 : 8.
133  
An  endocyclic  and  exocyclic  ￿-hydride  elimination  as  well  as  protonation  of  the 
intermediate 3.63b occurred to provide the corresponding compounds 3.65, 3.66 and 
3.67 as an inseparable mixture in 33% combined yield and following GC ratio 65 : 31 : 
4%, respectively. It is postulated that the cis ring junction intermediate 3.63a favours 
the carbenoid and phenyl acetylide insertion to give the final products 3.64, whereas the 
trans ring junction intermediate 3.63b favours ￿-hydride elimination.   88 
Results  obtained  from  insertion  of  lithiated  1,1-dibromoheptane  3.26a  and  phenyl 
acetylide 2.7 into zirconacycles 3.58 and 3.62 are consistent with those obtained from 
insertion  of  lithiated  1,1-dibromoheptane  and  phenyl  acetylide  into  unsaturated 
zirconacycle 2.75, and strongly indicate that the cyclohexane ring fused to zirconacycles 
introduces conformation constraints which somehow favours the ￿-hydride elimination 
process.  
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Scheme 3.11 Cuopling of zirconacycle 3.62, alkyl carbenoid and phenyl acetylide on zirconocene. 
 
3.2.2.5  Insertion of lithiated 1,1-dibromoheptane and phenyl acetylide into tricyclic 
zirconacycles 
Insertion of alkyl carbenoid and phenyl acetylide into tricyclic zirconacycle 3.69 has 
also been probed (Scheme 3.12). The insertion of lithiated 1,1-dibromoheptane occurred 
very  poorly  and  was  followed  by  ￿-hydride  elimination  to  provide  an  inseparable 
mixture of 3 : 1 (by 
13C NMR), E : Z isomers of 3.70 and 9% combined yield, the 
residue being the product of cyclisation 3.71. It remains unclear why the insertion of the 
carbenoid  did  not  work  well;  however,  steric  hindrance  in  the  zirconacycle  3.69  is 
postulated to greatly inhibit the carbenoid insertion.   89 
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Reagents and Conditions: (i) Cp2ZrCl2, n-BuLi, THF, -78  oC to RT, 2 h; (ii) 1.1 eq 
n-HexCHBr2, 1.15 eq LiTMP, -90 oC to -78  oC, 20 min; (iii) 3.0 eq PhCCLi,
-78  oC to RT, 2 h; (iv)  MeOH, aq NaHCO3, RT, 16 h.
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Scheme 3.12 Insertion of lithiated 1,1-dibromoheptane and acetylide 2.7 into tricyclic zirconacycle. 
 
3.2.2.6  Insertion  of  lithiated  1,1-dichloromethane  and  phenyl  acetylide  into 
zirconacyclopentane 
The  unusual  reactivity  of  lithiated  dichloromethane  3.26c  towards  insertion  into 
zirconacycle 3.8b was observed (Scheme 3.13).  
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Scheme 3.13 Insertion of lithiated dichloromethane and phenyl acetylide into zirconacycle 3.8b.   90 
The initial ‘ate’ complex 3.72, created by insertion of lithiated dichloromethane 3.26c 
into saturated zirconacycle 3.8b, and subsequent 1,2-metallate rearrangement provides 
the ring expanded zirconacyclohexane 3.73, which undergoes second insertion of the 
lithium  carbenoid  and  ring  closure  to  provide  the  carbobicyclo-Zr  complex  3.75. 
Addition  of  phenyl  acetylide  causes  a  second  1,2-metallate  rearrangement  to  occur, 
therefore the second molecule of the carbenoid is incorporated into the bicycle to give 
the intermediate 3.77. Further acetylide insertion allows for incorporation of the alkynyl 
moiety into the molecule to provide intermediate 3.79, which after protonolysis gives 
three  products:  3.80a,b  and  3.81  as  an  inseparable  mixture  of  compounds  in  10% 
combined yield and following ratio: 3.80a/b : 3.80b/a, 1.8 : 1 and 3.80 : 3.81, 1 : 2 by 
NMR.  Despite  considerable  optimization  undertaken,  the  reaction  proved  to  be  low 
yielding and the purification of the final product difficult due to many unidentifiable 
products.  
 
3.3.  Conclusions for chapter 3 
The  one-pot  three  component  coupling  on  zirconocene  template  was  probed  for 
construction of bicyclo[3.3.0]- and bicyclo[4.3.0]nonanes as well as tricyclic structures. 
Various saturated zirconacycles were examined for carbenoid insertion and subsequent 
1,3-Zr  rearrangement.  The  examined  method  was  successful  for  unsubstituted 
zirconacycles  and  the  expected  carbobicycles  were  obtained  in  reasonable  yields. 
However,  ￿-H  elimination  was  the  main  limitation  of  the  method  and  occurred 
exclusively  in  the  case  of  a-substituted  zirconacycles  to  provide  the  corresponding 
alkenes.  The  undesired  dehydrozirconation  process  was  also  competitive  with  the 
acetylide  driven  1,3-Zr  rearrangement  in  ￿-substituted  zirconacycles.  Insertion  of 
dihalocarbenoid into tricyclic zirconacycle was very low yielding, and such obtained 
expanded zirconacycle was subjected to immediate ￿-H elimination process. Lithiated 
dichloromethane  performed  multiple  insertion  into  saturated  zirconacycle  to  provide 
interesting bicyclic compounds, albeit in low yield. 
 
 
 
   91 
Chapter 4. Insertion of allenyl and propargyl carbenoids into 
acyclic organozirconium bonds 
4.1.  Introduction to research area 
Acyclic organochlorozirconocenes can be prepared via hydrozirconation of alkenes and 
alkynes with the Schwartz reagent 1.10 and are very useful class of transition metal 
derivatives  for  use  in  organic  synthesis.
192  Hydrozirconation  of  unsaturated  organic 
molecules is very easy to perform with no need for any special glove-box techniques. 
The insertion of C,C-double and -triple bonds into Zr-H bond (hydrozirconation) occurs 
via  a  four-atom,  concerted  transition  state  4.4  (Scheme  4.1)  which  is  formally 
symmetry-allowed due to the vacant d-orbitals on Zr atom.
193,194 The final outcome of 
this process is a hydrometallation product 4.3 obtained by cis-addition of zirconium and 
hydrogen across the double or triple bond. 
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Scheme 4.1 Hydrozirconation of alkenes/alkynes. 
 
Organochlorozirconocenes react with electrophiles such as halogens, acid chlorides and 
aldehydes  to  afford  the  corresponding  organic  halides,  ketones  and  alcohols.
93,195 
Insertion  of  carbon  monoxide  affords  the  acylzirconocene  chlorides  which  can  be 
converted into aldehydes, carboxylic acids, esters and acyl bromides by treatment with 
dilute HCl, NaOH/H2O2, Br2/MeOH and NBS, respectively.
94 Insertion of isonitriles 
into alkyl- and alkenylzirconocene chlorides and subsequent treatment of the resulting 
iminoacyl complex with dilute acid provides a reliable route of aldehyde synthesis from 
corresponding alkenes and alkynes with one-carbon homologation.
196  
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In spite of the substantial polarization of the zirconium-carbon bond, the organometallic 
chemistry of zirconocenes would be limited as a consequence of the steric shielding 
effect  of  the  cyclopentadienyl  ligands;  therefore,  much  of  the  development  of  this 
chemistry  has  focused  on  indirect  carbon-carbon  bond  forming  reactions  through 
transmetallation  to  other  metals  and  further  elaborations.  This  chemistry  has  been 
reviewed in depth by Wipf.
194  
An emerging field in this chemistry is the use of zirconium complexes in asymmetric 
and diastereocontrolled transformations. Hydrozirconation can also be a fundamental 
step  in  multicomponent  reactions  allowing  to  access  many  useful  organic  products. 
Representative example from Floreancig’s work
197 related to multicomponent synthesis 
of ‘oxidized’ amides through nitrile hydrozirconation is shown in Scheme 4.2. 
Reagents and Conditions: (i) Cp2Zr(H)Cl, CH2Cl2, RT, 10 min; (ii) 0 oC, 1.5 eq 4.7, 
10 min; (iii) 20 eq MeOH.
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Scheme 4.2 Multicomponent approach to amide synthesis through nitrile hydrozirconation. 
 
A  particulary  interesting  method  for  elaboration  of  organochlorozirconocenes  is  the 
insertion of a wide range of carbenoids. The first insertion of carbenoids into an acyclic 
C-Zr  bond  was  reported  by  Negishi,
134  and  concerned  the  insertion  of  ￿-  and  ￿-
haloorganolithiums into acyclic organozirconocene derivates to give a good yield of the 
corresponding alkene 4.16 and allene 4.14 on acid quench ( Scheme 4.3). 
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Reagents and Conditions: (i)  THF, -78  oC; (ii) HCl.
 Scheme 4.3 First insertion of lithium carbenoids into acyclic zirconocene systems.   93 
Kasatkin and Whitby have extended the existing methodology by insertion of a wide 
range of carbenoids into acyclic organozirconium species to give substituted alkenes, 
dienes, trienes and dienynes.  
 
4.1.1.  Insertion of alkenyl carbenoids into organochlorozirconocenes 
Alkenyl carbenoid 4.18, created in situ by deprotonation of the corresponding vinyl 
halide  4.17,  has  been  inserted  into  acyclic  zirconium  species  4.20  to give  the  ‘ate’ 
complex 4.21, which rearranges via 1,2-metallate rearrangement to afford the alkenyl 
zirconocene  intermediate  4.22.  Trapping  this  intermediate  with  various  electrophiles 
affords a range of useful organic products 4.23 (Scheme 4.4).
198,199 
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Reagents and Conditions: (i) 1.2 eq Cp2ZrHCl, 20 oC, 1 h; (ii) carbenoids formed
in-situ, 0.83 eq LiTMP, -90 oC to -80 oC, 15 min; (iii) a: 2M HCl, -78 oC to RT, 0.5 h; 
b: 1.5 eq I2, -60 oC to -40 oC, 1 h; c: 1.5 eq NBS, -60 oC to -40 oC, 1 h; d: 1.3 eq
BuNC, RT, 16 h, then 50% AcOH/H2O, RT, 1 h.  
Scheme 4.4 Elaboration of alkyl chlorozirconocenes via alkenyl carbenoid insertion. 
 
A broad range of alkenyl carbenoids have been inserted into acyclic zirconium systems 
(Scheme 4.5). Insertion of 2-monosubstituted vinyl carbenoids 4.29, 4.39 and butadiene 
derived  carbenoids 4.36, 4.40 provided the corresponding dienes  4.30, enynes  4.33, 
trienes and dienynes 4.37, 4.41 with expected inversion of configuration on carbenoid 
carbon and good level of stereoselectivity. The unsubstituted carbenoid 4.44 generated 
from 1,2-dichloroethane inserted successfully into alkyl- and alkenyl-Zr bond to give 
prducts 4.45 in modest yields (Scheme 4.5).    94 
Carbenoids  carrying  two  different  ￿-substituents  4.47  also  inserted  successfully; 
however,  poor  stereocontrol  was  observed  due  to  rapid  isomerisation  of  the 
carbenoid.
199  
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Scheme 4.5 Insertion of alkenyl carbenoids into acyclic organozirconium species. 
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4.1.2.  Insertion of alkyl carbenoids into organochlorozirconocenes 
Insertion of a range of lithium alkyl carbenoids was next examined (Scheme 4.6).
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over 1 h; (ii) aq NaHCO3; (iii) 1.3 eq PhCHO, BF3·Et2O, -78 oC to RT, 18 h.  
Scheme 4.6 Insertion of alkyl carbenoids into organochlorozirconocenes. 
 
The  insertion  of  alkyl  carbenoids  4.50  into  1-octenylzirconocene  4.49  results  in 
formation of functionalized allylmetallics 4.52. Protonation of these species gives the 
two alkenes, generally with good selectivity (Scheme 4.6). The organometallic products 
4.52 can be further elaborated by reacting with electrophiles such as aldehydes. Lewis 
acid promoted insertion of aldehydes into the resulting allylmetallics 4.52 gave higher 
selectivity for the ￿-hydroxysilane 4.54. 
 
4.1.3.  Insertion of lithiated epoxynitriles into organochlorozirconocenes 
Finally,  lithiated  epoxynitriles  4.57  were  successfully  inserted  into 
alkenylchlorozirconocene  4.49  through  1,2-metallate  rearrangement  to  give 
intermediate 4.59. Elimination of zirconocene oxide in 4.60 followed by acid quench 
provides the corresponding 2-cyano-1,3-dienes 4.61 in good yield (Scheme 4.7).
202 
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It is postulated that the lack of stereoselectivity of insertion of the carbenoids 4.57 is 
related to their configurational instabillity and rapid interconversion when formed under 
the reaction conditions.
202 
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Scheme 4.7 Insertion of metallated epoxynitriles into 1-octenylzirconocene. 
 
4.2.  Insertion of allenyl carbenoids into acyclic zirconium species 
Insertion of allenyl and propargyl carbenoids into bisalkyl/alkynyl biscyclopentadienyl 
zirconium  complex  led  to  a  1,2-zirconate  rearrangement  with  expulsion  of  the 
corresponding leaving group. Trapping the resulting allenyl/propargyl Zr species with 
aldehydes gave, after hydrolysis, a series of propargylic alcohols.  
Insertion of chiral carbenoids into alkyl/alkenyl organochlorozirconocenes and further 
asymmetric 1,2-metallate rearrangement provided the final alcohols as enantiomerically 
enriched products. 
 
4.2.1.  Insertion  of  allenyl  carbenoid  into  acyclic  bisalkyl-/alkynyl-zirconium 
species 
Insertion of an allenyl carbenoid into an acyclic bisalkyl-/alkenyl-zirconium systems is 
shown in Scheme 4.8. Treatment of zirconocene dichloride with two equivalents of 
organolithium reagent gives the corresponding acyclic organozirconocene species 4.62 
which  inserts  the  g-organolithium  reagent  4.64  to  provide  the  ‘ate’  complex  4.65. 
Subsequent 1,2-metallate rearrangement gives the allenyl Zr intermediate 4.66 which 
can be trapped with electrophiles such as aldehydes and ketones to give secondary and 
tertiary alcohols 4.68, respectively (Scheme 4.8).   97 
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Scheme 4.8 Insertion of allenyl carbenoid into bisalkyl/alkynyl Zr species. 
 
The secondary alcohols 4.68a-f were obtained with modest diastereocontrol and in most 
cases poor yields (Table 4.1). The low yields for the final products can be somewhat 
related to the decreased reactivity of these carbenoids towards insertion into such sort of 
organozirconium complexes. Insertion of the allenyl carbenoid and benzaldehyde into 
the alkynyl Zr species 4.62 (R
1 = CCPh) provided compound 4.68d in reasonable yield 
(62%), but worse diastereocontrol was observed in all the other examples. Insertion of 
acetone into the allenyl Zr intermediate 4.76 provided the corresponding tertiary alcohol 
4.68g only in 25% yield. This result is consistent to some extent with the observation 
regarding the low reactivity of allyl zirconocene species towards insertion of ketones.
138 
Entry  R
1  R
2  R
3  R
4  anti : syn  Yield of 4.68/ % 
a  n-Bu  n-Hex  Ph  H  77 : 23  35 
b  Me  n-Hex  Ph  H  79 : 21  40 
c  Ph  n-Hex  Ph  H  79 : 21  35 
d  PhCC  n-Hex  Ph  H  62 : 38  62 
e  Ph  Me  Ph  H  81 : 19  39 
f  Me  Me  Ph  H  73 : 27  37 
g  Me  n-Hex  Me  Me  -  25 
Table 4.1 Yields and anti : syn relationship of the secondary alcohols 4.68a-f.   98 
Asymmetric synthesis of the secondary alcohols 4.68e,f was attempted by insertion of 
the  chiral  carbenoid  4.64  (R
2  =  Me,  prepared  by  deprotonation  with  LDA  of  the 
corresponding tosylate 4.63 (R
2 = Me), derived from commercially available (S)-but-3-
yn-2-ol)  into  acyclic  organozirconium  systems  4.62  (R
1  =  Ph,  Me).  Such  obtained 
compounds 4.68e,f were analysed by chiral HPLC (on a Diacel OD-H column) which in 
both cases showed racemic products.  
The anti : syn relationship of the products 4.68a-f was assigned by correlation with 
literature precedent. In 1996 Harada et al. published a synthesis of a wide range of 
homopropargylic alcohols by trapping allenic zinc reagents with aldehydes (Scheme 
4.9).
203 
Reagents and Conditions: (i) 1.0 eq (R3)3ZnLi, THF, -85 oC, 15 min; (ii) 3.0 eq
ZnCl2 over 15 min, -85 oC, 1 h; (iii)  1.5 eq R4CHO, -85 oC to 0 oC over 2 h; (iv) HCl.
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(i) (ii), (iii)
(iv)
4.71, 18 - 98%
anti : syn, from 
56:44 to 99.7:0.3
Scheme 4.9 Harada’s synthesis of homopropargylic alcohols via allenic zinc complex. 
 
There  is  a  very  close  structural  similarity  between compound  4.68a  and  compound 
4.71a synthesised in the Harada group (Table 4.2). The very good chemical correlation 
of compounds 4.68a major and minor isomers with 4.71a anti and syn isomers provided 
strong evidence for the assignment of stereochemistry of compound 4.68a. The crucial 
proton adjacent to the hydroxyl group was shifted upfield in all anti isomers reported by 
Harada, and this trend is well retained for the major isomer of compounds 4.68a-f; 
therefore,  they  were  all  assigned  as  the  anti  isomers  and  the  minor  isomers  were 
identified as the syn isomers. 
Compound 
Ph
OH
H n-Oct
n-Bu
4.71a anti  
Ph
OH
H n-Hex
n-Bu
4.68a major  
Ph
OH
H n-Oct
n-Bu
4.71a syn  
Ph
OH
H n-Hex
n-Bu
4.68a minor  
￿H (CHOH) 
(ppm) 
4.47  4.49  4.69  4.71 
Multiplet  dd  dd  dd  app. t 
J (Hz)  6.8, 3.9  6.8, 4.3  5.3, 3.6  4.8 
Table 4.2 Correlation studies.   99 
4.2.2.  Insertion of propargyl carbenoid into acyclic bisalkylzirconium species 
Insertion of propargyl carbenoid 4.73 (Scheme 4.10), created in situ by deprotonation of 
the  propargyl  chloride  4.72  with  LDA,  into  bismethylzirconocene  4.62  (R
1  =  Me) 
provided the ‘ate’ complex 4.74 which led to the propargylic Zr intermediate 4.75 via 
1,2-metallate rearrangement. Trapping this species with benzaldehyde in the presence of 
BF3·OEt2,  gave  after  protonolysis  the  secondary  alcohol in  69%  yield  as a  77  :  23 
mixture of anti : syn diastereoisomers.  
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Reagents and Conditions: (i) 1.0 eq 4.72, LDA, -78 oC to -65 oC, 1.5 h; (ii) 1.5 eq PhCHO, 
BF3·OEt2, -60 oC to RT over 1 h, then RT, 3 h; (iii) MeOH, aq NaHCO3, RT, 12-16 h.
Cl
n-Bu
4.74
Li+
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Scheme 4.10 Insertion of propargyl carbenoid into acyclic Zr systems. 
 
Although  compound  4.76  structurally  resembles  the  alcohols  4.68a-f  and  has  been 
obtained with comparable stereoselectivity, it has been synthesised by insertion of a 
different sort of carbenoid into an acyclic Zr system. The significantly better yield is 
thought to be related to the improved general reactivity of the propargyl carbenoid in 
comparison with the allenyl carbenoids 4.64. 
 
4.2.3.  Insertion  of  allenyl  carbenoid  into  organochlorozirconocenes  with  the 
potential for asymmetric synthesis 
Hydrozirconation with Schwartz reagent of 1-octene 4.77a or 1-octyne 4.77b provides 
the  organochlorozirconocene  complex  4.78  which  undergoes  insertion  of  allenyl 
carbenoid  4.64  to  provide  the  ‘ate’  complex  4.79  (Scheme  4.11).  Subsequent  1,2-
metallate rearrangement gives the allenic zirconium intermediate 4.80 which can be 
further  elaborated  through  aldehyde  and  ketone  insertion  to  provide  secondary  and 
tertiary alcohols respectively.   100 
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BF3·OEt2, -78 oC to RT over 1 h, then RT, 2 h; b. for R3 = R4 = Me, 3.0 eq Me2CO, 
-78 oC to RT over 1 h, then reflux 20 h; c. for R3 = n-Hex, R4 = H, 3.0 eq n-HexCHO, 
-78 oC to RT over 1 h, then RT, 3 h; (iv) MeOH, aq NaHCO3, RT, 12-16 h.
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Scheme 4.11 Allenyl carbenoid insertion into organochlorozirconocenes. 
 
Insertion of aromatic and aliphatic aldehydes 4.81 into the allenyl zirconocene complex 
4.80 provides the corresponding secondary alcohols in modest yield and stereocontrol in 
favour of the anti isomer (Table 4.3). Insertion of heptanal into 4.80 occurred with the 
highest anti stereoselectivity compared with other examples to give the products 4.82c 
as an inseparable mixture of anti : syn isomers. Surprisingly, insertion of acetone into 
the allenic Zr intermediate provided the tertiary alcohol 4.82d in good 50% yield, which 
was contaminated with 10% of unidentified and inseparable products. 
Entry  R
1  R
2  R
3  R
4  anti : syn  Yield of 4.82/ % 
a  n-Oct  Me  Ph  H  74 : 26  60 
b  (E)-1-Oct  Me  Ph  H  69 : 31  40 
c  n-Oct  n-Hex  n-Hex  H  89 : 11  44 
d  n-Oct  n-Hex  Me  Me  -  50 
Table 4.3 Yields and anti : syn relationship of the alcohols 4.82a-d. 
   101 
In this system the 1,2-zirconate rearrangement occurred in only 80 % yield (by GC) 
provided that the reaction mixture was warmed to RT. It is postulated that the ‘ate’ 
complex 4.79 loses the chloride anion to give the neutral Zr species 4.83 (Scheme 4.12). 
Reaction with an additional nucleophile (PhCCLi) at this stage was expected to provide 
the new ‘ate’ complex 4.84; however, subsequent protonation gave two products: the 
rearranged product 4.85 and the product of initial hydrozirconation, 4.86 in approximate 
1 : 1 ratio, showing that application of phenyl acetylide was not helpful.  
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Cl
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R2 TsO
4.79
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R2 TsO
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Reagents and Conditions: (i) 1.0 eq PhCCLi, -78 oC to RT, over 1 h; 
(iv) MeOH, aq NaHCO3, RT.
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Scheme 4.12 Possible explanation of incomplete 1,2-rearrangement in organochlorozirconocenes. 
 
The concept of ‘dummy ligands’ has also been applied and the intermediate 4.78a was 
treated  with  different  nucleophiles  4.87  before  insertion  of  allenyl  carbenoid  4.63 
(Scheme  4.13).  The  resultant  intermediate  4.88  should  be  still  reactive  towards 
carbenoid  insertion  and  further  rearrangement.  However,  s-BuLi  and  Me3SiLi 
completely  inhibited  the  allenyl  carbenoid  insertion,  PhCCLi  afforded  the  desired 
intermediate 4.90 in approximately 25 % GC yield, though the reaction mixture was 
warmed  to RT.  Use  of PhLi  caused  the  R
5  group  migration  to  give  selectively  the 
intermediate  4.91,  which  after  benzaldehyde  insertion  and  protonolysis,  provided 
product 4.68e in low yield.   102 
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Scheme 4.13 Application of dummy ligands to organochlorozirconocenes. 
 
It  remains  unknown  why  the  1,2-metallate  rearrangement  is  retarded  for  the 
organochlorozirconocene system. Competition studies of the carbenoid insertion 4.63 
(R
2  =  Me) into  bisalkyl Zr  species  4.62 (R
1  =  Bu) and  1-octanylzirconocene 4.78a 
species have shown that this carbenoid inserts selectively into 4.78a in 80% GC yield (+ 
octane  detected)  (Scheme  4.14).  This  observation  would  be  consistent  with  the 
electronic properties of 4.78a, where the Zr atom is more electron poor (because of the 
chlorine atom present), than in 4.62. This information, however, does not explain the 
incomplete 1,2-metallate rearrangement in these systems. Another concern is related to 
the stability of the allenyl carbenoids, which decompose even at –78 
oC, immediately 
after deprotonation either with LDA or LiTMP to give unidentified products. 
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Scheme 4.14 Competition studies for allenyl carbenoid insertion.   103 
Insertion of carbamate carbenoid 4.95 (Scheme 4.15), prepared by deprotonation with 
LDA  of  the  corresponding  carbamate  derivative  4.94  (prepared  from  commercially 
available but-3-yn-2-ol, according to the known procedure
204), was unsuccessful. These 
results were unexpected as it is known that lithiated carbamates readily participate in 
1,2-metallate rearrangement.
205 
OCb
4.95
Li
Reagents and Conditions: (i) 1.0 eq LDA, THF, -78 oC, 15 min.
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Scheme 4.15 Preparation of carbamate carbenoid. 
 
Regardless of modest yields, asymmetric synthesis of the secondary alcohols 4.82a, b 
was  attempted  by  insertion  of  the  chiral  carbenoid  4.64  (R
2  =  Me,  prepared  by 
deprotonation with LDA of the corresponding tosylate 4.63 (R
2 = Me), derived from 
commercially available (S)-but-3-yn-2-ol) into organochlorozirconocenes 4.7a, b. 
It could be assumed that the 1,2-metallate rearrangement in intermediate 4.79 will cause 
the elimination of the tosyl group completely in an anti fashion, therefore the chiral 
information from  the  carbenoid  would  not  be  lost  and  the allenic  Zr  complex  4.80 
would  be  a  chiral  intermediate.  Subsequent  aldehyde  insertion  would  provide  the 
secondary alcohols as chiral products. Analysis by chiral HPLC (on a Diacel OD-H 
column) revealed that the compound 4.82a was obtained in 71% e.e. It was suspected 
that the transfer of chiral information may be affected by the presence of the Lewis acid 
in  the  reaction  mixture,  thus  the  reaction  for  4.82b  was  carried  out  without  using 
BF3·OEt2 in the final step. Analysis by chiral HPLC showed that the compound 4.82b 
was obtained with diminished, 62% e.e. These results imply, that the loss of chiral 
information occurs during the formation of the allenic Zr complex 4.80 (syn elimination 
of the tosyl group may occur partially); however, the loss of chiral information during 
aldehyde insertion into complex 4.80 cannot be  ruled  out. Nonetheless, insertion  of 
allenyl carbenoids derived from chiral precursors 4.63 into organochlorozirconocenes 
4.7a, b showed potential for asymmetric synthesis. 
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4.3.  Conclusion for chapter 4 
Allenyl and propargyl carbenoid have been inserted into acyclic zirconium systems. 
Trapping of the corresponding allenic and propargylic Zr intermediates with aldehydes 
and ketones gave after protonolysis secondary and tertiary alcohols respectively, mostly 
in  modest  yields  and  low  level  of  diastereocontrol.  The  insertion  of  chiral  allenyl 
carbenoid into organochlorozirconocenes showed promise for asymmetric synthesis of 
homopropargylic alcohols. More optimization studies in terms of yield and asymmetric 
course of the reaction are required to introduce the three component coupling of acyclic 
zirconocenes, carbenoid and aldehydes/ketones as a synthetically useful method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   105 
Chapter 5. Towards the total synthesis of mucosin 
5.1.  Introduction to research area 
5.1.1.  Mucosin: a new bicyclic eicosanoid 
Isolation  of  the  natural  product  mucosin  from  the  marine  sponge  Reniera  mucosa, 
which is native to the Mediterranean has been reported in 1997 by Casapullo et al. 
(Figure 5.1).
206 
OH
O
H
H
H
H 5.1  
Figure 5.1 Reported structure of mucosin. 
 
The natural product contains an unsaturated indene type skeleton with four contiguous 
stereocenters, a cis-6,5 ring junction and two  side chains, one of  which is  carrying 
double  bond  and  carboxyl  functionality.  The  C-20,  eicosanoid  character  of  this 
molecule  suggests  its  biosynthesis  from  arachidonic  acid  via  an  intramolecular 
cyclisation pathway. For characterisation purposes, the extracted carboxylic acid was 
converted to its methyl ester with diazomethane. The structure of the methyl ester was 
determined  by  its  mass,  infrared  and  high  field  NMR  spectroscopy  and  the 
stereochemistry  was  assigned  by  means  of  various  2D  NMR  experiments.  The 
compound was also optically active. 
Although  the  biological  activity  of  mucosin  is  unknown,  the  unusual 
bicyclo[4.3.0]nonene  core  and  carboxylic  acid  side  chain  containing  a  trans  double 
bond  make the structure attractive to both total synthesis and testing for biological 
activity. The synthesis of mucosin has already been attempted by Owen
207 within the 
Whitby group. 
 
5.1.2.  Literature precedent and Owen’s approach to mucosin 
Due to the four chiral centres present in the bicycle core of mucosin, stereocontrolled 
synthesis of the desired diastereoisomer would appear difficult, however, Taber and 
Louey
208 reported a reliable precedent for a zirconocene-mediated route to synthesise 
the natural product (Scheme 5.1).   106 
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Scheme 5.1 Stereocontrolled co-cyclisation of diene 5.2. 
 
The zirconocene mediated co-cyclisation of diene 5.2 followed by oxygen quench
122,209 
provided diol 5.4 as a 3 : 1 mixture of diastereoisomers, epimeric at the secondary 
alcohol centre. Thus, complete diastereoselectivity of the ring junction formed during 
cyclisation has been achieved through the presence of the methoxybenzyl substituent 
present in the cyclopentane ring. The anti relationship between the CH2OBn group and 
the newly created hydroxymethyl group can be considered to be analogous to the anti 
relationship between the cyclohexene bridge and carboxylic acid bearing side chain in 
the natural product. The retrosynthetic strategy for the first total synthesis of mucosin 
proposed by Owen is shown in Scheme 5.2. 
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Scheme 5.2 Owen’s retrosynthetic analysis of mucosin. 
 
Zirconocene(1-butene) mediated co-cyclisation of triene 5.5 provides the zirconacycle 
5.6  which  undergoes  allyl  carbenoid  insertion  to  give  the  corresponding  allyl 
zirconocene complex 5.7. 1,4-Attack of the resulting allyl zirconocene onto an acrolein 
acetal  would provide the  bicyclic molecule precursors  with all  carbon  atoms in the 
bicycle  and  the  desired  stereochemistry  and  trans  geometry  of  the  double  bond  in 
carboxylic acid side chain. Further strightforward transformations would provide the 
desired product.   107 
The precedent for selective insertion of an allyl carbenoid into less hindered C-Zr bond 
in saturated zirconacycles was reported by Gordon et al.
132 Therefore the desired allyl 
zirconocene 5.7 would be obtained selectively, and the remaining three carbons carrying 
carboxylic acid functionality would be incorporated into the molecule via a 1,4-attack of 
the  resulting  allyl  zirconocene  onto  an  appropriate  Michael  acceptor.  This  area  of 
organozirconium chemistry was explored by Luker,
139 and the corresponding example is 
shown in Scheme 5.3. 
ZrCp2
H
3.1
H
OEt
H
3.4c, 64%
H
H
5.8, 14%
H
OEt
+
OEt
OEt
BF3·OEt2
1,2-attack product 1,4-attack product
Scheme 5.3 1,4-Attack by an allyl zirconocene onto acrolein acetal. 
 
This strategy would provide an excellent method not only for bicyclic core construction 
but also for elaboration of the carboxylic acid side chain in a one-pot tandem reaction 
sequence on zirconocene, starting from the triene 5.5. Further simple transformations 
would provide the desired target. 
The  crucial  starting  material,  5.5a  was  initially  prepared  by  Owen  in  a  multistep 
reaction  sequence  as  a  77  :  23  mixture  of  Z  :  E  isomers.
207  Co-cyclisation  of  this 
precursor with Negishi reagent did not provide a single diastereomer but a mixture of 
three products, the major constituting 60%, as shown by 
13C NMR and GC analysis 
(Scheme 5.4). 
5.5
a. Z:E, 77:23 
b. Z:E, 91:9
c. Z:E, 73:27
Me
Negishi reagent
5.9
a
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Scheme 5.4 Owen’s cyclisation of triene 5.5. 
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To investigate the stereoselectivity, each of the mixtures of the double bond isomers of 
precursor 5.5, b and c were cyclised separately by Owen. As a result, the same product 
mixture was seen in each case, with three components dominating and roughly in the 
same GC ratio. Owen postulated that the probable reason for the mixture of products 5.9 
is a lack of diastereoselectivity. The anti relationship between the newly created chiral 
centres ‘c’ and ‘d’ (Scheme 5.4) is very likely, as is the propensity for the chiral centre 
‘b’  to  induce  complete  control  in  ‘c’  in  an  anti  fashion.  The  net  result  is  a  syn 
relationship between centres ‘b’ and ‘d’, and this would be in agreement with Taber’s 
observations.
208  Co-cyclisation  precursor  5.5,  however,  contains  an  additional  chiral 
centre ‘a’, and it is very likely that this centre will induce an anti relationship between 
itself and centre ‘d’, therefore contradicting the effects of centre ‘b’. A reasonable proof 
for  this  hypothesis  could  be  a  1,3-stereoinduction  observed  in  his  synthesis  of 
cyclopentanol  5.11  via  zirconocene-mediated  co-cyclisation  –  ￿-elimination  process 
(Scheme 5.5).
210  
HO
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Scheme 5.5 1,3-Stereoinduction observed by Owen. 
 
The other factors which could affect the stereoselectivity in the co-cyclisation step and 
proposed by Owen are the additional double bond present in the cyclohexene ring and 
the propyl substituent on the double bond. To test this hypothesis Owen prepared the 
appropriate analogues 5.12 and 5.14 of triene 5.5, which were next subjected to the 
zirconocene mediated co-cyclisation (Scheme 5.6).
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Scheme 5.6 Zirconocene mediated co-cyclisation of precursors 5.12 and 5.14.   109 
The co-cyclisation of diene 5.12 again provided a mixture of products 5.13 in combined 
yield 65%, whereas co-cylisation of 5.14 followed by oxygen quench of the C-Zr bonds 
provided the corresponding diol 5.15, as  a single diasteroisomer in 65% yield  after 
column chromatography. However gas chromatography of the crude reaction mixture of 
5.15  showed  the  major  component  making  up  80%  of  the  mixture  and  two  minor 
products. The improved diastereoselectivity observed for the triene 5.14 suggests that 
the  presence  of  a  propyl  chain  on  the  doble  bond  is  detrimental.  The  bis(p-
phenylbenzoyl)ester of diol 5.15, compound 5.16 proved the correct stereochemistry 
(Scheme 5.6).
207 
 
5.1.3.  Studies towards the carboxylic acid side chain of mucosin 
Owen also carried out thorough studies on elaboration of the carboxylic acid chain of 
the natural product ( Scheme 5.7).
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 Scheme 5.7 Owen’s studies towards the carboxylic acid side chain of mucosin. 
 
Relying on the discovery achieved within the Whitby group and relating to the selective 
insertion of allyl carbenoid into zirconacycles
132 and further elaboration of the resulting 
zirconocene ￿
3-complex via addition of different electrophiles,
139 Owen prepared the 
model ￿-allyl zirconocene system 5.17 and treated it with various Michael acceptors.  
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Owen  repeated  Luker’s  experiment,  in  which  the  allyl  zirconocene  attacks  acrolein 
diethyl acetal, first using the dimethyl acetal 2.36a ( Scheme 5.7). However, the results 
indicated almost exclusively 1,2-attack product 5.18 and very small amount (<5%) of 
the desired 1,4-attack product. In order to induce the required 1,4-attack, three other 
acrolein  acetals  2.36b,  c  and  d  were  prepared  by  Owen.
207  It  was  hoped  that  the 
additional  steric  encumbrance  present  in  these  Michael  acceptors  would  induce  the 
desired 1,4-attack of allyl Zr complex 5.17. Unfortunately, the extra hindrance proved 
too great, and none of the three acetals reacted with the allyl zirconocene. 
Owen,  in  his  studies  on  the  synthesis  of  the  carboxylic  acid  side  chain,  used  an 
alternative route, initially inspired by Luker’s work. Trapping of the intermediate 5.17 
with dithienium tetrafluoroborate provided the compound 5.19 in respectable yield and 
the chain was further elongated to obtain product 5.20. De-silylation with TBAF was 
followed  by  removal  of  the  dithiane  with  Raney-Ni,  which  also  resulted  in  clean 
reduction of the double bond, providing alcohol 5.21 in moderate yield. 
Although the synthesis was not completed, Owen had laid down groundwork for the 
second approach to the first total synthesis of mucosin. 
 
5.2.  Revised approach to the total synthesis of mucosin 
5.2.1.  Revised retrosynthetic analysis of mucosin 
The revised retrosynthetic analysis of mucosin is shown in Scheme 5.8. 
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Scheme 5.8 Modified approach to the synthesis of mucosin. 
 
This approach is very similar to that proposed by Owen; however, in this method the 
allyl zirconocene complex 5.7 is trapped with monomeric formaldehyde to give after 
protonolysis  the  desired  homoallylic  alcohol  5.22.  Subsequent  homologation  of  the 
chain using malonate chemistry should provide the desired natural product.   111 
5.2.2.  Preparation of the crucial co–cyclisation precursor 
The cheap and commercially available reagent, tetrahydrophthalic acid anhydride 5.23 
was reduced with sodium borohydride in DMF to the lactone 5.24 in good yield (62% 
on 1.0 mol scale) in a convenient one-pot procedure
211 (Scheme 5.9). The lactone was 
converted into the alcohol 5.26 by following the two-step literature precedent.
212 Partial 
reduction of the lactone 5.24 with DIBAL-H provided the corresponding lactol 5.25, 
which underwent a Wittig methylation to give the desired alcohol 5.26. The yield of the 
alcohol over these two steps was 74% on 100 mmol scale (86% for each step). The one-
pot procedure
213 was also followed in which DIBAL-H is added to the lactone 5.24 to 
form the aluminium salt of the lactol, and the resulting reaction mixture is added to a 
solution of methylene phosphorane. Refluxing the whole mixture for 16 h gave the 
desired alcohol 5.26 in modest 30% yield, on 30 mmol scale. Therefore the two-step 
procedure was applied on a scale-up process. The synthesis continues with one carbon 
homologation of alcohol 5.26. 
Quantitative  conversion  of  the  alcohol  to  its  mesylate  5.27,  followed  by  cyanide 
displacement provided nitrile 5.28 in 86%. DIBAL-H reduction of the resultant nitrile 
followed  by  imine  hydrolysis  gave  aldehyde  5.29  in  86%  yield,  which  was  further 
treated with the corresponding Wittig reagent to provide the co-cyclisation substrate 5.5 
as a 4 : 1 mixture of Z : E isomers and 94% yield for the last step (Scheme 5.9). Such 
prepared  triene  5.5  had  already  estabilished  stereochemistry  at  two  out  of  the  four 
stereocentres present in the bicycle core of the natural product. Spectral data of all the 
intermediates  and  the  triene  5.5  were  consistent  with  those  presented  in  the  cited 
literature or reported by Owen.
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Scheme 5.9 Preparation of the co-cyclisation precursor 5.5. 
 
5.2.3.  Studies on zirconocene(1-butene) mediated co-cyclisation of triene 5.5 
Screening of different Zr reagents for co-cyclisation of the triene 5.5 revealed that the 
best  reagent  for  this  purpose  still  remains  Negishi  reagent  i  and  Cp2ZrDMAP2  iii 
(Scheme  5.10).  Using  the  DMAP  method
214,215  cyclisation  of  the  starting  material 
occurred faster in comparison with Cp2ZrBu2. In the latter case, the Z isomer of the 
precursor was co-cyclised in the first instance (after about 1 h upon stirring at RT) to 
give presumably the zirconacycle 5.6a, which is a kinetic product of cyclisation.  
The zirconacycle 5.6a was then observed to be converting into another product, thought 
to be the needed 5.6b, and the E isomer started to undergo the initial co-cyclisation. 
Subsequent heating of the reaction mixture at 60 °C for 0.5 h forced the co-cyclisation 
of  the  E  isomer  to  completion  and  at  that  time  gas  chromatography  showed  four 
products to be created in the following ratio 58.5 : 22.5 : 14 : 5%. Also trace amounts of 
by-products were discernible by GC and further heating of the reaction mixture for 
several hours led to decomposition.   113 
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Scheme 5.10 Zirconocene mediated co-cyclisation of triene 5.5. 
 
Both  zirconacycles  were  prepared  separately  under  kinetic  and  thermodynamic 
conditions  and  were  further  elaborated  through  allyl  carbenoid  and  benzaldehyde 
insertion to obtain the corresponding alcohols 5.30a, b (Scheme 5.11). 
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Scheme 5.11 Elaboration of zirconacycles 5.6a, b via allyl carbenoid and benzaldehyde insertion. 
 
Alcohols 5.30 contained all the crucial carbons of the bicycle core and the double bond 
of  one  of  the  side  chains,  and  therefore  were  appropriate  for  correlation  with  the 
reported spectral data of the natural product (Table 5.1).   114 
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Thermodynamic 
product  Mucosin  Kinetic product 
￿C (ppm) 
C  Experimental data 
major/minor d.r. 
￿￿ 
Literature 
data 
of 
mucosin 
￿￿ 
Experimental data 
major/minor d.r. 
4  42.76  11.06  31.7  11.09  42.79 
5  133.62  3.82  129.8  4.03/3.99  133.83/133.79 
6  127.04  2.94  130.0  3.74/3.77  126.26/126.23 
7  36.49/36.55  0.19/0.25  36.3  1.26  37.56 
8  52.06/52.09  0.04/0.01  52.1  1.28/1.23  50.82/50.87 
9  47.03/47.08  0.07/0.02  47.1  3.1/3.07  44.00/44.03 
14  40.03  0.13  39.9  2.91/2.88  36.99 /37.02 
16  42.21/42.25  0.11/0.15  42.1  1.88/1.93  40.22/40.17 
Table 5.1 Comparison of 
13C signals of 5.30a, b with the reported spectral data of mucosin. 
 
Comparison  of  the  shifts  of  the  crucial carbons  in  both  products  5.30a,  b  with  the 
natural product led to the conclusion that the thermodynamic product 5.30b had the 
same relative stereochemistry as the natural product. Strong evidence for this hypothesis 
is the excellent agreement of the carbon signals between the thermodynamic product 
5.30b and mucosin 5.1, whereas product 5.30a showed significant inconsistency with 
the  natural  product  (Table  5.1).  Additional  support  was  provided  by  DFT  relative 
energy  calculations,
216  which  indicated  the  zirconacycle  5.6a  to  be  less  stable  (»  4 
kJ/mol) than zirconacycle 5.6b. Therefore the thermal equilibration of the zirconacycles 
for mucosin synthesis gives the desired zirconacycle as the main product, though only 
in 60% yield. 
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5.2.4.  Studies towards synthesis of the carboxylic acid side chain of mucosin 
Following encouraging results from the zirconocene-mediated co-cyclisation of triene 
5.5, the synthesis of the carboxylic acid side chain was addressed. 
Initial  ideas  for  elaboration  of  the  carboxylic  acid  side  chain  of  mucosin  through 
insertion of various carbenoids into zirconacycle were conceived (Scheme 5.12). All 
those experiments were carried out using the model zirconacycle 3.8c. 
Insertion  of  allyl  carbenoid  1.76  into  the  model  zirconacycle  3.8c  occurred 
quantitatively to give the ￿
3-Zr complex 5.31 (Scheme 5.12). Efforts were undertaken to 
trap the allyl zirconocene with monomeric formaldehyde (prepared according to the 
procedure reported by Schlosser et al.
217), MOM or BOM chloride to obtain the alcohol 
or its Me or Bn ethers 5.32a, b, c, respectively. Unfortunately, all three attempts failed. 
According  to  the  known  procedure,
218  allenyl  carbenoids  such  as  4.64  insert  into 
zirconacycles  to  give  intermediate  5.33,  which  after  aldehyde  quench,  provides 
secondary alcohols. In the probed example, the insertion of the carbenoid occurred in 
only 75% yield by GC (although 2 equivalents of the carbenoid were used) and upon 
basic quench, a 2 : 1 mixture of compounds 5.34a, b was obtained. The incomplete 
insertion of the carbenoid and difficulty to avoid the allene product makes this route less 
viable.  
The insertion of metallated epoxides 5.35 into zirconacycles
202 was explored next and it 
appeared  that  the  insertion  of  the  carbenoid  5.35  occurs  in  only  30%  by  gas 
chromatography.  Unfortunately,  all  the  examples  reported  in  the  literature  do  not 
include a-substituted saturated zirconacycles as it is in the example below (Scheme 
5.12).  The  results  presented  in  chapter  3  relating  to  the  carbenoid  insertion  in  a-
substituted saturated zirconacycles suggest, that substituents adjacent to the Zr atom 
may inhibit insertion of different types of carbenoids into such zirconacycles. Insertion 
of non-stabilized metallated epoxides 5.38 into zirconacyle 3.8c failed. 
According to Norton’s work,
146,219 insertion of lithiated trans-1,2-dichloroethylene 5.39 
into saturated zirconacycle should proceed via expulsion of the terminal chlorine in the 
intermediate  5.40  to  give  the terminal  alkyne  5.41  (Scheme  5.12).  In this  case,  the 
insertion did not occur at all indicating, that the ethyl substituent indeed has a big effect 
on reactivity of the zirconacycle.    116 
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Scheme 5.12 Studies towards synthesis of the carboxylic acid side chain of mucosin.   117 
Insertion of conjugated vinyl carbenoid 4.36 into zirconacycle
133 3.8c occurred in 75% 
(estimated by GC) to give upon acidic quench the compounds 5.43 as a mixture of E 
and Z isomers. Some loss of the stereo information must have happened during either 
deprotonation or the insertion step, as the 1,4-dichloro-trans-2-butene is contaminated 
with its cis isomer up to 10%, and the final compounds were obtained as a 3.7:1 mixture 
of E and Z isomers. If conjugated diene 5.43 had been formed cleanly and in high yield, 
it  could  have  been  elaborated via  selective  hydrometallation  of  the  terminal  double 
bond.  A  more  elegant  approach  entails  insertion  of  the  sulfone  carbenoid  5.44. 
According to the work published by Dixon et al.,
133 the reaction should yield the desired 
one-carbon homologation product with incorporated sulfone group in good yield. The 
homologated product would be an ideal substrate for Julia-Kocie￿ski
220,221 olefination 
as the crucial step in the construction of the trans double bond present in the side chain 
of mucosin. In this example insertion of the sulfone carbenoid occurs at temperatures 
above 0 °C and is immediately followed by ￿-H elimination from the ethyl substituent 
at the stage of the intermediate 5.45 to give the alkene products 5.46 in modest 45% 
yield, as a 3.8 : 1 mixture of E : Z isomers (Scheme 5.12). 
Further  attempts  at  selective  functionalization  of  the  unsubstituted  C-Zr  bond  in 
zirconacycles 3.8c or 3.71 are given in Scheme 5.13. Activation of the zirconacycle 3.8c 
by addition of 1.1 eq of n-BuLi led to halogen-metal exchange with ICH2Cl or CBr4, 
either directly via the 18-electron Zr complex 5.47a, or via the lithium species 5.47b,
133 
to give the corresponding iodide 5.48 or bromides 5.50 and 5.51. Such method for ring 
opening of zirconacyclopentanes with alkyllithium reagents is known in the literature.
150 
As the ClCH2¯
 anion is not the best leaving group, the desired iodide 5.48 was created 
in  66%  GC  yield  only,  and  the  protonated cyclised  starting  material  5.49  was also 
recovered (approximately 34% by GC). Choosing carbon tetrabromide as a source of 
halogen, the desired products 5.50 and 5.51 were obtained with 100% GC conversion 
and after column chromatography in 76% and 70% yield respectively. Following this 
idea,  efforts  were  made  to  halogenate  the  allyl  Zr  species  5.52  to  obtain  the 
corresponding  compound  containing  the  allyl  bromide  motif  5.53.  The  intermediate 
5.52 which in practice is an ￿
3-Zr complex does seem to be very unreactive and even 
addition of n-BuLi does not force this species to perform nucleophilic attack on CBr4. 
As a net result, the protonated zirconacycle 5.52 was obtained after quenching (Scheme 
5.13).   118 
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Scheme 5.13 Attempts to functionalise the unsubstituted C-Zr bond in saturated zirconacycles. 
 
It  was  hoped  that  treatment  of  the  zirconacycle  3.71  with  m-CPBA  under  various 
conditions might result in oxidation of the C-Zr bond. Unfortunately, none of these 
reactions worked. Addition of orthoacetate to the activated Zr complex 5.47 resulted in 
incorporation of the electrophile into the molecule in good GC yield; however, the dq at 
5.364 ppm (J = 13.0, 6.5 Hz) in the 
1H NMR spectra of the crude material strongly 
correlate to the vinylic proton in the ￿-H elimination product 5.55 (Scheme 5.13). 
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5.3.  Future work towards mucosin 
An idea for successful elaboration of the carboxylic acid side chain came at the end of 
the project and concerns the insertion of the carbenoid 5.57 (Scheme 5.14). 
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Scheme 5.14 Suggested elaboration of the carboxylic acid side chain of mucosin. 
 
It is known from the previous work that a-alkoxy carbenoids are thermally unstable and 
insert  into  zirconacycles  in  poor  yields  but  their  silyl  analogues  insert  usually 
selectively  into  C-Zr  bond  in  good  yields.
133  The  use  of  the  alkyl  carbenoid  5.57 
generated from the cheap and commercially available reagent, (chloromethyl)(methoxy) 
-dimethylsilane 5.56 could provide after quenching the product 5.58 which after Tamao 
oxidation
222  and  further  separation  of  the  resulting  diastereoisomers  would  give  the 
desired  alcohol  5.59.  Alcohols  5.59  could  be  oxidized  to  give  the  corresponding 
aldehyde, which in turn would be the substrate for a trans selective Julia-Kocie￿ski 
olefination.
220,221 Subsequent modifications could provide the desired natural product. 
Unfortunately, due to time constraints, this idea was not pursued. 
 
5.4.  Conclusions for chapter 5 
The synthesis of the natural product mucosin has been attempted. Extensive studies 
have been done on the zirconocene-mediated co-cyclisation of the appropriate triene as 
well as elaboration of the carboxylic acid side chain. This research revealed the Zr-
based total synthesis of mucosin to be significantly limited. Nevertheless, the correct 
stereochemistry of the major product of zirconocene mediated co-cyclisation and the 
latest idea for elaboration of the carboxylic acid side chain seem to be viable and are 
encouraging for further work on the first synthesis of mucosin.   120 
Chapter 6.  Experimental 
6.1.  General experimental 
All reactions involving air or moisture sensitive compounds were carried out under an 
argon  atmosphere  using  standard  Schlenk  equipment  and  syringe  techniques.  All 
glassware was dried in a hot oven (>140 ºC, for at least 12 hours) and cooled in a sealed 
desiccator over silica gel or assembled while hot and cooled under vacuum.  
Reactions were monitored by GC and/or TLC using Merck silica gel 60 F254 plates with 
detection  by  UV  and/or  polyphosphomolybdic  acid  and/or  potassium  permanganate 
stains. Silica gel 60A (particle size 35-70 microns) supplied by Fisher Scientific was 
used for flash chromatography columns and Merck silica gel 60 (0.040-0.063 mm) or 
basic alumina Brockman I deactivated with 6% of H2O, were used for purification of 
final compounds or acid sensitive products respectively. Columns were packed and run 
under light pressure. Solvent compositions are described as ratios prior to mixing.  
 
Unless  otherwise  stated,  reagents  were  obtained  from  commercial  suppliers  and  if 
necessary dried and distilled before use. Solvents for air or moisture sensitive reactions 
were prepared in the following ways. THF and diethyl ether were freshly distilled from 
sodium benzophenone ketal under argon. DCM and MeCN were freshly distilled over 
CaH2 under argon. HMPA was distilled over CaH2 and stored in stock bottles under 
argon. n-Butyllithium was used as a 2.5 M solution in hexanes (Aldrich), stored in stock 
bottles  under  argon.  Lithium  diisopropylamide  was  used  as  a  1.8  M  solution  in 
THF/heptane/ethylbenzene  (Aldrich),  stored  in  stock  bottles  under  argon.  DIBAL-H 
was used as a 1.0 M solution in toluene, stored in stock bottles under argon. Lithium 
2,2,6,6-tetramethylpiperidide was prepared from 2,2,6,6-tetramethylpiperidine (freshly 
distilled, or distilled and stored over 4Å sieves under argon) in THF by addition of 1 
equivalent of n-BuLi at 0 ºC and stirring for 20 minutes. 
 
NMR spectra were recorded on Bruker AV300, AM300 or DPX400 spectrometers. The 
chemical shifts, ￿, were recorded as values in ppm referenced to chloroform residual 
peaks at 7.27 ppm for 
1H spectra and 77.00 ppm (centre peak of triplet) for 
13C spectra 
and benzene 7.16 ppm for 
1H spectra and 128.39 ppm (centre peak of triplet) for 
13C 
spectra.  The  following  abbreviations  were  used  to  denote  multiplicity  and  may  be 
compounded: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad,   121 
fs = fine splitting. Coupling constants, J, are measured in Hertz (Hz). 
13C NMR spectra 
were proton decoupled and are reported as C, CH, CH2, CH3, depending on the number 
of directly attached protons. DEPT, COSY and 
1H-
13C correlation experiments were 
used to aid assignment of spectra. The lettered assignment for proton and carbon signal 
is  for  identification  purposes  only  and  does  not  represent  the  systematic  IUPAC 
numbering. Proton chemical shifts, ￿, are reported with three decimal places with the 
exception for compounds in experimental section for chapter 4 (whose chemical shifts, 
￿, are reported with two decimal places). Carbon-13 chemical shifts, ￿, are reported with 
two decimal places in all cases. 
 
Electron impact ionisation mass spectra (EI) were recorded on a ThermoQuest TraceMS 
GCMS. Electrospray mass spectra (ESI) were recorded using a VG platform quadrupole 
spectrometer. All electrospray were (ESI+) unless otherwise stated. Values of m/z are 
reported in atomic mass units and the peak intensity relative to the base peak is reported 
in parenthesis. Only the most abundant isotope is reported for compounds containing 
chlorine. Accurate mass spectra were recorded on a VG analytical 70-250-SE double 
focusing mass spectrometer using electron impact ionisation (EI) at 70 eV or a Bruker 
Apex III using electrospray ionisation.  
 
Infra-red  spectra  were  run  as  neat  films  on  a  Thermo  Mattson  FTIR  Golden  Gate 
spectrometer  and  a  Thermo  Nicolet  380  FT-IR  spectrometer  with  a  Smart 
Orbit Goldengate attachment. Absorptions are given in wavenumbers (cm
–1) and the 
following abbreviations used to denote peak intensities: s = strong, m = medium, w = 
weak, br = broad. 
 
Gas chromatography was performed on a Hewlett Packard HP 6890 series GC system, 
using a HP-5 (cross-linked 5% PH ME siloxane) 30 m column, with a film thickness of 
0.25 ￿m and 0.32 mm internal diameter. The carrier gas was helium and the flow rate 
was 2.7 mL min
-1.  
 
The  X-ray  structure  of  2.70-endo  was  determined  by  the  EPSRC  National 
Crystallography Service at the University of Southampton, Department of Chemistry.  
Melting points were recorded on a Reichert 349 360 melting point apparatus and are 
uncorrected.   122 
The  following  compounds  were  prepared  by  literature  methods  (or  found  in  the 
laboratory  chemicals  collection)  and  had  spectral  properties  consistent  with  those 
published or included in the thesis of former group members. These include: 
·  (hept-6-en-1-ynyl)trimethylsilane 1.83b,
96 
·  1-ethynyl-3-methoxybenzene 2.31,
153,154,223 
·  1,1-dibromoalkanes 2.33a, b, c,
155,224 
·  1- (hept-6-en-1-ynyl)benzene 2.35a,
225  
·  undec-1-en-6-yne 2.35b,
166  
·  tridec-1-en-6-yne 2.35c,
226 
·  1,1-diethoxy-3-iodopropane 2.37,
156, 
157 
·  7-phenylhept-1-en-6-yn-4-ol 2.47,
227 
·  2-((oxiran-2-yl)methoxy)-tetrahydro-2H-pyran 2.44,
160 
·  1-( tetrahydro-2H-pyran-2-yloxy)pent-4-en-2-ol 2.45,
161 
·  pent-4-ene-1,2-diol 2.46,
163 
·  7-phenylhept-1-en-6-yn-4-ol 2.47,
164,165,227 
·  1-phenylhept-6-en-1-yn-3-ol 2.51,
228 
·  (1-phenylhept-6-en-1-yn-3-yloxy)(tert-butyl)dimethylsilane 2.52,
228 
·  10-(tert-butyldimethylsiloxy)-l-decen-6-yn 2.54,
166 
·  N-allyl-N-benzylamine 2.59,
167 
·  1-(oct-7-en-1-ynyl)benzene 2.74,
229 
·  4,4-bis(methoxymethyl)-2-methyldec-1-en-6-yne 2.84,
141 
·  (2S,3aR)-2-hexyl-2,3,3a,4,5,6-hexahydro-1-phenylpentalen-2-ol 2.106,
83 
·  4,4-bis(methoxymethyl)hepta-1,6-diene 3.23,
230 
·  (Z)-4,4-bis(methoxymethyl)nona-1,6-diene 3.24,
132 
·  N-allyl-N-benzyl-2-methylprop-2-en-1-amine 3.25,
132 
·  1-allyl-2-vinylbenzene 3.36,
231 
·  N-allyl-N-benzylprop-2-en-1-amine 3.40a,
232 
·  N,N-diallylbenzenamine 3.40b,
233 
·  1-((E)-4,4-bis(methoxymethyl)hepta-1,6-dienyl)benzene 3.43,
132 
·  N-allyl-N-benzyl-2-phenylprop-2-en-1-amine 3.50,
234 
·  1,2-diallylbenzene 3.61,
235 
·  3-(1-methoxy-2- (methoxymethyl)pent-4-en-2-yl)cyclohex-1-ene 3.68,
132   123 
6.2.  Experimental from chapter 2 
 
6.2.1.  (7-Phenylhept-1-en-6-yn-3-yloxy)(tert-butyl)dimethylsilane (2.41) 
Procedure: A 1 L Schlenk flask was charged with NaI (36.0 g, 0.24 mol) and dry 
MeCN (0.40 L) was added. After stirring for 0.5 h at RT the reaction mixture was 
cooled to –5 
oC and addition of freshly distilled acrolein (12.6 mL, 0.20 mol), Me3SiCl 
(30.5 mL, 0.24 mol) and dry EtOH (24.5 mL, 0.42 mol) followed. After stirring for 15 
min at the same temperature, the reaction mixture was warmed to RT and the stirring 
was continued for 2 h before pouring the whole reaction mixture onto 5% aqueous 
NaHCO3 solution (0.40 L). The products were extracted with pentane (3 × 0.20 L). The 
organic phases were washed with 5% aqueous Na2S2O3 solution (0.30 L) and brine (3 × 
0.20 L). Drying over K2CO3 and concentration in vacuo gave the crude material as a 
yellow oil which was immediately purified by flash column chromatography on Al2O3 
(basic, grade III) with 10% Et2O in pentane to provide the desired material (24.30 g, 
47%). The pure iodide was immediately reacted in the next step. To a stirred solution of 
1-ethynylbenzene  (16.5  mL,  0.15  mol)  in  dry  THF  (0.30  L)  at  –78 
oC  was  added 
dropwise n-BuLi (60.0 mL of a 2.5 M solution in hexanes, 0.15 mol). The reaction 
mixture was allowed to warm to –50 
oC within 0.5 h. HMPA (26.0 mL, 0.15 mol) was 
added dropwise followed by dropwise addition of solution of the iodide (24.30 g, 0.094 
mol) in dry THF (0.10 L). The reaction mixture was stirred under an Ar atmosphere for 
13 h during which time it was allowed to warm to RT. The reaction was stopped by 
addition  of  saturated  aqueous  NH4Cl  solution  (0.10  L)  and  the  whole  mixture  was 
poured onto H2O (0.30 L). The products were extracted with Et2O (3 × 0.20 L) and the 
combined organic phases were washed with H2O (3 × 0.20 L) and brine (2 × 0.20 L), 
dried over K2CO3, filtered and concentrated in vacuo to give the crude material as a 
yellow oil which was immediately purified by flash chromatography column on Al2O3 
(basic, grade III) with 5% Et2O in hexanes as the eluent to give the pure material as a 
colourless liquid (17.7 g, 81%).    124 
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1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.382 – 7.357 (2H, m, H
o-Ph), 7.260 – 7.242 
(3H, m, H
m-Ph + p-Ph), 4.664 (1H, t, J = 5.7 Hz, H
3), 3.673 (2H, dq, J = 9.3, 7.0 Hz, H
2), 
3.528 (2H, dq, J = 9.5, 7.0 Hz, H
2), 2.476 (2H, t, J = 7.3 Hz, H
5), 1.897 (2H, td, J = 7.2, 
5.7 Hz, H
4), 1.212 (6H, t, J = 7.0 Hz, H
1). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 131.47 (2CH
o-Ph), 128.12 (2CH
m-Ph), 127.51 
(CH
p-Ph), 123.88 (C
i-Ph), 101.81 (CH
3), 89.32 (C
6/7), 80.76 (C
6/7), 61.54 (2CH2
2), 32.77 
(CH2
4), 15.30 (2CH3
1), 15.01 (CH2
5). 
HRMS (EI): Found: [M]
+, 232.1465. [C15H20O2]
+ requires: 232.1463. 
LRMS (EI): m/z: 232 ([M]
+, 1%), 231 ([M – H]
+, 3%), 186 ([M – EtOH]
+, 67%), 157 
([M – EtOH – Et]
+, 100%), 127 (91%). 
IR (thin film): n ~= 2975 (m), 2926 (m), 2869 (m), 1599 (w), 1489 (m), 1448 (m), 1368 
(m), 1123 (s), 1058 (s), 760 (s), 688 (s) cm
–1. 
 
Such obtained acetal (17.67 g, 0.076 mol) was dissolved in THF : H2O (4 : 1, 0.50 L) 
and after stirring at RT for 5 min, a 2 M solution of HCl (0.114 L, 0.228 mol) was 
slowly added and the stirring was continued for 3 h. The reaction mixture was poured 
onto saturated aqueous NaHCO3 solution (0.20 L) and the products extracted with Et2O 
(3 × 0.20 L), the combined organic phases were washed with H2O (3 × 0.20 L) and 
brine (0.30 L), dried over MgSO4, filtered and concentrated in vacuo to give the crude 
material (12.02 g, 100%) as a pale yellow oil which was immediately reacted in the next 
step without any purification. 
O    125 
1H NMR (300 MHz, CDCl3): ￿ (ppm) = 9.837 (1H, s), 7.379 – 7.241 (5H, m), 2.768 – 
2.703 (4H, m). 
 
To a stirred solution of the crude aldehyde (12.02 g, 0.076 mol) in dry THF (0.40 L) at 
–78 
oC was added dropwise vinylmagnesium bromide (0.114 L of a 1.0 M solution in 
THF, 0.114 mol). The reaction mixture was stirred for a further 5 h during which time it 
was allowed to warm to RT before quenching with saturated aqueous NH4Cl solution 
(0.10 L). The whole mixture was poured onto H2O (0.20 L) and the products extracted 
with  Et2O (3 × 0.20 L) and the combined organic phases were washed with H2O (3 × 
0.15 L) and brine (0.20 L), dried over MgSO4, filtered and concentrated in vacuo to give 
the crude material as a yellow oil. Purification by flash chromatography column on 
silica with EtOAc : hexane (1 : 3) as the eluent gave 7-phenylhept-1-en-6-yn-3-ol 2.40 
as a pale yellow oil (9.21 g, 65%).  
HO
1
3 2
5
4
7 6
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.431 – 7.381 (2H, m, H
o-Ph), 7.321 – 7.261 
(3H, m, H
m-Ph + p-Ph), 5.925 (1H, ddd, J = 17.1, 10.3, 6.0 Hz, H
2), 5.315 (1H, dt, J = 17.3, 
1.4 Hz, H
1t), 5.172 (1H, dt, J = 10.5, 1.3 Hz, H
1c), 4.353 (1H, m, H
3), 2.582 (1H, dt, J = 
17.0, 7.5 Hz, H
5), 2.522 (1H, dt, J = 17.0, 6.8 Hz, H
5), 1.871 – 1.812 (3H, m, 2H
4 + 
OH). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 140.45 (CH
2), 131.52 (2CH
o-Ph), 128.19 
(2CH
m-Ph), 127.65 (CH
p-Ph), 123.73 (C
i-Ph), 115.09 (CH2
1), 89.37 (C
6/7), 81.16 (C
6/7), 
72.01 (CH
3), 35.61 (CH2
4), 15.64 (CH2
5). 
HRMS (EI): Found: [M]
+, 186.1044. [C13H14O]
+ requires: 186.1045. 
LRMS (EI): m/z: 186 ([M]
+, 22%), 185 ([M – H]
+, 46%), 167 ([M – H2O + H]
+, 77%), 
152 (47%), 128 (69%), 115 (100%). 
IR (thin film): n ~= 3338 (m, br), 2941 (w), 2915 (w), 1599 (w), 1489 (m), 1433 (m), 
1047 (m), 987 (m), 926 (m), 748 (s), 688 (s) cm
–1. 
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To a stirred solution of imidazole (1.904 g, 28.00 mmol) and DMAP (1.709 g, 14.00 
mmol) in dry THF (60.0 mL) at RT was added dropwise TBDMSOTf (3.20 mL, 14.00 
mmol). After stirring for 10 min, a solution of the allylic alcohol (1.303 g, 7.00 mmol) 
in  dry  THF  (10  mL)  was  added  and  the  stirring  continued  for  18  h  at  the  same 
temperature before quenching with H2O (20 mL). The whole mixture was poured onto 
H2O  (100  mL)  and  the products  extracted  with  Et2O  (3  ×  100  mL).  The combined 
organic phases were washed with H2O (2 × 100 mL) and brine (100 mL), dried over 
MgSO4, filtered and concentrated in vacuo to give the crude material as a yellow oil. 
Purification by flash chromatography column on silica with 5% Et2O in hexanes as the 
eluent provided the title compound as a yellow oil (2.079 g, 99%).  
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1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.423 – 7.399 (2H, m, H
o-Ph), 7.326 – 7.258 
(3H, m, H
m-Ph + p-Ph), 5.850 (1H, ddd, J = 17.1, 10.5, 6.0 Hz, H
2), 5.228 (1H, dt, J = 17.1, 
1.5 Hz, H
1t), 5.092 (1H, dt, J = 10.5, 1.7 Hz, H
1c), 4.330 (1H, apparent q, J = 6.0 Hz, 
H
3), 2.522 (1H, dt, J = 16.8, 7.5 Hz, H
5), 2.458 (1H, dt, J = 16.8, 6.5 Hz, H
5), 1.823 – 
1.764 (2 H, m, H
4), 0.944 (9H, s, H
10), 0.129 (3H, s, H
8), 0.085 (3H, s, H
8). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 141.16 (CH
2), 131.50 (2CH
o-Ph), 128.18 
(2CH
m-Ph), 127.50 (CH
p-Ph), 124.04 (C
i-Ph), 114.20 (CH2
1), 89.98 (C
6/7), 80.83 (C
6/7), 
72.39 (CH
3), 36.88 (CH2
4), 25.89 (3CH3
10), 18.24 (C
9), 15.36 (CH2
5), –4.34 (CH3
8), –
4.86 (CH3
8). 
HRMS (EI): Found: [M]
+, 300.1908. [C19H28OSi]
+ requires: 300.1909. 
LRMS (EI): m/z: 300 ([M]
+, 1%), 299 ([M – H]
+, 2%), 243 ([M – C(CH3)3]
+, 87%), 
225 (15%), 189 (46%), 115 (71%), 75 (100%). 
IR (thin film): n ~= 2953 (m), 2911 (m), 2854 (m), 1467 (w), 1357 (w), 1247 (m), 1066 
(m), 979 (m), 922 (m), 839 (s), 779 (s), 756 (s), 692 (s) cm
–1. 
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6.2.2.  (R)-(7-Phenylhept-1-en-6-yn-3-yloxy)(tert-butyl)dimethylsilane ((R)-2.41) 
A solution of the racemic alcohol 2.40 (0.372 g, 2.00 mmol) in vinyl crotonate (0.91 
mL)  was  placed  in  Schlenk  tube  and  an  immobilized  Candida  antartica  lipase 
(Novozyme 435) was added (0.091 g). The reaction was incubated at 42 °C (without 
stirring) for  72 h. After  this time the reaction mixture was filtered through  sintered 
funnel and the resins were washed with dry Et2O. The filtrate was concentrated in vacuo 
to give the crude products as a yellow oil. Purification by column chromatography on 
SiO2 with hexane : ethyl acetate (4 : 1) as the eluent gave (R)-7-phenylhept-1-en-6-yn-
3-ol (R)-2.40 as a pale yellow oil (0.179 g, 96%, 90% e.e.) and (E)-(S)-7-phenylhept-1-
en-6-yn-3-ylbut-2-enoate 2.42 as a yellow oil (0.229 g, 90%). 
To a stirred solution of the alcohol (R)-2.40 (0.179 g, 0.96 mmol) in dry DCM (12.0 
mL)  was  added  dropwise  Et3N  (0.39  mL,  2.82  mmol)  at  0  °C.  The  stirring  was 
continued at the same temperature for 5 min before dropwise addition of TBDMSOTf 
(0.33 mL, 1.41 mmol). After stirring for 10 min at 0 °C the ice bath was removed and 
the stirring continued for 30 min at RT before quenching with H2O (20 mL). The whole 
mixture was poured onto H2O (100 mL) and the products extracted with DCM (2 × 75 
mL). The combined organic phases were washed with H2O (2 × 100 mL) and brine (100 
mL), dried over MgSO4, filtered and concentrated in vacuo to give the crude material as 
a yellow oil. Purification by flash chromatography column on Al2O3 (basic, grade III) 
with hexane as the eluent provided the title compound as a pale yellow oil (0.193 g, 
67%) whose spectral data was consistent with those obtained for racemic product. 
 
6.2.3.  (1-Phenylhept-6-en-1-yn-4-yloxy)(tert-butyl)dimethylsilane (2.48) 
To a stirred solution of pent-4-ene-1,2-diol 2.46 (2.05 g, 20.0 mmol) in dry THF (100 
mL) at –10 °C was added sequentially NaH ( 2.40 g of a 60 % dispersion in mineral oil, 
60.0 mmol). After 15 min N-tosyl imidazole (2.45 g, 20.0 mmol) (prepared in 62% 
yield by the known procedure)
236 was added and the reaction mixture continued to stir 
at –10 °C for 1 h. Freshly prepared lithium phenyl acetylide was added and the reaction 
mixture was allowed to warm to 0 °C. [Lithium phenyl acetylide was freshly prepared 
from phenylacetylene (4.40 mL, 40.0 mmol) in dry THF (50 mL) and n-BuLi (16.0 mL 
of a 2.5 M solution in hexanes, 40.0 mmol) at –10 °C for 30 min]. Subsequently, HMPA 
(14.0 mL, 40.0 mmol) was added dropwise to the reaction mixture and the stirring was 
continued at 0 °C for 1 h. After this time, the cooling bath was removed and the reaction   128 
mixture  was  left  at  RT  for  40  h.  The  reaction  mixture  was  poured  onto  saturated 
aqueous NaHCO3 solution (200 mL), and the products extracted with Et2O (2 × 200 
mL). The combined organic phases were washed with H2O (2 × 200 mL), dried over 
MgSO4, filtered and concentrated in vacuo to give the crude product, 7-phenylhept-1-
en-6-yn-4-ol 2.47 as a brown oil that was further purified by column chromatography 
on SiO2 (for flash chromatography) with hexane : ethyl acetate (3 : 1) as the eluent to 
yield the title compound as a yellow oil (1.045 g, 28%). The spectral properties of 2.47 
were consistent with those published.
227  
HO
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1H NMR (300 MHz, CDCl3): ￿ (ppm) = 7.316 – 7.257 (2H, m, H
o-Ph), 7.182 – 7.127 
(3H, m, H
m-Ph + p-Ph), 5.744 (1H, ddt, J = 17.2, 10.2, 7.1 Hz, H
2), 5.068 (1H, ddt, J = 
17.2, 2.0, 1.5 Hz, H
1t), 5.024 (1H, ddt, J = 10.2, 2.1, 1.1 Hz, H
1c), 3.778 (1H, tt, J = 7.1, 
5.7 Hz, H
4), 2.538 (1H, dd, J = 16.8, 5.7 Hz, H
5), 2.462 (1H, dd, J = 16.8, 6.5 Hz, H-5), 
2.383 – 2.171 (2H, m, H
3), 1.965 (1H, br s, OH). 
13C NMR (75 MHz, CDCl3): ￿ (ppm) = 134.14 (CH
2), 131.66 (2CH
o-Ph), 128.26 (2CH
 
m-Ph), 127.94 (CH
p-Ph), 123.39 (C
i-Ph), 118.38 (CH2
1), 85.92 (C
6/7), 83.13 (C
6/7), 69.38 
(CH
4), 40.77 (CH2
3), 27.63 (CH2
5). 
LRMS (EI): m/z: 186 ([M]
+·, 3%), 168 ([M – H2O]
+·, 21%), 115 (100%), 91 (12%), 89 
(33 %), 77 (13%). 
IR (thin film): n ~= 3380 (m, br), 2930 (w), 1637 (w), 1599 (w), 1486 (m), 1436 (w), 
1349 (w), 1066 (m), 756 (s), 696 (s) cm
–1. 
 
To a stirred solution of imidazole (2.250 g, 33.08 mmol) and DMAP (2.020 g, 16.54 
mmol) in dry THF (100 mL) at RT was added dropwise TBDMSOTf (3.78 mL, 16.54 
mmol). After stirring for 10 min, a solution of the alcohol 2.47 (1.54 g, 8.27 mmol) in 
dry THF (50 mL) was added and the stirring continued for 15 h at the same temperature 
before quenching with H2O (20 mL). The mixture was poured onto H2O (150 mL) and 
the products extracted with  Et2O (2 × 150 mL), the combined organic phases washed 
with H2O (2 × 100 mL) and brine (2 × 100 mL), dried over MgSO4, filtered and and 
concentrated in vacuo to give the crude material as a yellow oil.    129 
Purification  by  flash  chromatography  column  on  silica  with  3%  Et2O  in  hexanes 
provided pure title compound 2.48 as a pale yellow oil (2.034 g, 82%).  
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1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.447 – 7.388 (2H, m, H
o-Ph), 7.338 – 7.258 
(3H, m, H
m-Ph + p-Ph), 5.887 (1H, ddt, J = 17.1, 10.3, 6.0 Hz, H
2), 5.174 – 5.086 (2H, m, 
H
1), 3.971 (1H, quintet, J = 5.9 Hz, H
4), 2.562 (2H, d, J = 6.2 Hz, H
5), 2.515 – 2.294 
(2H, m, H
3), 0.931 (9H, s, H
10), 0.134 (3H, s, H
8), 0.115 (3H, s, H
8). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 134.61 (CH
2), 131.53 (2CH
o-Ph), 128.17 
(2CH
m-Ph), 127.59 (CH
p-Ph), 123.93 (C
i-Ph), 117.44 (CH2
1), 87.48 (C
6/7), 82.09 (C
6/7), 
71.03 (CH
4), 41.52 (CH2
3), 27.89 (CH2
5), 25.84 (3CH3
10), 18.12 (C
9), –4.49 (CH3
8), –
4.58 (CH3
8). 
HRMS (EI): Found: [M]
+, 300.1898. [C19H28OSi]
+ requires: 300.1909. 
LRMS  (EI):  m/z:  300  ([M]
+,  1%),  285  ([M  –  CH3]
+,  3%),  259  (17%),  243  ([M  – 
(CH3)3]
+, 83%), 225 (26%), 115 (67%), 75 (100%). 
IR (thin film): n ~= 2945 (m), 2922 (m), 2854 (m), 1489 (w), 1357 (w), 1247 (m), 1058 
(s), 832 (s), 775(s), 756 (s), 684 (s) cm
–1. 
 
6.2.4.  N-Methyl-N-(phenylprop-2-ynyl)prop-2-en-1-amine (2.57) 
N
1
4
3 2
6
5
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1-Ethynylbenzene (0.33 mL, 3.0 mmol), N-allyl-N-methylamine (0.235 g, 3.3 mmol), 
formaldehyde (1.2 mL of a 35% aqueous solution) and CuI (0.012 g, 0.063 mmol) were 
dissolved in DMSO (6 mL). The reaction mixture was stirred at 30
 oC for 15 h before 
quenching with saturated aqueous solution of NH4Cl (50 mL). The products extracted 
with Et2O (3 × 25 mL). The combined organic phases were washed with H2O (3 × 50 
mL) and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give 
the crude material which was purified by flash chromatography on silica with 25% Et2O 
in hexanes to give the title compound as a yellow oil (0.23 g, 41%).   130 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.463 – 7.430 (2H, m, H
o-Ph), 7.325 – 7.290 
(3H, m, H
m-Ph + p-Ph), 5.896 (1H, ddt, J = 17.0, 10.3, 6.6 Hz, H
2), 5.266 (1H, dq, J = 17.1, 
1.5 Hz, H
1t), 5.186 (1H, ddt, J = 10.1, 1.9, 1.0 Hz, H
1c), 3.554 (2H, s, H
5), 3.146 (2H, dt, 
J = 6.8, 1.1 Hz, H
3), 2.392 (3H, s, H
4). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 135.42 (CH
2), 131.69 (2CH
o-Ph), 128.22 
(2CH
m-Ph), 127.97 (CH
p-Ph), 123.28 (C
i-Ph), 118.01 (CH2
1), 85.34 (C
6/7), 84.47 (C
6/7), 
59.18 (CH2
3), 45.98 (CH2
5), 41.71 (CH3
4). 
HRMS (ESI+): Found: [M + H]
+, 186.1276. [C13H16N]
+ requires: 186.1277. 
LRMS (ESI+): m/z: 186 ([M + H]
+, 100%). 
IR (thin film): n ~= 3070 (w), 2933 (w), 2786 (w), 1641 (w), 1599 (w), 1493 (m), 1436 
(m), 1331 (m), 1123 (m), 1002 (m), 926 (m), 748 (s), 692 (s) cm
–1. 
 
6.2.5.  N-Benzyl-N-(phenylprop-2-ynyl)prop-2-en-1-amine (2.60) 
N
1
4
3 2
6
5
7
 
Benzyl bromide (19.99 g, 117 mmol) was added dropwise to neat allylamine (52.7 mL, 
702 mmol) at 0 °C. After 16 h at room temperature, the reaction was quenched with 
aqueous NaHCO3 solution (200 mL), extracted with Et2O (3 × 100 mL), and dried over 
K2CO3. Purification by flash chromatography on silica with 30 ￿ 50% Et2O in hexanes 
gave N-allyl-N-benzylamine 2.59 (13.45 g, 78%) as a yellow oil whose spectral data 
was consistent with those published.
167 1-Ethynylbenzene (1.10 mL, 10 mmol), N-allyl-
N-benzylamine (1.77 g, 12.0 mmol), formaldehyde (4 mL of a 35% aqueous solution) 
and CuI (0.040 g, 0.21 mmol) were dissolved in DMSO (20 mL). The reaction mixture 
was stirred at 30
 °C for 15 h before quenching with a saturated aqueous solution of 
NH4Cl  (200  mL).  The  products  extracted  with  Et2O  (3  ×  150  mL),  the  combined 
organic phases were washed with H2O (3 × 150 mL) and brine (200 mL), dried over 
MgSO4,  filtered  and  concentrated  in  vacuo  to  give  the  crude  material  which  was 
purified by flash chromatography on silica with 25% Et2O in hexanes to give the title 
compound as a yellow oil (2.34 g, 89%). 
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1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.502 – 7.259 (10H, m, H
Ar), 5.948 (1H, ddt, J 
= 17.0, 10.3, 6.4 Hz, H
2), 5.328 (1H, dq, J = 17.2, 1.6 Hz, H
1t), 5.212 (1H, ddt, J = 10.1, 
1.9, 1.0 Hz, H
1c), 3.738 (2H, s, H
4/5), 3.550 (2H, s, H
4/5), 3.276 (2H, dt, J = 6.4, 1.3 Hz, 
H
3). 
13C  NMR  (100.5  MHz,  CDCl3):  ￿  (ppm)  =  138.71  (C
i-Ph),  135.70  (CH
2),  131.74 
(2CH
Ar),  129.19  (2CH
Ar),  128.28  (2CH
Ar),  128.26  (2CH
Ar),  127.97  (CH
p-Ph),  127.11 
(CH
p-Ph), 123.41 (C
i-Ph), 117.94 (CH2
1), 85.66 (C
6/7), 84.46 (C
6/7), 57.44 (CH2
3/4), 56.84 
(CH2
3/4), 42.18 (CH2
5). 
HRMS (ESI+): Found: [M + H]
+, 262.1586. [C19H20N]
+ requires: 262.1590. 
LRMS (ESI+): m/z: 262 ([M + H]
+, 100%). 
IR (thin film): n ~= 3024 (w), 2922 (w), 2816 (w), 1644 (w), 1599 (w), 1489 (m), 1315 
(m), 1119 (m), 922 (m), 756 (s), 733 (s), 688 (s) cm
–1. 
 
6.2.6.  Preparation of compounds 2.20 and 2.63a-aa 
General procedure A: To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 
mL) cooled to –78 °C was added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 
mmol) dropwise (usually over 2 minutes). After 25 min, a solution of the appropriate 
enyne (1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at –78 °C the 
reaction mixture was allowed to warm to room temperature and continued to stir for 2 – 
3 h. After re-cooling the reaction mixture to –78 °C, a solution of the appropriate 1,1-
dihalo alkane (1.1 mmol) in dry THF (1 mL) was added followed by dropwise addition 
of LDA (0.64 mL of a 1.8 M solution, 1.15 mmol) or freshly prepared LiTMP, [LiTMP 
prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.187 mL, 1.1 mmol) in 
dry THF (2 mL) and n-BuLi (0.44 mL of a 2.5 M solution in hexanes, 1.1 mmol) at 0 °C 
over 20 min]. The reaction mixture was stirred at –78 °C for 15 min before dropwise 
addition of the corresponding lithium acetylide, [prepared from alkyne (3.0 mmol) in 
dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in hexanes, 3.0 mmol) at –5 °C 
over 15 min]. The stirring was continued for 0.5 – 1 h during which the reaction mixture 
was  allowed  to  warm  to  –55  °C  before  addition  of  MeOH  (10  mL)  and  saturated 
aqueous  solution  of  NaHCO3  (10  mL).  The  mixture  was  allowed  to  warm  to  room 
temperature and left stirring for 12 – 16 h. The mixture was poured onto H2O (100 mL), 
the  products  extracted with  Et2O  (3  ×  75  mL).  The  combined  organic  phases  were   132 
washed with H2O (3 × 100 mL) and brine (100 mL), dried over anhydrous MgSO4, 
filtered and concentrated in vacuo to give the crude products mostly as yellow oils.  
 
Stability tests 
The following compounds: 2.63a, 2.69-exo, 2.69-endo, 2.72-exo and 2.72-endo were 
stable after being kept in CDCl3 (in NMR tube) at RT in the presence of daylight for 2 
weeks.  The  compounds  also  turned  out  to  be  stable  after  being  exposed  to  1.0 
equivalent of (+)-camphorsulfonic acid in CDCl3 (in NMR tube) at RT in the presence 
of  daylight  for  1  week.  2.63a  was  also  resistant  to  2.0  equivalents  of  (+)-
camphorsulfonic acid in CDCl3 for 2 weeks regardless of warming the NMR tube to 50 
°C for the last two days. 
 
6.2.6.1.  rac-(1R,5R)-1-(4-tert-Butylphenyl)vinyl)-3-hexyl-2-propyl-
bicyclo[3.3.0]oct-2-ene (2.20) 
H Hb
Ha
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General  procedure A was used  with dec-1-en-6-yne, 1,1-dibromopentane and 1-tert-
butyl-4-ethynylbenzene as components except that LiTMP was used instead of LDA. 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexanes as the eluent gave the title compound as a pale yellow oil in yield of 0.242 
g (66%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.237 (2H, m, H
o-Ph), 7.129 (2H, m, H
m-Ph), 
5.114 (1H, d, J = 1.8 Hz, H
13), 4.986 (1H, d, J = 1.8 Hz, H
13), 2.354 (1H, tt, J = 8.9, 2.1 
Hz, H
5), 2.278 (1H, dd, J = 15.7, 8.9 Hz, H
4b), 2.082 (2H, t, J = 7.3 Hz, H
14/17), 1.966 
(2H, t, J = 8.4 Hz, H
14/17), 1.835 – 1.700 (4H, m), 1.586 – 1.273 (9H, m), 1.324 (9H, s, 
H
9), 0.931 (3H, t, J = 7.2 Hz, H
16/20), 0.923 (3H, t, J = 7.3 Hz, H
16/20).   133 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 155.93 (C
12), 149.00 (C
11), 141.49 (C
i-Ph/2/3), 
138.96 (C
i-Ph/2/3), 137.42 (C
i-Ph/2/3), 127.45 (2CH
o-Ph), 124.16 (2CH
m-Ph), 112.79 (CH2
13), 
70.37 (C
1), 43.96 (CH
5), 43.92 (CH2
4), 36.60 (CH2), 36.09 (CH2), 34.33 (C
10), 31.39 
(3CH3
9),  30.05  (CH2),  29.02  (CH2
14/17),  28.92  (CH2
14/17),  25.32  (CH2),  23.73  (CH2), 
22.91 (CH2), 15.09 (CH3
16/20), 14.11 (CH3
16/20). 
HRMS (EI): Found: [M]
+, 364.3128. C27H40 requires: 364.3130. 
LRMS (EI): m/z: 364 ([M]
+, 56 %), 335 ([M – Et]
+, 11 %), 307 ([M – p-t-Bu]
+, 55 %), 
205 ([M – p- t-Bu-Styrene]
+, 100 %). 
IR (thin film): n ~= 2949 (s), 2862 (s), 1610 (w), 1504 (w), 1467 (m), 1365 (w), 1266 
(w), 1119 (w), 1017 (w), 900 (s), 847 (s), 733 (s), 601 (w) cm
–1. 
 
6.2.6.2.  rac-(1R,5R)-3-Hexyl-2-phenyl-1-(1-phenylvinyl)-bicyclo[3.3.0]oct-2-ene 
(2.63a) 
H Hb
Ha
3
8
7
6 5 4
2 1
12 11
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and  1-ethynylbenzene  as  components.  Purification  of  the  crude  material  by  column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.318 g (86%). 
 
1H NMR (300 MHz, CDCl3): ￿ (ppm) = 7.350 – 7.235 (10H, m, H
Ar), 5.038 (1H, d, J = 
1.6 Hz, H
10), 5.022 (1H, d, J = 1.6 Hz, H
10), 2.433 (1H, tdd, J = 8.6, 3.2, 1.4 Hz, H
5), 
2.342 (1H, ddd, J = 16.2, 8.4, 1.0 Hz, H
4b),  2.148 – 1.968 (3H, m), 1.854 (1H, dtd, J = 
12.2, 9.7, 6.8 Hz), 1.706 – 1.661 (2H, m), 1.622 – 1.521 (3H, m), 1.429 – 1.206 (8H, 
m), 0.881 (3H, t, J = 6.8 Hz, H
16). 
13C NMR (75 MHz, CDCl3): ￿ (ppm) = 155.39 (C
9), 144.40 (C
i-Ph), 142.48 (C
i-Ph), 
138.95 (C
2 or 3), 137.98 (C
2 or 3), 129.69 (2CH
o-Ph or m-Ph), 127.93 (2CH
o-Ph or m-Ph), 127.55 
(2CH
m-Ph  or  o-Ph),  127.52  (2CH
m-Ph  or  o-Ph),  126.47  (CH
p-Ph),  126.33  (CH
p-Ph),  114.45   134 
(CH2
10), 70.16  (C
1), 45.71 (CH
5), 43.83 (CH2), 36.33 (CH2), 35.64 (CH2), 31.70 (CH2), 
29.89 (CH2), 29.41 (CH2), 27.87 (CH2), 25.60 (CH2), 22.60 (CH2), 14.06 (CH3
16). 
HRMS (EI): Found: [M]
+, 370.2655. C26H34 requires: 370.2661. 
LRMS (EI): m/z: 370 ([M]
+·, 100%), 299 ([M – C5H11]
+·, 35%), 267 ([M – Styrene]
+·, 
85%). 
IR (thin film): n ~= 2926 (m), 2851 (m), 1632 (w), 1596 (w), 1491 (m), 1439 (w), 902 
(m), 768 (m), 703 (s) cm
–1. 
 
6.2.6.3.  rac-(1R,5R)-3-Hexyl-1-(3-methoxyphenyl)vinyl)-2-phenyl-bicyclo[3.3.0]-
oct-2-ene (2.63b) 
H Hb
Ha
3
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-ethynyl-3-methoxybenzene as components. Purification of the crude material by 
column chromatography on SiO2 (230 – 400 mesh) with 2.5 % Et2O in hexane as the 
eluent gave the title compound as a pale yellow oil in yield of 0.312 g (78%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.355 – 7.251 (5H, m, H
Ar), 7.199 (1H, t, J = 
8.0 Hz, H
13), 6.957 (1H, ddd, J = 8.0, 1.5, 1.0 Hz, H
14), 6.916 (1H, dd, J = 2.5, 1.5 Hz, 
H
9), 6.833 (1H, ddd, J = 8.0, 2.5, 1.0 Hz, H
12), 5.081 (1H, d, J = 1.8 Hz, H
16), 5.017 
(1H, d, J = 1.8 Hz, H
16), 3.793 (3H, s, H
11), 2.508 – 2.414 (2H, m, H
5 + 4b), 2.104 (1H, 
dt, J = 21.5, 8.0 Hz, H
17), 2.051 (1H, dt, J = 21.5, 8.0 Hz, H
17), 2.046 (1H, d, J = 15.3 
Hz, H
4a), 1.870 (1H, tdd, J = 11.8, 10.0, 6.5 Hz,  H
6), 1.716 – 1.501 (4H, m), 1.444 – 
1.367 (3H, m), 1.332 – 1.240  (6H, m), 0.901 (3H, t, J = 7.0 Hz, H
22). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 158.90 (C
10), 155.23 (C
15), 145.88 (C
2 or 3), 
142.43 (C
2 or 3), 139.14 (C
i-Ph), 137.94 (C
i-Ph), 129.72 (2CH
m-Ph), 128.45 (CH
13), 127.54 
(2CH
o-Ph),  126.33  (CH
p-Ph),  120.48  (CH
14),  114.59  (CH2
16),  113.68  (CH
9),  111.90 
(CH
12),  70.13  (C
1),  55.10  (CH3
11),  45.74  (CH
5),  43.96  (CH2
4),  36.38  (CH2
6),  35.82   135 
(CH2
8), 31.71 (CH2), 29.91 (CH2
17), 29.41 (CH2), 27.96 (CH2), 25.55 (CH2
7), 22.58 
(CH2), 14.07 (CH3
22). 
HRMS (EI): Found: [M]
+, 400.2763. C29H36O requires: 400.2766. 
LRMS (CI): m/z: 400 ([M]
+, 100%), 267 ([M – m-MeO – Styrene]
+, 24%). 
IR (thin film): n ~= 2934 (m), 2848 (m), 1574 (m), 1455 (m), 1283 (m), 1040 (m), 889 
(m), 764 (m), 700 (s) cm
–1. 
 
6.2.6.4.  rac-(1R,5R)-3-Hexyl-1-(4-methoxyphenyl)vinyl)-2-phenyl-bicyclo[3.3.0]-
oct-2-ene (2.63c) 
H Hb
Ha
3
8
7
6 5 4
2 1
15 14
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10 9
11
 
General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-ethynyl-4-methoxybenzene as components. Purification of the crude material by 
column chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the 
title compound as a yellow oil in yield of 0.290 g (72%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.343 – 7.241 (7H, m, H
Ar), 6.838 – 6.801 
(2H, m, H
11), 5.018 (1H, d, J = 1.8 Hz, H
13), 4.994 (1H, d, J = 1.8 Hz, H
13), 3.827 (3H, 
s, H
9), 2.430 (1H, td, J = 8.5, 2.4 Hz, H
5), 2.375  (1H, dd, J = 16.0, 8.5 Hz, H
4b), 2.077 
(1H, dt, J = 21.3, 8.0 Hz, H
14), 2.058 (1H, dt, J = 21.3, 7.5 Hz, H
14), 2.012 (1H, d, J = 
16.0 Hz, H
4a), 1.856 (1H, tdd, J = 12.0, 9.5, 7.0 Hz,  H
6), 1.737 – 1.668 (2H, m, H
8), 
1.623 – 1.484 (2H, m, H
7), 1.423 – 1.341 (3H, m), 1.323 – 1.204 (6H, m), 0.892 (3H, t, 
J = 7.0 Hz, H
19). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 158.33 (C
10), 154.81 (C
12), 142.39 (C
2 or 3), 
138.98 (C
2 or 3), 137.96 (C
i-Ph), 136.91 (C
i-Ph), 129.64 (2CH
o- or m-Ph), 128.91 (2CH
o- or m-
Ph), 127.52 (2CH
o- or m-Ph), 126.29 (CH
p-Ph), 113.98 (CH2
13), 112.89 (2CH
11), 70.23 (C
1), 
55.16 (CH3
9), 45.64 (CH
5), 43.90 (CH2
4), 36.36 (CH2
6), 35.62 (CH2
8), 31.71 (CH2), 
29.88 (CH2
14), 29.41 (CH2), 27.87 (CH2), 25.59 (CH2
7), 22.60 (CH2), 14.07 (CH3
19).   136 
HRMS (EI): Found: [M]
+, 400.2768. C29H36O requires: 400.2766. 
LRMS (CI): m/z: 401 ([M + H]
+, 100%), 267 ([M – p-MeO – Styrene]
+, 55%). 
IR (thin film): n ~= 2930 (m), 2854 (m), 1607 (m), 1508 (s), 1244 (s), 1176 (m), 1036 
(m), 903 (w), 832 (s), 767 (m), 699 (s) cm
–1. 
 
6.2.6.5.  rac-(1R,5R)-3-Hexyl-1-(4-methylphenyl)vinyl)-2-phenyl-bicyclo[3.3.0]oct-
2-ene (2.63d) 
H Hb
Ha
3
8
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6 5 4
2 1
15 14 16 17 18 19
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-ethynyl-4-methylbenzene as components. Purification of the crude material by 
column chromatography on SiO2 (230 – 400 mesh) with hexane as the eluent gave the 
title compound as a pale yellow oil in yield of 0.237 g (62%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.344 – 7.234 (7H, m, H
Ar), 7.099 – 7.080 
(2H, m, H
9), 5.035 (1H, d, J = 1.8 Hz, H
13), 4.998 (1H, d, J = 1.8 Hz, H
13), 2.470 – 
2.346 (2H, m, H
5 + 4b), 2.370 (3H, s, H
9), 2.096 (1H, dt, J = 21.5, 7.8 Hz, H
14), 2.061 
(1H, dt, J = 21.5, 7.5 Hz, H
14), 2.016 (1H, d, J = 14.8 Hz, H
4a), 1.855 (1H, tdd, J = 12.0, 
9.8, 6.8 Hz, H
6), 1.701 – 1.667 (2H, m), 1.601 – 1.535 (2H, m), 1.431 – 1.356 (3H, m), 
1.325 – 1.229 (6H, m), 0.897 (3H, t, J = 7.0 Hz, H
19). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 155.21 (C
12), 142.33 (C
2 or 3), 141.53 (C
2 or 
3), 139.09 (C
i-Ph  or  10), 137.99  (C
i-Ph  or  10), 136.01 (C
i-Ph  or  10), 129.71 (2CH
o-  or  m-Ph), 
128.24 (2CH
o-  or  m-Ph), 127.76 (2CH
o-  or  m-Ph), 127.51 (2CH
o-  or  m-Ph), 126.28 (CH
p-Ph), 
114.24 (CH2
13), 70.19 (C
1), 45.67 (CH
5), 43.91 (CH2
4), 36.36 (CH2
6), 35.70 (CH2
8), 
31.72  (CH2),  29.88  (CH2
14),  29.40  (CH2),  27.88  (CH2),  25.58  (CH2
7),  22.60  (CH2), 
21.08 (CH3
11), 14.07 (CH3
19). 
HRMS (EI): Found: [M]
+, 384.2820. C29H36 requires: 384.2817. 
LRMS (CI): m/z: 384 ([M]
+, 100%), 267 ([M – p-Me – Styrene]
+, 33%).   137 
IR (thin film): n ~= 2929 (m), 2848 (m), 1596 (w), 1493 (w), 1445 (w), 894 (m), 824 
(m), 759 (m), 694 (s) cm
–1. 
 
6.2.6.6.  rac-(1R,5R)-1-(4-Ethylphenyl)vinyl)-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-
ene (2.63e) 
H Hb
Ha
3
8
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and  1-ethyl-4-ethynylbenzene  as  components.  Purification  of  the  crude  material  by 
column chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the 
title compound as a pale yellow oil in yield of 0.280 g (70%). 
 
1H NMR (400 MHz, BENZENE-D6): ￿ (ppm) = 7.440 – 7.047 (9H, m, H
Ar), 5.164 
(1H, d, J = 1.8 Hz, H
13), 5.094 (1H, d, J = 1.8 Hz, H
13), 2.592 (1H, tdd, J = 8.3, 4.3, 1.5 
Hz, H
5), 2.511 (1H, dd, J = 16.3, 8.3 Hz, H
4b), 2.500 (2H, q, J = 7.5 Hz, H
10), 2.154 – 
2.115 (2H, m, H
14), 1.987 (1H, d, J = 16.3 Hz, H
4a), 1.881 – 1.730 (3H, m), 1.688 – 
1.530 (2H, m), 1.426 – 1.348 (3H, m), 1.287 – 1.158 (6H, m), 1.131 (3H, t, J = 7.7 Hz, 
H
9), 0.863 (3H, t, J = 7.2 Hz, H
19). 
13C  NMR  (100.5 MHz,  BENZENE-D6):  ￿  (ppm)  =  156.22  (C
12),  143.09  (C
2  or  3), 
142.81  (C
11),  142.64  (C
2  or  3),  140.32  (C
i-Ph),  138.79  (C
i-Ph),  130.51  (2CH
o-  or  m-Ph), 
128.71 (2CH
o-  or  m-Ph), 128.46 (2CH
o-  or  m-Ph), 127.87 (2CH
o-  or  m-Ph), 127.26 (CH
p-Ph), 
114.96 (CH2
10), 71.14 (C
1), 46.50 (CH
5), 44.68 (CH2
4), 37.13 (CH2), 36.54 (CH2), 32.41 
(CH2), 30.64 (CH2), 30.15 (CH2), 29.24 (CH2), 28.67 (CH2), 26.39 (CH2), 23.36 (CH2), 
16.22 (CH3
9), 14.66 (CH3
19). 
HRMS (EI): Found: [M]
+, 398.2974. C30H38 requires: 398.2974. 
LRMS (CI): m/z: 399 ([M + H]
+, 100%), 267 ([M – p-Et – Styrene]
+, 45%). 
IR (thin film): n ~= 2933 (s), 2850 (m), 1493 (w), 1452 (w), 902 (m), 835 (s), 760 (m), 
695 (s) cm
–1. 
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6.2.6.7.  rac-(1R,5R)-1-(4-Butylphenyl)vinyl)-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-
ene (2.63f) 
H Hb
Ha
3
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and  1-butyl-4-ethynylbenzene  as  components.  Purification  of  the  crude  material  by 
column chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the 
title compound as a yellow oil in yield of 0.333 g (78%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.370 – 7.265 (7H, m, H
Ar), 7.125 – 7.099 
(2H, m, H
14), 5.066 (1H, d, J = 1.8 Hz, H
16), 5.025 (1H, d, J = 1.8 Hz, H
16), 2.650 (2H, 
t, J = 7.6 Hz, H
12), 2.466 (1H, td, J = 8.8, 2.8 Hz, H
5), 2.399 (1H, dd, J = 16.0, 8.8 Hz, 
H
4b), 2.118 (1H, dt, J = 21.0, 7.5 Hz, H
17), 2.087 (1H, dt, J = 21.0, 7.3 Hz, H
17), 2.027 
(1H, d, J = 16.0 Hz, H
4a), 1.880 (1H, tdd, J = 12.3, 9.3, 6.8 Hz, H
6), 1.730 – 1.506 (6H, 
m), 1.469 – 1.368  (5H, m), 1.349 – 1.256 (6H, m), 0.991 (3H, t, J = 7.3 Hz, H
9 or 22), 
0.920 (3H, t, J = 7.0 Hz, H
9 or 22). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 155.29 (C
15), 142.34 (C
2 or 3), 141.64 (C
13), 
141.05 (C
2 or 3), 139.06 (C
i-Ph), 138.02 (C
i-Ph), 129.71 (2CH
o- or m-Ph), 127.74 (2CH
o- or m-
Ph), 127.51 (4CH
o- or m-Ph), 126.27 (CH
p-Ph), 114.12  (CH2
10), 70.19 (C
1), 45.69 (CH
5), 
43.91 (CH2
4), 36.35 (CH2
6), 35.67 (CH2), 35.29 (CH2
12), 33.63 (CH2), 31.73 (CH2), 
29.90 (CH2
17), 29.43 (CH2), 27.87 (CH2), 25.60 (CH2), 22.61 (CH2), 22.42 (CH2), 14.08 
(CH3
9 or 22), 13.97 (CH3
9 or 22). 
HRMS (EI): Found: [M]
+, 426.3293. C32H42 requires: 426.3286. 
LRMS (CI): m/z: 427 ([M + H]
+, 100%), 267 ([M – p-Bu – Styrene]
+, 47%). 
IR (thin film): n ~= 2926 (s), 2854 (m), 1512 (w), 1459 (w), 900 (m), 835 (w), 752 (m), 
699 (s) cm
–1. 
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6.2.6.8.  rac-(1R,5R)-1-(4-tert-Butylphenyl)vinyl)-3-hexyl-2-phenyl-
bicyclo[3.3.0]oct-2-ene (2.63g) 
H Hb
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-tert-butyl-4-ethynylbenzene as components. Purification of the crude material by 
column chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the 
title compound as a pale yellow oil in yield of 0.221 g (51%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.332 – 7.222 (9H, m, H
Ar), 5.040 (1H, d, J = 
1.8 Hz, H
13), 4.976 (1H, d, J = 1.8 Hz, H
13), 2.440 (1H, td, J = 8.5, 2.2 Hz, H
5), 2.390 
(1H, dd, J = 15.5, 8.3 Hz, H
4b), 2.085 – 2.040 (2H, m, H
14), 1.993 (1H, d, J = 15.5 Hz, 
H
4a), 1.835 (1H, tdd, J = 12.3, 10.0, 6.9 Hz, H
6), 1.692 – 1.658 (2H, m, H
8), 1.601 – 
1.489 (2H, m, H
7), 1.409 – 1.208 (9H, m), 1.335 (9H, s, H
9), 0.877 (3H, t, J = 7.0 Hz, 
H
19). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 155.17 (C
12), 149.28 (C
11), 142.27 (C
2 or 3), 
141.37 (C
2 or 3), 139.17 (C
i-Ph), 138.00 (C
i-Ph), 129.74 (2CH
o- or m-Ph), 127.47 (4CH
o- or m-
Ph), 126.26 (CH
p-Ph), 124.37 (2CH
o-  or  m-Ph), 114.23 (CH2
13), 70.17 (C
1), 45.66 (CH
5), 
43.97 (CH2
4), 36.38 (CH2
6), 35.74 (CH2
8), 34.38 (C
10), 31.73 (CH2), 31.40 (3CH3
11), 
29.90 (CH2
14), 29.42 (CH2), 27.87 (CH2), 25.56 (CH2
7), 22.61 (CH2), 14.08 (CH3
19). 
HRMS (EI): Found: [M]
+, 426.3283. C32H42 requires: 426.3286. 
LRMS (CI): m/z: 427 ([M + H]
+, 100%), 267 ([M – p- t-Bu – Styrene]
+, 51%). 
IR (thin film): n ~= 2949 (s), 2930 (s), 2862 (m), 1508 (w), 1489 (w), 1467 (w), 1367 
(w), 1270 (w), 903 (m), 843 (s), 763 (m), 699 (s) cm
–1. 
 
   140 
6.2.6.9.  rac-(1R,5R)-3-Hexyl-2-phenyl-1-(4-phenylphenyl)vinyl)-bicyclo[3.3.0]oct-
2-ene (2.63h) 
H Hb
Ha
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-ethynyl-4-phenylbenzene as components. Purification of the crude material by 
column chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the 
title compound as a yellow oil in yield of 0.266 g (60%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.478 – 7.089 (14H, m, H
Ar), 4.943 (1H, d, J = 
1.6 Hz, H
10), 4.885 (1H, d, J = 1.6 Hz, H
10), 2.324 (1H, td, J = 8.4, 2.3 Hz, H
5), 2.272 
(1H, dd, J = 16.6, 8.4 Hz, H
4b), 1.937 (1H, dt, J = 21.6, 7.8 Hz, H
11), 1.906 (1H, dt, J = 
21.6, 7.3 Hz, H
11), 1.868 (1H, d, J = 16.6 Hz, H
4a), 1.710 (1H, tdd, J = 12.0, 10.3, 7.0 
Hz, H
6), 1.572 – 1.539 (2H, m, H
8), 1.477 – 1.382 (2H, m, H
7), 1.286 – 1.196 (3H, m), 
1.168 – 1.022 (6H, m), 0.715 (3H, t, J = 6.9 Hz, H
16). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 155.03 (C
9), 143.49 (C
2 or 3), 142.52 (C
2 or 3), 
140.96  (C
i-Ph),  139.30  (C
i-Ph),  139.07  (C
i-Ph),  137.94  (C
i-Ph),  129.71  (2CH
o-  or  m-Ph), 
128.71 (2CH
o-  or  m-Ph), 128.29 (2CH
o-  or  m-Ph), 127.57 (2CH
o-  or  m-Ph), 127.09 (CH
p-Ph), 
126.95 (2CH
o-  or  m-Ph), 126.36 (CH
p-Ph), 126.23 (2CH
o-  or  m-Ph), 114.64 (CH2
10), 70.20 
(C
1),  45.69  (CH
5),  43.98  (CH2
4),  36.41  (CH2),  35.78  (CH2
8),  31.71  (CH2),  29.90 
(CH2
11), 29.42 (CH2), 27.89 (CH2), 25.56 (CH2
7), 22.61 (CH2), 14.07 (CH3
16). 
HRMS (EI): Found: [M]
+, 446.2972. C34H38 requires: 446.2974. 
LRMS (CI): m/z: 446 ([M]
+, 100%), 267 ([M – p-Ph – Styrene]
+, 69%). 
IR (thin film): n ~= 2933 (m), 2858 (m), 1603 (w), 1482 (s), 1440 (w), 903 (m), 847 
(m), 767 (s), 737 (s), 699 (s) cm
–1. 
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6.2.6.10. rac-(1R,5R)-3-Hexyl-1-(pent-1-en-2-yl)-2-phenyl-bicyclo[3.3.0]oct-2-ene 
(2.63i) 
H Hb
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and  1-pentyne  as  components.  Purification  of  the  crude  material  by  column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a colourless oil in yield of 0.183 g (54%). 
 
1H NMR (400 MHz, BENZENE-D6): ￿ (ppm) = 7.248 – 7.187 (4H, m, H
o-  +  m-Ph), 
7.116 – 7.072 (1H, m, H
p-Ph), 4.988 (1H, d, J = 1.0 Hz, H
13), 4.941 (1H, q, J = 1.5 Hz, 
H
13), 2.852 (1H, dd, J = 16.8, 8.3 Hz, H
4b), 2.440  (1H, tdd, J = 8.3, 3.3, 1.8 Hz, H
5), 
2.287 – 2.070 (5H, m, H
4a + 4H), 1.918 – 1.741 (2H, m), 11.701 – 1.535 (5H, m), 1.459 
– 1.355 (3H, m), 1.267 – 1.107 (6H, m), 0.981 (3H, t, J = 7.3 Hz, H
9 or 19), 0.850 (3H, t, 
J = 7.1 Hz, H
9 or 19). 
13C  NMR  (100.5 MHz,  BENZENE-D6):  ￿  (ppm)  =  154.63  (C
12),  141.69  (C
2  or  3), 
140.80 (C
2  or  3), 138.75 (C
i-Ph), 130.16 (2CH
o-  or  m-Ph), 128.39 (2CH
o-  or  m-Ph), 127.12 
(CH
p-Ph), 108.43 (CH2
13), 72.04 (C
1), 46.35 (CH
5), 44.97 (CH2
4), 37.39 (CH2), 35.50 
(CH2), 34.60 (CH2), 32.36 (CH2), 30.30 (CH2), 29.84 (CH2), 28.81 (CH2), 26.52 (CH2), 
23.37 (CH2), 22.39 (CH2), 15.03 (CH3
9 or 19), 14.64 (CH3
9 or 19). 
HRMS (EI): Found: [M]
+, 336.2818. C25H36 requires: 336.2817. 
LRMS (CI): m/z: 337 ([M + H]
+, 100%), 293 ([M – C3H7]
+, 35%). 
IR (thin film): n ~= 2956 (s), 2926 (s), 2854 (m), 1633 (w), 1489 (w), 1455 (w), 892 
(m), 877 (m), 760 (m), 699 (s) cm
–1. 
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6.2.6.11. rac-(1R,5R)-1-(Hex-1-en-2-yl)-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-ene 
(2.63j) 
H Hb
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and  1-hexyne  as  components.  Purification  of  the  crude  material  by  column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.263 g (75%). 
 
1H NMR (300 MHz, CDCl3): ￿ (ppm) = 7.292 – 7.172 (3H, m, H
m-Ph + p-Ph),  7.055 – 
7.024 (2H, m, H
o-Ph), 4.806 (1H, q, J = 1.4 Hz, H
10), 4.792 (1H, q, J = 1.4 Hz, H
10),  
2.841 (1H, dd, J = 16.8, 8.4 Hz, H
4b), 2.431 (1H, dddd, J = 9.7, 8.4, 3.2, 1.6 Hz, H
5), 
2.207 – 2.006 (5H, m), 1.888 (1H, dtd, J = 12.0, 9.4, 7.0 Hz, H
6), 1.705 (1H, m), 1.595 
– 1.478 (6H, m), 1.456 – 1.326 (4H, m), 1.297 – 1.211 (6H, m), 0.950 (3H, t, J = 7.2 
Hz, H
11 or 20), 0.860 (3H, t, J = 6.9 Hz, H
20 or 11). 
13C NMR (75 MHz, CDCl3): ￿ (ppm) = 154.57 (C
9), 141.21 (C
i-Ph), 139.63 (C
2 or 3), 
138.04 (C
2 or 3), 129.40 (2CH
o- or m-Ph), 127.42 (2CH
m- or o-Ph), 126.11 (CH
p-Ph), 107.27 
(CH2
10), 71.24 (C
1), 45.53 (CH
5), 44.33 (CH2), 36.67 (CH2), 33.84 (CH2), 32.05 (CH2), 
31.68 (CH2), 30.75 (CH2), 29.59 (CH2), 29.13 (CH2), 28.06 (CH2), 25.70 (CH2), 23.05 
(CH2), 22.61 (CH2), 14.15 (CH3
11 or 20), 14.04 (CH3
20 or 11). 
HRMS (EI): Found: [M]
+, 350.2979. C26H38 requires: 350.2974. 
LRMS (EI): m/z:  350  ([M]
+·,  57%),  307  ([M –  C3H7]
+·,  26%),  293  ([M  –  C4H9]
+·, 
100%). 
IR (thin film): n ~= 2925 (m), 2852 (m), 1630 (w), 1487 (w), 1467 (m), 886 (m), 760 
(m), 698 (s) cm
–1. 
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6.2.6.12. rac-(1R,5R)-3-Hexyl-1-(oct-1-en-2-yl)-2-phenyl-bicyclo[3.3.0]oct-2-ene 
(2.63k) 
H Hb
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2 1
18 17
16
15
10
19 20 21 22
14 9 13 12 11
 
General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and  1-octyne  as  components.  Purification  of  the  crude  material  by  column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a colourless oil in yield of 0.247 g (65%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.286 – 7.186 (3H, m, H
o- + p-Ph), 7.053 – 7.023 
(2H, m, H
m-Ph), 4.806 (1H, q, J = 1.5 Hz, H
16), 4.791 (1H, d, J = 1.0 Hz, H
16), 2.844 
(1H, dd, J = 16.7, 8.3 Hz, H
4b), 2.430 (1H, tdd, J = 8.3, 3.3, 1.8 Hz, H
5), 2.193 – 2.018 
(4H, m), 2.132 (1H, d, J = 16.7 Hz, H
4a), 1.888 (1H, tdd, J = 12.3, 9.5, 7.0 Hz, H
6), 
1.736 – 1.667 (1H, m), 1.600 – 1.177 (20H, m), 0.916 (3H, t, J = 7.0 Hz, H
9 or 22), 0.862 
ppm (3H, t, J = 7.0 Hz, H
9 or 22). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 154.61 (C
15), 141.21 (C
i-Ph), 139.59 (C
2 or 3), 
138.01 (C
2 or 3), 129.38  (2CH
o- or m-Ph), 127.42 (2CH
o- or m-Ph), 126.10 (CH
p-Ph), 107.23 
(CH2
16),  71.22  (C
1),  45.50  (CH
5),  44.33  (CH2
4),  36.68  (CH2
6),  33.82  (CH2),  32.35 
(CH2), 31.95 (CH2), 31.69 (CH2), 29.70 (CH2), 29.59 (CH2), 29.14 (CH2), 28.47 (CH2), 
28.05 (CH2), 25.69 (CH2), 22.71 (CH2), 22.62 (CH2), 14.11 (CH3
9 or 22), 14.06 (CH3
9 or 
22). 
HRMS (EI): Found: [M]
+, 378.3289. C28H42 requires: 378.3286. 
LRMS (CI): m/z: 378 ([M]
+, 100%), 293 ([M – C6H13]
+, 63%). 
IR (thin film): n ~= 2926 (s), 2858 (m), 1633 (w), 1493 (w), 1467 (m), 884 (m), 763 
(m), 699 (s) cm
–1. 
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6.2.6.13. rac-(1R,5R)-1-(Dec-1-en-2-yl)-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-ene 
(2.63l) 
H Hb
Ha
3
8
7
6
5 4
2 1
20 19
13
12 10
21 22 23 24
11 9
14
15
17
18
16
 
General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and  1-decyne  as  components  Purification  of  the  crude  material  by  column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.229 g (56%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.291 – 7.192 (3H, m, H
o- + p-Ph), 7.060 – 7.030 
(2H, m, H
m-Ph), 4.813 (1H, apparent q, J = 1.5 Hz, H
18), 4.798 (1H, d, J = 1.0 Hz, H
18), 
2.852 (1H, dd, J = 16.6, 8.4 Hz, H
4b), 2.430  (1H, tdd, J = 8.4, 3.3, 1.5 Hz, H
5), 2.196 – 
2.023 (4H, m), 2.138 (1H, d, J = 16.6 Hz, H
4a), 1.895 (1H, tdd, J = 12.3, 9.8, 7.0 Hz,  
H
6), 1.744 – 1.674 (1H, m), 1.621 – 1.480 (5H, m), 1.420 – 1.168 (19H, m), 0.914 (3H, 
t, J = 7.0 Hz, H
9 or 24), 0.871 (3H, t, J = 7.0 Hz, H
9 or 24). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 154.61 (C
17), 141.21 (C
i-Ph), 139.60 (C
2 or 3), 
138.01 (C
2 or 3), 129.38  (2CH
o- or m-Ph), 127.41 (2CH
o- or m-Ph), 126.10 (CH
p-Ph), 107.28 
(CH2
18),  71.22  (C
1),  45.50  (CH
5),  44.34    (CH2
4),  36.68  (CH2),  33.82  (CH2),  32.34 
(CH2), 31.92 (CH2), 31.69 (CH2), 30.03 (CH2), 29.68 (CH2), 29.59 (CH2), 29.37 (CH2), 
29.14 (CH2), 28.49 (CH2), 28.05 (CH2), 25.69 (CH2), 22.70 (CH2), 22.63 (CH2), 14.12 
(CH3
9 or 24),14.06 (CH3
9 or 24). 
HRMS (EI): Found: [M]
+, 406.3598. C30H46 requires: 406.3600. 
LRMS (CI): m/z: 406 ([M ]
+, 100 %), 293 ([M – C8H17]
+, 47 %). 
IR (thin film): n ~= 2930 (s), 2858 (m), 1633 (w), 1493 (w), 1463 (m), 884 (m), 763 
(m), 699 (s) cm
–1. 
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6.2.6.14. rac-(1R,5R)-3-Hexyl-2-(3-methoxyphenyl)-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.63m) 
H Hb
Ha
3
8
7
6 5 4
2 1
14 13
12
15 16 17 18
10
9
11
O
 
General  procedure  A  was  used  with  1-(hept-6-en-1-ynyl)-3-methoxybenzene,  1,1-
dibromoheptane  and  1-ethynylbenzene  as  components.  Purification  of  the  crude 
material by column chromatography on SiO2 (230 – 400 mesh) with hexanes as the 
eluent gave the title compound as a pale yellow oil in yield of 0.302 g (75%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.346 – 7.219 (6H, m, H
Ar), 6.889 – 6.815 
(3H, m, H
Ar), 5.082 (1H, d, J = 1.6 Hz, H
10), 5.051 (1H, d, J = 1.6 Hz, H
10), 3.793 (3H, 
s, H
12), 2.420 (1H, tdd, J = 8.3, 3.0, 1.3 Hz,  H
5), 2.294 (1H, dd, J = 16.6, 8.3 Hz,  H
4b), 
2.116 (1H, dt, J = 25.5, 7.8 Hz,  H
13), 2.082 (1H, dt, J = 25.5, 7.5 Hz,  H
13), 1.985 (1H, 
d, J = 16.6 Hz,  H
4a), 1.860 (1H, tdd, J = 12.3, 10.0, 6.8 Hz, H
6), 1.718 – 1.682 (2H, m, 
H
8), 1.612 – 1.466 (2H, m, H
7), 1.413 – 1.202 (9H, m), 0.888 (3H, t, J = 7.0 Hz, H
18). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 158.92 (C
11), 155.54 (C
9), 144.28 (C
2 or 3), 
142.72 (C
2 or 3), 139.41 (C
i-Ph), 138.55 (C
i-Ph), 128.44 (CH
o- or m-Ph), 127.97 (2CH
o- or m-Ph), 
127.49 (2CH
o- or m-Ph), 126.46 (CH
p-Ph), 122.33 (CH
o- or m-Ph), 115.19 (CH
o- or m-Ph), 114.32 
(CH2
10), 111.74 (CH
o-  or  m-Ph), 70.09 (C
1), 55.07 (CH3
12), 45.74 (CH
5), 43.75 (CH2
4), 
36.26  (CH
6),  35.47  (CH2
8),  31.74  (CH2),  29.96  (CH2
13),  29.47  (CH2),  27.89  (CH2), 
25.67 (CH2
7), 22.61 (CH2), 14.08 (CH3
18). 
HRMS (EI): Found: [M]
+, 400.2763. C29H36O requires: 400.2766. 
LRMS (CI): m/z: 401 ([M + H]
+, 100%), 297 ([M – Styrene]
+, 30%). 
IR (thin film): n ~= 2930 (m), 2858 (m), 1595 (m), 1572 (m), 1489 (m), 1455 (m), 1281 
(m), 1051 (m), 903 (m), 779 (s), 703 (s) cm
–1. 
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6.2.6.15. rac-(1R,5R)-2-(4-Ethylphenyl)-3-hexyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-
ene (2.63n) 
H Hb
Ha
3
8
7
6
5 4
2 1
15 14
10
9
16 17 18 19
11
12
13
 
General  procedure  A  was  used  with  1-ethyl-4-(hept-6-en-1-ynyl)benzene,  1,1-
dibromoheptane  and  1-ethynylbenzene  as  components.  Purification  of  the  crude 
material by column chromatography on SiO2 (230 – 400 mesh) with hexanes as the 
eluent gave the title compound as a pale yellow oil in yield of 0.281 g (70%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.380 – 7.163 (9H, m, H
Ar), 5.080 (1H, d, J = 
1.8 Hz, H
10), 5.057 (1H, d, J = 1.8 Hz, H
10), 2.701 (2H, q, J = 7.5 Hz,  H
12), 2.436 (1H, 
tdd, J = 8.3, 2.8, 1.0 Hz, H
5), 2.318 (1H, dd, J = 16.6, 8.3 Hz, H
4b), 2.133 (1H, dt, J = 
21.3, 7.8 Hz, H
14), 2.080 (1H, dt, J = 21.3, 7.5 Hz, H
14), 2.002 (1H, d, J = 16,6 Hz, H
4a), 
1.875 (1H, tdd, J = 12.3, 10.3, 7.0 Hz, H
6), 1.725 – 1.687 (2H, m, H
8), 1.601 – 1.509 
(2H, m, H
7), 1.431 – 1.358 (3H, m), 1.339 – 1.211 (6H, m), 1.303 (3H, t, J = 7.5 Hz, 
H
13), 0.909 (3H, t, J = 7.0 Hz, H
19). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 155.49 (C
9), 144.38 (C
2 or 3), 142.17 (C
11), 
142.06 (C
2 or 3), 138.69 (C
i-Ph), 135.14 (C
i-Ph), 129.50 (2CH
o- or m-Ph), 128.00 (2CH
o- or m-
Ph), 127.46 (2CH
o- or m-Ph), 127.03 (2CH
o- or m-Ph), 126.42 (CH
p-Ph), 114.25 (CH2
10), 70.05 
(C
1),  45.72  (CH
5),  43.71  (CH2
4),  36.30  (CH2
6),  35.49  (CH2
8),  31.74  (CH2),  29.96 
(CH2
14), 29.44 (CH2), 28.52 (CH2
12), 27.90 (CH2), 25.64 (CH2
7), 22.61 (CH2), 15.33 
(CH3
13), 14.08 (CH3
19). 
HRMS (EI): Found: [M]
+, 398.2974. C30H38 requires: 398.2974. 
LRMS (CI): m/z: 399 ([M + H]
+, 100%), 369 ([M – Et]
+, 39%). 
IR (thin film): n ~= 2933 (s), 2854 (m), 1508 (w), 1489 (w), 1452 (w), 903 (m), 824 
(m), 771 (m), 703 (s) cm
–1. 
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6.2.6.16. rac-(1R,5R)-3-Hexyl-1-(phenylvinyl)-2-propyl-bicyclo[3.3.0]oct-2-ene 
(2.63o) 
H Hb
Ha
3
8
7
6
5 4
2 1
15 14
10
9
16 17 18 19
12 13
11
 
General  procedure  A  was  used  with  dec-1-en-6-yne,  1,1-dibromoheptane  and  1-
ethynylbenzene  as  components.  Purification  of  the  crude  material  by  column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.277 g (82%). 
 
1H NMR (400 MHz, BENZENE-D6): ￿ (ppm) = 7.306 – 7.270 (2H, m, H
o-Ph), 7.187 – 
7.082 (3H, m, H
m + p-Ph), 5.189 (1H, t, J = 2.1 Hz, H
10), 5.071 (1H, t, J = 2.1 Hz, H
10), 
2.484 (1H, tq, J = 8.8, 2.4 Hz, H
5), 2.333 (1H, dd, J = 16.0, 8.8 Hz, H
4b), 2.142 – 2.018 
(4H, m), 1.875 – 1.716 (4H, m), 1.613 – 1.455 (4H, m), 1.384 – 1.242 (9H, m), 0.951 
(3H, t, J = 7.3 Hz, H
13 or 19), 0.913 (3H, t, J = 7.5 Hz, H
13 or 19). 
13C NMR (100.5 MHz, BENZENE-D6): ￿ (ppm) = 156.88 (C
9), 145.26 (C
i-Ph), 139.96 
(C
2 or 3), 138.03 (C
2 or 3), 128.76 (2CH
m-Ph), 128.16 (2CH
o-Ph), 127.15 (CH
p-Ph), 113.77 
(CH2
10), 71.26 (C
1), 44.84 (CH
5), 44.51 (CH2
4), 37.31 (CH2), 36.70 (CH2), 32.58 (CH2), 
30.29 (CH2), 30.06 (CH2), 29.78 (CH2), 28.57 (CH2), 26.17 (CH2), 24.61 (CH2), 23.43 
(CH2), 15.68 (CH3
13 or 19), 14.71 (CH3
13 or 19). 
HRMS (EI): Found: [M]
+, 336.2820. C25H36 requires: 336.2817. 
LRMS (CI): m/z: 336 ([M]
+, 100%), 233 ([M – Styrene]
+, 51%). 
IR (thin film): n ~= 2952 (s), 2926 (s), 2858 (m), 1486 (w), 1444 (m), 900 (m), 775 (m), 
699 (s) cm
–1. 
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6.2.6.17. rac-(1R,5R)-2-Butyl-3-hexyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene 
(2.63p) 
H Hb
Ha
3
8
7
6 5 4
2 1
16 15
10
9
17 18 19 20
12 13
11
14
 
General  procedure  A  was  used  with  undec-1-en-6-yne,  1,1-dibromoheptane  and  1-
ethynylbenzene  as  components.  Purification  of  the  crude  material  by  column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.308 g (88%). 
 
1H NMR (300 MHz, CDCl3): ￿ (ppm) = 7.238 – 7.151 (5H, m, H
Ar), 5.127 (1H, d, J = 
1.8 Hz, H
10), 4.954 (1H, d, J = 1.8 Hz, H
10), 2.317 (1H, tt, J = 8.8, 2.3 Hz, H
5), 2.201 
(1H, dd, J = 15.7, 8.8 Hz, H
4b), 2.081 – 1.962 (4H, m), 1.818 – 1.687 (4H, m), 1.564 – 
1.503 (3H, m), 1.404 – 1.271 (12H, m), 0.916 (3H, t, J = 6.8 Hz, H
14 or 20), 0.909 (3H, t, 
J = 6.8 Hz, H
14 or 20). 
13C  NMR  (75  MHz,  CDCl3):  ￿  (ppm)  =  156.09  (C
9),  144.55  (C
i-Ph),  139.13  (C
2), 
137.16  (C
3),  127.93  (2CH
o-  or  m-Ph),  127.30  (2CH
m-  or  o-Ph),  126.22  (CH
p-Ph),  113.05 
(CH2
10), 70.44 (C
1), 44.01 (CH
5), 43.79 (CH2), 36.57 (CH2), 35.93 (CH2), 32.66 (CH2), 
31.83 (CH2), 29.51 (CH2), 29.26 (CH2), 27.74 (CH2), 26.24 (CH2), 25.37 (CH2), 23.68 
(CH2), 22.65 (CH2), 14.10 (CH3
14 or 20), 13.91 (CH3
20 or 14). 
HRMS (EI): Found: [M]
+, 350.2965. C26H38 requires: 350.2974. 
LRMS (EI): m/z: 351 ([M + H]
+·, 48%), 307 ([M – C3H7]
+·, 25%), 247 ([M – Styrene]
+·, 
100%). 
IR (thin film): n ~= 2926 (s), 2856 (m), 1614 (w), 1497 (w), 1450 (w), 896 (m), 762 
(m), 692 (s) cm
–1. 
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6.2.6.18. rac-(1R,5R)-2-Hexyl-3-hexyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene 
(2.63q) 
H Hb
Ha
3
8
7
6 5 4
2 1
18 17
10
9
19 20 21 22
12 13
11
15 16
14
 
General  procedure  A  was  used  with  tridec-1-en-6-yne,  1,1-dibromoheptane  and  1-
ethynylbenzene  as  components.  Purification  of  the  crude  material  by  column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.325 g (86%). 
 
1H NMR (300 MHz, CDCl3): ￿ (ppm) = 7.224 – 7.148 (5H, m, H
Ar), 5.124 (1H, d, J = 
1.8 Hz, H
10), 4.951 (1H, d, J = 1.8 Hz, H
10), 2.315 (1H, tt, J = 9.0, 2.0 Hz, H
5), 2.196 
(1H, dd, J = 15.9, 9.0 Hz, H
4b), 2.056 – 1.953 (4H, m), 1.818 – 1.722 (4H, m), 1.579 – 
1.500 (3H, m), 1.479 – 1.2700 (16H, m), 0.909 (3H, t, J = 6.7 Hz, H
16 or 22), 0.897 (3H, 
t, J = 6.7 Hz, H
16 or 22). 
13C  NMR  (75  MHz,  CDCl3):  ￿  (ppm)  =  156.01  (C
9),  144.55  (C
i-Ph),  139.13  (C
2), 
137.23  (C
3),  127.94  (2CH
o-  or  m-Ph),  127.30  (2CH
m-  or  o-Ph),  126.22  (CH
p-Ph),  113.03  
(CH2
10), 70.44 (C
1), 44.02 (CH
5), 43.80 (CH2), 36.57 (CH2), 35.94 (CH2), 31.84 (CH2), 
31.63 (CH2), 30.39 (CH2), 30.33 (CH2), 29.52 (CH2), 29.28 (CH2), 27.76 (CH2), 26.56 
(CH2), 25.38 (CH2), 22.70 (CH2), 22.66 (CH2), 14.09 (2CH3
16 + 22).  
HRMS (EI): Found: [M]
+, 378.3276. C28H42 requires: 378.3286. 
LRMS (EI): m/z: 379 ([M + H]
+·, 56%), 349 ([M – CH3]
+·, 13%), 293 ([M – C6H13]
+·, 
21%), 276 ([M – Styrene + H]
+·, 100%). 
IR (thin film): n ~= 2926 (s), 1640 (w), 1491 (w), 1456 (w), 884 (w), 768 (w), 698 (m) 
cm
–1. 
 
 
 
 
   150 
6.2.6.19. rac-(1R,5R)-2-Cyclohexyl-3-hexyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene 
(2.63r) 
H Hb
Ha
3
8
7
6 5 4
2 1
18 17
12
19 20 21 22
10
9
11
13 14
15
16
 
General procedure A was used with (hept-1-en-6-yne)cyclohexane, 1,1-dibromoheptane 
and  1-ethynylbenzene  as  components.  Purification  of  the  crude  material  by  column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.300 g (80%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.311 – 7.202 (5H, m, H
Ar), 5.133 (1H, d, J = 
1.8 Hz, H
10), 5.012 (1H, d, J = 1.8 Hz, H
10), 2.376 (1H, dd, J = 16.3, 9.0 Hz, H
4b), 2.272 
– 2.234 (2H, m, H
17), 2.195 (1H, tt, J = 9.0, 2.2 Hz, H
5), 1.989 (1H, tt, J = 11.9, 3.9 Hz,  
H
11), 1.873 – 1.158 (25H, m), 0.926 (3H, t, J = 6.9 Hz, H
22). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 156.09 (C
9), 145.02 (C
2 or 3), 140.67 (C
2 or 3), 
138.47 (C
i-Ph), 127.70 (2CH
o-  or  m-Ph), 127.46 (2CH
o-  or  m-Ph), 126.35 (CH
p-Ph), 113.48 
(CH2
10),  71.29  (C
1),  45.07  (CH2
4),  43.70  (CH
5),  38.02  (CH
11),  37.00  (CH2),  36.73 
(CH2),  33.12  (CH2),  32.25  (CH2),  31.90  (CH2),  30.34  (CH2),  29.75  (CH2
17),  28.10 
(CH2),  27.55  (CH2),  27.39  (CH2),  26.50  (CH2),  25.25  (CH2),  22.70  (CH2),  14.13 
(CH3
22). 
HRMS (EI): Found: [M]
+, 376.3127. C28H40 requires: 376.3130. 
LRMS (CI): m/z: 377 ([M + H]
+, 100 %), 271 (77%). 
IR (thin film): n ~= 2926 (s), 2850 (s), 1614 (w), 1486 (w), 1440 (m), 900 (m), 771 (m), 
699 (s) cm
–1. 
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6.2.6.20. rac-(1R,5R)-3-Hexyl-1-(phenylvinyl)-2-(propan-3-ol)-bicyclo[3.3.0]oct-2-
ene (2.63s) 
H Hb
Ha
3
8
7
6 5 4
2 1
16 15
12
17 18 19 20
10
9 11 OH
14 13
 
General  procedure  A  was  used  with  TBDMS  protected  dec-9-en-4-yn-1-ol,  1,1-
dibromoheptane  and  1-ethynylbenzene  as  components  with  the  exception  that  the 
reaction was carried out on 2.0 mmol scale. Crude product from the three component 
coupling was purified by flash column chromatography on silica to give the desired 
material which was put into TBDMS group cleavage with TBAF [2.0 mL of a 1.0 M 
solution in THF, (2.0 mmol) in dry THF (8.0) mL, at RT for 20 h]. Purification of the 
crude material by column chromatography on SiO2 (230 – 400 mesh) with hexanes as 
the eluent gave the title compound as a yellow oil in yield of 0.430 g (61% over two 
steps). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.236 – 7.163 (5H, m, H
Ar), 5.146 (1H, d, J = 
1.8 Hz, H
10), 4.983 (1H, d, J = 1.8 Hz, H
10), 3.649 (2H, q, J = 6.5 Hz, H
13), 2.343 (1H, 
tt, J = 9.0, 2.0 Hz, H
5), 2.244 (1H, dd, J = 16.0, 9.0 Hz, H
4b), 2.133 – 2.020 (4H, m, H
11 
+ 15), 1.870 – 1.611 (6H, m), 1.587 – 1.521 (1H, m), 1.485 – 1.385 (1H, m), 1.370 – 
1.261 (10H, m), 0.909 (3H, t, J = 6.9 Hz, H
20). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 155.95 (C
9), 144.36 (C
i-Ph), 139.80 (C
2 or 3), 
136.21 (C
2 or 3), 127.83 (2CH
o- or m-Ph), 127.37 (2CH
m- or o-Ph), 126.33 (CH
p-Ph), 113.26 
(CH2
10),  70.38  (C
1),  63.62  (CH2
13),  43.99  (CH
5),  43.80  (CH2
4),  36.55  (CH2),  36.05 
(CH2), 33.45 (CH2), 31.84 (CH2), 29.52 (CH2), 29.27 (CH2), 27.73 (CH2), 25.34 (CH2), 
22.65 (CH2), 22.54 (CH2), 14.10 (CH3
20). 
HRMS (EI): Found: [M]
+, 352.2767. C25H36O requires: 352.2766. 
LRMS (CI): m/z: 353 ([M + H]
+, 100%), 249 ([M – Styrene]
+, 37%). 
IR (thin film): n ~= 3312 (w, br), 2930 (s), 2854 (m), 1448 (m), 1062 (m), 900 (m), 771 
(m), 699 (s) cm
–1. 
   152 
6.2.6.21. rac-(1R,5R)-2-Phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene (2.63t) 
H Hb
Ha
3
8
7
6 5 4
2 1
9
10
H
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, dichloromethane and 
1-ethynylbenzene  as  components.  Purification  of  the  crude  material  by  column 
chromatography on SiO2 (230 – 400 mesh) with hexane as the eluent gave the title 
compound as a pale yellow oil in yield of 0.332 g (58%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.609 – 7.579 (2H, m, H
o-Ph), 7.350 – 7.249 
(8H, m, H
Ar), 6.149 (1H, t, J = 2.7 Hz, H
3), 5.296 (1H, d, J = 1.8 Hz, H
10), 5.032 (1H, d, 
J = 1.8 Hz, H
16), 2.693 (1H, J = 8.3, 6.0, 1.5 Hz, H
5), 2.396 (1H, ddd, J = 17.6, 8.0, 2.2 
Hz, H
4b), 2.117 (1H, dt, J = 12.8, 7.3 Hz, H
8a or 8b), 2.084 (1H, ddd, J = 17.6, 3.0, 1.5 Hz, 
H
4a), 1.968 (1H, ddt, J = 12.3, 8.8, 6.8 Hz, H
6b), 1.792 (1H, dt, J = 12.8, 6.0 Hz, H
8a or 
8b), 1.540 (2H, apparent quintet, J = 7.0 Hz, H
7) 1.366 (1H, dq, J = 12.3, 6.2 Hz, H
6a). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 155.03 (C
9), 145.92 (C
2), 143.34 (C
i-Ph), 
136.41 (C
i-Ph), 128.45 (3CH
p- + o- or m-Ph), 127.99 (2CH
o- or m-Ph), 127.40 (2CH
o- or m-Ph), 
127.25 (2CH
o or m-Ph), 126.68 (CH
3 or p-Ph), 126.53 (CH
3  or p-Ph), 113.51 (CH2
10), 67.12 
(C
1), 50.12 (CH
5), 38.84 (CH2
4), 35.73 (CH2
6), 35.04 (CH2
8), 26.65 (CH2
7). 
HRMS (EI): Found: [M]
+, 286.1721. C22H22 requires: 286.1722. 
LRMS (CI): m/z: 287 ([M + H]
+, 100%), 208 ([M – Ph]
+, 14%), 169 (20%). 
IR (thin film): n ~= 2949 (m), 2858 (w), 1493 (m), 1440 (m), 907 (m), 748 (s), 695 (s) 
cm
–1. 
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6.2.6.22. rac-(1R,5R)-3-Butyl-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene 
(2.63u) 
H Hb
Ha
3
8
7
6 5 4
2 1
12 11 13 14
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromopentane 
and  1-ethynylbenzene  as  components.  Purification  of  the  crude  material  by  column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.244 g (71%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.348 – 7.237 (10H, m, H
Ar), 5.037 (1H, d, J = 
1.6 Hz, H
10), 5.024 (1H, d, J = 1.6 Hz, H
10), 2.430 (1H, tdd, J = 8.3, 3.0, 1.5 Hz, H
5), 
2.338 (1H, dd, J = 16.3, 8.3 Hz, H
4b), 2.090 (1H, dt, J = 24.5, 7.8 Hz, H
11), 2.055 (1H, 
dt, J = 24.5, 7.3 Hz, H
11), 1.995 (1H, d, J = 16.3 Hz, H
4a), 1.851 (1H, tdd, J = 12.0, 10.0, 
6.8 Hz, H
6), 1.697 – 1.663 (2H, m, H
8), 1.607 – 1.473 (2H, m, H
7), 1.419 – 1.214  (5H, 
m), 0.861 (3H, t, J = 7.2 Hz, H
14). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 155.37 (C
9), 144.38 (C
2 or 3), 142.46 (C
2 or 3), 
138.92  (C
i-Ph),  137.96  (C
i-Ph),  129.67  (2CH
o-  or  m-Ph),  127.92  (2CH
o-  or  m-Ph),  129.55 
(2CH
o- or m-Ph), 127.51 (2CH
o- or m-Ph), 126.46 (CH
p-Ph), 126.33 (CH
p-Ph), 114.44 (CH2
10), 
70.14 (C
1), 45.69 (CH
5), 43.83 (CH2
4), 36.33 (CH
6), 35.61 (CH2
8), 30.17 (CH2), 29.65 
(CH2
11), 25.60 (CH2
7), 22.84 (CH2), 14.13 (CH3
14). 
HRMS (EI): Found: [M]
+, 342.2351. C26H30 requires: 342.2348. 
LRMS (CI): m/z: 343 ([M + H]
+, 100%) 239 ([M – Styrene]
+, 24%). 
IR (thin film): n ~= 2941 (m), 2850 (m), 2835 (w), 1595 (w), 1489 (m), 1436 (w), 907 
(m), 763 (m), 695 (s) cm
–1. 
 
 
 
 
   154 
6.2.6.23. rac-(1R,5R)-3-Octyl-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene 
(2.63v) 
H Hb
Ha
3
8
7
6 5 4
2 1
12 11 13 14
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromononane 
and  1-ethynylbenzene  as  components.  Purification  of  the  crude  material  by  column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.291 g (73%). 
 
1H NMR (400 MHz, BENZENE-D6): ￿ (ppm) = 7.457 – 7.393 (4H, m, H
m-  +  p-Ph), 
7.257 – 7.111 (6H, m, H
o- + m- + p-Ph), 5.117 (1H, d, J = 1.8 Hz, H
10), 5.084 (1H, d, J = 1.8 
Hz, H
10), 2.536 (1H, tdd, J = 8.5, 2.8, 1.3 Hz, H
5), 2.436 (1H, dd, J = 16.4, 8.5 Hz, H
4b), 
2.147 – 2.108 (2H, m, H
11), 1.967 (1H, d, J = 16.4 Hz, H
4a), 1.856 – 1.513 (5H, m), 
1.419 – 1.348 (3H, m), 1.302 – 1.192 (10H, m), 0.899 (3H, t, J = 6.9 Hz, H
18). 
13C NMR (100.5 MHz, BENZENE-D6): ￿ (ppm) = 156.27 (C
9), 145.21 (C
2 or 3), 142.99 
(C
2  or  3), 140.08 (C
i-Ph), 138.73 (C
i-Ph), 130.46 (2CH
o-  or  m-Ph), 128.72 (2CH
o-  or  m-Ph), 
128.48 (2CH
o- or m-Ph), 128.35 (2CH
o- or m-Ph), 127.31 (CH
p-Ph), 127.29 (CH
p-Ph), 115.17 
(CH2
10), 71.05 (C
1), 46.48 (CH
5), 44.59 (CH2
4), 37.10 (CH2), 36.43 (CH2), 32.63 (CH2), 
30.64 (CH2), 30.49 (CH2), 30.19 (CH2), 30.04 (CH2), 28.70 (CH2), 26.38 (CH2), 23.43 
(CH2), 14.70 (CH3
18). 
HRMS (EI): Found: [M]
+, 398.2978. C30H38 requires: 398.2974. 
LRMS (CI): m/z: 399 ([M + H]
+, 100%), 295 ([M – Styrene]
+, 29%). 
IR (thin film): n ~= 2926 (s), 2858 (m), 1599 (w), 1493 (m), 1440 (w), 900 (m), 763 
(m), 695 (s) cm
–1. 
 
 
 
   155 
6.2.6.24. rac-(1R,5R)-3-Dimethyl(phenyl)silane-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.63w) 
H
Si
5
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General  procedure  B  was  used  with  1-(hept-6-en-1-ynyl)benzene, 
(dichloromethyl)dimethyl(phenyl)silane  and  1-ethynylbenzene  as  components.  The 
carbenoid  was  generated  in  situ  from  (dichloromethyl)dimethyl(phenyl)silane  (1.3 
mmol) and LDA (0.83 mL of a 1.8 M solution, 1.50 mmol) at –85 °C for 15 min before 
dropwise  addition  of  phenylacetylide.  Purification  of  the  crude  material  by  column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.191 g (45%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.501 – 7.201 (15H, m, H
Ar), 5.097 (1H, d, J = 
1.6 Hz, H
10), 4.970 (1H, d, J = 1.6 Hz, H
10), 2.533 – 2.448 (2H, m, H
5 + 4b), 2.186 (1H, 
d, J = 15.1 Hz, H
4a), 1.902 (1H, m, H
6), 1.818 (1H, m, H
7), 1.733 (1H, dd, J = 11.3, 5.5 
Hz, H
8), 1.674 (1H, m, H
7), 1.614 (1H, dd, J = 11.3, 5.6 Hz, H
8), 1.474 (1H, m, H
6), 
0.115 (3H, s, H
11or 12), 0.096 (3H, s, H
11 or 12). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 157.10 (C
2 or 9), 154.13 (C
2 or 9), 144.39 (C
i-
Ph), 140.63 (C
i-Ph), 139.36 (C
3), 138.87 (C
Si-i-Ph), 133.62 (2CH
Si-o-Ph), 129.75 (2CH
Si-m-
Ph), 128.62 (CH
Si-p-Ph), 127.72 (2CH
o- or m-Ph), 127.64 (2CH
o- or m-Ph), 127.56 (2CH
o- or m-
Ph), 127.12 (2CH
o- or m-Ph), 126.88 (CH
p-Ph), 126.53 (CH
p-Ph), 115.04 (CH2
10), 73.06 (C
1), 
46.99 (CH2
4), 46.65 (CH
5), 36.71 (CH2
6), 36.02 (CH2
7), 25.57 (CH2
8), –2.36 (CH3
11or 
12), –2.72 (CH3
11or 12). 
HRMS (EI): Found: [M]
+, 420.2288. C30H32Si requires: 420.2273. 
LRMS (CI): m/z: 420 ([M]
+·, 6%), 342 ([M – Ph]
+·, 17%), 284 ([M – HSiMe2Ph]
+·, 
18%), 135 ([SiMe2Ph]
+·, 100%). 
IR (thin film): n ~= 2964 (m), 2896 (w), 1610 (w), 1580 (m), 1486 (m), 1421 (m), 1251 
(m), 1051 (m), 779 (s), 733 (s), 695 (s) cm
–1. 
   156 
6.2.6.25. rac-(1R,5R)-2-Butyl-3-dimethyl(phenyl)silane-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.63x) 
H
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General  procedure  A  was  used  with  undec-1-en-6-yne, 
(dichloromethyl)dimethyl(phenyl)silane  and  1-ethynylbenzene  as  components.  The 
carbenoid  was  generated  in  situ  from  (dichloromethyl)dimethyl(phenyl)silane  (1.3 
mmol) and LDA (0.83 mL of a 1.8 M solution, 1.50 mmol) at –85 °C for 15 min before 
dropwise  addition  of  phenylacetylide.  Purification  of  the  crude  material  by  column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.275 g (69%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.428 – 7.074 (10H, m, H
Ar), 5.074 (1H, d, J = 
1.8 Hz, H
10), 4.892 (1H, d, J = 1.8 Hz, H
10), 2.291 (1H, J = 8.8, 2.2 Hz, H
5), 2.186 (1H, 
dd, J = 15.2, 8.5 Hz, H
4b), 1.985 – 1.852 (2H, m, H
13), 1.886 (1H, d, J = 16.2, Hz, H
4a), 
1.762 (1H, dd, J = 10.5, 5.9 Hz, H
8), 1.731 (1H, dd, J = 10.5, 5.5 Hz, H
8), 1.681 (1H, m, 
H
6), 1.484 (1H, quintet t, J = 6.0, 3.0 Hz, H
7), 1.361 (1H, m, H
7), 1.266 – 1.182 (3H, m, 
H
6 + 14), 1.104 – 0.969 (2H, m, H
15),  0.698 (3H, t, J = 7.3 Hz, H
16), 0.300 (3H, s, H
11/12), 
0.278 (3H, s, H
11/12). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 157.46 (C
2 or 9), 155.29 (C
2 or 9), 144.25 (C
i-
Ph), 139.33 (C
3), 144.25 (C
Si-i-Ph), 133.79 (2CH
Si-o-Ph), 128.71 (CH
Si-p-Ph), 127.95 (2CH
Si-
m-Ph), 127.66 (2CH
o or m-Ph), 127.32 (2CH
o or m-Ph), 126.36 (CH
p-Ph), 113.35 (CH2
10), 73.31 
(C
1),  46.58  (CH2
4),  45.68  (CH
5),  36.62  (CH2
6),  36.14  (CH2
8),  34.05  (CH2
14),  28.87 
(CH2
13), 25.53 (CH2
7), 23.57 (CH2
15), 13.80 (CH3
16), –1.95 (CH3
11/12), –2.03 (CH3
11/12). 
HRMS (EI): Found: [M]
+, 400.2587. C28H36Si requires: 400.2586. 
LRMS  (CI):  m/z:  400  ([M]
+·,  11%),  297  ([M  –  Styrene]
+·,  13%),  264  ([M  – 
HSiMe2Ph]
+·, 15%), 135 (100%). 
IR (thin film): n ~= 2945 (m), 2854 (w), 1603 (w), 1251 (m), 1100 (m), 816 (m), 771 
(s), 699 (s) cm
–1.   157 
6.2.6.26. rac-(1R,5R)-2-Hexyl-3-cyclohexyl-1-(1-phenylvinyl)-bicyclo[3.3.0]oct-2-
ene (2.63y) 
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General  procedure  A  was  used  with  tridec-1-en-6-yne,  (dibromomethyl)cyclohexane 
(1.0  mmol)  and  1-ethynylbenzene  (2.2  mmol)  as  components.  The  carbenoid  was 
generated  in  situ  by  using  LiTMP  [freshly  prepared  from  distilled  2,2,6,6-
tetramethylpiperidine (0.17 mL, 1.0 mmol) in dry THF (2 mL) and n-BuLi (0.40 mL of 
a 2.5 M solution in hexanes, 1.0 mmol) at 0 °C over 20 min] at –85 °C for 30 min 
before dropwise addition of phenylacetylide (2.2 mmol). 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexanes as the eluent gave the title compound as a pale yellow oil in yield of 0.038 
g (10%). 
 
1H NMR (300 MHz, CDCl3): ￿ (ppm) = 7.232 – 7.161 (5H, m, H
Ar), 5.119 (1H, d, J = 
1.8 Hz, H
10), 4.938 (1H, d, J = 1.8 Hz, H
10), 2.362 – 2.243 (2H, m, H
5 + H), 2.114 (1H, 
dd, J = 16.0, 8.7 Hz, H
4b), 1.989 – 1.937 (2H, m), 1.816 – 1.682 (5H, m), 1.592 – 1.392 
(10H, m), 1.370 – 1.268 (10H, m), 0.904 (3H, t, J = 6.8 Hz, H
16). 
13C  NMR  (75  MHz,  CDCl3):  ￿  (ppm)  =  156.01  (C
9),  143.81  (C
i-Ph),  135.70  (C
2), 
128.00  (2CH
o-  or  m-Ph),  127.21  (2CH
o-  or  m-Ph),  126.20  (CH
p-Ph),  124.44  (C
3),  112.86 
(CH2
10), 70.16 (C
1), 43.64 (CH
5), 40.11 (CH2), 38.64 (CH
17), 36.64 (CH2), 35.73 (CH2), 
31.91 (CH2), 31.57 (CH2), 30.63 (CH2), 30.30 (CH2), 29.70 (CH2), 26.63 (CH2), 26.41 
(CH2), 26.30 (CH2), 25.28 (CH2), 22.68 (CH2), 14.09 (CH3
16). 
HRMS (EI): Found: [M]
+, 376.3125. C28H40 requires: 376.3130. 
LRMS (EI): m/z: 376 ([M]
+·, 54%),
 293 ([M – C6H11]
+·, 33%), 273 ([M – Styrene]
+·, 
100%). 
IR (thin film): n ~= 2909 (s), 2845 (s), 1573 (w), 1439 (m), 686 (m) cm
–1. 
   158 
6.2.6.27. rac-(1R,5R)-2-Hexyl-3-hexyl-1-(hex-1-en-2-yl)bicyclo[3.3.0]oct-2-ene 
(2.63z) 
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General  procedure  A  was  used  with  tridec-1-en-6-yne,  1,1-dibromoheptane  and  1-
hexyne as components. Purification of the crude material by column chromatography on 
SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title compound as a pale 
yellow oil in yield of 0.243 g (68%). 
 
1H NMR (300 MHz, CDCl3): ￿ (ppm) = 4.851 (1H, d, J = 1.4 Hz, H
10), 4.731 (1H, q, J 
= 1.4 Hz, H
10), 2.643 (1H, dd, J = 16.2, 8.8 Hz, H
4b), 2.306 (1H, tt, J = 8.8, 2.1 Hz, H
5), 
2.059 (2H, td, J = 7.3, 0.5 Hz, H
26), 1.949 – 1.843 (3H, m), 1.818 – 1.703 (4H, m), 
1.667 – 1.518 (4H, m), 1.389 – 1.258 (20H, m), 0.925 – 0.867 (9H, m, H
16 + 22 + 23). 
13C NMR (75 MHz, CDCl3): ￿ (ppm) = 155.49 (C
9), 137. 99 (C
2 or 3), 137.88 (C
2 or 3), 
106.24  (CH2
10),  71.15  (C
1),  44.28  (CH2),  43.95  (CH–5),  36.91  (CH2),  34.16  (CH2), 
31.92 (CH2), 31.86 (CH2), 31.68 (CH2), 30.97  (CH2), 30.25 (CH2), 30.19 (CH2), 29.70 
(CH2), 29.36 (CH2), 29.06 (CH2), 28.03 (CH2), 26.36 (CH2), 25.40 (CH2), 22.95 (CH2), 
22.66 (CH2), 14.09 (3CH3
16 + 22 + 23). 
HRMS (EI): Found: [M]
+, 358.3601. C26H46 requires: 358.3600. 
LRMS (EI): m/z: 358 ([M]
+·, 52%), 315 ([M – C3H7]
+·, 55%), 301 ([M – C4H9]
+·, 74%), 
287 ([M – C5H11]
+·, 48%), 273 ([M – C6H13]
+·, 100%). 
IR (thin film): n ~= 2921 (s), 2862 (s), 1637 (w), 1450 (w), 884 (m) cm
–1. 
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6.2.6.28. rac-(1R,5R)-1-(4-tert-Butylphenyl)vinyl)-3-hexyl-2-propyl-
bicyclo[3.3.0]oct-2-ene (2.63aa) 
H Hb
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General  procedure A was used  with dec-1-en-6-yne, 1,1-dibromoheptane and 1-tert-
butyl-4-ethynylbenzene as components. Purification of the crude material by column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.341 g (86%). 
 
1H NMR (400 MHz, BENZENE-D6): ￿ (ppm) = 7.348 – 7.273 (4H, m, H
o-  +  m-Ph), 
5.222 (1H, d, J = 1.9 Hz, H
13), 5.154 (1H, d, J = 1.9 Hz, H
13), 2.560 (1H, tt, J = 8.9, 2.2 
Hz, H
5), 2.438 (1H, dd, J = 16.2, 8.9 Hz, H
4b), 2.186 – 2.051 (4H, m), 1.906 – 1.849 
(3H, m), 1.777 (1H, dddd, J = 12.0, 10.8, 8.9, 6.5 Hz, H
6), 1.654 – 1.475 (4H, m), 1.421 
– 1.291 (9H, m), 1.257 (9H, s, H
9), 0.959 (3H, t, J = 7.3 Hz, H
16 or 22), 0.919 (3H, t, J = 
6.9 Hz, H
16 or 22). 
13C NMR (100 MHz, BENZENE-D6): ￿ (ppm) = 156.83 (C
12), 149.74 (C
11), 142.44 
(C
i-Ph), 139.68 (C
2  or  3), 138.41 (C
2  or  3), 128.47 (2CH
o-Ph), 125.09 (2CH
m-Ph), 113.65 
(CH2
13), 71.26 (C
1), 44.94 (CH
5), 44.64 (CH2
4), 37.31 (CH2), 36.98 (CH2), 34.80 (C
10), 
32.60 (CH2), 31.89 (3CH3
9), 30.32 (CH2), 30.11 (CH2), 29.85 (CH2), 28.61 (CH2), 26.17 
(CH2), 24.60 (CH2), 23.44 (CH2), 15.69 (CH3
16 or 22), 14.71 ppm (CH3
16 or 22). 
HRMS (EI): Found: [M]
+, 392.3448. C29H44 requires: 392.3443. 
LRMS (CI): m/z: 392 ([M]
+, 100%), 335 ([M – t-Bu]
+, 24%), 233 ([M – p-t-Bu –
Styrene]
+, 57%). 
IR (thin film): n ~= 2952 (s), 2926 (s), 2862 (m), 1614 (w), 1504 (w), 1463 (m), 1361 
(w), 1270 (w), 1119 (w), 1017 (w), 896 (s), 835 (s), 601 (w) cm
–1. 
   160 
6.2.6.29. rac-(1S,5R)-3-Hexyl-2-phenyl-1-(phenylvinyl)-7-methylaza-
bicyclo[3.3.0]oct-2-ene (2.67a) 
N
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General  procedure  A  was  used  with  N-methyl-N-(phenylprop-2-ynyl)prop-2-en-1-
amine, 1,1-dibromoheptane and 1-ethynylbenzene as components. Purification of the 
crude material by column chromatography on Al2O3 (basic, gr. III) with 2.5% of Et2O in 
hexanes as the eluent gave the title compound as a pale yellow oil in yield of 0.240 g 
(62%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.385 – 7.251 (10H, m, H
Ar), 5.101 (1H, d, J = 
1.1 Hz, H
10), 4.929 (1H, d, J = 1.1 Hz, H
10), 2.691 (1H, d, J = 9.4 Hz, H
8a or 8b), 2.679 
(1H, dd, J = 8.4, 4.0 Hz, H
6a or 6b), 2.632 (1H, d, J = 9.4 Hz, H
8a or 8b), 2.626 (1H, tdd, J = 
7.9, 4.0, 2.0 Hz, H
5), 2.496 (1H, fs ddd, J = 16.8, 8.8, Hz, H
4b), 2.446 (1H, dd, J = 8.4, 
4.0 Hz, H
6a or 6b), 2.311 (3H, s, H
7), 2.152 (1H, dd, J = 16.8, 1.7 Hz, H
4a), 2.120 – 2.082 
(2H, m, H
11), 1.454 – 1.345 (2H, m), 1.319 – 1.218 (6H, m), 0.892 (3H, t, J = 7.0 Hz, 
H
16). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 153.64 (C
2 or 9), 143.66 (C
2 or 9), 141.53 (C
i-
Ph), 139.52 (C
i-Ph), 137.54 (C
3), 129.89 (2CH
o-  or  m-Ph), 127.73 (2CH
o-  or  m-Ph), 127.65 
(2CH
o- or m-Ph), 127.57 (2CH
o- or m-Ph), 126.71 (CH
p-Ph), 126.46 (CH
p-Ph), 114.98 (CH2
10), 
70.11 (C
1), 65.77 (2CH2
6 + 8), 46.35 (CH
5), 42.73 (CH3
7), 41.98 (CH2
4), 31.67 (CH2), 
29.81 (CH2), 29.39 (CH2
11), 27.72 (CH2), 22.58 (CH2), 14.06 (CH3
16). 
HRMS (ESI+): Found: [M + H]
+, 386.2832. [C28H36N]
+ requires: 386.2842. 
LRMS (ESI+): m/z: 386 ([M + H]
+, 100%). 
IR (thin film): n ~= 2933 (m), 2858 (m), 2775 (m), 1595 (w), 1497 (m), 1436 (m), 1157 
(m), 900 (m), 771 (m), 699 (s) cm
–1. 
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6.2.6.30. rac-(1S,5R)-3-Hexyl-2-phenyl-1-(phenylvinyl)-7-benzylaza-
bicyclo[3.3.0]oct-2-ene (2.67b) 
N
H
Ha
Ha
Hb
Hb Ha
Hb
11
3
5
2 1
10 9
6
8
16
15 14
13
12 4
17
7
 
General  procedure  A  was  used  with  N-benzyl-N-(phenylprop-2-ynyl)prop-2-en-1-
amine, 1,1-dibromoheptane and 1-ethynylbenzene as components. The carbenoid was 
generated in situ from 1,1-dibromoheptane (1.3 mmol) and LDA (0.83 mL of a 1.8 M 
solution, 1.50 mmol) at –85 °C for 15 min before dropwise addition of phenyl acetylide. 
Purification of the crude material by column chromatography on Al2O3 (basic, grade III) 
with 1% of Et2O in hexanes as the eluent gave the title compound as a colourless oil in 
yield of 0.341 g (74%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.404 – 7.185 (15H, m, H
Ar), 5.071 (1H, d, J = 
1.4 Hz, H
10), 4.856 (1H, d, J = 1.4 Hz, H
10), 3.583 (1H, d, J = 13.4 Hz, H
11), 3.538 (1H, 
d, J = 13.4 Hz, H
11), 2.725 (1H, dd, J = 8.5, 7.5 Hz, H
6b), 2.672 (1H, d, J = 9.4 Hz, H
8), 
2.622 (1H, dddd, J = 8.6, 7.5, 3.8, 1.8 Hz, H
5), 2.542 (1H, d, J = 9.4 Hz, H
8), 2.512 (1H, 
dd, J = 16.8, 9.2 Hz, H
4b), 2.476 (1H, d, J = 8.5 Hz, H
6a), 2.184 (1H, dd, J = 16.8, 1.8 
Hz, H
4a), 2.131 – 2.087 (2H, m, H
12), 2.106 (1H, dd, J = 6.6, 2.5 Hz), 1.465 – 1.392 
(2H, m), 1.343 – 1.238 (6H, m), 0.906 (3H, t, J = 7.0 Hz, H
17). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 153.64 (C
9), 143.67 (C
2 or 3), 141.50 (C
2 or 3), 
139.84 (C
i-Ph), 139.63 (C
i-Ph), 137.59 (C
i-Ph), 129.90 (2CH
o- or m-Ph), 128.30 (2CH
o- or m-
Ph), 128.01 (2CH
o- or m-Ph), 127.73 (2CH
o- or m-Ph), 127.66 (2CH
o- or m-Ph), 127.48 (2CH
o- or 
m-Ph), 126.69 (CH
p-Ph), 126.59 (CH
p-Ph), 126.37 (CH
p-Ph), 115.02 (CH2
10), 69.41 (C
1), 
63.44 (CH2
6), 62.77 (CH2
8), 59.93 (CH2
11), 45.98 (CH
1), 42.03 (CH2
4), 31.75 (CH2), 
29.71 (CH2
12), 29.26 (CH2), 27.83 (CH2), 22.62 (CH2), 14.11 (CH3
17). 
HRMS (ESI+): Found: [M + H]
+, 462.3149. [C34H40N]
+ requires: 462.3155. 
LRMS (ESI+): m/z: 462 ([M + H]
+, 100 %).    162 
IR (thin film): n ~= 2924 (m), 2848 (w), 2783 (w), 1498 (m), 1428 (w), 1142 (w), 1018 
(w), 899 (m), 775 (m), 694 (s) cm
–1. 
 
6.2.7.  Preparation of compounds 2.69 and 2.70 
General procedure B: To a solution of Cp2ZrCl2 (1.465 g, 5.0 mmol) in dry THF (25 
mL) cooled to –78 °C was added n-BuLi (4.0 mL of a 2.5 M solution in hexanes, 10.0 
mmol) dropwise. After 20 min, a solution of TBDMS protected 7-phenylhept-1-en-6-
yn-3-ol 2.41 (1.50 g, 5.0 mmol) in dry THF (15 mL) was added dropwise. After 30 min 
at –78 °C the reaction mixture was allowed to warm to room temperature and continued 
to  stir  for  3  h.  After  re-cooling  the  reaction  mixture  to  –78  °C,  a  solution  of  1,1-
dibromoheptane  (1.42  g,  5.5  mmol)  in  dry  THF  (5  mL)  was  added  followed  by 
dropwise  addition  of  LDA  (3.06  mL  of  a  1.8 M  solution,  5.5  mmol).  The  reaction 
mixture was stirred at –78 °C for 15 min before dropwise addition of phenyl acetylide. 
[Lithium phenyl acetylide was freshly prepared from phenylacetylene (1.65 mL, 15.0 
mmol) in dry THF (15 mL) and n-BuLi (6.0 mL of a 2.5 M solution in hexanes, 15.0 
mmol) at –10 °C over 15 min].  
The stirring was continued for 45 min during which the reaction mixture was allowed to 
warm to –55 °C before addition of MeOH (30 mL) and a saturated aqueous solution of 
NaHCO3 (30 mL). The whole mixture was allowed to warm to room temperature and 
was left stirring for 5 h. The mixture was then poured onto H2O (200 mL) and the 
products were extracted with Et2O (3 × 200 mL). The combined organic phases were 
washed with H2O (3 × 300 mL) and brine (300 mL), dried over anhydrous MgSO4, 
filtered and concentrated in vacuo to give the crude products as yellow oils. Purification 
of the crude material by flash chromatography column with 2.5% of Et2O in hexanes as 
the eluent provided the TBDMS protected alcohols 2.68 as a yellow oil (2.20 g, 88%). 
 
The TBDMS protected alcohols 2.68 (2.20 g, 4.40 mmol) were dissolved in dry THF 
(44  and  38  mL  respectively)  followed  by  addition  of  TBAF  (17.60  mL  of  1.0  M 
solution in THF), and the reaction mixture was stirred at RT for 20 h. Then the mixture 
was poured onto H2O (200 mL), the products extracted with Et2O (2 × 150 mL). The 
organic phases were washed with H2O (3 × 200 mL), brine (1 × 200 mL), and dried 
over  MgSO4.  Concentration  in  vacuo,  followed  by  separation  by  column 
chromatography on Al2O3 (basic, grade III) and 2.5% EtOAc in hexanes as the eluent   163 
gave the partially separated isomers: 0.277 g of pure 2.69-endo (14%), 0.650 g of mixed 
fractions (33%) and 0.556 of pure 2.69-exo (29%), combined yield of 1.483 g (76%). 
Further chromatography of the mixed fractions allowed additional pure 2.69-exo and 
2.69-endo to be isolated. 
 
6.2.7.1.  rac-(1R,5R,6R)-3-Hexyl-6-hydroxy-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.69-exo) 
H H
OH Ha
Hb
7 3
5
2
1
6
8
4
9 10
11
12
13
14
16
15
 
Yellow oil. 
1H NMR (300 MHz, CDCl3): ￿ (ppm) = 7.372 – 7.192 (10H, m, H
Ar), 5.078 (1H, d, J = 
1.5 Hz, H
10), 5.001 (1H, d, J = 1.5 Hz, H
10), 3.958 (1H, br s, H
6), 2.388 (1H, dd, J = 
16.2, 9.6 Hz, H
4b), 2.303 (1H, fs dd, J = 9.6 Hz, H
5), 2.152 – 2.004 (4H, m), 1.792 – 
1.670 (3H, m), 1.376 – 1.222 (9H, m, 8H
aliphatic + OH), 0.869 (3H, t, J = 6.8 Hz, H
16). 
13C NMR (75 MHz, CDCl3): ￿ (ppm) = 154.69 (C
9), 144.21 (C
2 or 3), 141.19 (C
2 or 3), 
139.17  (C
i-Ph),  137.43  (C
i-Ph),  129.73  (2CH
o-  or  m-Ph),  127.78  (2CH
o-  or  m-Ph),  127.72 
(2CH
o- or m-Ph), 127.62 (2CH
o- or m-Ph), 126.66 (CH
p-Ph), 126.59 (CH
p-Ph), 114.99 (CH2
10), 
82.10 (CH
6), 69.40 (C
1), 55.92 (CH
5), 40.29 (CH2), 34.04 (CH2), 32.13 (CH2), 31.66 
(CH2), 29.73 (CH2), 29.37 (CH2), 27.83 (CH2), 22.58 (CH2), 14.06 (CH3
16). 
HRMS (EI): Found: [M]
+, 386.2611. C28H34O requires: 386.2610. 
LRMS (EI): m/z: 386 ([M]
+·, 36%), 283 ([M – H2O]
+·, 21%), 283 ([M – Styrene]
+·, 
100%). 
IR (thin film): n ~= 3327 (m, br), 2918 (m), 1599 (w), 1493 (m), 1338 (w), 771 (m), 699 
(s) cm
–1. 
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6.2.7.2.  (1S,5S,6S)-3-Hexyl-6-hydroxy-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-
2-ene (2.69-exo-ent-1) 
Rt 11.7 min on chiral HPLC on a Diacel OD-H, (1 mL/min 1% isopropanol in hexane on 
4.6 x 250 mm column). 
[a]D
25 –46.7 (c = 0.48, CHCl3, 100% e.e.). 
 
6.2.7.3.  (1R,5R,6R)-3-Hexyl-6-hydroxy-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.69-exo-ent-2) 
Rt 18.5 min on chiral HPLC on a Diacel OD-H, (1 mL/min 1% isopropanol in hexane on 
4.6 x 250 mm column). 
[a]D
25 +45.1 (c = 0.49, CHCl3, 100% e.e.). 
 
6.2.7.4.  rac-(1R,5R,6S)-3-Hexyl-6-hydroxy-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.69-endo) 
H HO
H Ha
Hb
Hb
Ha
7 3
5
2
1
6
8
4
9 10
11
12
13
14
16
15
 
Yellow oil. 
1H NMR (300 MHz, CDCl3): ￿ (ppm) = 7.350 – 7.207 (10H, m, H
Ar), 5.074 (1H, d, J = 
1.5 Hz, H
10), 4.955 (1H, d, J = 1.5 Hz, H
10), 4.178 (1H, ddd, J = 9.1, 8.5, 5.5 Hz, H
6), 
2.633 (1H, dd, J = 17.2, 2.1 Hz, H
4a), 2.500 (1H, td, J = 8.5, 2.1 Hz, H
5), 2.166 – 2.006 
(3H, m), 1.855 (1H, ddt, J = 10.4, 5.5, 4.4 Hz, H
7b), 1.742 – 1.699 (2H, m), 1.573 (1H, 
ddd, J = 10.4, 9.1, 8.1 Hz, H
7a), 1.496 – 1.346 (2H, m), 1.287 – 1.239 (7H, m, 6H
aliphatic 
+ OH), 0.872 (3H, t, J = 6.8 Hz, H
16). 
13C NMR (75 MHz, CDCl3): ￿ (ppm) = 154.86 (C
9), 144.00 (C
2 or 3), 143.28 (C
2 or 3), 
139.37  (C
i-Ph),  137.06  (C
i-Ph),  129.82  (2CH
o-  or  m-Ph),  127.78  (2CH
o-  or  m-Ph),  127.70 
(2CH
o- or m-Ph), 127.61 (2CH
o- or m-Ph), 126.70 (CH
p-Ph), 126.56 (CH
p-Ph), 114.88 (CH2
10), 
74.55 (CH
6), 68.83 (C
1), 49.19 (CH
5), 33.77 (CH2), 33.49 (CH2), 31.83 (CH2), 31.66 
(CH2), 29.89 (CH2), 29.47 (CH2), 27.93 (CH2), 22.60 (CH2), 14.06 (CH3
16).   165 
HRMS (EI): Found: [M]
+, 386.2600. C28H34O requires: 386.2610. 
LRMS (EI): m/z: 386 ([M]
+·, 12%), 368 ([M – H2O]
+·, 17%), 283 ([M – Styrene]
+·, 
69%). 
IR (thin film): n ~= 3323 (m, br), 2922 (m), 1595 (w), 1489 (m), 1289 (w), 1073 (m), 
900 (m), 775 (m), 692 (s) cm
–1. 
 
6.2.7.5.  rac-(1R,5R,6R)-6-Acetoxy-3-hexyl-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.70-exo) 
H H
O Ha
Hb
7 3
5
2
1
6
8
4
O
9 10
11
12
13
14
16
15
17 18
 
Alcohol 2.69-exo (0.028 g, 0.072 mmol) was dissolved in the mixture of anhydrous 
pyridine (0.15 mL, 1.85 mmol) and freshly distilled acetic anhydride (0.50 mL, 5.25 
mmol). After stirring for 10 min at RT, DMAP (0.005 g, 0.041 mmol) was added and 
the stirring was continued at RT for 13 h. Then H2O (5 mL) was added to the reaction 
mixture and the whole mixture was poured onto Et2O (15 mL). The organic phase was 
separated  and  washed  with  HCl  (15  mL  of  a  1.0  M  solution),  a  saturated  aqueous 
solution of NaHCO3 (15 mL) and brine (2 × 15 mL), dried over MgSO4, filtered and 
concentrated in vacuo to give the crude product as a yellow oil. Purification of the crude 
material by column chromatography on SiO2 (230 – 400 mesh) with 3% of EtOAc in 
hexanes as the eluent gave the title compound (exo diastereoisomer) as a colourless oil 
in yield of 0.0254 g (82%). 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.350 – 7.220 (10H, m, H
Ar), 5.076 (1H, d, J = 
1.5 Hz, H
10), 5.035 (1H, d, J = 1.5 Hz, H
10), 4.828 (1H, t, J = 2.9 Hz,  H
6), 2.391 (1H, d, 
J = 9.4 Hz, H
5), 2.348 (1H, dd, J = 15.5, 9.4 Hz, H
4b), 2.182 (1H, d, J = 15.5 Hz, H
4a), 
2.085 – 1.963 (3H, m), 2.010 (3H, s, H
18), 1.783 – 1.686 (3H, m), 1.365 – 1.193 (8H, 
m), 0.872 (3H, t, J = 7.0 Hz, H
16).   166 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 170.77 (C
17), 154.41 (C
9), 143.85 (C
2 or 3), 
141.87 (C
2 or 3), 138.59 (C
i-Ph), 137.28 (C
i-Ph), 129.58 (2CH
o- or m-Ph), 127.76 (2CH
o- or m-
Ph),  127.69  (4CH
o-  or  m-Ph),  126.71  (CH
p-Ph),  126.65  (CH
p-Ph),  115.03  (CH2
10),  84.83 
(CH
6), 69.35 (C
1), 53.23 (CH
5), 40.29 (CH2), 32.38 (CH2), 31.62 (CH2), 31.44 (CH2), 
29.72 (CH2), 29.37 (CH2), 27.79 (CH2), 22.57 (CH2), 21.41 (CH3
18), 14.06 (CH3
16). 
HRMS (ESI+): Found: [M + Na]
+, 451.2604. [C30H36O2Na]
+ requires: 451.2608. 
LRMS (EI): m/z: 428 ([M]
+·, 6%), 368 ([M – AcOH]
+·, 86%), 283 ([M – AcOH – 
Hex]
+·, 43%), 265 ([M – Ph – C2H5]
+·, 100%). 
IR (thin film): n ~= 2922 (m), 1731 (s), 1603 (w), 1493 (m), 1239 (s), 1021 (m), 907 
(m), 767 (m), 703 (s) cm
–1. 
 
6.2.7.6.  rac-(1R,5R,6S)-6-Acetoxy-3-hexyl-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.70-endo) 
H O
H Ha
Hb
7 3
5
2
1
6
8
4
O
9 10
11
12
13
14
16
15 17
18  
Alcohol 2.69-endo (0.028 g, 0.072 mmol) was dissolved in the mixture of anhydrous 
pyridine (0.150 mL, 1.85 mmol) and freshly distilled acetic anhydride (0.50 mL, 5.25 
mmol). After stirring for 10 min at RT, DMAP (0.005 g, 0.041 mmol) was added and 
the stirring was continued at RT for 13 h. Then H2O (5 mL) was added to the reaction 
mixture and the whole mixture was poured onto Et2O (15 mL). The organic phase was 
separated and washed with HCl (15 mL of a 1.0 M solution), saturated aqueous solution 
of  NaHCO3  (15  mL)  and  brine  (2  ×  15  mL),  dried  over  MgSO4,  filtered  and 
concentrated in vacuo to give the crude product as a pale yellow oil. Purification of the 
crude  material  by  column  chromatography  on  SiO2  (230  –  400  mesh)  with  3%  of 
EtOAc in hexanes as the eluent gave the title compound (endo diastereoisomer) as a 
colourless oil (0.021 g, 95%). Crystallization from hexanes gave white crystals. 
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1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.342 – 7.214 (10H, m, H
Ar), 5.078 (1H, d, J = 
1.5 Hz, H
10), 5.012 (1H, td, J = 9.1, 7.0 Hz, H
6), 4.973 (1H, d, J = 1.5 Hz, H
10), 2.682 
(1H, dd, J = 8.8, 1.8 Hz, H
5), 2.283 (1H, dd, J = 17.4, 1.8 Hz, H
4a), 2.120 – 2.024 (2H, 
m), 2.062 (3H, s, H
18), 1.998 (1H, dd, J = 17.4, 8.8 Hz, H
4b), 1.913 (1H, m), 1.754 – 
1.626 (3H, m), 1.429 – 1.357 (2H, m), 1.310 – 1.205 (6H, m), 0.877 (3H, t, J = 6.9 Hz, 
H
16). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 170.64 (C
17), 154.35 (C
9), 143.67 (C
2 or 3), 
143.22 (C
2 or 3), 138.58 (C
i-Ph), 136.95 (C
i-Ph), 129.72 (2CH
o- or m-Ph), 127.81 (2CH
o- or m-
Ph),  127.71  (2CH
o-  or  m-Ph),  127.66  (2CH
o-  or  m-Ph),  126.75  (CH
p-Ph),  126.63  (CH
p-Ph), 
115.16 (CH2
10), 76.37 (CH
6),  68.59 (C
1), 46.94 (CH
5), 34.61 (CH2), 31.73 (CH2), 31.16 
(CH2),  30.12  (CH2),  29.77  (CH2),  29.39  (CH2),  27.85  (CH2),  22.61  (CH2),  21.08 
(CH3
18), 14.08 (CH3
16). 
HRMS (EI): Found: [M]
+, 428.2721. C30H36O2 requires: 428.2715. 
LRMS (EI): m/z: 428 ([M]
+·, 14%), 368 ([M – AcOH]
+·, 94%), 325 ([M – Styrene]
+·, 
22%), 283 ([M – AcOH – Hex]
+·, 42%), 265 ([M – Ph – C2H5]
+·, 61%). 
IR (thin film): n ~= 2924 (m), 1741 (s), 1599 (w), 1493 (m), 1239 (s), 1055 (m), 907 
(m), 770 (m), 703 (s) cm
–1. 
m.p. 42 – 44 
oC. 
 
6.2.8.  Preparation of compounds 2.72 and 2.73 
Following general procedure B and using TBDMS protected 7-phenylhept-1-en-6-yn-4-
ol 2.48. Purification of the product by flash chromatography column with 2.5% of Et2O 
in hexanes provided the TBDMS protected alcohols 2.71 as a yellow oil, in yield of 
1.94 g (78%). The TBDMS protected alcohols (1.94 g, 3.88 mmol) were dissolved in 
dry THF (38 mL) followed by addition of TBAF (7.76 mL of 1.0 M), and the reaction 
mixture was stirred at RT for 20 h. Then the mixture was poured onto H2O (200 mL), 
the products extracted with Et2O (2 × 150 mL). The organic phases were washed with 
H2O (3 × 200 mL), brine (1 × 200 mL), and dried over MgSO4. Concentration in vacuo, 
followed by separation by column chromatography on Al2O3 (basic, grade III) and 2.5% 
EtOAc in hexanes as the eluent gave the partially separated isomers: 0.632 g of pure 
2.72-endo (33%), 0.349 g of mixed fractions (18%) and 0.361 of pure 2.72-exo (19%), 
combined  yield  of  1.342  g  (70%).  Further  chromatography  of  the  mixed  fractions 
allowed additional pure 2.72-exo and 2.72-endo to be isolated.   168 
6.2.8.1.  rac-(1R,5R,7R)-3-Hexyl-7-hydroxy-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.72-exo) 
H Ha
Hb Ha
Hb
7 3
5
2 1
6
8
4
Ph Ha
HO
Hb
H
9
10
11
12
13
14
16
15
 Pale yellow oil. 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.291 – 7.191 (10H, m, H
Ar), 4.992 (1H, d, J = 
1.5 Hz, H
10), 4.980 (1H, d, J = 1.5 Hz, H
10), 4.197 (1H, tt, J = 8.0, 5.9 Hz, H
7), 2.554 
(1H, dddd, J = 10.0, 8.4, 3.6, 1.5 Hz, H
5), 2.186 (1H, dd, J = 16.8, 8.3 Hz, H
4b), 2.064 – 
1.890 (3H, m, 2H
11 +
 H
4a), 1.927 (1H, ddd, J = 12.4, 5.5, 1.5 Hz, H
8a), 1.823 (1H, ddd, J 
= 12.7, 10.0, 8.3 Hz, H
6b), 1.718 (1H, dd, J = 12.4, 8.5 Hz, H
8b), 1.642 (1H, dddd, J = 
12.7, 6.3, 3.6, 1.5 Hz, H
6a), 1.498 (1H, br s, OH) 1.301 – 1.152 (9H, m), 0.812 (3H, t, J 
= 7.0 Hz, H
16). 
1H NMR (400 MHz, BENZENE-D6): ￿ (ppm) = 7.406 – 7.366 (4H, m, H
o-Ph), 7.252 – 
7.095 (6H, m, H
m + p-Ph), 5.056 (2H, br s, H
10), 4.163 (1H, tt, J = 8.0, 5.9 Hz, H
7), 2.626 
(1H, dddd, J = 10.0, 8.4, 3.6, 1.5 Hz, H
5), 2.225 (1H, dd, J = 16.6, 8.3 Hz, H
4b), 2.068 
(2H, apparent t, J = 7.8 Hz, H
11), 2.035 (1H, ddd, J = 12.4, 5.5, 1.5 Hz, H
8a), 1.841 (1H, 
dd, J = 16.6, 1.5 Hz, H
4a),  1.804 (1H, ddd, J = 12.6, 10.0, 8.3 Hz, H
6b), 1.752 (1H, dd, J 
= 12.4, 8.8 Hz, H
8b), 1.582 (1H, dddd, J = 12.6, 6.3, 3.6, 1.5 Hz, H
6a), 1.321 – 1.098 
(9H, m, 8H
aliphatic + OH), 0.863 (3H, t, J = 7.0 Hz, H
16). 
13C NMR (100.5 MHz, BENZENE-D6): ￿ (ppm) = 155.97 (C
9), 144.35 (C
2 or 3), 142.36 
(C
2  or  3), 140.17 (C
i-Ph), 138.41 (C
i-Ph), 130.35 (2CH
o-  or  m-Ph), 128.91 (2CH
o-  or  m-Ph), 
128.69 (2CH
o- or m-Ph), 128.59 (2CH
o- or m-Ph), 127.44 (CH
p-Ph), 127.41 (CH
p-Ph), 115.14 
(CH2
10), 73.34 (CH
7),  68.49 (C
1), 45.09 (CH2
6), 44.77 (CH
5), 44.30 (CH2
4 or 8), 43.96 
(CH2
4 or 8), 32.37 (CH2), 30.59 (CH2), 30.17 (CH2), 28.55 (CH2), 23.34 (CH2
15), 14.66 
(CH3
16). 
HRMS (EI): Found: [M]
+, 386.2597. C28H34O requires: 386.2610. 
LRMS (EI): m/z: 386 ([M]
+·, 25%), 368 ([M – H2O]
+·, 22%), 283 ([M – Styrene]
+·, 
100%). 
IR (thin film): n ~= 3330 (m, br), 2930 (m), 1603 (w), 1504 (m), 1349 (w), 1073 (m), 
907 (m), 775 (m), 692 (s) cm
–1.   169 
6.2.8.2.  rac-(1R,5R,7S)-3-Hexyl-7-hydroxy-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.72-endo) 
H Ha
Hb Ha
Hb
7 3
5
2 1
6
8
4
Ph Ha
H
Hb
HO
9
10
11
12
13
14
16
15
 Yellow oil. 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.283 – 7.155 (10H, m, H
Ar), 4.990 (1H, d, J = 
1.3 Hz, H
10), 4.939 (1H, d, J = 1.3 Hz, H
10), 4.107 (1H, quintet, J = 5.4 Hz, H
7), 2.472 
(1H, tdd, J = 8.8, 6.2, 1.4 Hz, H
5), 2.311 (1H, dd, J = 16.8, 8.5 Hz, H
4b), 2.210 (1H, 
dddd, J = 13.3, 9.3, 5.6, 1.0 Hz, H
6b), 2.103 (1H, dd, J = 16.8, 1.4 Hz, H
4a), 2.070 – 
1.966 (2H, m, H
11), 2.028 (1H, ddd, J = 13.5, 6.2, 1.1 Hz, H
8b), 1.791 (1H, ddd, J = 
13.5, 4.6, 1.1 Hz, H
8a), 1.459 (1H, dddd, J = 13.3, 6.0, 5.0, 1.3 Hz, H
6a), 1.332 – 1.261 
(2H, m), 1.221 – 1.135 (7H, m, 6H
aliphatic + OH), 0.792 (3H, t, J = 7.0 Hz, H
16). 
1H NMR (400 MHz, BENZENE-D6): ￿ (ppm) = 7.498 (2H, dd, J = 8.1, 1.3 Hz, H
o-Ph), 
7.322 (2H, dd, J = 8.1, 1.3 Hz, H
o-Ph), 7.257 – 7.109 (6H, m, H
m + p-Ph), 5.054 (1H, d, J = 
1.5 Hz, H
10), 5.036 (1H, d, J = 1.5 Hz, H
10), 4.031 (1H, br s, H
7), 2.519 (1H, tdd, J = 
8.8, 6.2, 1.4 Hz, H
5), 2.388 (1H, dd, J = 16.6, 8.5 Hz, H
4b), 2.115 – 2.011 (5H, m, 2H
11 
+ 3H), 1.912 (1H, ddd, J = 13.6, 5.3, 1.3 Hz, H
8a), 1.485 (1H, dddd, J = 12.8, 6.5, 3.9, 
1.3 Hz, H
6a), 1.382 – 1.307 (2H, m) 1.244 – 1.097 (7H, m, 6H
aliphatic + OH), 0.855 (3H, 
t, J = 7.0 Hz, H
16). 
13C NMR (100.5 MHz, BENZENE-D6): ￿ (ppm) = 156.04 (C
9), 144.57 (C
2 or 3), 142.39 
(C
2  or  3), 141.00 (C
i-Ph), 138.59 (C
i-Ph), 130.66 (2CH
o-  or  m-Ph), 128.84 (2CH
o-  or  m-Ph), 
128.68 (2CH
o- or m-Ph), 128.58 (2CH
o- or m-Ph), 127.41 (CH
p-Ph), 127.38 (CH
p-Ph), 114.85 
(CH2
10),  74.60  (CH
7),    69.51  (C
1),  46.09  (CH
5),  45.05  (CH2
6),  44.79  (CH2
8),  43.39 
(CH2
4),  32.35  (CH2),  30.65  (CH2),  30.15  (CH2),  28.53  (CH2),  23.33  (CH2),  14.66 
(CH3
16). 
HRMS (EI): Found: [M]
+, 386.2597. C28H34O requires: 386.2610. 
LRMS (EI): m/z:  386 ([M]
+·, 2%), 368  ([M  – H2O]
+·, 16%), 283 ([M –  Styrene]
+·, 
100%). 
IR (thin film): n ~= 3328 (m, br), 2932 (m), 1603 (w), 1504 (m), 1349 (w), 1070 (m), 
907 (m), 775 (m), 692 (s) cm
–1.   170 
6.2.8.3.  rac-(1R,5R,7R)-7-Acetoxy-3-hexyl-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.73-exo) 
H Ha
Hb Ha
Hb
7 3
5
2 1
6
8
4
Ph Ha
O
Hb
H
O
9
10
11
12
13
14
16
15
17
18
 
Alcohol 2.72-exo (0.026 g, 0.067 mmol) was dissolved in the mixture of anhydrous 
pyridine (0.14 mL, 1.72 mmol) and freshly distilled acetic anhydride (0.48 mL, 5.06 
mmol). After stirring for 10 min at RT, DMAP (0.0048 g, 0.038 mmol) was added and 
the stirring was continued at RT for 17 h. Then H2O (5 mL) was added to the reaction 
mixture and the whole mixture was poured onto Et2O (15 mL). The organic phase was 
separated  and  washed  with  HCl  (15  mL  of  a  1.0  M  solution),  a  saturated  aqueous 
solution of NaHCO3 (15 mL) and brine (2 × 15 mL), dried over MgSO4, filtered and 
concentrated in vacuo to give the crude product as a yellow oil. Purification of the crude 
material by column chromatography on SiO2 (230 – 400 mesh) with 3% of EtOAc in 
hexanes as the eluent gave the title compound (exo diastereoisomer) as a colourless oil 
in yield of 0.023 g (80%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.359 – 7.253 (10H, m, H
Ar), 5.056 (1H, tt, J = 
8.0, 6.1 Hz, H
7), 5.027 (1H, d, J = 1.5 Hz, H
10), 5.019 (1H, d, J = 1.5 Hz, H
10), 2.622 
(1H, dddd, J = 9.8, 7.8, 4.2, 1.0 Hz, H
5), 2.285 (1H, dd, J = 16.8, 8.0 Hz, H
4b), 2.121 – 
1.907 (4H, m, 2H
11 +
 H
6b + H
8b), 1.996 (1H, dd, J = 16.8, 1.0 Hz, H
4a), 1.961 (3H, s, 
H
18), 1.893 (1H, dd, J = 12.8, 8.3 Hz, H
8a), 1.807 (1H, dddd, J = 12.8, 6.6, 4.4, 1.5 Hz, 
H
6a), 1.378 – 1.180 (8H, m), 0.867 (3H, t, J = 7.0 Hz, H
16). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 170.87 (C
17), 154.32 (C
9), 143.29 (C
2 or 3), 
142.04 (C
2 or 3), 138.86 (C
i-Ph), 137.16 (C
i-Ph), 129.61 (2CH
o- or m-Ph), 128.14 (2CH
o- or m-
Ph),  127.80  (2CH
o-  or  m-Ph),  127.57  (2CH
o-  or  m-Ph),  126.70  (CH
p-Ph),  126.65  (CH
p-Ph), 
114.73 (CH2
10), 75.56 (CH
7),  67.21 (C
1), 43.95 (CH
5), 42.80 (CH2), 40.67 (CH2), 39.79 
(CH2),  31.65  (CH2),  29.88  (CH2),  29.42  (CH2),  27.75  (CH2),  22.56  (CH2),  21.21 
(CH3
18), 14.06 (CH3
16). 
HRMS (ESI+): Found: [M + Na]
+, 451.2605. [30H36O2Na]
+ requires: 451.2608.   171 
LRMS (EI): m/z: 428 ([M]
+·, 9%), 368 ([M – AcOH]
+·, 30%), 283 ([M – AcOH – 
Hex]
+·, 16%), 265 ([M – Ph – C2H5]
+·, 100%). 
IR (thin film): n ~= 2926 (m), 1741 (s), 1603 (w), 1493 (m), 1245 (s), 1051 (m), 907 
(m), 767 (m), 703 (s) cm
–1. 
 
6.2.8.4.  rac-(1R,5R,7S)-7-Acetoxy-3-hexyl-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.73-endo) 
H Ha
Hb Ha
Hb
7 3
5
2 1
6
8
4
Ph Ha
H
Hb
O O
9
10
11
12
13
14
16
15
17
18
 
Alcohol 2.72-endo (0.018 g, 0.046 mmol) was dissolved in the mixture of anhydrous 
pyridine (0.10 mL, 1.23 mmol) and freshly distilled acetic anhydride (0.33 mL, 3.46 
mmol). After stirring for 10 min at RT, DMAP (0.0033 g, 0.027 mmol) was added and 
the stirring was continued at RT for 17 h. Then H2O (5 mL) was added to the reaction 
mixture and the whole mixture was poured onto Et2O (15 mL). The organic phase was 
separated  and  washed  with  HCl  (15  mL  of  a  1.0  M  solution),  a  saturated  aqueous 
solution of NaHCO3 (15 mL) and brine (2 × 15 mL), dried over MgSO4, filtered and 
concentrated in vacuo to give the crude product as a pale yellow oil. Purification of the 
crude  material  by  column  chromatography  on  SiO2  (230  –  400  mesh)  with  5%  of 
EtOAc in hexanes as the eluent gave the title compound (endo diastereoisomer) as a 
colourless oil in yield of 0.016 g (79%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.340 – 7.248 (10H, m, H
Ar), 5.102 (1H, d, J = 
1.4 Hz, H
10), 5.083 (1H, tt, J = 6.2, 5.1 Hz, H
7),  5.045 (1H, d, J = 1.4 Hz, H
10), 2.550 
(1H, tdd, J = 8.5, 6.5, 1.9 Hz, H
5), 2.363 (1H, ddd, J = 13.5, 9.3, 6.2 Hz, H
6b), 2.314 
(1H, dd, J = 16.8, 8.3 Hz, H
4b), 2.261 (1H, ddd, J = 13.9, 6.2, 0.5 Hz, H
8b), 2.171 – 
2.048 (3H, m, 2H
11 + H
4a), 1.998 (3H, s, H
18), 1.904 (1H, ddd, J = 13.9, 5.0, 1.1 Hz, 
H
8a), 1.568 (1H, dddd, J = 13.5, 6.5, 5.3, 1.2 Hz, H
6a), 1.423 – 1.339 (2H, m), 1.312 – 
1.199 (6H, m), 0.883 (3H, t, J = 7.0 Hz, H
16).   172 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 170.78 (C
17), 154.60 (C
9), 143.33 (C
2 or 3), 
140.49 (C
2 or 3), 139.62 (C
i-Ph), 137.68 (C
i-Ph), 129.70 (2CH
o- or m-Ph), 128.10 (2CH
o- or m-
Ph),  127.67  (2CH
o-  or  m-Ph),  127.60  (2CH
o-  or  m-Ph),  126.72  (CH
p-Ph),  126.47  (CH
p-Ph), 
114.49 (CH2
10), 76.37 (CH
7),  68.29 (C
1), 45.15 (CH
5), 42.42 (CH2), 40.75 (CH2), 40.65 
(CH2),  31.70  (CH2),  30.02  (CH2),  29.49  (CH2),  27.84  (CH2),  22.58  (CH2),  21.36 
(CH3
18), 14.07 (CH3
16). 
HRMS (ESI+): Found: [M + Na]
+, 451.2606. [C30H36O2Na]
+ requires: 451.2608. 
LRMS (EI): m/z: 428 ([M]
+·, 8%), 368 ([M – AcOH]
+·, 59%), 283 ([M – AcOH –
Hex]
+·, 30%), 265 ([M – Ph – C2H5]
+·, 100%). 
IR (thin film): n ~= 2926 (m), 1735 (s), 1599 (w), 1501 (m), 1236 (s), 1017 (m), 907 
(m), 775 (m), 703 (s) cm
–1.   
 
6.2.9.  Preparation of other bicyclic compounds 
 
6.2.9.1.  rac-(1R,5R)-3-Hexyl-2-phenyl-1-(phenylvinyl)-bicyclo[4.3.0]oct-2-ene 
(2.78) 
Ha Hb
Ha
H
Hb
3
9
8
7
6
5
4 2
1
14 13
12 11
10
15
16 17
Ha Hb
Ph
Ph
 
General procedure A was used with 1-(oct-7-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-ethynylbenzene as components, except that LiTMP [which was freshly prepared 
from 2,2,6,6-tetramethylpiperidine (0.19 mL, 1.1 mmol) in dry THF (1 mL) and n-BuLi 
(0.44 mL of a 2.5 M solution in hexanes, 1.1 mmol) at 0 °C over 15 min] was used 
instead of LDA. The carbenoid was generated in situ from 1,1-dibromoheptane (1.05 
mmol)  and  LiTMP  at  –90  °C  for  25  min  (during  which  the  reaction  mixture  was 
warmed to –80 °C), before dropwise addition of phenyl acetylide. Purification of the 
crude  material  by  careful  column  chromatography  on  SiO2  (230  –  400  mesh)  with 
hexanes as the eluent gave the title compound as a pale yellow oil in yield of 0.101 g 
(26%).   173 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.352 – 7.224 (10H, m, H
Ar), 5.250 (1H, d, J = 
1.6 Hz, H
7), 5.130 (1H, d, J = 1.6 Hz, H
7), 2.376 (1H, dt, J = 12.0, 6.3 Hz,  H
2), 2.725 
(1H, dd, J = 15.5, 7.0 Hz,  H
11a or b), 2.207 – 2.169 (2H, m,  H
12), 2.129 (1H, dd, J = 
15.5, 6.1 Hz, H
11a or b), 2.010 (1H, ddd, J = 13.8, 7.8, 3.3 Hz, H
6a or b), 1.610 (1H, ddd, J 
= 13.8, 8.5, 3.5 Hz, H
6a or b), 1.525 – 1.236 (13H, m), 0.899 (3H, t, J = 7.0 Hz, H
17). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 152.84 (C
8), 143.92 (C
9 or 10 or i-Ph), 142.08 
(C
9 or 10 or i-Ph), 141.87 (C
9 or 10 or i-Ph), 137.84 (C
9 or 10 or i-Ph),  129.40 (2CH
o- or m-Ph), 128.84 
(2CH
o-  or  m-Ph), 127.55 (2CH
o-  or  m-Ph), 127.36 (2CH
o-  or  m-Ph), 126.29 (CH
p-Ph), 126.13 
(CH
p-Ph), 116.43 (CH2
7), 58.89 (C
1), 40.84 (CH
2), 38.97 (CH2
11), 31.70 (CH2), 30.96  
(CH2
6),  29.96  (CH2
12),  29.38  (CH2),  28.11  (CH2),  27.64  (CH2),  22.63  (CH2),  22.34 
(CH2), 21.43 (CH2), 14.07 (CH3
17). 
HRMS (EI): Found: [M]
+, 384.2806. C29H36 requires: 384.2817. 
LRMS (CI): m/z: 384 ([M]
+·, 3%), 281 ([M – Styrene]
+·, 100%), 197 ([M – Styrene – 
Hex]
+·, 9%). 
IR (thin film): n ~= 2918 (s), 2853 (m), 1639 (m), 1527 (m), 1179 (w), 694 (s), 500 (s) 
cm
–1. 
 
6.2.9.2.  rac-(3aR)-2-Hexyl-2,3,3a,4,5,6,7-heptahydro-1-phenyl-2-(1-phenylvinyl)-
2H-indene (2.79) 
Ph
Ha
Hb
11
8
9
7
16
15 14
13
12
10
17
Ph
H
3
6
5
4 2
1
 
The product was obtained simultaneously with product 2.78. Purification of the crude 
material by careful column chromatography on SiO2 (230 – 400 mesh) with hexanes as 
the eluent gave a pure fraction of the title compound as a pale yellow oil in yield of 
0.016 g (4%). 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.392 – 7.326 (4H, m, H
Ar), 7.294 – 7.246 
(6H, m, H
Ar), 5.114 (1H, d, J = 1.6 Hz, H
10), 5.001 (1H, d, J = 1.6 Hz, H
10), 2.641 (1H, 
d, J = 14.3 Hz, H
9a), 2.074 (1H, dd, J = 13.1, 7.8 Hz, H
6), 1.881 – 1.783 (2H, m), 1.751 
– 1.710 (1H, m), 1.661 – 1.571 (3H, m), 1.552 – 1.438 (2H, m), 1.365 – 1.083 (10H, m), 
1.047 – 0.947 (1H, m), 0.845 (3H, t, J = 7.0 Hz, H
17).   174 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 155.83 (C
11), 144.83 (C
1 or 7), 143.90 (C
7 or 
1), 137.85 (C
i-Ph), 136.24 (C
i-Ph),  129.31 (2CH
o- or m-Ph), 128.82 (2CH
o- or m-Ph), 127.69 
(2CH
o- or m-Ph), 127.14 (2CH
o- or m-Ph), 126.34 (CH
p-Ph), 126.21 (CH
p-Ph), 113.33 (CH2
10), 
59.11 (C
8), 44.77 (CH
2), 41.19 (CH2
6), 36.27 (CH2), 35.99 (CH2), 31.73 (CH2), 29.97 
(CH2),  27.32  (CH2
12),  26.96  (CH2),  25.99  (CH2),  24.33  (CH2),  22.56  (CH2),  14.04  
(CH3
17). 
HRMS (EI): Found: [M]
+, 384.2818. C29H36 requires: 384.2817. 
LRMS (CI): m/z: 385 ([M + H]
+·, 100 %), 281 ([M – Styrene]
+·, 83 %). 
IR (thin film): n ~= 2930 (s), 2843 (m), 1482 (w), 1440 (w), 907 (w), 771 (w), 695 (s) 
cm
–1. 
 
6.2.9.3.  rac-(3aR,6aR)-5-Hexyl-1,2,3,3a,4,6a-hexahydro-2,2-bis(methoxymethyl)-
3a-methyl-6a-(1-phenylvinyl)-6-propylpentalene (2.87) 
Ha
Ha
Hb
Hb Ha
Hb
9
3
4
2
5
1
6
8
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O
Ph
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General procedure A was used with 4,4-bis(methoxymethyl)-2-methyldec-1-en-6-yne, 
1,1-dibromoheptane and 1-ethynylbenzene as components, except that LiTMP [freshly 
prepared from 2,2,6,6-tetramethylpiperidine (0.19 mL, 1.1 mmol) in dry THF (1 mL) 
and n-BuLi (0.44 mL of a 2.5 M solution in hexanes, 1.1 mmol) at 0 °C over 15 min] 
was  used  instead  of  LDA.  The  carbenoid  was  generated  in  situ  from  1,1-
dibromoheptane  (1.05  mmol)  and  LiTMP  at  –90  °C  for  25  min  (during  which  the 
reaction mixture was warmed to –80 °C), before dropwise addition of phenyl acetylide. 
Subsequently the reaction mixture was allowed to warm to RT over 2 h before quench.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 5% of Et2O in hexanes as the eluant gave the title compound as a pale yellow oil in 
yield of 0.110 g (25%). 
 
   175 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.343 – 7.320 (2H, m, H
o-Ph), 7.192 – 7.176 
(2H, m, H
m-Ph), 7.112 (1H, tt, J = 7.3, 1.3 Hz, H
p-Ph), 5.252 (1H, d, J = 2.0 Hz, H
10), 
5.124 (1H, d, J = 2.0 Hz, H
10), 3.353 (2H, s, H
12), 3.308 (1H, d, J = 8.3 Hz, H
12), 3.241 
(3H, s, H
13), 3.163 (1H, d, J = 8.3 Hz, H
12), 3.120 (3H, s, H
13), 2.402 (1H, d, J = 14.3 
Hz, H
6), 2.329 – 2.081 (6H, m), 1.978 (1H, d, J = 14.1 Hz, H
8), 1.956 (1H, d, J = 14.3 
Hz, H
6), 1.859 – 1.688 (2H, m), 1.654 (1H, d, J = 14.1 Hz, H
8), 1.523 – 1.432 (2H, m), 
1.413 – 1.339 (6H, m), 1.255 (3H, s, H
11), 1.020 (3H, t, J = 7.3 Hz, H
16 or 22), 0.956 (3H, 
t, J = 6.8 Hz, H
16 or 22).
 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 154.43 (C
9), 145.33 (C
2), 142.02 (C
i-Ph), 
138.60  (C
3),  129.60  (2CH
o-Ph),  128.08  (2CH
m-Ph),  126.98  (CH
p-Ph),  118.14  (CH2
10), 
79.21 (CH2
12),  77.02  (CH2
12), 54.20  (C
1),  59.20  (CH3
13), 59.09  (CH3
13), 53.03 (C
5), 
51.49 (CH2
6), 50.58 (CH2
4), 46.24 (C
7), 40.12 (CH2
8), 32.56 (CH2), 30.89 (CH2), 30.48 
(CH2),  30.17  (CH2),  28.40  (CH2),  25.51  (CH3
11),  24.27  (CH2),  23.44  (CH2),  15.90 
(CH3
16 or 22), 14.71 (CH3
16 or 22). 
HRMS (EI): Found: [M]
+, 438.3490. C30H46O2 requires: 438.3498. 
LRMS (CI): m/z: 438 ([M]
+, 15%), 406 ([M – MeOH]
+, 17%), 335 ([M – Styrene]
+, 
77%), 303 ([M – MeOH – Styrene]
+, 100%). 
IR (thin film): n ~= 2949 (m), 2930 (s), 2862 (m), 1455 (m), 1376 (w), 1194 (m) 1104 
(s), 964 (m), 911 (m), 771 (m), 703 (s) cm
–1. 
 
6.2.9.4.  rac-(1,2,3,5-Tetrahydro-5-(dimethyl(phenyl)silyl)-5-
(trimethylsilyl)pentalene (2.92) 
Si
Si
1
2'
2 3
3'
4
4' 5
6
7
 
To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes.  After  25  min,  a  solution  of  (hept-6-en-1-ynyl)trimethylsilane  (0.166  g,  1.0 
mmol) in dry THF (3 mL) was added dropwise. After 30 min at –78 °C the reaction   176 
mixture was allowed to warm to room temperature and stirred for 3 h.  After this time, 
the  reaction  mixture  (previously  cooled  to  –94  °C)  was  transferred  via  cannula  to 
freshly  prepared  carbenoid.  The  carbenoid  was  prepared  from 
(dichloromethyl)dimethyl-(phenyl)silane (0.285 g, 1.3 mmol) in dry THF (2 mL) and n-
BuLi (0.52 mL of a 2.5 M solution in hexanes, 2.0 mmol) for 5 min at –94 °C. The 
reaction mixture was stirred for further 7 h within which time was allowed to warm to -
20  °C.  After  re-cooling  to  –78  °C,  a  dropwise  addition  of  lithium  phenylacetylide 
followed. [Lithium phenyl acetylide was freshly prepared from phenylacetylene (0.33 
mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in hexanes, 
3.0 mmol) at –5 
oC over 15 min]. The stirring was continued for 1 h during which the 
reaction mixture was allowed to warm to –50 °C before addition of MeOH (5 mL) and 
saturated  aqueous  solution  of  NaHCO3  (6  mL).  The  whole  mixture  was  allowed  to 
warm to room temperature and was left stirring overnight. The mixture was poured onto 
H2O (100 mL), the products extracted with Et2O (3 × 75 mL). The combined organic 
phases were washed with H2O (3 × 100 mL) and brine (100 mL), dried over anhydrous 
MgSO4, filtrated and concentrated in vacuo to give the crude product as a yellow oil. 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexanes as the eluent gave the title compound as a colourless oil in yield of 0.165 g 
(53% of material in 91% GC purity). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.463 – 7.206 (5H, m, H
Ar), 5.947 (2H, s, H
4, 
4’), 2.432 – 2.276 (4H, m, H
2, 2’), 2.173 – 2.009 (2H, m, H
1), 0.180 (6H, s, H
7), –0.281 
(9H, s, H
6). 
13C NMR (100 MHz, CDCl3): ￿ (ppm) = 153.58 (2C
3, 3’), 138.76 (C
i-Ph), 134.10 (2CH
o-
Ph),  128.69  (CH
p-Ph),  127.12  (2CH
m-Ph),  122.84 (2CH
4,  4’),  60.66  (C
5),  31.70  (CH2
1), 
25.71 (2CH2
2, 2’), –0.97 (3CH3
6), –2.62 (2CH3
7). 
HRMS (EI): Found: [M]
+, 312.1731. C19H28Si2 requires: 312.1730. 
LRMS (CI): m/z: 312 ([M + H]
+·, 30%), 135 ([SiMe2Ph]
+·, 100%). 
IR (thin film): n ~= 2949 (w), 1429 (w), 1247 (s), 1111 (w), 968 (s), 869 (m), 828 (s), 
775 (s), 733 (s), 699 (s) cm
–1. 
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6.2.9.5.  rac-2-Hexyl-3,3a,4,5-tetrahydro-1-phenylpentalene (2.96) 
1
7 5
6
4 3
2
15 14 13 12 11 8 16
 
General procedure A was used with TBDMS protected 7-phenylhept-1-en-6-yn-5-ol, 
1,1-dibromoheptane and 1-ethynyl-4-methoxybenzene as  components.  Purification  of 
the crude material by column chromatography on SiO2 (230 – 400 mesh) with hexanes 
as the eluent gave a mixture of three compounds: 2.96, and rac-((3aR,4S,6aR)-2-hexyl-
1,3a,4,5,6,6a-hexahydro-3-phenylpentalen-4-yloxy)(tert-butyl)dimethylsilane  2.99  and 
rac-((3aS,4S,6aR)-2-hexyl-1,3a,4,5,6,6a-hexahydro-3-phenyl-3a-(1-phenylvinyl)-
pentalen-4-yloxy)(tert-butyl)dimethylsilane 2.100 as a pale yellow oil, 0.264 g. Further 
careful purification of the material by column chromatography gave the title compound 
as  a  colourless  oil  in  yield  of  0.056  (21%);  however,  the  yield  of  this  compound 
estimated by GC in the crude reaction mixture was 33%. 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.324 – 7.178 (5H, m, H
Ar), 5.183 (1H, q, J = 
3.0 Hz, H
1), 3.094 (1H, tddd, J = 12.9, 6.6, 3.0, 1.5 Hz, H
3), 2.631 (1H, m, H
5), 2.518 
(1H, m, H
5), 2.486 (1H, dd, J = 15.8, 8.0 Hz, H
8), 2.249 (2H, t, J = 8.0 Hz, H
11), 2.135 – 
2.062 (2H, m, H
4 + 8), 1.499 – 1.382 (3H, m, H
4 + 12), 1.268 – 1.135 (6H, m), 0.812 (3H, 
t, J = 7.0 Hz, H
16). 
13C NMR (100 MHz, CDCl3): ￿ (ppm)  =  158.99 (C
7), 152.74 (C
2), 136.40  (C
i-Ph), 
133.73 (C
6), 128.52 (2CH
o-Ph), 128.08 (2CH
m-Ph), 126.60 (CH
p-Ph), 111.90 (CH
1), 49.73 
(CH
3), 39.63 (CH2
8), 37.56 (CH2
5), 32.84 (CH2
4), 31.67 (CH2), 30.33 (CH2
11), 29.35 
(CH2), 28.22 (CH2), 22.59 (CH2), 14.06 (CH3
16). 
HRMS (EI): Found: [M]
+, 266.2033. C20H26 requires: 266.2034. 
LRMS (CI): m/z: 267 ([M + H]
+·, 100%), 181 ([M – Hex]
+·, 30%). 
IR (thin film): n ~= 2926 (s), 2854 (m), 2831 (m), 1603 (w), 1489 (m), 1463 (m), 1433 
(m), 797 (m), 767 (m), 699 (s) cm
–1. 
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6.2.9.6.  rac-((3aS,4S,6aR)-2-Hexyl-1,3a,4,5,6,6a-hexahydro-3-phenyl-3a-(1-
phenylvinyl)pentalen-4-yloxy)(tert-butyl)dimethylsilane (2.100) 
H Hb
Ph
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H
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Ha
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The  title  compound  was  obtained  simultaneously  with  compounds  2.96  and  2.99. 
Careful  purification  of  the  material  by  column  chromatography  allowed  for  partial 
separation to give a pure fraction of the title compound as a pale yellow oil in yield of 
0.011  g  (2%);  however,  the  yield  of  this  compound  estimated  by  GC  in  the  crude 
reaction mixture was 12%. 
1H NMR (400 MHz, BENZENE-D6): ￿ (ppm) = 5.522 (2H, dd, J = 8.5, 1.5 Hz, H
o-Ph), 
5.460 (2H, dd, J = 8.5, 2.0 Hz, H
o-Ph), 7.254 – 7.083 (10H, m, H
m- + p-Ph), 5.586 (1H, d, J 
= 1.9 Hz, H
13), 5.270  (1H, d, J = 1.9 Hz, H
13), 4.581 (1H, dd, J = 8.9, 5.4 Hz, H
8), 
2.476 (1H, tt, J = 8.8, 2.8 Hz, H
5), 2.320 (1H, dd, J = 16.6, 8.5 Hz, H
4b), 2.192 (1H, dt, J 
= 22.0, 7.8 Hz, H
14), 2.138 (1H, dt, J = 22.0, 8.0 Hz, H
14), 1.974 (1H, dd, J = 16.6, 2.0 
Hz, H
4a), 1.879 – 1.755 (2H, m, H
7), 1.696 (1H, tdd, J = 12.7, 10.3, 7.0 Hz, H
6), 1.434 – 
1.360 (2H, m, H
15), 1.300 (1H, ddt, J = 12.7, 6.5, 3.0 Hz, H
6), 1.245 – 1.167 (6H, m), 
0.866 (3H, t, J = 7.3 Hz, H
19), 0.772 (9H, s, H
9), –0.072 (3H, s, H
11), –0.076 (3H, s, H
11) 
13C NMR (100.5 MHz, BENZENE-D6): ￿ (ppm) = 155.43 (C
12), 145.95 (C
2), 145.00 
(C
i-Ph), 140.72 (C
i-Ph), 137.48 (C
3), 130.56 (2CH
o- or m-Ph), 129.00 (2CH
o- or m-Ph), 128.68 
(CH
o- or m-Ph), 128.36 (2CH
o- or m-Ph), 128.06 (CH
o- or m-Ph), 127.39 (CH
p-Ph), 126.44 (CH
p-
Ph), 116.12 (CH2
13), 80.65 (CH
8), 72.83 (C
1),  45.40 (CH2
4), 45.05 (CH
5), 35.27 (CH2
7), 
32.42 (CH2), 30.69 (CH2), 30.60 (CH2), 30.31 (CH2), 28.84 (CH2), 26.64 (3CH3
9), 23.37 
(CH2), 18.61 (C
10), 14.67 (CH3
19), –3.62 (CH3
11), –4.21 (CH3
11). 
HRMS (EI): Found: [M]
+, 500.3465. C34H48OSi requires: 500.3474. 
LRMS (CI): m/z: 369 ([M – TBDMSO]
+, 100%). 
LRMS (ESI+): m/z: 539 ([M + K]
+, 2%), 168 (100%). 
IR (thin film): n ~= 2949 (m), 2930 (m), 2850 (m), 1599 (w), 1467 (w), 1255 (m), 1115 
(m), 828 (s), 775 (s), 703 (s) cm
–1.   179 
6.2.10.  Preparation of monocyclic compounds 
 
6.2.10.1. 1,2,3-Trihexylcyclopenta-1,3-diene (2.103a) and 1,2-dihexyl-3-hexylidene-
cyclopent-1-ene (2.104a) 
n-Hex
n-Hex
H
n-Hex
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n-Hex
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added  EtMgBr  (2.0  mL  of  a  1.0  M  solution  in  THF,  2.0  mmol)  dropwise  over  3 
minutes. After 45 min, a solution of tetradec-7-yne (0.194 g, 1.0 mmol) in dry THF (3 
mL) was added dropwise. After 30 min at –78 °C the reaction mixture was allowed to 
warm to +5 °C over a period of 3 h.  
After cooling the reaction mixture to –78 °C, a solution of 1,1-dibromoheptane (0.271 g, 
1.05 mmol) in dry THF (1 mL) was added, followed by dropwise addition of LDA (0.61 
mL of a 1.8 M solution, 1.1 mmol). The reaction mixture was stirred at –78 °C for 15 
min  before  dropwise  addition  of  the  lithium  phenylacetylide,  [prepared  from 
phenylacetylene (0.33 ml, 3.0 mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M 
solution in hexanes, 3.0 mmol) at –5 °C over 15 min]. The stirring was continued for 2 
h during which the reaction mixture was allowed to warm to 0 °C before addition of 
MeOH  (10  mL)  and  a  saturated aqueous  solution  of  NaHCO3  (10  mL).  The  whole 
mixture  was  allowed  to  warm  to  room  temperature  and  left  stirring  overnight.  The 
mixture was poured onto H2O (100 mL), the products extracted with Et2O (3 × 75 mL). 
The combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried  over  anhydrous  MgSO4,  filtered  and  concentrated  in  vacuo  to  give  the  crude 
products as yellow oils.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexanes as the eluant gave the title products as an inseparable mixture of two 
compounds 2.103a and 2.104a in GC ratio 64 : 36, respectively in combined yield of 
0.204 g (64%, colourless oil).   180 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 5.849 (1H, t, J = 1.5 Hz, H
4), 5.134 (1H, tt, J 
= 7.3, 2.3 Hz, H
7), 2.804 (2H, d, J = 1.5 Hz, H
5), 2.458 – 2.427 (2H, m, H
12), 2.380 – 
2.360 (2H, m, H
11), 2.444 – 2.117 (10H, m), 2.380 – 2.360 (2H, q, J = 7.3 Hz, H
6),1.616 
– 1.314 (46H, m), 0.913 – 0.899 (18H, m, 6CH3). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 148.62 (C
3), 147.51 (C
10), 144.95 (C
8), 
142.04 (C
1), 140.12 (C
2), 137.56 (C
9), 122.28 (CH
4), 114.84 (CH
7), 41.42 (CH2
5), 32.83 
(CH2
11), 31.87 (CH2
major), 31.84 (2CH2
major  +  minor), 31.78 (CH2
major), 31.72 (CH2
minor), 
30.59 (CH2
major), 30.31 (CH2
major), 29.74 (CH2
minor), 29.66 (CH2
minor), 29.63 (CH2
major), 
29.51  (3CH2
major  +  minor),  29.45  (CH2
6),  29.25  (CH2
minor),  28.92  (CH2
minor),  28.57 
(CH2
major), 28.47 (3CH2
major  +  minor), 28.16 (CH2
minor), 26.18 (CH2
12), 25.64 (CH2
major), 
24.86 (CH2
 minor), 22.68 (6CH2
major + minor), 14.10 (6Me
major + minor). 
HRMS (EI): Found: [M]
+, 318.3286. C23H42 requires: 318.3286. 
LRMS (CI): m/z: 322 ([M + 4H]
+, 100%), 289 ([M – Et]
+, 100%). 
IR (thin film): n ~= 2952 (m), 2926 (s), 2847 (s), 1463 (m), 1377 (m), 722 (m) cm
–1. 
 
6.2.10.2. 1-(3-Hexyl-2-phenylcyclopenta-1,3-dienyl)benzene  (2.103b),  1-(4-hexyl-5-
phenylcyclopenta-1,4-dienyl)benzene (2.103b’)  and 1-((3E)-3-hexylidene-
2-phenylcyclopent-1-enyl)benzene (2.104b) 
Ph
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H
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added  EtMgBr  (2.0  mL  of  a  1.0  M  solution  in  THF,  2.0  mmol)  dropwise  over  3 
minutes. After 45 min, a solution of 1,2-diphenylethyne (0.178 g, 1.0 mmol) in dry THF 
(3 mL) was added dropwise. After 30 min at –78 °C the reaction mixture was allowed to 
warm to +6 °C over a period of 8 h. After cooling the reaction mixture to –78 °C, a 
solution of 1,1-dibromoheptane (0.271 g, 1.05 mmol) in dry THF (1 mL) was added, 
followed by dropwise addition of LDA (0.58 mL of a 1.8 M solution, 1.05 mmol). The 
reaction  mixture  was  stirred  at  –78  °C  for  15  min  before  dropwise  addition  of  the 
lithium phenylacetylide, [prepared from phenylacetylene (0.33 ml, 3.0 mmol) in dry   181 
THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in hexanes, 3.0 mmol) at –5 °C 
over 15 min]. The reaction mixture was allowed to warm to –15 °C before addition of 
MeOH  (10  mL)  and  a  saturated aqueous  solution  of  NaHCO3  (10  mL).  The  whole 
mixture  was  allowed  to  warm  to  room  temperature  and  left  stirring  overnight.  The 
mixture was poured onto H2O (100 mL), the products extracted with Et2O (3 × 75 mL). 
The combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried  over  anhydrous  MgSO4,  filtered  and  concentrated  in  vacuo  to  give  the  crude 
products as yellow oils.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexanes as the eluant gave the title products as an inseparable mixture of three 
compounds in GC ratio 54 : 30 : 16 in combined yield of 0.136 g (45%, pale yellow oil). 
NMR characterysation does not contain complete data for compound 2.103b’. 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.550 – 7.205 (30H, m, H
Ar), 6.534 (1H, t, J = 
1.8 Hz, H
10), 6.298 (1H, quintet, J = 1.8 Hz, H
4), 5.233 (1H, tt, J = 7.4, 2.6 Hz, H
12), 
3.608 (1H, d, J = 1.8 Hz, H
5), 3.598 (1H, d, J = 1.8 Hz, H
5), 3.241 (2H, d, J = 1.8 Hz, 
H
9), 3.164 – 3.131 (2H, m, H
16), 2.916 – 2.883 (2H, m, H
17), 2.860 – 2.783 (2H, m), 
2.678 – 2.219 (10H, m), 2.013 – 1.938 (2H, m), 1.851 – 1.814 (1H, m), 1.724 – 1.336 
(13H, m), 1.057 – 0.985 (9H, m, 6CH3). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 149.47 (C), 149.27 (C), 146.24 (C), 146.08 
(C), 143.82 (C), 142.24 (C), 142.05 (C), 141.56 (C), 141.19 (C), 138.39 (C), 138.04 (C), 
137.68 (C), 137.32 (C),  137.10  (C),  136.90 (C), 129.73 (CH),  129.62  (CH), 128.66 
(CH),  128.47  (CH),  128.39  (CH),  128.32  (CH),  128.20  (CH),  127.98  (CH),  127.81 
(CH), 127.74 (2CH), 127.61 (CH), 127.51 (CH), 127.36 (CH), 126.86 (CH), 126.79 
(CH),  126.60  (CH),  126.48  (CH),  126.25  (CH),  125.94  (CH),  125.72  (CH),  125.63 
(CH), 124.99 (CH), 121.17 (CH), 42.54 (CH2), 42.29 (CH2), 35.32 (CH2), 34.02 (CH2), 
33.67 (CH2), 31.72 (CH2), 31.65 (CH2), 30.62 (CH2), 30.33 (CH2), 29.57 (CH2), 29.41 
(CH2), 29.34 (CH2), 29.28 (CH2), 29.13 (CH2), 28.94 (CH2), 28.78 (CH2), 28.41 (CH2), 
28.28 (CH2), 26.52 (CH2), 22.65 (CH2), 22.59 (CH2), 22.54 (CH2), 14.08 (3CH3). 
HRMS (EI): Found: [M]
+, 302.2040. C23H26 requires: 302.2035. 
LRMS (CI): m/z: 304 ([M + 2H]
+, 68%), 289 ([M – C6H13 + 2H]
+, 100%). 
IR (thin film): n ~= 2952 (m), 2922 (m), 2858 (m), 1486 (w), 1436 (w), 752 (s), 699 (s)  
cm
–1.   182 
6.2.11.  Procedure for crossover experiment 
Method a: To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to 
–78  °C  was  added  n-BuLi  (0.80  mL  of  a  2.5  M  solution  in  hexanes,  2.0  mmol) 
dropwise. After 20 min, a solution of dec-1-en-6-yne (0.136 g, 1.0 mmol) in dry THF (3 
mL) was added dropwise. After 30 min at –78 °C the reaction mixture was allowed to 
warm to RT and continued to stir for 2 h. After re-cooling the reaction mixture to –78 
°C, a solution of the appropriate 1,1-dibromopentane (0.242 g, 1.05 mmol) in dry THF 
(1 mL) was added followed by dropwise addition of freshly prepared LiTMP [prepared 
from freshly distilled 2,2,6,6-tetramethylpiperidine (0.187 mL, 1.1 mmol) in dry THF (2 
mL) and n-BuLi (0.44 mL of a 2.5 M solution in hexanes, 1.1 mmol) at 0 °C over 20 
min].  The  reaction  mixture  was  stirred  at  –78  °C  for  20  min  before  addition  of 
previously prepared and cooled to –78 °C bis(phenylethynyl)zirconocene 2.18.  
Complex  2.18  was  prepared  by  dropwise  addition  of  lithium  phenyl  acetylide 
[generated from phenyl acetylene (0.22 mL, 2.0 mmol) and n-BuLi (0.80 mL of a 2.5 M 
solution in hexanes, 2.0 mmol) at 0 °C over 15 min], to a stirred solution of Cp2ZrCl2 
(0.293 g, 1.0 mmol) in dry THF (5 mL) at –78 °C, and the stirring was continued for 30 
min at the same temperature before warming to RT and stirring for 5 h. 
The whole reaction mixture was stirred at –78 °C for 5 min before first equivalent of 
lithium  p-tert-butylphenyl  acetylide  2.7a  [freshly  prepared  from  p-tert-butylphenyl-
ethynylbenzene (0.54 mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 
M solution in hexanes, 3.0 mmol) at –5 °C over 15 min] was added and the reaction 
mixture was stirred at the same temperature for 15 min. In the meantime, the reaction 
was sampled for GC analysis. After this time, the second equivalent of lithium p-tert-
butylphenyl acetylide was added and the reaction mixture was stirred at –78 °C for 15 
min. In the meantime, the reaction was sampled for GC analysis. The addition of the 
third  equivalent  of  lithium  p-tert-butylphenyl  acetylide  followed  and  the  reaction 
mixture was stirred at the same temperature for 15 min. In the meantime, the reaction 
was sampled for GC analysis. The reaction mixture was then allowed to warm gradually 
to RT before addition of MeOH (10 mL) and a saturated aqueous solution of NaHCO3 
(10 mL). The whole mixture was allowed to warm to room temperature and left stirring 
for 16 h. The mixture was poured onto H2O (100 mL), the products extracted with Et2O 
(3 × 75 mL). The combined organic phases were washed with H2O (3 × 100 mL) and   183 
brine (100 mL), dried over anhydrous MgSO4, filtered and concentrated in vacuo to 
give the crude product as a yellow oil. 
 
Method b: Exactly as method a but bis(p-tert-butylphenylethynyl) zirconocene 2.18a 
was used instead of 2.18 and PhCCLi 2.7 instead of p-t-BuPhCCLi 2.7a. 
 
Method c: Exactly as method a but the p-tert-butylphenyl acetylide 2.7a (3.0 eq) was 
added all at once at –78 °C to the reaction mixture. The stirring was continued for 30 
min at the dame temperature before quenching. 
 
6.2.12.  Preparation of compounds 2.107a-j 
General  procedure  C:  To  a  stirred  solution  of  (2S,3aR)-2-hexyl-2,3,3a,4,5,6-
hexahydro-1-phenylpentalen-2-ol 2.106 (prepared as shown in Scheme 2.12) (142 mg, 
0.50 mmol) in dry THF (4 ml) at RT was added ROH (5.0 mmol) followed by addition 
of a solution of (+)-camphorsulfonic acid (11.6 mg, 0.050 mmol) in dry THF (1 ml). 
The stirring was continued at the same temperature for 3.5 h after which the reaction 
mixture  was  poured  onto  a  saturated  aqueous  solution  of  NaHCO3  (100  mL),  the 
products extracted with Et2O (3 × 75 mL).  
The combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried  over  anhydrous  MgSO4,  filtered  and  concentrated  in  vacuo  to  give  the  crude 
products as yellow oils.  
 
6.2.12.1. rac-(1S,5R)-3-Hexyl-1-methoxy-2-phenyl-bicyclo[3.3.0]oct-2-ene (2.107a) 
O
H Hb
Ha
3
8
7
6 5 4
2 1
11 10 12 13 14 15
9
 
General procedure C was used with ROH = MeOH. Purification of the crude material 
by column chromatography on Al2O3 (basic, grade III) with 2.5% Et2O in petroleum 
ether as the eluent gave the title compound as a yellow oil in yield of 0.112 g (75%). 
   184 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.277 – 7.148 (5H, m, H
Ar), 3.160 (3H, s, H
9), 
2.672 (1H, dd, J = 17.3, 8.5 Hz, H
4b), 2.416 (1H, tdd, J = 8.3, 6.0, 1.8 Hz, H
5), 2.186 – 
2.070 (2H, m, H
10), 2.019 (1H, ddd, J = 12.3, 6.0, 2.5 Hz, H
6), 1.978 (1H, dd, J = 17.3, 
1.8 Hz, H
4a), 1.644 – 1.504 (3H, m), 1.467 – 1.314 (3H, m), 1.243 – 1.097 (7H, m), 
0.776 (3H, t, J = 6.9 Hz, H
15). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 145.38 (C
i-Ph), 136.92 (C
2 or 3), 135.15 (C
2 or 
3), 128.98 (2CH
o-  or  m-Ph), 127.93 (2CH
o-  or  m-Ph), 126.45 (CH
p-Ph), 103.77 (C
1), 50.82 
(CH3
9),  42.40  (CH
5),  41.80  (CH2
4),  37.63  (CH2),  35.63  (CH2),  31.61  (CH2),  29.69 
(CH2), 29.22 (CH2), 28.06 (CH2), 25.36 (CH2), 22.58 (CH2), 14.03 (CH3
15). 
HRMS (EI): Found: [M]
+, 298.2284. C21H30O requires: 298.2297. 
LRMS (CI): m/z: 266 ([M – MeOH]
+, 74%), 195 ([M – MeOH – C5H12]
+, 100%). 
IR (thin film): n ~= 2940 (s), 2864 (m), 1493 (w), 1461 (w), 1061 (s), 770 (s), 700 (s) 
cm
–1. 
 
6.2.12.2. rac-(1S,5R)-1-Ethoxy-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-ene (2.107b) 
O
H Hb
Ha
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General procedure C was used with ROH = EtOH. Purification of the crude material by 
column chromatography on Al2O3 (basic, grade III) with 2.5% Et2O in petroleum ether 
as the eluent gave the title compound as a yellow oil in yield of 0.108 g (69%). 
Spectral data were consistent with those reported previously.
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   185 
6.2.12.3. rac-(1S,5R)-3-Hexyl-2-phenyl-1-propoxy-bicyclo[3.3.0]oct-2-ene (2.107c) 
O
H Hb
Ha
3
8
7
6
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2 1
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General procedure C was used with ROH = PrOH. Purification of the crude material by 
column chromatography on Al2O3 (basic, grade III) with 2% Et2O in petroleum ether as 
the eluent gave the title compound as a yellow oil in yield of 0.115 g (71%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.356 – 7.225 (5H, m, H
Ar), 3.394 (1H, dt, J = 
9.0, 7.0 Hz, H
9), 3.202 (1H, dt, J = 9.0, 7.0 Hz, H
9), 2.755 (1H, dd, J = 17.3, 8.3 Hz, 
H
4b), 2.490 (1H, tdd, J = 8.3, 5.8, 2.0 Hz, H
5), 2.239 – 2.199 (2H, m, H
12), 2.346 (1H, 
m, H
6), 2.060 (1H, dd, J = 17.3, 2.0 Hz, H
4a), 1.762 – 1.580 (5H, m), 1.532 – 1.405 (3H, 
m), 1.326 – 1.207 (7H, m), 0.944 (3H, t, J = 7.4 Hz, H
11 or 17), 0.868 (3H, t, J = 7.0 Hz, 
H
11 or 17). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 144.73 (C
i-Ph), 137.06 (C
2 or 3), 135.92 (C
2 or 
3), 129.00 (2CH
o-  or  m-Ph), 127.86 (2CH
o-  or  m-Ph), 126.35 (CH
p-Ph), 103.08 (C
1), 64.84 
(CH3
9),  42.89  (CH
5),  41.93  (CH2
4),  37.64  (CH2),  35.60  (CH2),  31.63  (CH2),  29.72 
(CH2), 29.22 (CH2), 28.02 (CH2), 25.26 (CH2), 23.54 (CH2), 22.61 (CH2), 14.04 (CH3
11 
or  17), 10.87 (CH3
11 or  17). 
HRMS (EI): Found: [M]
+, 326.2600. C23H34O requires: 326.2610. 
LRMS (CI): m/z: 267 ([M – OPr]
+, 100%), 195 ([M – PrOH – C5H12]
+, 81%). 
IR (thin film): n ~= 2918 (s), 2859 (m), 1450 (w), 1083 (s), 770 (m), 694 (s) cm
–1. 
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6.2.12.4. rac-(1S,5R)-3-Hexyl-1-isopropoxy-2-phenyl-bicyclo[3.3.0]oct-2-ene 
(2.107d) 
O
H Hb
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General procedure C was used with ROH = i-PrOH. Purification of the crude material 
by column chromatography on Al2O3 (basic, grade III) with 1% Et2O in petroleum ether 
as the eluent gave the title compound as a yellow oil in yield of 0.011 g (7%). 
Spectral data were consistent with those reported previously.
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6.2.12.5. rac-(1S,5R)-1-Butoxy-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-ene (2.107e) 
O
H Hb
Ha
3
8
7
6 5 4
2 1
14 13 15 16 17 18
9 10 11 12
 
General procedure C was used with ROH = BuOH. Purification of the crude material by 
column chromatography on Al2O3 (basic, grade III) with 1% Et2O in petroleum ether as 
the eluaent gave the title compound as a yellow oil in yield of 0.116 g (68%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.327 – 7.195 (5H, m, H
Ar), 3.401 (1H, ddd, J 
= 9.0, 7.2, 6.2 Hz, H
9), 3.216 (1H, dt, J = 9.0, 7.0 Hz, H
9), 2.724 (1H, dd, J = 17.3, 8.3 
Hz, H
4b), 2.454 (1H, tdd, J = 8.3, 5.8, 2.0 Hz, H
5), 2.211 – 2.168 (2H, m, H
13), 2.066 
(1H, m, H
6), 2.028 (1H, dd, J = 17.3, 1.3 Hz, H
4a), 1.726 – 1.532 (5H, m), 1.479 – 1.317 
(5H, m), 1.293 – 1.170 (7H, m), 0.907 (3H, t, J = 7.3 Hz, H
12 or 18), 0.837 (3H, t, J = 6.9 
Hz, H
12 or 18). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 144.70 (C
i-Ph), 137.07 (C
2 or 3), 135.93 (C
2 or 
3), 128.99 (2CH
o-  or  m-Ph), 127.86 (2CH
o-  or  m-Ph), 126.34 (CH
p-Ph), 103.08 (C
1), 62.91   187 
(CH3
9),  42.91  (CH
5),  41.94  (CH2
4),  37.64  (CH2),  35.60  (CH2),  32.53  (CH2),  31.63 
(CH2), 29.72 (CH2), 29.21 (CH2), 28.02 (CH2), 25.26 (CH2), 22.60 (CH2), 19.64 (CH2), 
14.08 (CH3
12  or  18), 14.04 (CH3
12  or  18).
 
HRMS (EI): Found: [M]
+, 340.2767. C24H36O requires: 340.2766. 
LRMS (CI): m/z: 266 ([M – BuOH]
+, 75%), 195 ([M – BuOH – C5H12]
+, 100%). 
IR (thin film): n ~= 2934 (s), 2853 (s), 1471 (m), 1083 (s), 764 (m), 710 (s) cm
–1. 
 
6.2.12.6. rac-(1S,5R)-3-Hexyl-1-(2-methylbutoxy)-2-phenyl-bicyclo[3.3.0]oct-2-ene 
(2.107f) 
O
H Hb
Ha
3
8
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6
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General  procedure  C  was  used  with ROH  =  2-Me-BuOH.  Purification  of  the crude 
material  by  column  chromatography  on  Al2O3  (basic,  grade  III)  with  0.5%  Et2O  in 
petroleum ether as the eluent gave the title compound as a pale yellow oil in yield of 
0.114 g (64%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.352 – 7.298 (4H, m, H
o-  +  m-Ph), 7.262 – 
7.219 (1H, m, H
p-Ph), 3.327 (0.5H, dd, J = 8.9, 5.4 Hz, H
9), 3.215 (0.5H, dd, J = 8.8, 6.3 
Hz, H
9), 3.058 (0.5H, dd, J = 9.0, 6.8 Hz, H
9), 2.958 (0.5H, dd, J = 8.9, 7.4 Hz, H
9), 
2.748 (1H, dd, J = 17.2, 8.4 Hz, H
4b), 2.455 (1H, tdd, J = 8.6, 6.3, 1.8 Hz, H
5), 2.286 – 
2.172 (2H, m, H
14), 2.086 (1H, m), 2.051 (1H, dd, J = 17.2, 1.3 Hz, H
4a), 1.734 (1H, m),  
1.671 – 1.403 (7H, m), 1.312 – 1.205 (7H, m), 1.137 (1H, m), 0.945 (1.5H, d, J = 6.5 
Hz, H
11), 0.906 (1.5H, t, J = 7.4 Hz, H
13), 0.904 (1.5H, d, J = 6.5 Hz, H
11), 0.900 (1.5H, 
7, J = 7.4 Hz, H
13), 0.864 (3H, t, J = 7.0 Hz, H
19). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 144.46 (C
i-Ph), 137.12 (C
2 or 3), 136.14 (C
2 or 
3), 129.03 (2CH
o- or m-Ph), 127.82 (2CH
o- or m-Ph), 126.30 (CH
p-Ph), 102.97 (C
1), 102.94 
(C
1), 68.49 (CH3
9), 68.47 (CH3
9), 43.09 (CH
5), 43.06 (CH
5), 41.92 (CH2
4), 37.61 (CH2), 
37.59 (CH2), 35.57 (CH
10), 35.55 (CH2), 35.37 (CH
10), 31.65 (CH2), 29.73 (CH2), 29.18   188 
(CH2),  27.98  (CH2
14),  26.61  (CH2),  26.57  (CH2),  25.34  (CH2),  22.61  (CH2),  17.16 
(CH3
11), 16.74 (CH3
11), 14.04 (CH3
19), 11.55 (CH3
13), 11.34 (CH3
13).
 
HRMS (ESI+): Found: [M + Na]
+, 377.2808. [C25H38NaO]
+ requires: 377.2815. 
LRMS (CI): m/z:  267  ([M  –  2-Me-BuOH  + H]
+,  75%),  195  ([M  – 2-Me-BuOH  – 
C5H12]
+, 100%). 
IR (thin film): n ~= 2961 (s), 2924 (s), 2853 (s), 1455 (w), 1077 (s), 764 (m), 700 (s) 
cm
–1. 
 
6.2.12.7. rac-(1S,5R)-3-Hexyl-1-pentyloxy-2-phenyl-bicyclo[3.3.0]oct-2-ene (2.107g) 
O
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General procedure C was used with ROH = PentOH. Purification of the crude material 
by column chromatography on Al2O3 (basic, grade III) with 0.5% Et2O in petroleum 
ether as the eluent gave the title compound as a yellow oil in yield of 0.110 g (62%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.328 – 7.196 (5H, m, H
Ar), 3.395 (1H, ddd, J 
= 8.9, 7.3, 6.3 Hz, H
9), 3.208 (1H, dt, J = 8.9, 7.1 Hz, H
9), 2.723 (1H, dd, J = 17.1, 8.3 
Hz, H
4b), 2.455 (1H, tdd, J = 8.3, 5.8, 1.8 Hz, H
5), 2.212 – 2.169 (2H, m, H
14), 2.068 
(1H, m, H
6), 2.027 (1H, dd, J = 17.1, 1.5 Hz, H
4a), 1.727 – 1.562 (5H, m), 1.492 – 1.373 
(3H, m), 1.354 – 1.179 (11H, m), 0.887 (3H, t, J = 6.8 Hz, H
13 or 19), 0.839 (3H, t, J = 
6.8 Hz, H
13 or 19). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 144.71 (C
i-Ph), 137.07 (C
2 or 3), 135.93 (C
2 or 
3), 129.00 (2CH
o-  or  m-Ph), 127.86 (2CH
o-  or  m-Ph), 126.34 (CH
p-Ph), 103.09 (C
1), 63.21 
(CH3
9),  42.89  (CH
5),  41.94  (CH2
4),  37.65  (CH2),  35.60  (CH2),  31.64  (CH2),  30.10 
(CH2), 29.72 (CH2), 29.21 (CH2), 28.63 (CH2), 28.02 (CH2), 25.26 (CH2), 22.67 (CH2), 
22.60 (CH2), 14.07 (CH3
13  or  19), 14.04 (CH3
13 or  19).
 
HRMS (ESI+): Found: [M + Na]
+, 377.2809. [C25H38NaO]
+ requires: 377.2815. 
LRMS (CI): m/z: 266 ([M – PentOH]
+, 75%), 195 ([M – PentOH – C5H12]
+, 100%).   189 
IR (thin film): n ~= 2930 (s), 2853 (s), 1466 (m), 1083 (s), 759 (m), 707 (s) cm
–1. 
 
6.2.12.8. rac-(1S,5R)-3-Hexyl-1-hexyloxy-2-phenyl-bicyclo[3.3.0]oct-2-ene (2.107h) 
O
H Hb
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6
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General procedure C was used with ROH = HexOH. Purification of the crude material 
by column chromatography on Al2O3 (basic, grade III) with 0.5% Et2O in petroleum 
ether as the eluent gave the title compound as a pale yellow oil in yield of 0.119 g 
(65%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.353 – 7.223 (5H, m, H
Ar), 3.418 (1H, ddd, J 
= 8.9, 7.3, 6.5 Hz, H
9), 3.233 (1H, dt, J = 8.9, 7.3 Hz, H
9), 2.750 (1H, dd, J = 17.2, 8.5 
Hz, H
4b), 2.482 (1H, tdd, J = 8.3, 5.8, 1.8 Hz, H
5), 2.237 – 2.193 (2H, m, H
15), 2.093 
(1H, m, H
6), 2.052 (1H, dd, J = 17.2, 1.3 Hz, H
4a), 1.752 – 1.577 (5H, m), 1.513 – 1.399 
(3H, m), 1.387 – 1.205 (13H, m), 0.899 (3H, t, J = 6.5 Hz, H
14 or 20), 0.864 (3H, t, J = 
6.8 Hz, H
14 or 20). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 144.71 (C
i-Ph), 137.07 (C
2 or 3), 135.93 (C
2 or 
3), 129.00 (2CH
o-  or  m-Ph), 127.86 (2CH
o-  or  m-Ph), 126.34 (CH
p-Ph), 103.09 (C
1), 63.24 
(CH3
9),  42.89  (CH
5),  41.94  (CH2
4),  37.65  (CH2),  35.59  (CH2),  31.83  (CH2),  31.63 
(CH2), 30.38 (CH2), 29.72 (CH2), 29.21 (CH2), 28.02 (CH2), 26.13 (CH2), 25.26 (CH2), 
22.67 (CH2), 22.60 (CH2), 14.05 (2CH3
14 + 20).
 
HRMS (EI): Found: [M]
+, 368.3064. C26H40O requires: 368.3079. 
LRMS (CI): m/z: 266 ([M – HexOH]
+, 60%), 195 ([M – HexOH – C5H12]
+, 100%). 
IR (thin film): n ~= 2930 (s), 2854 (s), 1463 (w), 1092 (s), 767 (m), 699 (s) cm
–1. 
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6.2.12.9. rac-(1S,5R)-1-Cyclohexyloxy-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-ene 
(2.107i) 
O
H Hb
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3
8
7
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General procedure C was used with ROH = c-HexOH. Purification of the crude material 
by column chromatography on Al2O3 (basic, grade III) with 1% Et2O in petroleum ether 
as the eluent gave the title compound as a yellow oil in yield of 0.022 g (12%). 
Spectral data were consistent with those reported previously.
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6.2.12.10.  rac-(1S,5R)-1-Benzyloxy-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-ene 
(2.107j) 
O
H Hb
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3
8
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General procedure C was used with ROH = c-HexOH. Purification of the crude material 
by column chromatography on Al2O3 (basic, grade III) with 1% Et2O in petroleum ether 
as the eluent gave the title compound as a yellow oil in yield of 0.118 g (63%). 
Spectral data were consistent with those reported previously.
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6.3.  Experimental from chapter 3 
 
6.3.1.  rac-(3aS,6aS)-2-Hexyl-octahydro-5,5-bis(methoxymethyl)-2-(1-
phenylvinyl)pentalene (3.34a) 
O
O
Hb
Ha
Ha
Ha
Hb
Hb
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Hb
Hb
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of bis(methoxymethyl)hepta-
1,6-diene (0.184 g, 1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at 
–78 °C the reaction mixture was allowed to warm to room temperature and stirred for 3 
h.  
After cooling the reaction to –78 °C, a solution of 1,1-dibromoheptane (0.335 g, 1.3 
mmol) in dry THF (1 mL) was added followed by dropwise addition of freshly prepared 
LiTMP [prepared from freshly  distilled  2,2,6,6-tetramethylpiperidine  (0.255  mL, 1.5 
mmol) in dry THF (2 mL) and n-BuLi (0.6 mL of a 2.5 M solution in hexanes, 1.5 
mmol) at –5 °C over 20 min]. The reaction mixture was stirred at –78 °C for 15 min 
before  dropwise  addition  of  lithium  phenylacetylide  [prepared  from  phenylacetylene 
(0.33 mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in 
hexanes, 3.0 mmol) at –5 
oC over 15 min]. The stirring was continued for 1 h during 
which the reaction mixture was allowed to warm to –55 °C before addition of MeOH (5 
mL)  and  saturated  aqueous  solution  of  NaHCO3  (6  mL).  The  whole  mixture  was 
allowed  to  warm  to  room  temperature  and  left  stirring  overnight.  The  mixture  was 
poured  onto  H2O  (100  mL),  the  products  extracted  with  Et2O  (3  ×  50  mL).  The 
combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as a 
yellow oil.    192 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 2.5% of Et2O in hexanes as the eluent gave the title compound as a pale yellow oil 
in yield of 0.295 g (77%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.330 – 7.240 (5H, m, H
Ar), 5.200 (1H, d, J = 
1.2 Hz, H
14), 5.000 (1H, d, J = 1.2 Hz, H
14), 3.390 (3H, s, H
1 or 2), 3.380 (3H, s, H
1 or 2), 
3.321 (1H, d, J = 8.8 Hz, H
3 or 4), 3.303 (1H, d, J = 8.8 Hz, H
3 or 4), 3.297 (1H, d, J = 8.8 
Hz, H
3 or 4), 3.276 (1H, d, J = 8.8 Hz, H
3 or 4), 2.186 (1H, dd, J = 12.4, 5.9 Hz, H
10a or 11b), 
1.900 (1H, tt, J = 11.8, 5.9 Hz, H
8 or 9), 1.808 (1H, tt, J = 11.8, 5.9 Hz, H
8 or 9), 1.749 
(1H, dd, J = 11.5, 5.8 Hz, H
10a or 11b), 1.632 (1H, d, J = 12.0 Hz, H
6a or 7b), 1.618 (1H, d, J 
= 12.2 Hz, H
6a or 7b), 1.610 (1H, t, J = 6.0 Hz), 1.566 (1H, d, J = 11.5 Hz, H
10b or 11a), 
1.498 (1H, m), 1.357 – 1.172 (6H, m), 1.256 (1H, t, J = 6.9 Hz, H
15), 1.117 (1H, t, J = 
12.0 Hz, H
10b or 11a), 1.012 (2H, t, J = 11.6 Hz, H
6b + 7a), 0.936 (1H, t, J = 6.9 Hz, H
15), 
0.891 (3H, t, J = 7.0 Hz, H
20). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 158.04 (C
13), 144.03 (C
i-Ph), 128.20 (2CH
o-
Ph), 127.52 (2CH
m-Ph), 126.36 (CH
p-Ph), 113.05 (CH2
14), 78.08 (2CH2
3 + 4), 59.20 (CH3
1 or 
2), 59.18 (CH3
1  or 2), 58.42 (C
12), 54.20 (C
5), 51.10 (CH
8 or 9), 50.82 (CH
8 or 9), 42.84 
(CH2), 42.67 (CH2
10 or 11), 39.70 (CH2
10 or 11), 34.74 (CH2
6 or 7), 34.70 (CH2
6 or 7), 31.75 
(CH2), 29.75 (CH2), 24.86 (CH2), 22.60 (CH2), 14.04 (CH3
20). 
HRMS (EI): Found: [M]
+, 384.3021. C26H40O2 requires: 384.3028. 
LRMS (CI): m/z: 385 ([M + H]
+·, 32%), 353 ([M – MeOH + H]
+·, 32%), 339 ([M – 
Et2O + H]
+·, 13%), 321 ([M – 2MeOH + H]
+·, 49%), 300 ([M – Hex + H]
+·, 75%), 45 
(100%). 
IR (thin film): n ~= 2929 (m), 2870 (m), 1461 (m), 1196 (m) 1104 (s), 894 (m), 775 
(m), 700 (s) cm
–1. 
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6.3.2.  rac-(3aS,6aS)-2-Hexyl-octahydro-5,5-bis(methoxymethyl)-2-(oct-1-en-2-
yl)pentalene (3.34b) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of bis(methoxymethyl)hepta-
1,6-diene (0.184 g, 1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at 
–78 °C the reaction mixture was allowed to warm to room temperature and stirred for 
12 h. After cooling the reaction to –78 °C, a solution of 1,1-dibromoheptane (0.335 g, 
1.3 mmol) in dry THF (1 mL) was added followed by dropwise addition of freshly 
prepared LiTMP, [prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.255 
mL, 1.5 mmol) in  THF (2 mL) and n-BuLi (0.6 mL of a 2.5 M solution in hexanes, 1.5 
mmol) at –5 °C over 20 min]. The reaction mixture was stirred at –78 °C for 15 min 
before dropwise addition of lithium 1-octyne, [prepared from 1-octyne (0.59 mL, 4.0 
mmol) in dry THF (4 mL) and n-BuLi (1.6 mL of a 2.5 M solution in hexanes, 4.0 
mmol) at –5 
oC over 15 min]. 
The  stirring  was  continued  for  2.5  h  during  which  time  the  reaction  mixture  was 
allowed to warm to –25 °C before addition of MeOH (5 mL) and saturated aqueous 
solution  of  NaHCO3  (6  mL).  The  whole  mixture  was  allowed  to  warm  to  room 
temperature and left stirring overnight. The mixture then was poured onto H2O (100 
mL), the products extracted with Et2O (3 × 50 mL). The combined organic phases were 
washed with H2O (3 × 100 mL) and brine (100 mL), dried over MgSO4, filtered and 
concentrated in vacuo to give the crude product as a yellow oil. 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 2.5% of Et2O in hexanes as the eluent gave the title compound as a pale yellow oil 
in yield of 0.185 g (47%). 
   194 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 4.830 (1H, br s, H
14), 4.742 (1H, q, J = 1.3 Hz, 
H
14), 3.352 (3H, s, H
1 or 2), 3.331 (3H, s, H
1 or 2), 3.276 (1H, d, J = 8.8 Hz,  H
3 or 4), 3.250 
(1H, d, J = 8.8 Hz, H
3 or 4), 3.250 (1H, d, J = 8.8 Hz, H
3 or 4), 3.220 (1H, d, J = 8.8 Hz,  
H
3 or 4), 2.066 (1H, dd, J = 12.3, 5.8 Hz), 1.951 – 1.912 (2H, m, H
21), 1.783 (1H, qt, J = 
11.7, 5.9 Hz, H
8 or 9), 1.684 (1H, qt, J = 11.9, 6.1 Hz, H
8 or 9), 1.601 – 1.519 (4H, m), 
1.487 – 1.367 (3H, m), 1.349 – 1.217 (13H, m), 1.110 – 1.013 (2H, m), 0.987 – 0.907 
(3H, m), 0.903 (3H, t, J = 7.0 Hz, H
20 or 26), 0.879 ppm (3H, t, J = 7.0 Hz, H
20 or 26). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 155.95 (C
13), 105.73 (CH2
14), 78.10 (CH2
3 or 
4), 78.08 (CH2
3 or 4), 59.23 (CH3
1 or 2), 59.19 (CH3
1 or 2), 59.14 (C
12), 54.10 (C
5), 50.77 
(CH
8 or 9), 50.24 (CH
8 or 9), 42.40 (CH2), 40.92 (CH2), 38.34 (CH2), 34.84 (CH2), 34.73 
(CH2), 32.19 (CH2), 31.92 (CH2), 31.88 (CH2), 29.97 (CH2), 29.58 (CH2), 28.92 (CH2), 
24.92 (CH2), 22.70 (CH2), 22.68 (CH2), 14.08 (2CH3
20 + 26). 
HRMS (EI): Found: [M ]
+, 392.9761. C26H48O2 requires: 392.3654. 
LRMS (CI): m/z: 393 ([M + H]
+·, 13%), 361 ([M – MeOH + H]
+·, 58%), 330 ([M – 
2MeOH + H]
+·, 28%), 243 ([M – 2MeOH – Hex + H]
+·, 70%), 45 (100%). 
IR (thin film): n ~= 2929 (m), 2853 (m), 1461 (m), 1202 (m) 1110 (s), 883 (m) cm
–1. 
 
6.3.3.  rac-((3aR,6aR)-Octahydro-2,2-bis(methoxymethyl)-5-(1-phenylvinyl)-
pentalen-5-yl)dimethyl(phenyl)silane (3.34c) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of bis(methoxymethyl)hepta-
1,6-diene (0.184 g, 1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at -
78 °C the reaction mixture was allowed to warm to room temperature and stirred for 2 
h.  After  cooling  the  reaction  mixture  to  –78  °C,  a  solution  of   195 
(dichloromethyl)dimethyl(phenyl)silane (0.285 g, 1.3 mmol) in dry THF (1 mL) was 
added followed by dropwise addition of LDA (0.85 mL of a 1.8 M solution, 1.5 mmol). 
The reaction mixture was stirred for 0.5 h during which time was allowed to warm to –
60 °C before re-cooling to –78 °C and dropwise addition of lithium phenyl acetylide, 
[prepared from phenylacetylene (0.33 mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi 
(1.2 mL of a 2.5 M solution in hexanes, 3.0 mmol) at –5 
oC over 15 min]. The stirring 
was continued for 3 h during which the reaction mixture was allowed to warm to –15 °C 
before addition of MeOH (5 mL) and a saturated aqueous solution of NaHCO3 (6 mL). 
The  whole  mixture  was  allowed  to  warm  to  room  temperature  and  left  stirring 
overnight. The mixture was poured onto H2O (100 mL), the products extracted with 
Et2O (3 × 75 mL). The combined organic phases were washed with H2O (3 × 100 mL) 
and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give the 
crude product as a red oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 2.5% of EtOAc in hexanes as the eluent gave the title compound as a yellow oil in 
yield of 0.152 g (35%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.600 – 7.565 (2H, m, H
Ar), 7.421 – 7.334 
(3H, m, H
Ar), 7.177 – 7.125 (3H, m, H
Ar), 6.873 – 6.835 (2H, m, H
Ar), 4.976 (1H, d, J = 
1.3 Hz, H
14), 4.850 (1H, d, J = 1.3 Hz, H
14), 3.327 (3H, s, H
1 or 2), 3.321 (3H, s, H
1 or 2), 
3.228 (1H, d, J = 8.8 Hz, H
3 or 4), 3.202 (1H, d, J = 8.8 Hz, H
3 or 4), 3.129 (2H, s, H
3 or 4), 
2.166 (1H, dd, J = 11.5, 5.5 Hz, H
10b or 11a), 2.004 (1H, dd, J = 12.0, 5.5 Hz, H
10b or 11a), 
1.712 (1H, qt, J = 11.5, 5.9 Hz, H
8 or 9), 1.525 (1H, t, J = 12.0 Hz, H
10a or 11b), 1.494 (1H, 
dd, J = 12.4, 6.2 Hz, H
6b or 7a), 1.448 (1H, dd, J = 12.0, 6.0 Hz, H
6b or 7a), 1.426 (1H, d, J 
= 11.5 Hz, H
10a or 11b), 1.379 (1H, tt, J = 11.8, 5.5 Hz, H
8 or 9), 0.862 (1H, t, J = 11.2 Hz, 
H
6a or 7b), 0.810 (1H, t, J = 12.0 Hz, H
6a or 7b), 0.397 (3H, s, H
15 or 16), 0.392 (3H, s, H
15 or 
16). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 159.63 (C
13), 144.41 (C
Si-i-Ph), 138.21 (C
i-
Ph), 134.79 (2CH
Si-o-Ph), 129.01 (CH
Si-p-Ph), 128.58 (2CH
Si-m-Ph), 127.53 (2CH
o- or m-Ph), 
127.26 (2CH
o- or m-Ph), 126.10 (CH
p-Ph), 114.19 (CH2
14), 77.84 (2CH2
3 + 4), 59.15 (2CH3
1 
+ 2), 54.63 (C
12), 52.10 (CH
8 or 9), 51.13 (CH
8 or 9), 47.74 (C
5), 39.22 (CH2
10 or 11), 37.73 
(CH2
10 or 11), 34.58 (CH2
6 or  7), 34.06 (CH2
6 or  7), –4.09 (CH3
15 or 16), –4.18 (CH3
15 or 16). 
HRMS (EI): Found: [M]
+, 434.2643. C28H38O2Si requires: 434.2641.   196 
LRMS (CI): m/z: 434 ([M]
+·, 10%), 300 ([M – HSiMe2Ph]
+·, 35%), 269 ([M – MeOH – 
HSiMe2Ph]
+·, 22%), 237 ([M – 2MeOH – HSiMe2Ph]
+·, 100%). 
IR (thin film): n ~= 2933 (m), 2873 (m), 1595 (w), 1448 (m), 1251 (m), 1202 (m), 1107 
(s), 813 (s), 771 (s), 733 (s), 703 (s) cm
–1. 
 
6.3.4.  rac-((3aS,6aS)-Octahydro-2,2-bis(methoxymethyl)pentalen-5-yl)-
dimethyl(phenyl)silane (major d.r.) (3.35a) and rac-((3aS,6aR)-octahydro-
2,2-bis(methoxymethyl)pentalen-5-yl)-dimethyl(phenyl)silane  (minor  d.r.) 
(3.35b) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of bis(methoxymethyl)hepta-
1,6-diene (0.184 g, 1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at 
–78 °C the reaction mixture was allowed to warm to room temperature and stirred for 2 
h.  After  cooling  the  reaction  mixture  to  –78  °C,  a  solution  of 
(dichloromethyl)dimethyl(phenyl)silane (0.285 g, 1.3 mmol) in dry THF (1 mL) was 
added followed by dropwise addition of LDA (0.85 mL of a 1.8 M solution, 1.5 mmol). 
The reaction mixture was stirred for 0.5 h during which was allowed to warm to –60 °C 
before dropwise addition of lithium phenyl acetylide pre-mixed with HMPA. [Lithium 
phenyl acetylide was freshly prepared from phenylacetylene (0.33 mL, 3.0 mmol) in dry 
THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in hexanes, 3.0 mmol) at 0 
oC over 
10 min, then HMPA (0.52 mL, 3.0 mmol) was added and the stirring was continued at 
the same temperature for further 15 min]. The stirring was continued for 3 h during   197 
which time the reaction mixture was allowed to warm to –15 °C before addition of 
MeOH (5 mL) and a saturated aqueous solution of NaHCO3 (6 mL). The whole mixture 
was allowed to warm to room temperature and left stirring overnight. The mixture then 
was poured onto H2O (100 mL), the products extracted with Et2O (3 × 75 mL). The 
combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as a red 
oil.  
Purification of the crude material by column chromatography on Al2O3 (basic, grade III) 
with 5% of Et2O in hexanes as the eluent gave the title compounds as a yellow oil in 
yield of 0.072 g (22%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.547 – 7.496 (4H, m, H
o-Ph major + minor), 7.368 
– 7.336 (6H, m, H
m- + p-Ph major + minor), 3.360 (3H, s, H
1/2 minor), 3.357 (3H, s, H
1/2 minor), 
3.352 (3H, s, H
1/2 major), 3.344 (3H, s, H
1/2 major), 3.280 (1H, d, J = 8.8 Hz, H
3/4 major), 
3.276 (1H, d, J = 8.8 Hz, H
3/4 major), 3.244 (1H, d, J = 8.8 Hz, H
3/4 major), 3.218 (1H, d, J 
= 8.8 Hz, H
3/4 major), 3.291 – 3.208 (4H, m, H
3 + 4 minor), 1.936 (1H, dddd, J = 12.0, 10.5, 
8.3, 3.8 Hz, H
major), 1.790 (1H, m, H
major), 1.696 (1H, ddd, J = 11.3, 8.0, 5.5 Hz, H
major), 
1.605 – 1.479 (12H, m, H
major + minor), 1.387 – 1.290 (2H, m, H
major + minor), 1.049 – 0.867 
(5H, m, H
major + minor), 0.342 (3H, s, H
13/13’ minor), 0.340 (3H, s, H
13/13’ minor), 0.260 (3H, s, 
H
13/13’ major), 0.250 (3H, s, H
13/13’ major). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 139.27 (2C
Si-i-Ph major + minor), 133.82 (4CH
Si-
p-Ph  major  +  minor), 128.69 (2CH
Si-p-Ph  major  +  minor), 127.60  (4CH
Si-m-Ph  major  +  minor), 78.02 
(CH2
3/4 minor), 78.02 (2CH2
3/4 major + minor), 77.99 (CH2
3/4 major), 59.20 (CH3
1/2 major), 59.17 
(CH3
1/2 major), 58.06 (2CH3
1 + 2 minor), 54.95 (C
5 major), 54.24 (C
5 minor), 53.49 (CH
8/9 major), 
52.96 (CH
8/9 major), 52.53 (2CH
8 + 9 minor), 34.28 (CH2
6/7 major), 33.97 (CH2
6/7 major), 31.57 
(2CH2
6 + 7 minor), 29.35 (CH2
10/11 major), 29.11 (2CH2
12 major + minor), 27.27 (CH2
10/11 major), 
26.32 (2CH2
10 + 11  minor), –3.12 (CH3
13/13’  minor), –3.20 (CH3
13/13’  minor), –4.56 (CH3
13/13’ 
major),  –4.71 (CH3
13/13’ major). 
HRMS (ESI+): Found: [M + Na]
+, 355.2604. [C20H32NaO2Si]
+ requires: 355.2604.
 
LRMS  (CI):  m/z:  254  ([M  –  Ph]
+·,  1%),  222  ([M  –  MeOH]
+·,  2%),  190  ([M  – 
2MeOH]
+·, 2%), 135 ([M – 2MeOH – SiMe2Ph]
+·, 100 %). 
IR (thin film): n ~= 2952 (m), 2922 (m), 2869 (m), 2820 (m), 1452 (w), 1421 (w), 1251 
(m), 1202 (m), 1107 (s), 813 (s), 775 (s), 722 (s), 695 (s) cm
–1.   198 
6.3.5.  rac-(3aS,8aR)-2-Hexyl-1,2,3,3a,8,8a-hexahydro-2-(1-phenylvinyl)-
cyclopenta[a]indene  and  rac-(3aR,8aR)-2-hexyl-1,2,3,3a,8,8a-hexahydro-2-
(1-phenylvinyl)-cyclopenta[a]indene (3.39a, b) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to  –78 °C 
was added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of 1-allyl-2-vinyllbenzene 
(0.144 g, 1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at –78 °C the 
reaction mixture was allowed to warm to room temperature and stirred for 2 h. After 
cooling the reaction to –78 °C, a solution of 1,1-dibromoheptane (0.271 g, 1.05 mmol) 
in dry THF (1 mL) was added followed by dropwise addition of LDA (0.61 mL of a 1.8 
M solution, 1.1 mmol). After stirring the reaction mixture for 15 min at –78 °C, lithium 
phenylacetylide  was  added  dropwise,  [prepared from  phenylacetylene (0.33  mL, 3.0 
mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in hexanes, 3.0 
mmol) at –5 
oC over 15 min]. The stirring was continued for 1.5 h during which the 
reaction mixture was allowed to warm to –30 °C before addition of MeOH (5 mL) and a 
saturated  aqueous  solution  of  NaHCO3  (6  mL).  The  whole  mixture  was  allowed  to 
warm to room temperature and left stirring overnight. The mixture then was poured 
onto H2O  (100 mL),  the  products extracted  with Et2O (3 × 50  mL). The combined 
organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), dried over 
MgSO4, filtered and concentrated in vacuo to give the crude product as a yellow oil. 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexanes as the eluent gave the title compound as an inseparable mixture of isomers 
in NMR ratio of 1.4 : 1 and combined yield of 0.165g (48%, pale yellow oil).   199 
1H NMR (400 MHz, BENZENE-D6): ￿ (ppm) = 7.311 – 7.249 (4H, m, H
o-Ph), 7.194 – 
7.070 (14H, m, H
Ar), 5.211 (1H, d, J = 1.3 Hz, H
10 major), 5.146 (1H, d, J = 1.3 Hz, H
10 
minor), 5.068 (1H, d, J = 1.3 Hz, H
10 major), 5.029 (1H, d, J = 1.3 Hz, H
10 minor), 2.952 (1H, 
td, J = 12.3, 5.8 Hz, H
5b major), 2.891 (1H, td, J = 11.8, 6.3 Hz, H
5b minor), 2.665 (1H, dd, J 
= 13.8, 5.8 Hz, H
3a major), 2.635 (1H, dd, J = 13.8, 5.8 Hz, H
3a minor), 2.550 (1H, dd, J = 
12.3, 6.0 Hz, H
7a major), 2.329 (1H, ddt, J = 13.8, 11.5, 1.3 Hz, H
3b major), 2.316 (1H, t, J = 
13.8 Hz, H
3b minor), 2.252 (1H, dd, J = 12.2, 5.7 Hz, H
7a minor), 2.157 – 1.940 (3H, m, 2H
4 
+ H
6 minor), 1.885 (1H, t, J = 11.3 Hz, H
6b major), 1.753 – 1.622 (2H, m, H
6 minor + H), 
1.740 (1H, dd, J = 11.3, 5.8 Hz, H
6a major), 1.538 – 1.129 (19H, m), 1.412 (1H, t, J = 12.3 
Hz, H
7b major), 1.324 (1H, t, J = 12.2 Hz, H
7b minor), 0.897 (3H, t, J = 7.0 Hz, H
16 minor), 
0.875 (3H, t, J = 7.0 Hz, H
16 major). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 158.49 (C
9 major ), 158.40 (C
9 minor ), 149.66 
(C
i-Ph major), 149.63 (C
i-Ph minor), 145.60 (C
1/2 major), 145.56 (C
1/2 minor), 144.68 (C
1/2 minor), 
144.63 (C
1/2  major), 128.99 (4CH
Ar), 128.68 (2CH
Ar), 128.40 (2CH
Ar), 127.30 (CH
Ar), 
127.27 (CH
Ar), 126.73 (CH
Ar), 126.70 (CH
Ar), 126.44  (2CH
Ar), 125.65 (CH
Ar), 125.61 
(CH
Ar), 122.93 (CH
Ar), 122.88 (CH
Ar), 114.10 (CH2
10 minor), 113.99 (CH2
10 major), 58.10 
(C
8  major),  58.05  (C
8  minor),  56.97  (CH
4/5  major),  56.61  (CH
4/5  minor), 55.40 (CH
4/5  minor), 
55.04    (CH
4/5  major),  43.40  (CH2
major),  43.28  (CH2
minor),  42.67  (CH2
major),  41.24 
(CH2
minor), 39.54 (CH2
minor),  38.09 (CH2
major), 35.00 (2CH2
major + minor), 32.54 (CH2
minor), 
32.49 (CH2
major), 30.58 (CH2
minor), 30.53 (CH2
major),  25.74 (CH2
minor), 25.63 (CH2
major), 
23.40 (2CH2
major + minor), 14.67 (2CH3
16 major + minor). 
HRMS (EI): Found: [M]
+, 344.2505. C26H32 requires: 344.2504. 
LRMS (CI): m/z: 345 ([M + H]
+·, 61%), 260 ([M – Hex + H]
+·, 14%), 130 (100%). 
IR (thin film): n ~= 2933 (m), 2858 (m), 1622 (w), 1489 (w), 1459 (m), 900 (m), 775 
(m), 741 (s), 699 (s) cm
–1. 
 
 
 
 
 
 
   200 
6.3.6.  rac-(3aR,6aR)-2-Benzyl-5-hexyl-octahydro-5-(1-phenylvinyl)cyclopenta[c]-
pyrrole (3.42a trans) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to  –78 °C 
was added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of N-allyl-N-benzylprop-2-en-
1-amine (0.187 g, 1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at –
78 °C the reaction mixture was allowed to warm to room temperature and stirred for 3 
h. After cooling the reaction to –78 °C, a solution of 1,1-dibromoheptane (0.271 g, 1.05 
mmol) in dry THF (1 mL) was added followed by dropwise addition of freshly prepared 
LiTMP, [prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.187 mL, 1.1 
mmol) in dry THF (2 mL) and n-BuLi (0.44 mL of a 2.5 M solution in hexanes, 1.1 
mmol) at 0 °C over 20 min]. The reaction mixture was stirred at –78 °C for 20 min 
before dropwise addition of lithium phenyl acetylide, [prepared from phenylacetylene 
(0.33 mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in 
hexanes, 3.0 mmol) at 0 
oC over 15 min]. The stirring was continued for 1 h during 
which time the reaction mixture was allowed to warm to –45 °C before addition of 
MeOH (5 mL) and a saturated aqueous solution of NaHCO3 (6 mL). The whole mixture 
was allowed to warm to room temperature and left stirring overnight. The mixture was 
poured  onto  H2O  (100  mL),  the  products  extracted  with  Et2O  (3  ×  50  mL).  The 
combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as an 
orange oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 10 ￿ 50% of Et2O in hexanes as the eluant gave the title compound as a yellow oil 
in yield of 0.175 g (45%).   201 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.295 – 7.148 (10H, m, H
Ar), 5.124 (1H, d, J = 
1.2 Hz, H
10), 4.936 (1H, d, J = 1.2 Hz, H
10), 3.813 (1H, d, J = 13.3 Hz, H
1), 3.754 (1H, 
d, J = 13.3 Hz, H
1), 2.771 (1H, dd, J = 8.8, 6.3 Hz, H
2b or 3a), 2.744 (1H, dd, J = 8.8, 6.3 
Hz, H
2b or 3a), 2.404 (1H, dd, J = 10.0, 8.8 Hz, H
2a or 3b), 2.398 (1H, dd, J = 10.0, 8.8 Hz, 
H
2a or 3b), 2.124 (1H, dd, J = 12.0, 6.0 Hz, H
6b or 8a), 2.106 (1H, m, H
4 or 5), 2.017 (1H, tt, 
J = 12.0, 6.0 Hz, H
4 or 5), 1.696 (1H, dd, J = 11.8, 6.0 Hz, H
6b or 8a), 1.614 (1H, t, J = 11.8 
Hz, H
6a or 8b), 1.572 (1H, m), 1.442 (1H, m), 1.272 – 1.104 (6H, m), 1.169 (1H, t, J = 7.0 
Hz, H
11), 1.147 (1H, t, J = 12.0 Hz, H
6a or 8b), 0.851 (1H, t, J = 7.0 Hz, H
11), 0.809 (3H, 
t, J = 7.0 Hz, H
16). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 157.67 (C
9), 143.79 (C
i-Ph), 140.25 (C
i-Ph), 
128.53 (2CH
o- or m-Ph), 128.18 (2CH
o- or m-Ph), 128.16 (2CH
o- or m-Ph), 127.58 (2CH
o- or m-
Ph), 126.62 (CH
p-Ph), 126.45 (CH
p-Ph), 113.29 (CH2
10), 61.80 (CH2
1), 58.69 (C
7), 55.05 
(2CH2
2 + 3), 50.92 (CH
4 or 5), 50.59 (CH
4 or 5), 42.71 (CH2), 40.94 (CH2
6 or 8), 38.09 (CH2
6 
or 8), 31.71 (CH2), 29.71 (CH2), 24.86 (CH2
11), 22.58 (CH2), 14.04 (CH3
16). 
HRMS (ESI+): Found: [M + H]
+, 388.2994. [C28H38N]
+ requires: 388.2999. 
LRMS (ESI+): m/z: 388 ([M + H]
+, 100%). 
IR (thin film): n ~= 2924 (m), 2853 (m), 2783 (m), 1498 (m), 1450 (m), 1029 (m) 894 
(s), 770 (m), 737 (m), 700 (s) cm
–1. 
 
6.3.7.  rac-(3aS,6aR)-2-Benzyl-5-hexyl-octahydro-5-(1-phenylvinyl)cyclopenta[c]-
pyrrole (3.42a cis) 
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This compound was obtained simultaneously with isomer 3.42a trans. 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 10 ￿ 50% of Et2O in hexanes as the eluant gave the title compound as a pale 
yellow oil in yield of 0.055 g (14%).   202 
1H  NMR  (400 MHz, CDCl3):  ￿  (ppm)  =  7.357  –  7.212  (8H,  m,  H
Ar),  7.134  (2H, 
apparent dd, J = 7.7, 1.7 Hz, H
N-o-Ph), 5.170 (1H, d, J = 1.5 Hz, H
10), 5.009 (1H, d, J = 
1.5 Hz, H
10), 3.584 (2H, br s, H
1), 2.627 – 2.560 (2H, m, H
4 + 5), 2.512 (2H, d, J = 9.0 
Hz, H
2 + 3), 2.242 – 2.170 (4H, m, H
2 + 3 + 6 + 8), 1.556 – 1.516 (2H, m, H
11), 1.392 – 
1.310 (8H, m), 1.269 – 1.216 (2H, m, H
6 +  8), 0.920 (3H, t, J = 6.8 Hz, H
16). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 153.33 (C
9), 143.52 (C
i-Ph), 139.83 (C
i-Ph), 
128.50 (2CH
o- or m-Ph), 128.42 (2CH
o- or m-Ph), 128.06 (2CH
o- or m-Ph), 127.45 (2CH
o- or m-
Ph), 126.58 (CH
p-Ph), 126.37 (CH
p-Ph), 115.34 (CH2
10), 60.43 (2CH2
2 + 3), 59.76 (CH2
1), 
54.98  (C
7),  44.05  (2CH2
6  +  8),  41.36  (2CH
4  +  5),  39.66  (CH2
11),  31.94  (CH2),  29.93 
(CH2), 25.93 (CH2), 22.73 (CH2), 14.12 (CH3
16). 
HRMS (ESI+): Found: [M + H]
+, 388.2997. [C28H38N]
+ requires: 388.2999. 
LRMS (ESI+): m/z: 388 ([M + H]
+, 100%). 
IR (thin film): n ~= 2933 (m), 2850 (m), 2778 (m), 1489 (m), 1452 (m), 1334 (m) 896 
(m), 775 (m), 737 (m), 699 (s) cm
–1. 
 
6.3.8.  rac-(3aR,6aR)-2-Benzyl-5-hexyl-octahydro-5-(1-phenylvinyl)cyclopenta[c]-
pyrrole (3.42a, b cis + trans) 
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 69 : 31
Minor d.r.
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of N,N-diallylbenzenamine 
(0.173 g, 1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at –78 °C the 
reaction mixture was allowed to warm to room temperature and stirred for 3 h. After 
cooling the reaction to –78 °C, a solution of 1,1-dibromoheptane (0.271 g, 1.05 mmol) 
in  dry  THF  (1  mL)  was  added  followed  by  dropwise  addition  of  freshly  prepared 
LiTMP, [prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.187 mL, 1.1 
mmol) in dry THF (2 mL) and n-BuLi (0.44 mL of a 2.5 M solution in hexanes, 1.1 
mmol) at 0 °C over 20 min]. The reaction mixture was stirred at –78 °C for 20 min 
before dropwise addition of lithium phenyl acetylide, [prepared from phenylacetylene 
(0.33 mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi i (1.2 mL of a 2.5 M solution in 
hexanes, 3.0 mmol) at 0 
oC over 15 min]. The stirring was continued for 1 h during 
which time the reaction mixture was allowed to warm to –45 °C before addition of 
MeOH (5 mL) and a saturated aqueous solution of NaHCO3 (6 mL). The whole mixture 
was allowed to warm to room temperature and left stirring overnight. The mixture was 
poured  onto  H2O  (100  mL),  the  products  extracted  with  Et2O  (3  ×  50  mL).  The 
combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as a 
yellow oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh)  
with 5% of Et2O in hexanes as the eluant gave the title compound as a pale yellow oil in 
yield of 0.263 g (70%) as inseparable mixture of 3.8 : 52.3 : 43.9 cis : cis : trans ring 
junction isomers. Re-crystallization from cold hexane provided the 2.2 : 1 cis (major 
isomer) :  trans mixture of final compounds. 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.356 – 7.178 (14H, m, H
Ar), 6.747 (1H, t, J = 
7.3 Hz, H
N-p-Ph major), 6.699 (2H, dd, J = 7.8, 1.0 Hz, H
N-o-Ph major), 6.647 (1H, t, J = 7.3 
Hz, H
N-p-Ph minor), 6.520 (2H, d, J = 7.8 Hz, H
N-o-Ph minor), 3.748 (1H, d, J = 1.3 Hz, H
9 
major), 5.236 (1H, br s, H
9 minor), 5.086 (1H, d, J = 1.3 Hz, H
9 major), 5.046 (1H, br s, H
9 
minor), 3.422 – 3.361 (2H, ddd, J = 9.5, 8.4, 6.5 Hz, H
(1 + 2) a/b minor), 3.290 – 3.266 (2H, d, 
J = 9.5 Hz, H
(1 + 2) a/b major), 3.159 – 3.118 (2H, apparent dd, J = 9.5, 7.3 Hz, H
(1 + 2) a/b 
major), 2.984 – 2.928 (2H, td, J = 8.4, 4.5 Hz, H
(1 + 2) a/b minor), 2.901 – 2.803 (2H, septet, J   204 
= 8.4 Hz, H
(3 + 4) major), 2.412 – 2.361 (2H, dd, J = 12.8, 7.4  Hz, H
(5 + 6) a/b major), 2.351 – 
2.306 (1H, dd, J = 12.5, 5.7 Hz, H
(5 + 6) a/b minor), 2.272 – 2.082 (2H, m, H
(3 + 4) minor), 
1.904 (1H, dd, J = 11.8, 5.8 Hz, H
(5/6) a/b minor), 1.824 (1H, t, J = 11.8 Hz, H
(5/6) a/b minor), 
1.742 – 1.670 (1H, m, H
minor), 1.609 – 1.52 (4H, m), 1.385 – 1.238 (18H, m), 0.911 (3H, 
t, J = 7.0 Hz, H
15 major), 0.888 (3H, t, J = 7.0 Hz, H
15 minor). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 157.37 (C
8 minor), 153.27 (C
8 major), 149.46 
(C
N-i-Ph major), 148.30 (C
N-i-Ph minor), 143.64 (C
i-Ph minor), 143.27 (C
i-Ph major), 129.13 (2CH
o- 
or m-Ph minor), 129.05 (2CH
o- or m-Ph major), 128.40 (2CH
o- or m-Ph major), 128.22 (2CH
o- or m-Ph 
minor), 127.68 (2CH
o- or m-Ph minor), 127.59 (2CH
o- or m-Ph major), 126.59 (CH
p-Ph minor), 126.55 
(CH
p-Ph major), 116.91 (CH
N-p-Ph major), 115.47 (CH2
9 major), 114.94 (CH
N-p-Ph minor), 113.75 
(2CH
N-o-Ph major), 113.54 (CH2
9 minor), 110.81 (2CH
N-o-Ph minor), 58.23 (C
7 minor), 55.07 (C
7 
major), 55.00 (2CH2
1 + 2 major), 50.31 (CH2
3/4 minor), 50.01 (CH2
4/3 minor), 49.77 (2CH2
1 + 2 
minor), 44.73 (2CH2
5 + 6 major), 42.76 (CH2
minor), 41.08 (2CH
3 + 4 major), 40.71 (CH
5/6 minor), 
39.84 (CH2
major), 37.94 (CH
6/5 minor), 31.84 (CH2
major), 31.74 (CH2
minor), 29.81 (CH2
major), 
29.71 (CH2
minor), 25.84 (CH2
major), 24.91 (CH2
minor), 22.67 (CH2
major), 22.61 (CH2
minor), 
14.09 (CH3
16 major), 14.07 (CH3
16 minor). 
HRMS (ESI+): Found: [M + H]
+, 374.2838. [C27H36N]
+ requires: 374.2842. 
LRMS (ESI+): m/z: 374 ([M + H]
+, 100%). 
IR (thin film): n ~= 2922 (m), 2922 (m), 2854 (m), 2812 (m), 1595 (s), 1504 (s), 1467 
(s), 1357 (m), 1327 (m), 892 (m), 741 (s), 692 (s) cm
–1. 
 
6.3.9.  rac-(E,3aR,6aR)-1-Ethyl-2-hexylidene-octahydro-5,5-bis(methoxymethyl)-
pentalene (3.45a) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to  –78 °C 
was added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes.  After  25  min  at  the  same  temperature,  a  solution  of  (Z)-4,4-
bis(methoxymethyl)nona-1,6-diene (0.212 g, 1.0 mmol) in dry THF (3 mL) was added   205 
dropwise. After 30 min at –78 °C the reaction mixture was allowed to warm to room 
temperature and stirred for 14 h.  
After cooling the reaction to –78 °C, a solution of 1,1-dibromoheptane (0.335 g, 1.3 
mmol) in dry THF (1 mL) was added followed by dropwise addition of freshly prepared 
LiTMP, [prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.255 mL, 1.5 
mmol) in dry THF (2 mL) and n-BuLi (0.6 mL of a 2.5 M solution in hexanes, 1.5 
mmol) at –5 °C over 20 min]. The reaction mixture was stirred at –78 °C for 30 min 
before dropwise addition of lithium phenyl acetylide, [prepared from phenylacetylene 
(0.33 mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in 
hexanes, 3.0 mmol) at –5 
oC over 15 min]. The stirring was continued for 3 h during 
which the reaction mixture was allowed to warm to –35 °C before addition of MeOH (5 
mL)  and  a  saturated  aqueous  solution  of  NaHCO3  (6  mL).  The  whole  mixture  was 
allowed  to  warm  to  room  temperature  and  left  stirring  overnight.  The  mixture  was 
poured  onto  H2O  (100  mL),  the  products  extracted  with  Et2O  (3  ×  50  mL).  The 
combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as a 
yellow oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 5% of Et2O in hexanes as the eluant gave the title compound as colorless oil in 
yield of 0.231 g (75%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 5.126 (1H, tq, J = 7.0, 2.3 Hz, H
15), 3.355 
(3H, s, H
1 or 2), 3.353 (3H, s, H
1 or 2), 3.296 (1H, d, J = 8.8 Hz, H
3 or 4), 3.288 (1H, d, J = 
8.8 Hz, H
3 or 4), 3.257 (1H, d, J = 8.8 Hz, H
3 or 4), 3.253 (1H, d, J = 8.8 Hz, H
3 or 4), 2.386 
(1H, dd, J = 20.3, 12.3 Hz, H
10), 1.993 – 1.867 (3H, m, 2H
16 + H
9), 1.805 – 1.660 (2H, 
m, H
10 + H
8), 1.684 (1H, dd, J = 12.0, 6.3 Hz, H
7a), 1.611 (1H, dd, J = 11.8, 5.9 Hz, 
H
6b), 1.394 – 1.229 (8H, m), 1.182 (1H, ddd, J = 13.8, 7.3, 2.0 Hz, H
11), 1.076 (1H, t, J 
= 12.0 Hz, H
7b), 0.958  (1H, t, J = 11.8 Hz, H
6a), 0.918 (3H, t, J = 7.4 Hz, H
14), 0.890 
(3H, t, J = 7.0 Hz, H
20). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 150.27 (C
12), 121.42 (CH
15), 78.50 (CH2
3/4), 
78.41 (CH2
4/3), 59.24 (2CH3
1 + 2), 56.84 (CH
11), 53.57 (C
5), 48.84 (CH
8), 48.32 (CH
9), 
35.15 (CH2
7), 34.31 (CH2
6), 31.96 (CH2
10), 31.57 (CH2
13), 29.35 (CH2), 29.12 (CH2
16), 
26.28 (CH2), 22.62 (CH2), 14.09 (CH3
20), 12.18 (CH3
14).   206 
HRMS (EI): Found: [M - MeOH]
+, 276.2458. [C19H32O]
+ requires: 276.2453. 
LRMS (CI): m/z: 309 ([M + H]
+·, 100%), 277 ([M – MeOH + H]
+·, 57%), 245 ([M – 
2MeOH + H]
+·, 43%). 
IR (thin film): n ~= 2952 (m), 2918 (m), 2858 (m), 1448 (w), 1198 (w), 1107 (s), 960 
(w) cm
–1. 
 
6.3.10. rac-(E,3aR,6aR)-2-Hexylidene-octahydro-5,5-bis(methoxymethyl)-1-
phenylpentalene (major d.r.) and  rac-(Z,3aR,6aR)-2-hexylidene-octahydro-
5,5-bis(methoxymethyl)-1-phenylpentalene (minor d.r.) (3.45b) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes.  After  25  min  at  the  same  temperature,  a  solution  of  1-((E)-4,4-
bis(methoxymethyl)hepta-1,6-dienyl)benzene (0.260 g, 1.0 mmol) in dry THF (3 mL) 
was added dropwise. After 30 min at –78 °C the reaction mixture was allowed to warm 
to room temperature and stirred for 15 h. After cooling the reaction to –78 °C, a solution 
of 1,1-dibromoheptane (0.335 g, 1.3 mmol) in dry THF (1 mL) was added followed by 
dropwise addition of freshly prepared LiTMP, [prepared from freshly distilled 2,2,6,6-
tetramethylpiperidine (0.255 mL, 1.5 mmol) in dry THF (2 mL) and n-BuLi (0.6 mL of 
a 2.5 M solution in hexanes, 1.5 mmol) at –5 °C over 20 min]. The reaction mixture was 
stirred  at  –78  °C  for  30  min  before  dropwise  addition  of  lithium  phenyl  acetylide, 
[prepared from phenylacetylene (0.33 mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi   207 
(1.2 mL of a 2.5 M solution in hexanes, 3.0 mmol) at –5 
oC over 15 min]. The stirring 
was continued for 4.5 h during which time the reaction mixture was allowed to warm to 
–15 °C before addition of MeOH (5 mL) and a saturated aqueous solution of NaHCO3 
(6 mL). The whole mixture was allowed to warm to room temperature and left stirring 
overnight. The mixture was poured onto H2O (100 mL), the products extracted with 
Et2O (3 × 50 mL). The combined organic phases were washed with H2O (3 × 100 mL) 
and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give the 
crude product as a yellow oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 5% of Et2O in hexanes as the eluant gave the title compound as a pale yellow oil in 
yield of 0.303 g (85%) as an inseparable mixture of isomers (9 : 1). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.304 – 7.155 (10H, m, H
Ar major + minor), 5.371 
(1H, fs tq, J = 6.9 Hz, H
13 minor), 4.869 (1H, tq, J = 6.7, 2.5Hz, H
13 major), 3.366 – 3.125 
(16H, m, H-1 + H-2 + H-3 + H-4 + H-11 (major + minor)), 3.331 (3H, s, H
1/2 major), 
3.303 (3H, s, H
2/1 major), 2.564 (1H, fs dd, J = 11.0 Hz,  H
10a major), 2.426 (1H, dd, J = 
13.8, 5.0 Hz, H
10b minor), 2.288 – 2.113 (1H, m, H
10a minor), 1.959 – 1.770 (9H, m, H-10
b 
major + 2H-8 + 2H-9 + 2H-14 (major + minor)), 1.725 (1H, dd, J = 12.3, 5.6 Hz, H
6/7 
major), 1.666 (1H, dd, J = 12.3, 6.0 Hz, H
6/7 minor), 1.546 (1H, dd, J = 12.0, 6.0 Hz, H
7/6 
minor), 1.489 (1H, dd, J = 12.3, 6.0 Hz, H
7/6 major), 1.323 – 1.181 (10H, m), 1.158 – 0.953 
(6H, m), 0.876 (3H, t, J = 7.0 Hz, H
18 major), 0.790 (3H, t, J = 7.0 Hz, H
18 minor). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 150.57 (C
12 major), 148.97 (C
12 minor), 146.01 
(C
i-Ph  minor), 144.68 (C
i-Ph  major), 128.47 (2CH
o-  or  m-Ph  major), 128.20 (2CH
o-  or  m-Ph  minor), 
128.09 (2CH
o- or m-Ph major), 127.45 (2CH
o- or m-Ph minor), 125.77 (CH
p-Ph major), 125.40 (CH
p-
Ph minor), 125.22 (CH
13 minor), 125.12 (CH
13 major), 78.02 (CH2
3/4 major), 77.97 (CH2
4/3 major), 
77.76 (CH2
3/4 minor), 77.21 (CH2
4/3 minor), 62.89 (CH3
1/2 minor), 59.48 (CH3/CH
1/2/8/9 major), 
59.24 (CH3/CH
1/2/8/9 major), 59.15 (CH3/CH
1/2/8/9 major), 59.08 (CH3/CH
1/2/8/9 minor), 54.16 
(2CH
11  major  +  minor), 53.12 (C
5  major), 52.96 (C
5  minor), 50.90 (CH
8/9  minor), 48.95 (CH
8/9 
major), 38.53 (CH2
10 minor), 34.60 (CH2
6/7 major), 34.29 (CH2
minor), 33.40 (CH2
minor), 33.20 
(CH2
7/6  major), 32.25 (CH2
10  major), 31.54 (CH2
major), 31.43 (CH2
minor), 29.18 (CH2
major), 
29.04 (CH2
major), 28.74 (CH2
minor), 28.59 (CH2
minor), 22.54 (CH2
major), 22.41 (CH2
minor), 
14.07 (CH3
18 major), 13.99 (CH3
18 major). 
HRMS (ESI+): Found: [M + Na]
+, 379.2607. [C24H36NaO2]
+ requires: 379.2608.   208 
LRMS (CI): m/z: 357 ([M + H]
+·, 74%), 353 ([M – MeOH]
+·, 65%), 293 ([M – 2MeOH 
+ H]
+·, 72%), 279 ([M – Ph]
+·, 59%), 181 (72%), 91 (96%), 45 (100%). 
IR (thin film): n ~= 2929 (m), 2864 (m), 1450 (m), 1191 (m) 1099 (s), 964 (w), 700 (s) 
cm
–1. 
 
6.3.11. rac-(2S,3aR,6aS)-5-Benzyl-2-hexyl-octahydro-3a-methyl-2-(1-phenylvinyl)-
cyclopenta[c]pyrrole  (major  d.r.)  and  rac-(2R,3aR,6aS)-5-benzyl-2-hexyl-
octahydro-3a-methyl-2-(1-phenylvinyl)cyclopenta[c]pyrrole  (minor  d.r.) 
(3.53a) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes.  After  25  min  at  the  same  temperature,  a  solution  N-allyl-N-benzyl-2-
methylprop-2-en-1-amine  (0.201  g,  1.0  mmol)  in  in  dry  THF  (3  mL)  was  added 
dropwise. After 30 min at –78 °C the reaction mixture was allowed to warm to room 
temperature and stirred for 3 h. After cooling the reaction mixture to –90 °C, a solution 
of 1,1-dibromoheptane (0.284 g, 1.1 mmol) in dry THF (1 mL) was added followed by 
dropwise addition of freshly prepared LiTMP, [prepared from freshly distilled 2,2,6,6-
tetramethylpiperidine (0.196 mL, 1.15 mmol) in dry THF (2 mL) and n-BuLi (0.46 mL   209 
of a 2.5 M solution in hexanes, 1.15 mmol) at 0 °C over 20 min]. The reaction mixture 
was stirred for 30 min during which was allowed to warm to –78 °C before dropwise 
addition  of  lithium  phenyl  acetylide,  [prepared  from  phenylacetylene  (0.33  mL,  3.0 
mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in hexanes, 3.0 
mmol) at 0 
oC over 15 min]. The stirring was continued for 3 h during which time the 
reaction mixture was allowed to warm to –20 °C before addition of MeOH (5 mL) and a 
saturated  aqueous  solution  of  NaHCO3  (6  mL).  The  whole  mixture  was  allowed  to 
warm to room temperature and left stirring overnight. The mixture was poured onto 
H2O (100 mL), the products extracted with Et2O (3 × 50 mL). The combined organic 
phases were washed with H2O (3 × 100 mL) and brine (100 mL), dried over MgSO4, 
filtered and concentrated in vacuo to give the crude product as a yellow oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 2.5% of Et2O in hexanes as the eluant gave the title compounds as an inseparable 
mixture (97 : 3) of both diastereomers in yield of 0.142 g (35%, pale yellow oil). 
 
NMR characterysation does not contain complete data for the minor isomer. 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.383 – 7.220 (10H, m, H
Ar), 5.270 (1H, d, J = 
1.6 Hz, H
11), 5.110 (1H, d, J = 1.6 Hz, H
11), 5.071 (1H, d, J = 1.8 Hz, H
11 minor), 4.958 
(1H, d, J = 1.8 Hz, H
11 minor), 3.587 (2H, br s, H
1), 2.701 (1H, d, J = 8.8 Hz, H
2), 2.568 
(1H, d, J = 8.8 Hz, H
3b), 2.342 (1H, ddd, J = 13.0, 7.8, 2.5 Hz, H
9b), 2.295 (1H, dd, J = 
8.8, 6.5 Hz, H
3a), 2.208 (1H, dd, J = 13.0, 2.3 Hz, H
7b), 2.112 (1H, dddd, J = 9.5, 7.8, 
6.5, 1.3 Hz, H
6), 1.884 (1H, d, J = 8.8 Hz, H
2), 1.654 (1H, m), 1.610 (1H, d, J = 13.0 
Hz, H
7a), 1.480 (1H, dd, J = 13.0, 9.5 Hz, H
9a), 1.470 (1H, m), 1.395 – 1.312 (7H, m), 
1.241 (3H, s, H
4), 0.939 (3H, t, J = 6.9 Hz, H
17), 0.932 (1H, t, J = 6.9 Hz, H
12). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 154.09 (C
10), 143.94 (C
i-Ph minor), 143.73 (C
i-
Ph), 139.94 (C
i-Ph), 128.61 (2CH
o- or m-Ph), 128.38 (2CH
o- or m-Ph), 128.06 (2CH
o- or m-Ph), 
127.48 (2CH
o-  or  m-Ph), 126.56 (CH
p-Ph), 126.38 (CH
p-Ph), 125.83 (CH
p-Ph  minor), 115.97 
(CH2
11),  113.63  (CH2
11  minor),  70.67  (CH2
2  minor),  70.34  (CH2
2),  60.51  (CH2
3),  60.03 
(CH2
1/3 minor), 59.81 (CH2
3/1 minor), 59.69 (CH2
1), 53.98 (C
8), 53.26 (C
8), 51.67 (CH2
7), 
50.54  (CH2
minor),  49.64  (CH
6),  49.31  (C
5),  49.24  (C
5  minor),  48.10  (CH2
minor),  45.15 
(CH2
minor), 45.04 (CH2
9), 41.82 (CH2
minor), 41.52 (CH2), 31.96 (CH2), 30.34 (CH2
minor), 
29.87 (CH2), 29.69 (CH2
minor), 28.82 (CH3
4 minor), 28.36 (CH3
4), 27.39 (CH2
minor), 25.72 
(CH2), 24.62 (CH2
minor), 22.73 (CH2), 14.13 (CH3
17).   210 
HRMS (ESI+): Found: [M + H]
+, 402.3148. [C29H40N]
+ requires: 402.3155. 
LRMS (ESI+): m/z: 402 ([M + H]
+, 100%). 
IR (thin film): n ~= 2924 (m), 2843 (m), 2767 (m), 1488 (m), 1455 (m), 1029 (m) 905 
(s), 775 (m), 737 (m), 700 (s) cm
–1. 
 
6.3.12. rac-(3aR,5S,6aS)-2-Benzyl-5-hexyl-octahydro-3a-phenyl-5-(1-phenylvinyl)- 
cyclopenta[c]pyrrole  (major  d.r.)  and  rac-(3aR,5R,6aS)-2-benzyl-5-hexyl-
octahydro-3a-phenyl-5-(1-phenylvinyl)-cyclopenta[c]pyrrole  (minor  d.r.) 
(3.53b) 
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Major d.r.
96 : 6
Minor d.r.
 
To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes.  After  25  min  at  the  same  temperature,  a  solution  N-benzyl-N-(2-
phenylallyl)prop-2-en-1-amine  (0.263  g,  1.0  mmol)  in  dry  THF  (3  mL)  was  added 
dropwise. After 30 min at –78 °C the reaction mixture was allowed to warm to room 
temperature and stirred for 3 h. After cooling the reaction mixture to –90 °C, a solution 
of 1,1-dibromoheptane (0.264 g, 1.1 mmol) in dry THF (1 mL) was added followed by 
dropwise addition of freshly prepared LiTMP, [prepared from freshly distilled 2,2,6,6-
tetramethylpiperidine (0.196 mL, 1.15 mmol) in dry THF (2 mL) and n-BuLi (0.46 mL   211 
of a 2.5 M solution in hexanes, 1.15 mmol) at 0 °C over 20 min]. The reaction mixture 
was stirred for 30 min during which was allowed to warm to –78 °C before dropwise 
addition  of  lithium  phenyl  acetylide,  [prepared  from  phenylacetylene  (0.33  mL,  3.0 
mmol) in dry THF (3 mL) and n–BuLi (1.2 mL of a 2.5 M solution in hexanes, 3.0 
mmol) at 0 
oC over 15 min]. The stirring was continued for 3 h during which time the 
reaction mixture was allowed to warm to –20 °C before addition of MeOH (5 mL) and a 
saturated  aqueous  solution  of  NaHCO3  (6  mL).  The  whole  mixture  was  allowed  to 
warm to room temperature and left stirring overnight. The mixture was poured onto 
H2O (100 mL), the products extracted with Et2O (3 × 50 mL). The combined organic 
phases were washed with H2O (3 × 100 mL) and brine (100 mL), dried over MgSO4, 
filtered and concentrated in vacuo to give the crude product as a yellow oil.  
Purification of the crude material by column chromatography on SiO2 (230-400 mesh) 
with  5  ￿  10%  of  Et2O  in  hexanes  as  the  eluant  gave  the  title  compounds  as  an 
inseparable mixture (94 : 6) of both diastereomers in yield of 0.066 g (14%, pale yellow 
oil). 
 
NMR characterysation does not contain complete data for the minor isomer. 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.331 – 6.938 (13H, m, H
Ar), 6.506 (2H, d, J = 
6.8 Hz, H
C1-o-Ph), 5.054 (1H, d, J = 1.3 Hz, H
10 minor), 4.916 (1H, d, J = 1.0 Hz, H
10), 
4.002 (1H, d, J = 1.3 Hz, H
10 minor), 4.710 (1H, d, J = 1.0 Hz, H
10), 3.604 (1H, d, J = 
13.3 Hz, H
1 minor), 3.542 (1H, d, J = 13.2 Hz, H
1), 3.464 (1H, d, J = 13.2 Hz, H
1), 3.071 
(1H, q, J = 7.7 Hz, H
5), 3.011 (1H, d, J = 8.8 Hz, H
2), 2.711 (1H, d, J = 8.7 Hz, H
3b), 
2.579 (1H, d, J = 13.0 Hz, H
6), 2.428 (1H, apparent t, J = 11.4 Hz, H
8a), 2.269 (1H, t, J 
= 7.7 Hz, H
3a), 1.943 (1H, d, J = 8.8 Hz, H
2), 1.862 (1H, d, J = 12.8 Hz, H
6), 1.642 (1H, 
m), 1.592 (1H, d, J = 11.4 Hz, H
8b), 1.432 (1H, m), 1.267 – 1.204 (8H, m), 0.864 (3H, t, 
J = 6.8 Hz, H
16 major), 0.713 (1H, t, J = 7.3 Hz, H
16 
minor). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 156.05 (C
9 major), 152.19 (C
9 minor), 149.78 
(C
i-Ph minor), 149.29 (C
i-Ph major), 143.79 (C
i-Ph minor), 143.16 (C
i-Ph major), 139.76 (C
i-Ph major), 
139.71 (C
i-Ph minor), 128.49 (2CH
o- or m-Ph major), 128.44 (2CH
o- or m-Ph minor), 128.43 (2CH
o- 
or m-Ph minor), 128.37 (2CH
o- or m-Ph major), 128.19 (2CH
o- or m-Ph minor), 128.12  (2CH
o- or m-Ph 
major), 128.09 (2CH
o- or m-Ph minor), 128.01 (2CH
o- or m-Ph major), 127.49 (2CH
o- or m-Ph minor), 
127.14 (2CH
o- or m-Ph major), 126.66 (CH
p-Ph major), 126.46 (2CH
o- or m-Ph major), 126.41 (CH
p-
Ph minor), 126.26 (2CH
o- or m-Ph minor), 126.05 (CH
p-Ph major), 125.80 (CH
p-Ph minor), 125.42   212 
(CH
p-Ph  minor),  125.27  (CH
p-Ph  major),  116.56  (CH2
10  major),  113.76  (CH2
10  minor),  71.38 
(CH2
2 major), 68.09 (CH2
2 minor), 61.86 (CH2
3 minor), 60.93 (CH2
3 major), 59.65 (CH2
1 minor), 
59.44 (CH2
1 major), 58.02 (C
7 minor), 57.75 (C
7 major), 53.55 (C
4 major), 53.13 (CH2
6 major), 
52.80 (C
4 minor), 49.03 (CH2
minor), 48.68 (CH2
minor), 48.45 (CH
5 minor), 44.67 (CH
5 major), 
44.54 (CH2
8 major), 40.68 (CH2
major), 40.31 (CH2
minor), 31.98 (CH2
major), 31.88 (CH2
minor), 
29.88 (CH2
major), 29.69 (CH2
minor), 25.77 (CH2
major), 24.23 (CH2
minor), 22.74 (CH2
major), 
22.63 (CH2
minor), 14.13 (CH3
16 major), 14.10 (CH3
16 minor). 
HRMS (ESI+): Found: [M + H]
+, 464.3303. [C34H42N]
+ requires: 464.3312. 
LRMS (ESI+): m/z: 464 ([M + H]
+, 100%). 
IR (thin film): n ~= 2956 (m), 2933 (m), 2847 (m), 2775 (m), 1607 (w), 1493 (m), 1452 
(m), 1024 (m) 907 (s), 733 (s), 699 (s) cm
–1. 
 
6.3.13. rac-(3aR,7aS)-2-Hexyl-octahydro-2-(1-phenylvinyl)-1-H-indene (major d.r.) 
and  rac-(3aR,7aR)-2-hexyl-octahydro-2-(1-phenylvinyl)-1-H-indene  (minor 
d.r.) (3.59) 
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Major d.r.                           68 : 32                            Minor d.r.  
To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of 1,7-octadiene (0.110 g, 1.0 
mmol) in dry THF (3 mL) was added dropwise. After 30 min at –78 °C the reaction 
mixture was allowed to warm to room temperature and stirred for 2 h. After cooling the 
reaction to –78 °C, a solution of 1,1-dibromoheptane (0.335 g, 1.30 mmol) in dry THF 
(1 mL) was added followed by dropwise addition of LDA (0.83 mL of a 1.8 M solution, 
1.50 mmol). The reaction mixture was stirred at –78 °C for 15 min before dropwise 
addition  of  lithium  phenyl  acetylide,  [prepared  from  phenylacetylene  (0.33  mL,  3.0 
mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in hexanes, 3.0   213 
mmol) at –5 
oC over 15 min]. The stirring was continued for 30 min during which time 
the reaction mixture was allowed to warm to –50 °C before addition of MeOH (5 mL) 
and a saturated aqueous solution of NaHCO3 (6 mL). The whole mixture was allowed to 
warm to room temperature and left stirring overnight. The mixture was poured onto 
H2O (100 mL), the products extracted with Et2O (3 × 50 mL). The combined organic 
phases were washed with H2O (3 × 100 mL) and brine (100 mL), dried over MgSO4, 
filtered and concentrated in vacuo to give the crude product as an orange oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexanes as the eluant gave the title compounds as a pale yellow oil in combined 
yield of 0.165 g (53%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.315 – 7.214 (10H, m, H
Ar major + minor), 5.189 
(1H, d, J = 1.4 Hz, H
11 major), 5.172 (1H, d, J = 1.5 Hz, H
11 minor), 5.008 (1H, d, J = 1.4 Hz, 
H
11 major), 4.982 (1H, d, J = 1.5 Hz, H
11 minor), 2.220 (1H, dd, J = 12.3, 5.5 Hz, H
minor), 
2.158 – 2.041 (4H, m), 1.862 – 1.735 (3H, m), 1.612 – 1.394 (16H, m), 1.372 – 1.076 
(22H, m), 1.024 – 0.916 (2H, m), 0.878 (3H, t, J = 7.0 Hz, H
17 major), 0.870 (3H, t, J = 7.0 
Hz, H
17 minor). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 158.24 (C
10 minor), 156.95 (C
10 major), 144.14 
(C
i-Ph  minor), 143.90 (C
i-Ph  major), 128.40 (2CH
o-  or  m-Ph  major), 128.20 (2CH
o-  or  m-Ph  minor), 
127.50  (2CH
o-  or  m-Ph  minor),  127.44  (2CH
o-  or  m-Ph  major),  126.31  (2CH
p-Ph  major  +  minor), 
113.82 (CH
11  major), 113.05 (CH
11  minor), 50.71 (C
8  major), 49.31 (C
8  minor), 46.88 (CH2
 
minor), 45.91 (CH
1/2 minor), 45.64 (CH
2/1 minor), 44.32 (CH2
minor), 43.35 (2CH2
 minor), 43.07 
(2CH2
 major), 42.78 (CH2
 minor), 37.84 (2CH
1 + 2 major), 31.87 (CH2
minor), 31.77 (2CH2
major), 
29.80  (2CH2
major  +  minor),  28.34  (2CH2
major),  26.43  (CH2
minor),  26.35  (CH2
minor),  25.81 
(CH2
major), 25.03 (CH2
minor), 23.17 (2CH2
major), 22.63 (2CH2
major + minor), 14.08 (2CH3
17 
major + minor). 
HRMS (EI): Found: [M]
+, 310.2661. C23H34 requires: 310.2661. 
LRMS (CI): m/z: 311 ([M + H]
+·, 4%), 310 ([M]
+·, 3%), 226 ([M – Hex + H]
+·, 100%). 
IR (thin film): n ~= 2922 (s), 2847 (s), 1444 (m), 896 (s), 771 (s), 695 (s) cm
–1. 
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6.3.14. rac-(3aS,7aR)-2-Hexylidene-octahydro-1-H-indene (3.60) 
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The product was obtained simultaneously with products 3.59. Purification of the crude 
material by column chromatography on SiO2 (230 – 400 mesh) with hexanes as the 
eluant gave the title compound as a pale yellow oil in yield of 0.084 g (40%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 5.258 (1H, tdd, J = 9.3, 4.5, 2.3 Hz, H
10), 
2.305 – 1.929 (8H, m), 1.538 – 1.279 (14H, m), 0.902 (3H, t, J = 7.0 Hz, H
15). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 141.95 (C
8),  122.05 (CH
10), 38.21 (CH
1/2), 
38.18 (CH
2/1), 37.91 (CH2), 33.05 (CH2), 31.62 (CH2), 29.51 (CH2), 29.40 (CH2), 27.55 
(CH2), 27.19 (CH2), 23.29 (CH2), 22.76 (CH2), 22.63 (CH2), 14.10 (CH3
15). 
HRMS (EI): Found: [M]
+, 206.2036. C15H26 requires: 206.2034. 
LRMS (CI): m/z: 207 ([M + H]
+·, 10%), 206 ([M]
+·, 18%), 121 ([M – Hex]
+·, 100%). 
IR (thin film): n ~= 2922 (s), 2850 (m), 1448 (m) cm
–1. 
 
6.3.15. rac-(3aS,9aR)-2-Hexyl-2,3,3a,4,9,9a-hexahydro-2-(1-phenylvinyl)-1H-
cyclopenta[b]napthalene (3.64) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of 1,2-diallylbenzene (0.158 
g, 1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at –78 °C the   215 
reaction mixture was allowed to warm to room temperature and stirred for 2.5 h. After 
cooling the reaction to –85 °C, a solution of 1,1-dibromoheptane (0.335 g, 1.3 mmol) in 
dry THF (1 mL) was added followed by dropwise addition of LDA (0.85 mL of a 1.8 M 
solution,  1.5  mmol).  After  15  min  a  dropwise  addition  of  lithium  phenyl  acetylide 
followed, [prepared from phenylacetylene (0.33 mL, 3.0 mmol) in dry THF (3 mL) and 
n-BuLi (1.2 mL of a 2.5 M solution in hexanes, 3.0 mmol) at –5 
oC over 15 min]. The 
stirring was continued for 1 h during which time the reaction mixture was allowed to 
warm to –55 °C before addition of MeOH (5 mL) and a saturated aqueous solution of 
NaHCO3 (6 mL). The whole mixture was allowed to warm to room temperature and left 
stirring overnight. The mixture was poured onto H2O (100 mL), the products extracted 
with Et2O (3 × 50 mL). The combined organic phases were washed with H2O (3 × 100 
mL) and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give 
the crude product as a yellow oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexanes as the eluant gave the title compound as a pale yellow oil in yield of 0.142 
g (40%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.447 – 7.373 (3H, m, H
Ar), 7.291 – 7.222 
(6H, m, H
Ar), 5.357 (1H, d, J = 1.8 Hz, H
9), 5.158 (1H, d, J = 1.8 Hz, H
9), 2.888 (2H, 
dd, J = 13.9, 5.5 Hz, H
1b + 2b), 2.611 (2H, tdd, J = 16.2, 10.0, 5.7 Hz, H
3 + 4), 2.494 (2H, 
dd, J = 13.9, 6.2 Hz, H
1a + 2a), 2.305 (2H, ddd, J = 12.2, 5.0, 2.4 Hz, H
5b + 7b), 1.588 – 
1.378 (10H, m), 1.074 (2H, dd, J = 12.2, 10.0 Hz, H
5a + 7a), 1.029 (3H, t, J = 6.9 Hz, 
H
15). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 153.39 (C
8), 143.44 (C
i-Ph), 139.54 (2C
i-Ph), 
128.40 (2CH
o-  or  m-Ph), 127.57 (2CH
o-  or  m-Ph), 127.49 (2CH
o-  or  m-Ph), 126.41 (CH
p-Ph), 
125.81 (2CH
o- or m-Ph), 115.40 (CH2
9), 51.99 (C
6), 44.03 (2CH2
5 + 7), 40.07 (CH2), 36.02 
(2CH 
3 + 4), 34.53 (2CH2
1 + 2), 31.91 (CH2), 29.86 (CH2),  25.78 (CH2), 22.71 (CH2), 
14.10 (CH3
15). 
HRMS (EI): Found: [M]
+, 358.2673. C27H34 requires: 358.2661. 
LRMS (CI): m/z: 359 ([M + H]
+·, 30%), 274 ([M – Hex + H]
+·, 100%). 
IR (thin film): n ~= 2929 (s), 2853 (m), 2767 (m), 1488 (m), 1455 (m), 899 (m), 775 
(m), 748 (s), 705 (s) cm
–1.   216 
6.3.16. rac-(3aR,9aS)-1-Hexyl-3a,4,9,9a-tetrahydro-1H-cyclopenta[b]naphtalene 
(major  compound,  3.65),  rac-(3aS,9aR)-2-hexylidene-2,3,3a,4,9,9a-
hexahydro-1H-cyclopenta[b]naphtalene  (minor  compound,  3.66)  and  rac-
(3aS,9aR)-2-hexyl-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphtalene 
(trace, 3.67) 
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Major compound: 65 %
Trace: 4 %  
These  products  were  obtained  simultaneously  with  product  3.64.  Purification  of  the 
crude material by column chromatography on SiO2 (230 – 400 mesh) with hexanes as 
the eluant gave the title compounds as colourless oil in yield of 0.083 g (33%) as an 
inseparable mixture of compounds with the ratio stated above. 
 
NMR characterysation does not contain data for the compound 3.67. 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.277 – 7.120 (8H, m, H
Ar major + minor), 5.264 
(1H, m, H
8 
minor), 5.198 (1H, br s, H
7 
major), 3.084 (1H, m), 2.914 – 2.781 (4H, m), 2.741 
– 2.660 (1H, m), 2.612 – 2.307 (9H, m), 2.098 (1H, dd, J = 15.0, 6.0 Hz, H
minor), 2.015 
– 1.959 (6H, m), 1.415 – 1.184 (14H, m), 0.927 – 0.892 (6H, m, H
13 major + minor). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 153.39 (C
6 major), 141.12 (C
6 minor), 139.77 
(C
i-Ph  major), 139.45 (C
i-Ph  major),  137.74 (C
i-Ph  minor), 137.52  (C
i-Ph  minor), 128.17 (CH
Ar 
minor), 127.28 (CH
Ar  major), 127.12 (CH
Ar  major), 126.70 (CH
7  major), 125.82 (CH
Ar  minor), 
125.69 (2CH
Ar major), 125.66 (CH
Ar minor), 125.64 (CH
Ar minor), 121.62 (CH
8 minor), 45.41   217 
(CH
4  major), 42.22 (CH2
major), 39.87 (CH2
minor), 36.65 (CH
3/4  minor), 36.09 (CH
4/3  minor), 
35.89  (CH2
major), 35.79 (CH
3 major), 34.68 (CH2
minor), 34.39 (CH2
major), 33.19 (CH2
minor), 
32.80 (CH2
minor), 31.72 (CH2
major), 31.55 (CH2
minor), 30.92 (CH2
major), 29.47 (CH2
minor), 
29.37  (CH2
minor),  28.83  (CH2
major),  27.49  (CH2
major),  22.59  (2CH2
major  +  minor),  14.10 
(2CH3
13 major + minor). 
HRMS (EI): Found: [M]
+, 254.2031. C19H26 requires: 254.2034. 
LRMS (CI): m/z: 256  ([M]
+·, 13%),  255 ([M + H]
+·, 69%), 254  ([M]
+·,  88%),  169 
(67%), 128 (79%), 104 (100%). 
IR (thin film): n ~= 2922 (s), 2854 (m), 2824 (m), 1463 (m), 733 (s) cm
–1. 
 
6.3.17. rac-(2aR,4E,4aR,7aS,7bR)-1,1-Bis(methoxymethyl)-4-hexylidenedecahydro-
1H-cyclopenta[cd]indene  (major  d.r.)  and  rac-(2aR,4Z,4aR,7aS,7bR)-1,1-
bis(methoxymethyl)-4-hexylidenedecahydro-1H-cyclopenta[cd]indene 
(minor d.r.) (3.70) 
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Major d.r.
3 : 1
Minor d.r.
 
To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes.  After  25  min  at  the  same  temperature,  a  solution  of  3-(1-methoxy-2-
(methoxymethyl)pent-4-en-2-yl)cyclohex-1-ene (0.224 g, 1.0 mmol) in dry THF (3 mL) 
was added dropwise. After 30 min at –78 °C the reaction mixture was allowed to warm 
to room temperature and stirred for 2 h. After cooling the reaction mixture to –90 °C, a 
solution of 1,1-dibromoheptane (0.284 g, 1.1 mmol) in dry THF (1 mL) was added   218 
followed  by  dropwise  addition  of  freshly  prepared  LiTMP,  [prepared  from  freshly 
distilled 2,2,6,6-tetramethylpiperidine (0.196 mL, 1.15 mmol) in dry THF (2 mL) and n-
BuLi (0.46 mL of a 2.5 M solution in hexanes, 1.15 mmol) at 0 °C over 20 min]. The 
reaction mixture was stirred for 20 min during which was allowed to warm to –78 °C 
before dropwise addition of lithium phenyl acetylide. [prepared from phenylacetylene 
(0.33 mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in 
hexanes, 3.0 mmol) at 0 
oC over 15 min]. The stirring was continued for 2 h during 
which time the reaction mixture was allowed to warm to RT before addition of MeOH 
(5 mL) and a saturated aqueous solution of NaHCO3 (6 mL). The whole mixture was 
allowed  to  warm  to  room  temperature  and  left  stirring  overnight.  The  mixture  was 
poured  onto  H2O  (100  mL),  the  products  extracted  with  Et2O  (3  ×  50  mL).  The 
combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as a 
yellow oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 5% of Et2O in hexanes and Kugelrohr distillation (200 °C, 1.0 mmHg) gave the 
title compounds as an inseparable mixture 3 : 1 of E : Z isomers as a pale yellow oil in 
yield of 0.029 g (9%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 5.196 – 5.157 (2H, m, H
14 major + minor), 3.383 
(2H, d, J = 9.0 Hz, H
2 major + minor), 3.345 (6H, s, H
1 major + minor), 3.313 (6H, s, H
1 major + 
minor), 3.345 – 3.313 (4H, m, H
2 major + minor), 3.230 (1H, d, J = 8.8 Hz, H
2 major), 3.225 
(1H, d, J = 8.8 Hz, H
2 minor), 2.538 (1H, dd, J = 17.3, 7.8 Hz,  H
13 minor), 2.421  (1H, dd, 
J = 15.0, 6.0 Hz,  H
13 major), 2.363 – 2.190 (4H, m, H
major + minor), 2.001 – 1.832 (6H, m, 
H
major + minor), 1.800 – 1.502 (14H, m, H
major + minor), 1.352 – 1.194 (14H, m, H
major + 
minor), 1.152 – 0.918 (4H, m, H
major + minor), 0.884 (6H, t, J = 6.8 Hz, H
19 major +  minor). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 152.16 (C
12 major), 151.44 (C
12 minor), 123.28 
(CH
14  minor), 122.41 (CH
14  major), 78.50 (2CH2
2  major  +  minor), 74.53 (2CH2
2  major  +  minor), 
59.18 (2CH3
1  major  +  minor), 58.91 (2CH3
1  major  +  minor), 55.73 (C
3  major), 55.60 (C
3  minor), 
53.78 (CH
minor), 53.24 (CH
major), 41.70 (CH
major), 41.52 (CH
minor), 39.21 (CH
major), 38.83 
(CH
minor), 38.67 (CH
major), 36.56 (CH
minor), 36.27 (CH2
13 minor), 35.06 (CH2
major), 34.95 
(CH2
minor),  32.12  (CH2
13  major),  31.66  (CH2
minor),  31.52  (CH2
major),  29.91  (CH2
minor  ), 
29.51  (CH2
major)  29.35  (2CH2
major  +  minor),  29.13  (CH2
major),  27.74  (CH2
minor),  24.97   219 
(CH2
minor), 24.84 (CH2
major), 23.22 (CH2
minor), 23.19 (CH2
major), 22.63 (CH2
minor), 22.59 
(CH2
major), 14.08 (2CH3
19 major + minor). 
HRMS (EI): Found: [M]
+, 320.2710. C21H36O2 requires: 320.2715. 
LRMS (EI): m/z: 322 ([M + 2H]
+·, 5%), 321 ([M + H]
+·, 23%), 320 ([M]
+·, 28%), 289 
([M – MeOH + H]
+·, 46%), 288 ([M – MeOH]
+·, 56%), 243 (65%), 203 (100%). 
IR (thin film): n ~= 2926 (s), 2854 (s), 1452 (m), 1202 (m), 1111 (s), 956 (m) cm
–1. 
 
6.3.18. rac-(3aS,6aS)-Octahydro-2,2-bis(methoxymethyl)-5-(3-phenylpropa1,2-
dienyl)pentalene  (3.80a,  b)  and  rac-(3aS,6aS)-octahydro-2,2-
bis(methoxymethyl)-5-(3-phenylprop-2-ynyl)pentalene (3.81) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of bis(methoxymethyl)hepta-
1,6-diene (0.184 g, 1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at 
–78 °C the reaction mixture was allowed to warm to room temperature and stirred for 
12 h. After cooling the reaction to –78 °C, 1,1-dichloromethane (0.064 mL, 1.0 mmol) 
was added followed by dropwise addition of freshly prepared LiTMP, [prepared from 
freshly distilled 2,2,6,6-tetramethylpiperidine (0.20 mL, 1.2 mmol) in dry THF (2 mL) 
and n-BuLi (0.48 mL of a 2.5 M solution in hexanes, 1.15 mmol) at 0 °C over 20 min]. 
The reaction mixture was stirred for 1 h during which was allowed to warm to –65 °C   220 
before  re-cooling  to  –78  °C  and  dropwise  addition  of  lithium  phenyl  acetylide, 
[prepared from phenylacetylene (0.33 mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi 
(1.2 mL of a 2.5 M solution in hexanes, 3.0 mmol) at 0 
oC over 15 min]. The stirring 
was continued for 3 h during which time the reaction mixture was allowed to warm to –
35 °C before addition of MeOH (5 mL) and a saturated aqueous solution of NaHCO3 (6 
mL). The whole mixture was allowed to warm to room temperature and left stirring for 
18 h. The mixture then was poured onto H2O (100 mL), the products were extracted 
with Et2O (3 × 50 mL). The combined organic phases were washed with H2O (3 × 100 
mL) and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give 
the crude product as a brown oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 5% of Et2O in hexanes gave the title compounds as an inseparable mixture of 
compounds in the following ratio: 3.80a/b : 3.80b/a, 1 : 1.8 and 3.80 : 3.81, 1 : 2, as a 
pale yellow oil in combined yield of 0.033 g (10%). 
 
Spectral data contain NMR and LRMS analysis only. 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.393 – 7.145 (15H, m, H
Ar), 6.162 (1H, dd, J 
= 6.3, 3.0 Hz, H
17a/b), 6.160 (1H, dd, J = 6.3, 2.9 Hz, H
17a/b), 5.685 (2H, td, J = 6.5, 3.5 
Hz, H
15), 3.334 – 3.218 (30H, m), 2.723 – 2.650 (2H, m, H
14), 2.433 (2H, d, J = 7.0 
Hz, H
10), 1.989 – 1.348 (27H, m), 1.319 – 0.841 (14H, m). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 203.46 (C
16a/b), 203.40 (C
16a/b), 135.18 (2C
i-
Ph  B), 131.54 (2CH
o-Ph  A), 128.53 (4CH
m-Ph  B), 128.14 (2CH
m-Ph  A), 127.40 (CH
p-Ph  A), 
126.59 (2CH
o-Ph  B), 126.54 (2CH
p-Ph  B), 126.49 (2CH
o-Ph  B), 124.15 (C
i-Ph  A), 101.81  
(CH
17a/b), 101.76 (CH
17a/b), 95.73 (2CH
15a + b), 89.90 (C
12), 80.45 (C
13), 78.17 (2CH2
2), 
78.10 (4CH2
2), 59.20 (6CH3
1), 54.42 (2C
3), 54.34 (C
3), 52.33 (3CH
6/7), 50.90 (2CH
6/7), 
50.76 (CH
6/7), 43.33 (CH
 10), 42.92 (2CH
 14), 34.72 (2CH2), 34.40 (CH2), 34.33 (2CH2), 
34.25 (2CH2), 34.20 (2CH2), 33.61 (2CH2), 32.51 (CH2), 26.99 (CH2). 
LRMS (CI): m/z: 313 ([M + H]
+·, 9%), 268 ([M – MeOH + H]
+·, 6%), 267 ([M – Et2O 
+ H]
+·, 4%), 249 ([M – 2MeOH + H]
+·, 9%), 235 ([M – Ph]
+·, 7%), 115 ([C9H7]
+·, 34%). 
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6.4.  Experimental from chapter 4 
 
6.4.1.  rac-(1R,2R)-2-Hexyl-1-phenyloct-3-yn-1-ol (4.68a) 
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To a stirred solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 
°C was added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise 
over 3 minutes. After 25 min at the same tempereature, a solution of the non-1-yn-3-yl 
benzensulfonate (0.294 g, 1.0 mmol) in dry THF (1 mL) was added dropwise followed 
by dropwise addition of LDA (0.56 mL of a 1.8 M solution, 1.0 mmol). The stirring was 
continued for a further 1 h during which time the reaction mixture was allowed to warm 
to –50 °C. The reaction mixture was re-cooled to –78 °C and a solution of benzaldehyde 
(0.15 mL, 1.5 mmol) in dry THF (1 mL) was added followed by dropwise addition of 
BF3·OEt2 (0.18 ml, 1.5 mmol). The reaction mixture was warmed gradually to RT and 
stirred at the same temperature for 3 h before quenching with MeOH (5 mL) and a 
saturated  aqueous  solution  of  NaHCO3  (6  mL)  and  the  mixture  was  left  stirring 
overnight. The mixture was poured onto H2O (100 mL), the products extracted with 
Et2O (3 × 75 mL). The combined organic phases were washed with H2O (2 × 100 mL) 
and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give the 
crude product as a yellow oil (anti : syn diastereoisomers in the ratio of 77 : 23). 
Purification of the crude material by careful column chromatography on SiO2 (230 – 
400 mesh) with hexane : EtOAc (10 : 1) as the eluent to allow partial separation of the 
diasteroisomers to give a pure fraction of the title compound (anti isomer) as a pale 
yellow oil and a mixed fraction of both isomers in combined yield of 0.10 g (35%).   222 
Spectral data of the anti diastereoisomer: 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.36 – 7.29 (5H, m, H
Ar), 4.49 (1H, dd, J = 
6.8, 4.3 Hz, H
5), 2.67 (1H, ddt, J = 6.8, 4.3, 2.3 Hz, H
4), 2.64 (1H, d, J = 4.3 Hz, OH
6), 
2.23 (2H, td, J = 7.0, 2.3 Hz, H
1), 1.54 – 1.21 (14H, m), 0.92 (3H, t, J = 7.3 Hz, H
12/15), 
0.87 (3H, t, J = 6.9 Hz, H
12/15). 
13C NMR (100 MHz, CDCl3): ￿ (ppm)  =  142.12 (C
i-Ph), 128.18 (2CH
m-Ph), 127.68 
(CH
p-Ph), 126.61 (2CH
o-Ph), 85.29 (C
2), 79.35 (C
3), 76.37 (CH
5), 41.82 (CH
4), 31.71 
(2CH2),  31.07  (CH2),  28.97  (CH2),  27.36  (CH2),  22.55  (CH2),  21.92  (CH2),  18.46 
(CH2
1), 14.04 (CH3
12/15), 13.58 (CH3
12/15). 
HRMS (EI): Found: [M – H2O]
+, 268.2186. [C20H28]
+ requires: 268.2191. 
LRMS (CI): m/z: 287 ([M + H]
+, 38%), 286 ([M]
+, 42%), 269 ([M – H2O + H, 100%). 
IR (thin film): n ~= 3457 (m, br), 2958 (m), 2925 (s), 2848 (m), 1454 (m), 1185 (w), 
1054 (w), 698 (s) cm
–1. 
 
The following H and C signals of the syn isomer were identified in the spectra of the 
mixed fraction: 
1H NMR (400 MHz, CDCl3): ￿ = 7.40 – 7.28 (5H, m, H
Ar), 4.71 (1H, apparent t, J = 
4.8 Hz, H
5), 2.77 (1H, br s, H
4), 2.30 (1H, d, J = 4.3 Hz, OH
6), 2.16 (2H, td, J = 6.9, 2.3 
Hz, H
1), 1.54 – 1.20 (14H, m), 0.90 (3H, t, J = 7.3 Hz, H
12/15), 0.87 ppm (3H, t, J = 6.9 
Hz, H
12/15). 
13C NMR (100.5 MHz, CDCl3): ￿ = 141.86 (C
i-Ph), 127.94 (2CH
m-Ph), 127.47 (CH
p-Ph), 
126.60 (2CH
o-Ph), 84.44 (C
2), 79.95 (C
3), 75.99 (CH
5), 40.39 (CH
4), 31.75 (CH2), 31.01 
(CH2),  29.97  (CH2),    29.06  (CH2),  27.41  (CH2),  22.58  (CH2),  21.83  (CH2),  18.41 
(CH2
1), 14.03 (CH3
12/15), 13.57 ppm (CH3
12/15). 
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6.4.2.  rac-1-Phenyl-2-(prop-1-ynyl)octan-1-ol (4.68b) 
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To a stirred solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 
°C was added MeLi (1.25 mL of a 1.6 M solution, 2.0 mmol) dropwise over 3 minutes. 
After 25 min at the same tempereature, a solution of the non-1-yn-3-yl benzensulfonate 
(0.294 g, 1.0 mmol) in dry THF (1 mL) was added dropwise followed by dropwise 
addition of LDA (0.56 mL of a 1.8 M solution, 1.0 mmol). The stirring was continued 
for a further 1 h during which time the reaction mixture was allowed to warm to –50 °C. 
The reaction mixture was re-cooled to –78 °C and a solution of benzaldehyde (0.15 mL 
1.5 mmol) in dry THF (1 mL) was added followed by dropwise addition of BF3·OEt2 
(0.18 mL, 1.5 mmol) and the reaction mixture warmed gradually to RT. The reaction 
mixture was stirred at the same temperature for 3 h before quenching with MeOH (5 
mL) and saturated aqueous solution of NaHCO3 (6 mL) and the mixture left stirring 
overnight. The mixture was poured onto H2O (100 mL), the products extracted with 
Et2O (3 × 75 mL). The combined organic phases were washed with H2O (2 × 100 mL) 
and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give the 
crude product as an orange oil (anti : syn diastereoisomers in the ratio of 79 : 21). 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexane : EtOAc (10 : 1) as the eluent to yield the title compounds as an inseparable 
mixture of anti : syn diastereoisomers in combined yield of 0.097 g (40%, pale yellow 
oil). 
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1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.31 – 7.18 (10H, m, H
Ar), 4.62 (1H, dd, J = 
5.4, 3.7 Hz, H
5 minor), 4.40 (1H, dd, J = 6.8, 3.9 Hz, H
5 major), 2.65 (1H, m, H
4 minor), 2.58 
(1H, d, J = 3.9 Hz, OH
6 major), 2.56 (1H, apparent ddq, J = 14.0, 7.0, 2.3 Hz, H
4 major), 
2.30 (1H, d, J = 3.7 Hz, OH
6 minor), 1.77 (3H, d, J = 2.3 Hz, H
1 major), 1.71 (3H, d, J = 2.5 
Hz, H
1 minor), 1.47 – 1.10 (20H, m), 0.96 (3H, overlap t, J = 7.1 Hz, H
12 minor), 0.96 (3H, 
t, J = 7.0 Hz, H
12 major). 
13C NMR (100.5 MHz, CDCl3):  ￿  (ppm)  =  142.08  (C
i-Ph  major),  141.80  (C
i-Ph  minor), 
128.16  (2CH
m-Ph  major), 127.90    (2CH
m-Ph  minor),  127.67  (CH
p-Ph  major),  127.41  (CH
p-Ph 
minor), 126.57 (2CH
o-Ph major), 126.53 (2CH
o-Ph minor), 80.26 (C
2 major), 79.47 (C
2 or 3 minor), 
79.19 (C
3 or 2 minor), 78.61 (C
3 major), 76.38 (CH
5 major), 75.87 (CH
5 minor), 41.67 (CH
4 major), 
40.34  (CH
4  minor),  31.73  (CH2
minor),  31.66  (CH2
major),  31.60  (2CH2
major  +  minor),  29.77 
(CH2
minor), 29.06 (CH2
minor), 28.97 (CH2
major), 27.43 (CH2
minor), 27.34 (CH2
major), 22.54 
(CH2
major), 14.00 (2CH3
major + minor), 3.57 (CH3
1 major), 3.51 (CH3
1 minor). 
HRMS (EI): Found: [M – H2O]
+, 226.1720. [C17H22]
+ requires: 226.1722. 
LRMS (CI): m/z: 245 ([M + H]
+, 70%), 227 ([M – H2O + H]
+, 100%). 
IR (thin film): n ~= 3436 (m, br), 2917 (m), 2848 (m), 1454 (m), 1197 (w), 1042 (w), 
706 (s) cm
–1. 
 
6.4.3.  rac-1-Phenyl-2-(2-phenylethynyl)octan-1-ol (4.68c) 
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To a stirred solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 
°C was added PhLi (1.11 mL of a 1.8 M solution, 2.0 mmol) dropwise over 3 minutes. 
After 25 min at the same tempereature, a solution of the non-1-yn-3-yl benzensulfonate 
(0.294 g, 1.0 mmol) in dry THF (1 mL) was added dropwise followed by dropwise 
addition of LDA (0.56 mL of a 1.8 M solution, 1.0 mmol). The stirring was continued 
for a further 1 h during which time the reaction mixture was allowed to warm to –65 °C. 
The reaction mixture was re-cooled to –78 °C and a solution of benzaldehyde (0.15 mL 
1.5 mmol) in dry THF (1 mL) was added followed by dropwise addition of BF3·OEt2 
(0.18 mL, 1.5 mmol). The reaction mixture was warmed gradually to RT. The reaction 
mixture was stirred at the same temperature for 3 h before quenching with MeOH (5 
mL) and a saturated aqueous solution of NaHCO3 (6 mL) and the mixture left stirring 
overnight. The mixture was poured onto H2O (100 mL), the products extracted with 
Et2O (3 × 75 mL). The combined organic phases were washed with H2O (2 × 100 mL) 
and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give the 
crude product as a yellow oil (anti : syn diastereoisomers in the ratio of 79 : 21). 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexane : EtOAc (10 : 1) as the eluent to yield the title compounds as an inseparable 
mixture of anti : syn diastereoisomers in combined yield of 0.106 g (35%, yellow oil). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.48 – 7.28 (20H, m, H
Ar), 4.82 (1H, dd, J = 
6.0, 4.0 Hz, H
4 minor), 4.68  (1H, dd, J = 6.5, 4.3 Hz, H
4 major), 3.02 (1H, ddd, J = 9.8, 6.0, 
3.9 Hz, H
3 minor), 2.94 (1H, ddd, J = 9.6, 6.5, 4.3 Hz, H
3 major), 2.60 (1H, dd, J = 4.3, 1.4 
Hz, OH
6 major), 2.30 (1H, dd, J = 3.9. 2.0 Hz, OH
6 minor), 1.64 – 1.40 (8H, m), 1.35 – 1.23 
(12H, m), 0.90 (3H, t, J = 7.2 Hz, H
11 minor), 0.89 (3H, t, J = 6.8 Hz, H
11 major). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 141.92 (C
i-Ph B major), 141.85 (C
i-Ph B minor), 
131.69 (2CH
o-Ph A major), 131.55 (2CH
o-Ph A minor), 128.27 (2CH
m-Ph A major), 128.23 (2CH
m-
Ph B major), 128.15 (2CH
m-Ph A/B minor), 128.05 (2CH
m-Ph B/A minor), 127.97 (CH
p-Ph A/B major), 
127.86 (CH
p-Ph B/A major), 127.75 (CH
p-Ph A/B minor), 127.73 (CH
p-Ph B/A minor), 126.68 (2CH
o-
Ph B minor), 126.60 (2CH
o-Ph B major),  123.53 (C
i-Ph A minor), 123.27 (C
i-Ph A major), 90.02 (C
1 
minor), 89.34 (C
1  major), 84.86 (C
2  major), 84.30 (C
2  minor), 76.32 (CH
4  major), 76.09 (CH
4 
minor),  42.20  (CH
3  major),  41.09  (CH
3  minor),  31.76  (CH2
minor),  31.70  (CH2
major),  31.46 
(CH2
major), 30.15 (CH2
minor), 29.11 (CH2
minor), 29.00 (CH2
major), 27.44 (2CH2
minor + minor), 
22.58 (2CH2
major + minor), 14.04 (2CH3
11 major + minor).   226 
HRMS (EI): Found: [M – H2O]
+, 288.1885. [C22H24]
+ requires: 288.1878. 
LRMS (CI): m/z: 306 ([M]
+, 34%), 289 ([M – H2O + H]
+, 66%). 
IR (thin film): n ~= 3363 (m, br), 2933 (m), 2864 (m), 1491 (m), 1446 (m), 1029 (m), 
760 (s), 686 (s) cm
–1. 
 
6.4.4.  rac-1-Phenyl-2-(4-phenylbuta-1,3-diynyl)octan-1-ol (4.68d) 
3
7
6
5
4
2
1
OH
10
9
8
13
12
11
A
B
 
To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to -78 °C was 
added PhCCLi (freshly prepared from PhCCH (0.22 ml, 2.0 mmol) and n-BuLi (0.8 ml 
of a 2.5 M solution, 2.0 mmol) at 0 °C over 15 min) dropwise over 5 minutes. After 25 
min the cooling bath was removed and the stirring was continued at RT for 4 h before 
re-cooling  the  reaction  mixture  to  –78  °C.  A  solution  of  the  non-1-yn-3-yl 
benzensulfonate (0.294 g, 1.0 mmol) in dry THF (1 mL) was added dropwise followed 
by dropwise addition of LDA (0.56 mL of a 1.8 M solution, 1.0 mmol). After stirring 
the reaction mixture for 30 min at the same temperature, a solution of benzaldehyde 
(0.15 mL, 1.5 mmol) in dry THF (1 mL) was added followed by dropwise addition of 
BF3·OEt2 (0.18 mL, 1.5 mmol). The reaction mixture was warmed gradually to RT. The 
reaction mixture was stirred at RT for 1 h before quenching with MeOH (5 mL) and a 
saturated aqueous solution of NaHCO3 (6 mL), the mixture left stirring overnight. The   227 
mixture was poured onto H2O (100 mL), the products extracted with Et2O (3 × 75 mL). 
The combined organic phases were washed with H2O (2 × 100 mL) and brine (100 mL), 
dried  over  MgSO4,  filtered  and  concentrated  in  vacuo  to  give  the  crude  product  as 
yellow oil (anti : syn diastereoisomers in the ratio of 62 : 38). 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexane : EtOAc (10 : 1) as the eluent to yield the title compounds as an inseparable 
mixture of anti : syn diastereoisomers in combined yield of 0.208 g (62%, yellow oil). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.39 – 7.14 (20H, m, H
Ar), 4.66 (1H, dd, J = 
5.9, 3.6 Hz, H
6 minor), 4.53 (1H, dd, J = 6.5, 4.3 Hz, H
6 major), 2.84 (1H, dddd, J = 10.0, 
6.0, 3.7, 0.5 Hz, H
5 minor), 2.76 (1H, dddd, J = 10.8, 6.5, 4.4, 0.8 Hz, H
5 major), 2.35 (1H, 
dd, J = 4.4 Hz, OH
7 major), 2.15 (1H, dd, J = 3.8 Hz, OH
7 minor), 1.49 – 1.14 (20H, m), 
0.77 (3H, t, J = 6.5 Hz, H
13 minor), 0.76 (3H, t, J = 6.7 Hz, H
13 major). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 141.54 (C
i-Ph B major), 141.48 (C
i-Ph B minor), 
132.50 (2CH
o-Ph A major), 132.48 (CH
p-Ph A major), 128.97 (2CH
o-Ph A minor), 128.89 (CH
p-Ph A 
minor), 128.39 (2CH
m-Ph A major), 128.34 (2CH
m-Ph B major), 128.30 (2CH
m-Ph A minor), 128.22 
(CH
p-Ph B major), 128.05 (2CH
m-Ph B minor), 127.92 (CH
p-Ph B minor), 126.55  (2CH
o-Ph B minor), 
126.48 (2CH
o-Ph B major),  121.88 (C
i-Ph A minor), 121.80 (C
i-Ph A major), 84.44 (C
1 major), 84.08 
(C
4 major), 76.22 (CH
6 major), 75.90 (C
4 minor), 75.73 (CH
6 minor), 75.65 (C
1 minor), 74.16 (C
2 
or 3 minor), 74.05 (C
3 or 2 minor), 68.84 (C
2 or 3 major), 68.49 (C
3 or 2 major), 42.22 (CH
5 major), 
41.30 (CH
5 minor), 31.68 (CH2
minor), 31.61 (CH2
major), 31.26 (CH2
major), 29.82 (CH2
minor), 
29.05 (CH2
minor), 28.94 (CH2
major), 27.36 (CH2
minor), 27.34 (CH2
major), 22.59 (CH2
minor), 
22.56 (CH2
major), 14.02 (2CH3
11 major + minor). 
HRMS (EI): Found: [M]
+, 330.1984. C24H26O requires: 330.1984. 
LRMS (CI): m/z: 331 ([M + H]
+, 34%), 313 ([M – H2O + H]
+, 60%). 
IR (thin film): n ~= 3371 (m, br), 2925 (m), 2852 (m), 1487 (m), 1458 (m), 1025 (m), 
764 (s), 690 (s) cm
–1. 
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6.4.5.  rac-(1R,2R)-2-Methyl-1,4-diphenylbut-3-yn-1-ol (4.68e) 
1
5
4
3
2
OH
6
A
B
 
To a stirred solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 
°C was added PhLi (1.11 mL of a 1.8 M solution, 2.0 mmol) dropwise over 3 minutes. 
After 25 min at the same tempereature, a solution of the but-3-yn-2-yl benzensulfonate 
(0.224 g, 1.0 mmol) in dry THF (1 mL) was added dropwise followed by dropwise 
addition of LDA (0.56 mL of a 1.8 M solution, 1.0 mmol). The stirring was continued 
for a further 1 h during which the reaction mixture was allowed to warm to –65 °C.  
The reaction mixture was re-cooled to –78 °C and a solution of benzaldehyde (0.15 mL 
1.5 mmol) in dry THF (1 mL) was added followed by dropwise addition of BF3·OEt2 
(0.18 mL, 1.5 mmol). The reaction mixture was warmed gradually to RT. The reaction 
mixture was stirred at the same temperature for 2 h before quenching with MeOH (5 
mL)  and  a  saturated  aqueous  solution  of  NaHCO3  (6  mL),  the  mixture  left  stirring 
overnight. The whole mixture was poured onto H2O (100 mL), the products extracted 
with Et2O (3 × 75 mL). The combined organic phases were washed with H2O (2 × 100 
mL) and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give 
the crude product as a yellow oil (anti : syn diastereoisomers in the ratio of 81 : 19). 
Purification of the crude material by careful column chromatography on SiO2 (230 – 
400 mesh) with hexane : EtOAc (10 : 1) as the eluent to allow partial separation of the 
diasteroisomers to give a pure fraction of the title compound (anti isomer) as a pale 
yellow oil and a mixed fraction (yellow oil) of both isomers in combined yield of 0.091 
g (39%). 
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Spectral data of the anti diastereoisomer: 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.44 – 7.30 (10H, m, H
Ar), 4.62 (1H, dd, J = 
7.0, 3.8 Hz, H
4), 3.04 (1H, quintet, J = 7.0 Hz, H
3), 2.60 (1H, d, J = 3.8 Hz, OH
6), 1.20   
(3H, d, J = 7.0 Hz, H
6). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 141.92 (C
i-Ph B), 131.68 (2CH
o-Ph A), 128.28 
(2CH
m-Ph  A/B), 128.24  (2CH
m-Ph  B/A), 128.02 (CH
p-Ph  A/B), 127.97 (CH
p-Ph  B/A), 126.69 
(2CH
o-Ph B),  123.15 (C
i-Ph A), 90.48 (C
1), 83.71 (C
2), 77.64 (CH
4), 36.08 (CH
3), 17.44 
(CH3
6). 
HRMS (EI): Found: [M – H2O]
+, 218.1094. [C17H14]
+ requires: 218.1096. 
LRMS (CI): m/z: 237 ([M + H]
+, 41%), 221 ([M – CH3]
+, 100%). 
IR (thin film): n ~= 3383 (m, br), 3032 (w), 2964 (w), 2877 (w), 1588 (w), 1493 (m), 
1444 (m), 1032 (m), 752 (s), 692 (s) cm
–1. 
 
6.4.6.  rac-2-Methyl-1-phenylpent-3-yn-1-ol (4.68f) 
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To a stirred solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 
°C was added MeLi (1.25 mL of a 1.6 M solution, 2.0 mmol) dropwise over 3 minutes. 
After 25 min at the same tempereature, a solution of the but-3-yn-2-yl benzensulfonate 
(0.224 g, 1.0 mmol) in dry THF (1 mL) was added dropwise followed by dropwise 
addition  of  freshly  prepared  LiTMP,  [prepared  from  freshly  distilled  2,2,6,6-
tetramethylpiperidine (0.17 mL, 1.0 mmol) in dry THF (2 mL) and n-BuLi (0.4 mL of a 
2.5 M solution in hexanes, 1.0 mmol) at –5 °C over 15 min]. The stirring was continued 
for a further 1 h during which time the reaction mixture was allowed to warm to –50 °C.  
The reaction mixture was re-cooled to –60 °C and a solution of benzaldehyde (0.30 mL 
3.0 mmol) in dry THF (1 mL). The reaction mixture was warmed gradually to RT. The   230 
reaction mixture was stirred at the same temperature for 3 h before quenching with 
MeOH (5 mL) and a saturated aqueous solution of NaHCO3 (6 mL), the mixture left 
stirring overnight. The mixture was poured onto H2O (100 mL), the products extracted 
with Et2O (3 × 75 mL). The combined organic phases were washed with H2O (2 × 100 
mL) and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give 
the crude product as a yellow oil (anti : syn diastereoisomers in the ratio of 73 : 27). 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexane : EtOAc (10 : 1) as the eluent to yield the title compounds as an inseparable 
mixture of anti : syn diastereoisomers in combined yield of 0.064 g (37%, yellow oil). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.30 – 7.18 (10H, m, H
Ar), 4.63 (1H, dd, J = 
4.9, 3.4 Hz, H
6 minor), 4.33  (1H, dd, J = 7.3, 3.5 Hz, H
6 major), 2.74 (1H, m, H
4 minor), 2.64 
(1H, quintet q, J = 7.3, 2.4 Hz, H
4 major), 2.58 (1H, dd, J = 3.5, 1.8 Hz, OH
7 major), 2.25 
(1H, t, J = 3.4 Hz, OH
7 minor), 1.76 (3H, dd, J = 2.4, 0.5 Hz, H
1 major), 1.71 (3H, dd, J = 
2.5, 0.5 Hz, H
1 minor), 0.96 (3H, overlap d, J = 7.0 Hz, H
5 minor), 0.96 (3H, d, J = 7.0 Hz, 
H
5 major). 
13C NMR (100.5 MHz, CDCl3):  ￿  (ppm)  =  141.64  (C
i-Ph  major),  141.48  (C
i-Ph  minor), 
128.19 (2CH
m-Ph major), 127.94 (2CH
m-Ph minor), 127.80 (CH
p-Ph major), 127.45 (CH
p-Ph minor), 
126.66 (2CH
o-Ph major), 126.40 (2CH
o-Ph minor), 80.53 (C
2 minor), 80.00 (C
2 major), 79.20 (C
3 
major), 78.54 (C
3 minor), 77.82 (CH
6 major), 76.27 (CH
6 minor), 35.55 (CH
4 major), 34.25 (CH
4 
minor), 17.72 (CH3
5 major), 15.56 (CH3
5 minor), 3.55 (CH3
1 major), 3.50 (2CH3
1 minor). 
HRMS (EI): Found: [M]
+, 174.1045. C12H14O requires: 174.1045. 
LRMS (CI): m/z: 174 ([M]
+, 2%), 156 ([M – H2O]
+, 4%), 118 (27%), 107 (100%). 
IR (thin film): n ~= 3424 (br), 1454 (m), 1029 (m), 756 (s), 702 (s) cm
–1. 
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6.4.7.  rac-2-Methyl-3-(prop-1-ynyl)nonan-2-ol (4.68g) 
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To a stirred solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 
°C was added MeLi (1.25 mL of a 1.6 M solution, 2.0 mmol) dropwise over 3 minutes. 
After 25 min at the same tempereature, a solution of the non-1-yn-3-yl benzensulfonate 
(0.294 g, 1.0 mmol) in dry THF (1 mL) was added dropwise followed by dropwise 
addition of LDA (0.56 mL of a 1.8 M solution, 1.0 mmol). The stirring was continued 
for a further 0.5 h during which time the reaction mixture was allowed to warm to –65 
°C. At the same temperature a solution of acetone (0.22 mL 3.0 mmol) in dry THF (1 
mL) was added to the reaction mixture followed by dropwise addition of BF3·OEt2 (0.36 
mL,  3.0  mmol).    The  reaction  mixture  was  warmed  gradually  to  RT.  The  reaction 
mixture was stirred at the same temperature for 2 h before refluxing for 20 h. After that 
time, the reaction mixture was cooled to RT and quenched with MeOH (5 mL) and a 
saturated aqueous solution of NaHCO3 (6 mL), left stirring overnight. The mixture was 
poured  onto  H2O  (100  mL),  the  products  extracted  with  Et2O  (3  ×  75  mL).  The 
combined organic phases were washed with H2O (2 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as a 
yellow oil. 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexane : EtOAc (10 : 1) as the eluent to yield the title compound as a pale yellow 
oil in yield of 0.048 g (25%). 
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1H NMR (400 MHz, CDCl3): ￿ (ppm) = 2.31 (1H, m, H
4), 1.96 (1H, s, OH), 1.96 (3H, 
d, J = 2.3 Hz, H
1), 1.62 – 1.45 (2H, m), 1.39 – 1.28 (8H, m), 1.24 (3H, s, H
6/7), 1.23 
(3H, s, H
6/7), 0.89 (3H, t, J = 6.9 Hz, H
13). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 79.46 (C
2/3), 79.33 (C
2/3), 72.03 (C
5), 45.35 
(CH
4),  31.80  (CH2),  30.07  (CH2),  29.17  (CH2),  28.38  (CH2),  27.07  (CH3
6/7),  26.26 
(CH3
6/7), 22.65 (CH2), 14.06 (CH3
13), 3.52 (CH3
1). 
HRMS (ESI+): Found: [M + Na]
+, 219.1721. [C13H24NaO]
+ requires: 219.1719. 
LRMS (CI): m/z: 196 ([M]
+, 42%), 179 ([M – OH]
+, 90%), 68 (100%). 
IR (thin film): n ~= 3375 (m, br), 2954 (s), 2933 (s), 2835 (s), 1438 (m), 1377 (s), 1148 
(s), 760 (s), 894 (s) cm
–1. 
 
6.4.8.  rac-(1R,2R)-2-Methyl-1-phenyloct-3-yn-1-ol (4.76) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added MeLi (1.25 mL of a 1.8 M solution, 2.0 mmol) dropwise over 3 minutes. After 25 
min at the same tempereature, a solution of 1-chlorohept-2-yne (0.131 g, 1.0 mmol) in 
dry THF (1 mL) was added dropwise followed by dropwise addition of LDA (0.56 mL 
of a 1.8 M solution, 1.0 mmol). The stirring was continued for a further 1.5 h during 
which time the reaction mixture was allowed to warm to –65 °C. The reaction mixture 
was re-cooled to –78 °C and a solution of benzaldehyde (0.15 mL, 1.5 mmol) in dry 
THF  (1  mL)  was  added  followed  by  dropwise  addition  of  BF3·OEt2  (0.18  mL,  1.5 
mmol). The reaction mixture warmed gradually to RT within. The reaction mixture was 
stirred at RT for 3-5 h before quenching with MeOH (5 mL) and a saturated aqueous 
solution of NaHCO3 (6 mL), the mixture was left stirring overnight. The mixture was 
poured  onto  H2O  (100  mL),  the  products  extracted  with  Et2O  (3  ×  75  mL).  The   233 
combined organic phases were washed with H2O (2 × 100 mL) and brine (100 mL), 
dried  over  MgSO4,  filtered  and  concentrated  in  vacuo  to  give  the  crude  product  as 
yellow oil (anti : syn diastereoisomers in the ratio of 77 : 23). 
Purification of the crude material by careful column chromatography on SiO2 (230 – 
400 mesh) with hexane : EtOAc (10 : 1) as the eluent to allow partial separation of the 
diasteroisomers to give a pure fraction of the title compound (anti isomer) as a pale 
yellow oil and a mixed fraction (yellow oil) of both isomers in combined yield of 0.150 
g (69%). 
 
Spectral data of the anti diastereoisomer: 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.29 – 7.18 (5H, m, H
Ar), 4.34 (1H, dd, J = 
7.1, 3.7 Hz, H
6), 2.67 (1H, quintet t, J = 7.1, 2.3 Hz, H
4), 2.56 (1H, d, J = 3.7 Hz, OH
7), 
2.12 (2H, td, J = 7.0, 2.3 Hz, H
1), 1.45 – 1.27 (4H, m, H
7 + 8), 0.97 (3H, d, J = 7.1 Hz, 
H
5), 0.83 (3H, t, J = 7.2 Hz, H
9). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 141.67 (C
i-Ph), 128.16 (2CH
m-Ph), 127.77 
(CH
p-Ph), 126.67 (2CH
o-Ph), 84.10 (C
2), 80.71 (C
3), 77.76 (CH
6), 35.69 (CH
4), 31.03 
(CH2
1), 21.92 (CH2
7 or 8), 18.42 (CH2
8 or 7), 17.82 (CH3
5), 13.58 (CH3
9). 
HRMS (EI): Found: [M]
+, 216.1521. C15H20O requires: 216.1514. 
LRMS (CI): m/z: 216 ([M]
+, 64%), 199 ([M – OH]
+, 100%). 
IR (thin film): n ~= 3375 (m, br), 2954 (s), 2933 (s), 2835 (s), 1438 (m), 1377 (s), 1148 
(s), 760 (s), 894 (s) cm
–1. 
 
6.4.9.  rac-(1R,2R)-2-Methyl-1-phenyldodec-3-yn-1-ol (4.82a) 
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To a stirred suspension of Cp2ZrHCl (0.258 g, 1.0 mmol) in dry THF (10 mL) at RT 
was added neat 1-octene (0.125 mL, 0.8 mmol) dropwise over 3 minutes. After stirring 
the yellow solution for 1 h at RT, the reaction mixture was cooled to –78 °C  and a 
solution of the but-3-yn-2-yl benzensulfonate (0.224 g, 1.0 mmol) in dry THF (1 mL) 
was  added  dropwise  followed  by  dropwise  addition  of  freshly  prepared  LiTMP, 
[prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.17 mL, 1.0 mmol) in 
dry THF (2 mL) and n-BuLi (0.4 mL of a 2.5 M solution in hexanes, 1.0 mmol) at –5 °C 
over  15  min].  The  stirring  was  continued  for  a  further  1  h  during  which  time  the 
reaction mixture was allowed to warm to RT. The reaction mixture was re-cooled to –60 
°C and a solution of benzaldehyde (0.30 mL, 3.0 mmol) in dry THF (1 mL) was added. 
The reaction mixture was warmed gradually to RT. The stirring was continued at the 
same temperature for 3 h before quenching with MeOH (5 mL) and a saturated aqueous 
solution  of    NaHCO3  (6  mL),  the  mixture  left  stirring  overnight.  The  mixture  was 
poured  onto  H2O  (100  mL),  the  products  extracted  with  Et2O  (3  ×  75  mL).  The 
combined organic phases were washed with H2O (2 × 100 mL) and brine (100 mL), 
dried  over  MgSO4,  filtered  and  concentrated  in  vacuo  to  give  the  crude  product  as 
yellow oil (anti : syn diastereoisomers in the ratio of of 74 : 26). 
Purification of the crude material by careful column chromatography on SiO2 (230-400 
mesh) with hexane : EtOAc (10 : 1) as the eluent to allow partial separation of the 
diasteroisomers to give a pure fraction of the title compound (anti isomer) as a yellow 
oil and a mixed fraction (yellow oil) of both isomers in combined yield of 0.130 g 
(60%). 
 
Spectral data of the anti diastereoisomer: 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.29 – 7.17 (5H, m, H
Ar), 4.34 (1H, dd, J = 
7.2, 3.6 Hz, H
6), 2.67 (1H, quintet t, J = 7.1, 2.1 Hz, H
4), 2.56 (1H, d, J = 3.5 Hz, OH
7), 
2.11 (2H, td, J = 7.2, 2.3 Hz, H
1), 1.46 – 1.38 (2H, m), 1.32 – 1.14 (10H, m), 0.98 (3H, 
d, J = 6.8 Hz, H
5), 0.81 (3H, t, J = 6.9 Hz, H
14). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 141.68 (C
i-Ph), 128.17 (2CH
m-Ph), 127.78 
(CH
p-Ph), 126.67 (2CH
o-Ph), 84.20 (C
2), 80.70 (C
3), 77.77 (CH
6), 35.70 (CH
4), 31.83 
(CH2
1), 29.18 (CH2), 29.09 (CH2), 28.95 (CH2), 28.86 (CH2), 22.64 (CH2), 18.74 (CH2), 
17.83 (CH3
5), 14.08 (CH3
14). 
HRMS (EI): Found: [M – H2O]
+, 254.2040. [C19H26]
+ requires: 254.2034.   235 
LRMS (CI): m/z: 273 ([M + H]
+, 54%), 255 ([M – OH]
+, 72%). 
IR (thin film): n ~= 3448 (m, br), 2925 (s), 2852 (m), 1454 (m), 1021 (m), 1760 (w), 
706 (s) cm
–1. 
 
Preparation of the enantioenriched product: (1R,2R/S)-2-methyl-1-phenyldodec-3-
yn-1-ol (4.82a) 
To a stirred suspension of Cp2ZrHCl (0.258 g, 1.0 mmol) in dry THF (10 mL) at RT 
was added neat 1-octene (0.125 mL, 0.8 mmol) dropwise over 3 minutes. After stirring 
the yellow solution for 1 h at RT, the reaction mixture was cooled to –78 °C  and a 
solution of the (S)-but-3-yn-2-yl benzensulfonate (0.224 g, 1.0 mmol) in dry THF (1 
mL) was added dropwise followed by dropwise addition of freshly prepared LiTMP, 
[prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.17 mL, 1.0 mmol) in 
dry THF (2 mL) and n-BuLi (0.4 mL of a 2.5 M solution in hexanes, 1.0 mmol) at –5 °C 
over  15  min].  The  stirring  was  continued  for  a  further  1  h  during  which  time  the 
reaction mixture was allowed to warm to RT. The reaction mixture was re-cooled to –78 
°C and a solution of benzaldehyde (0.30 mL, 3.0 mmol) in dry THF (1 mL) was added 
followed by dropwise addition of BF3·OEt2 (0.36 mL, 3.0 mmol). The reaction mixture 
was warmed gradually to RT. The stirring was continued at the same temperature for 3 
h before quenching with MeOH (5 mL) and a saturated aqueous solution of  NaHCO3 (6 
mL), the mixture left stirring overnight. The mixture was poured onto H2O (100 mL), 
the  products  extracted with  Et2O  (3  ×  75  mL).  The  combined  organic  phases  were 
washed with H2O (2 × 100 mL) and brine (100 mL), dried over MgSO4, filtered and 
concentrated  in  vacuo  to  give  the  crude  product  as  yellow  oil  (anti  :  syn 
diastereoisomers in the ratio of of 75 : 25). 
Purification of the crude material by careful column chromatography on SiO2 (230-400 
mesh) with hexane : EtOAc (10 : 1) as the eluent to allow partial separation of the 
diasteroisomers to give a pure fraction of the title compound (anti isomer) as a yellow 
oil and a mixed fraction (yellow oil) of both isomers in combined yield of 0.134 g 
(61%). 
 
Rt 11.0 min (minor enantiomer) and 12.9 min (major enantiomer) on chiral HPLC on a 
Diacel OD-H, (1 mL/min 2% isopropanol in hexane on 4.6 x 250 mm column).   236 
6.4.10. rac-(E,1R,2R)-2-Methyl-1-phenyldodec-5-en-3-yn-1-ol (4.82b) 
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To a stirred suspension of Cp2ZrHCl (0.258 g, 1.0 mmol) in dry THF (10 mL) at RT 
was added neat 1-octene (0.125 mL, 0.8 mmol) dropwise over 3 minutes. After stirring 
the yellow solution for 1.5 h at RT, the reaction mixture was cooled to –78 °C  and a 
solution of the but-3-yn-2-yl benzensulfonate (0.202 g, 0.9 mmol) in dry THF (1 mL) 
was  added  dropwise  followed  by  dropwise  addition  of  LDA  (0.50  mL  of  a  1.8  M 
solution,  0.9  mmol).  The  stirring  was  continued  for a further  2  h  during  which  the 
reaction mixture was allowed to warm to RT. After re-cooling the reaction mixture to –
78 °C a solution of benzaldehyde (0.12 mL, 1.2 mmol) in dry THF (1 mL) was added 
followed by dropwise addition of BF3·OEt2 (0.15 mL, 1.2 mmol). The reaction mixture 
was warmed gradually to RT and the stirring was continued at the same temperature for 
2 h before quenching with MeOH (5 mL) and a saturated aqueous solution of NaHCO3 
(6 mL). The whole mixture was left stirring overnight. The mixture was poured onto 
H2O (100 mL), the products extracted with Et2O (3 × 75 mL). The combined organic 
phases were washed with H2O (2 × 100 mL) and brine (100 mL), dried over MgSO4, 
filtered and concentrated in vacuo to give the crude product as yellow oil (anti : syn 
diastereoisomers in the ratio of 69 : 31). 
Purification of the crude material by careful column chromatography on SiO2 (230 – 
400 mesh) with hexane : EtOAc (10 : 1) as the eluent to allow partial separation of the 
diasteroisomers to give a pure fraction of the title compound (anti isomer) as a yellow 
oil and a mixed fraction (yellow oil) of both isomers in combined yield of 0.987 g 
(40%). 
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Spectral data of the anti diastereoisomer: 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.29 – 7.16 (5H, m, H
Ar), 6.03 (1H, dt, J = 
15.8, 7.0 Hz, H
1), 5.39 (1H, dq, J = 15.8, 2.0 Hz, H
2), 4.38 (1H, dd, J = 7.2, 3.7 Hz, H
6), 
2.79 (1H, quintet d, J = 7.2, 2.0 Hz, H
5), 2.47 (1H, dd, J = 3.7, 0.6 Hz, OH
7), 2. 2.00 
(2H, qd J = 7.3, 1.5 Hz, H
9), 1.31 – 1.16 (8H, m), 0.99 (3H, d, J = 7.0 Hz, H
8), 0.80 
(3H, t, J = 6.9 Hz, H
14). 
13C  NMR  (100.5  MHz,  CDCl3):  ￿  (ppm)  =  144.75  (CH
1),  141.51  (C
i-Ph),  128.25 
(2CH
m-Ph), 127.92 (CH
p-Ph), 126.71  (2CH
o-Ph), 109.14 (CH
2), 88.68 (C
3), 82.52 (C
4), 
77.78 (CH
6), 36.11 (CH
5), 33.01 (CH2
9), 31.65 (CH2), 28.78  (CH2), 28.70 (CH2), 22.58 
(CH2), 17.52 (CH3
8), 14.07 (CH3
14). 
HRMS (EI): Found: [M]
+, 270.1982. C19H26O requires: 270.1984. 
LRMS (CI): m/z: 271 ([M + H]
+, 40%), 253 ([M – H2O]
+, 28%). 
IR (thin film): n ~= 3379 (m, br), 2938 (m), 2864 (w), 1450 (m), 1029 (m), 935 (m), 
756 (m), 706 (s) cm
–1. 
 
Preparation of the enantioenriched product: (E,1R,2R)-2-methyl-1-phenyldodec-5-
en-3-yn-1-ol (4.82b) 
To a stirred suspension of Cp2ZrHCl (0.258 g, 1.0 mmol) in dry THF (10 mL) at RT 
was added neat 1-octene (0.125 mL, 0.8 mmol) dropwise over 3 minutes. After stirring 
the yellow solution for 1 h at RT, the reaction mixture was cooled to –78 °C  and a 
solution of the (S)-but-3-yn-2-yl benzensulfonate (0.224 g, 1.0 mmol) in dry THF (1 
mL) was added dropwise followed by dropwise addition of freshly prepared LiTMP, 
[prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.17 mL, 1.0 mmol) in 
dry THF (2 mL) and n-BuLi (0.4 mL of a 2.5 M solution in hexanes, 1.0 mmol) at –5 °C 
over  15  min].  The  stirring  was  continued  for  a  further  1  h  during  which  time  the 
reaction mixture was allowed to warm to RT. The reaction mixture was re-cooled to –60 
°C and a solution of benzaldehyde (0.30 mL, 3.0 mmol) in dry THF (1 mL) was added. 
The reaction mixture was warmed gradually to RT. The stirring was continued at the 
same temperature for 3 h before quenching with MeOH (5 mL) and a saturated aqueous 
solution  of    NaHCO3  (6  mL),  the  mixture  left  stirring  overnight.  The  mixture  was 
poured  onto  H2O  (100  mL),  the  products  extracted  with  Et2O  (3  ×  75  mL).  The 
combined organic phases were washed with H2O (2 × 100 mL) and brine (100 mL),   238 
dried  over  MgSO4,  filtered  and  concentrated  in  vacuo  to  give  the  crude  product  as 
yellow oil (anti : syn diastereoisomers in the ratio of of 70 : 30). 
Purification of the crude material by careful column chromatography on SiO2 (230-400 
mesh) with hexane : EtOAc (10 : 1) as the eluent to allow partial separation of the 
diasteroisomers to give a pure fraction of the title compound (anti isomer) as a yellow 
oil and a mixed fraction (yellow oil) of both isomers in combined yield of 0.074 g 
(34%). 
 
Rt 11.9 min (minor enantiomer) and 15.4 min (major enantiomer) on chiral HPLC on a 
Diacel OD-H, (1 mL/min 2% isopropanol in hexane on 4.6 x 250 mm column). 
 
6.4.11. rac-8-Hexyloctadec-9-yn-7-ol (4.82c) 
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To a stirred suspension of Cp2ZrHCl (0.258 g, 1.0 mmol) in dry THF (10 mL) at RT 
was added neat 1-octene (0.125 mL, 0.8 mmol) dropwise over 3 minutes. After stirring 
the yellow solution for 1 h at RT, the reaction mixture was cooled to –78 °C  and a 
solution of the non-1-yn-3-yl benzensulfonate (0.294 g, 1.0 mmol) in dry THF (1 mL) 
was  added  dropwise  followed  by  dropwise  addition  of  freshly  prepared  LiTMP, 
[prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.17 mL, 1.0 mmol) in 
dry THF (2 mL) and n-BuLi (0.4 mL of a 2.5 M solution in hexanes, 1.0 mmol) at –5 °C 
over 15 min]. The stirring was continued for a further 1.5 h during which time the 
reaction mixture was allowed to warm to RT. The reaction mixture was re-cooled to –78 
°C and a solution of 1-heptanal (0.42 mL, 3.0 mmol) in dry THF (1 mL) was added. The   239 
reaction mixture warmed gradually to RT. The reaction mixture was stirred at RT for 3 
h before quenching with MeOH (5 mL) and NaHCO3 (6 mL). The mixture left stirring 
overnight. The mixture was poured onto H2O (100 mL), the products extracted with 
Et2O (3 × 75 mL). The combined organic phases were washed with H2O (2 × 100 mL) 
and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give the 
crude product as a yellow oil (anti : syn diastereoisomers in the ratio of 89 : 11). 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexane : EtOAc (10 : 1) as the eluent to yield the title compounds as an inseparable 
mixture of anti : syn diastereoisomers in combined yield of 0.123 g (44%, yellow oil). 
 
NMR characterysation does not contain complete data of the minor (syn) isomer. 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 3.42 (1H, m, H
5 major), 3.33 (1H, m, H
5 minor), 
2.38 – 2.36 (2H, m, H
4 major + minor), 2.19 (2H, overlap td, J = 6.9, 2.3 Hz, H
1 major), 2.16 
(2H, overlap td, J = 7.0, 2.0 Hz, H
1 minor), 1.74 (1H, d, J = 7.8 Hz, OH
major), 1.70 (1H, d, 
J = 8.3 Hz, OH
minor), 1.67 – 1.63 (2H, m, H
minor), 1.56 – 1.24 (62H, m, H
major + minor),  
0.91 – 0.87 (18H, m, H
11 + 17 + 24 (major + minor)). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 84.53 (C
2 major), 83.72 (C
2 minor), 79.29 (C
3 
major), 78.96 (C
3  minor), 73.30 (C
5  major), 73.23 (C
5  minor), 39.91 (CH
4  major), 39.22 (CH
4 
minor), 35.75 (CH2
major), 35.71 (CH2
minor), 32.22 (CH2
major), 31.83 (4CH2
major + minor), 31.79 
(2CH2
major  +  minor),  31.75  (CH2
minor),  29.33  (2CH2
major  +  minor),  29.23  (CH2
major),  29.14 
(CH2
major),  29.10  (2CH2
major  +  minor),  29.08  (CH2
major),  28.85  (2CH2
major  +  minor),  28.75 
(CH2
minor), 27.62 (CH2
major), 27.57 (CH2
minor), 25.82 (2CH2
major + minor), 22.65 (CH2
major), 
22.62 (4CH2
major + minor), 18.73 (CH2
1 major), 18.69 (CH2
1 minor), 14.06 (6CH3
11 + 17 + 24 (major 
+ minor)). 
HRMS (EI): Found: [M – C6H13]
+, 265.2536. [C18H33O]
+ requires: 265.2531. 
LRMS (CI): m/z: 351 ([M + H]
+, 69%), 333 ([M – H2O + H]
+, 55%). 
IR (thin film): n ~= 3387 (w, br), 2960 (m), 2933 (s), 2854 (s), 1467 (m), 1372 (w), 
1043 (w, br), 718 (w) cm
–1. 
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6.4.12. rac-3-Hexyl-2-methyltridec-4-yn-2-ol (4.82d) 
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To a stirred suspension of Cp2ZrHCl (0.258 g, 1.0 mmol) in dry THF (10 mL) at RT 
was added neat 1-octene (0.125 mL, 0.8 mmol) dropwise over 3 minutes. After stirring 
the yellow solution for 1 h at RT, the reaction mixture was cooled to –78 °C  and a 
solution of the non-1-yn-3-yl benzensulfonate (0.294 g, 1.0 mmol) in dry THF (1 mL) 
was  added  dropwise  followed  by  dropwise  addition  of  freshly  prepared  LiTMP, 
[prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.17 mL, 1.0 mmol) in 
dry THF (2 mL) and n-BuLi (0.4 mL of a 2.5 M solution in hexanes, 1.0 mmol) at –5 °C 
over 15 min]. The stirring was continued for a further 1.5 h during which time the 
reaction mixture was allowed to warm to RT. The reaction mixture was re-cooled to –78 
°C and a solution of acetone (0.22 mL 3.0 mmol) in dry THF (1 mL) was added, the 
reaction mixture warmed gradually to RT. The reaction mixture was then refluxing for 
20 h before cooling to RT and quenching with MeOH (5 mL) and a saturated aqueous 
solution of NaHCO3 (6 mL), the mixture left stirring overnight. The mixture was poured 
onto H2O  (100 mL),  the  products extracted  with Et2O (3 × 75  mL). The combined 
organic phases were washed with H2O (2 × 100 mL) and brine (100 mL), dried over 
MgSO4, filtered and concentrated in vacuo to give the crude product as a yellow oil. 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexane : EtOAc (10 : 1) as the eluent to yield the title compound as a yellow oil in 
yield of 0.118 g (50%, contained 10% of unidentified by-products). 
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1H NMR (400 MHz, CDCl3): ￿ (ppm) = 2.34 (1H, m, H
4), 2.20 (2H, td, J = 7.0, 2.0 Hz, 
H
1), 1.97 (1H, br s, OH), 1.61 (1H, m), 1.54 – 1.47 (3H, m), 1.41 – 1.26 (18H, m), 1.25 
(3H, s, H
6/7), 1.24 (3H, s, H
6/7), 0.90 (3H, t, J = 6.8 Hz, H
13/20), 0.89 (3H, t, J = 6.8 Hz, 
H
13/20). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 84.33 (C
2), 80.35 (C
3), 71.98 (C
5), 45.34 
(CH
4),  31.81  (2CH2),  30.07  (CH2),  29.21  (CH2),  29.14  (CH2),  29.07  (2CH2),  28.84 
(CH2), 28.36 (CH2), 27.01 (CH3
6/7), 26.24 (CH3
6/7), 22.63 (2CH2), 18.70 (CH2
1), 14.06  
(2CH3
13 + 20). 
HRMS (EI): Found: [M – CH3]
+, 279.2694. [C19H35O]
+ requires: 279.2688. 
LRMS (CI): m/z: 294 ([M]
+, 26%), 277 ([M – H2O + H]
+, 100 %). 
IR (thin film): n ~= 3410 (w, br), 2930 (s), 2854 (s), 1478 (m), 1372 (m), 1183 (m), 
1142 (m), 903 (w), 722 (w) cm
–1. 
 
6.5.  Experimental from chapter 5 
 
6.5.1.  rac-(R,3E)-5-((2S,3R,3aS,7aS)-2-Butyl-2,3,3a,4,7,7a-hexahydro-1H-inden-3-
yl)-1-phenylpent-3-en-1-ol  and    rac-(S,3E)-5-((2S,3R,3aS,7aS)-2-butyl-
2,3,3a,4,7,7a-hexahydro-1H-inden-3-yl)-1-phenylpent-3-en-1-ol (5.30a) 
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To a solution of Cp2ZrCl2 (0.307 g, 1.05 mmol) in dry THF (5 mL) cooled to –78 °C 
was added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of triene 5.5 (0.190 g, 1.0 
mmol) in dry THF (3 mL) was added dropwise, the stirring continued for 20 min at –78 
°C before the reaction mixture was allowed to warm to RT gradually and the stirring 
continued for 75 min. The reaction mixture was re-cooled to –78 °C, a solution of allyl 
chloride (0.098 mL, 1.2 mmol) in dry THF (1 mL) was added followed by dropwise 
addition of LiTMP, [prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.20   242 
mL, 1.2 mmol) in dry THF (2 mL) and n-BuLi (0.48 mL of a 2.5 M solution in hexanes, 
1.2 mmol) at 0 °C over 20 min]. The reaction mixture was allowed to warm to –65 °C 
within  20  min  before  benzaldehyde  (0.30  mL,  3.0  mmol)  in  dry  THF  (3  mL)  and 
BF3·OEt2 (0.36 ml, 3.0 mmol) were added dropwise. The reaction mixture was warmed 
gradually to –1 °C within 4 h before addition of MeOH (5 mL) and a saturated aqueous 
solution  of  NaHCO3
  (6  mL).  The  mixture  left  stirring  overnight.  The  mixture  was 
poured  onto  H2O  (100  mL),  the  products  extracted  with  Et2O  (3  ×  50  mL).  The 
combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as a pale 
yellow oil. Purification of the crude material by  careful column chromatography  on 
SiO2 (230 – 400 mesh) with 10% of EtOAc in hexanes as the eluent gave a fraction of 
the  title  compounds  as  an  inseparable  mixture  of  diastereoisomers,  epimeric  at  the 
secondary alcohol centre in the 
13C NMR ratio of 1.5 : 1 (0.20 g, pale yellow oil, 69% 
GC purity). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.270 – 7.163 (10H, m, H
Ar major + minor), 5.615 
– 5.440 (6H, m, 2H
11 + 2H
12 + 2H
6), 5.345 – 5.264 (2H, m, H
5 major + minor), 4.603 (2H, br 
dd, J = 7.3, 5.3 Hz, H
3 major + minor), 2.444 – 2.316 (4H, m, H
4 major + minor), 2.134 – 1.869 
(12H, m, H
major + minor), 1.802 – 1.254 (13H, m, H
major + minor), 1.209 – 0.960 (13H, m, 
H
major + minor), 0.807 (6H, br t, J = 7.2 Hz, H
20 major + minor).  
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 143.97 (2C
i-Ph  major  +  minor), 133.83 (CH
5 
major),  133.79  (CH
5  minor),  128.31  (4CH
m-Ph  major  +  minor),  128.31  (2CH
11/12),  126.37 
(2CH
11/12), 126.26 (CH
6 major), 126.23 (CH
6 minor), 125.99 (2CH
p-Ph major + minor), 125.82 
(2CH
o-Ph minor), 125.79 (2CH
o-Ph major), 73.54 (CH
3 minor), 73.50 (CH
3 major), 50.87 (CH
8 
minor), 50.82 (CH
8  major), 44.03 (CH
9  minor), 44.00 (CH
9  major), 42.79 (2CH
4  major  + minor), 
40.22 (CH
16 major), 40.17 (CH
16 minor), 38.09 (2CH2
major + minor), 38.09 (2CH2
7 major + minor), 
37.02 (CH
14 minor), 36.99 (CH
14 major), 34.89 (2CH2
major + minor), 30.97 (2CH2
major + minor), 
27.77 (2CH2
major + minor), 27.63 (2CH2
major + minor), 22.91 (2CH2
major + minor), 14.12 (2CH3
20 
major + minor). 
LRMS (EI): m/z: 321 ([M – H2O]
+, 11%), 232 ([M – BnOH + H]
+, 5%), 175 (29%), 
130 (32%), 107 (100%). 
IR (thin film): n ~= 3353 (w, br), 3028 (w), 2922 (m, br), 1452 (m), 1024 (m), 975 (m), 
745 (m), 688 (s) cm
–1.   243 
6.5.2.  rac-(R,3E)-5-((2R,3S,3aS,7aS)-2-Butyl-2,3,3a,4,7,7a-hexahydro-1H-inden-3-
yl)-1-phenylpent-3-en-1-ol  and    rac-(S,3E)-5-((2R,3S,3aS,7aS)-2-butyl-
2,3,3a,4,7,7a-hexahydro-1H-inden-3-yl)-1-phenylpent-3-en-1-ol (5.30b) 
5.30b
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To a solution of Cp2ZrCl2 (0.307 g, 1.05 mmol) in dry THF (5 mL) cooled to –78 °C 
was added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of triene 5.5 (0.190 g, 1.0 
mmol) in dry THF (3 mL) was added dropwise, the stirring continued for 15 min at –78 
°C before the reaction mixture was allowed to warm to RT gradually and heated at 65 
°C for 30 min. The reaction mixture was re-cooled to –78 °C, a solution of allyl chloride 
(0.098 mL, 1.2 mmol) in dry THF (1 mL) was added followed by dropwise addition of 
LiTMP,  [prepared  from  freshly  distilled  2,2,6,6-tetramethylpiperidine  (0.20  mL,  1.2 
mmol) in dry THF (2 mL) and n-BuLi (0.48 mL of a 2.5 M solution in hexanes, 1.2 
mmol) at 0 °C over 20 min]. The reaction mixture was allowed to warm to –65 °C 
within  20  min  before  benzaldehyde  (0.30  mL,  3.0  mmol)  in  dry  THF  (3  mL)  and 
BF3·OEt2 (0.36 ml, 3.0 mmol) were added dropwise. The reaction mixture was warmed 
gradually to –5 °C within 4 h before addition of MeOH (5 mL) and a saturated aqueous 
solution  of  NaHCO3
  (6  mL).  The  mixture  left  stirring  overnight.  The  mixture  was 
poured  onto  H2O  (100  mL),  the  products  extracted  with  Et2O  (3  ×  50  mL).  The 
combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as a pale 
yellow oil.  
Purification of the crude material by careful column chromatography on SiO2 (230 – 
400 mesh) with 2.5 ￿ 10% of EtOAc in hexanes as the eluent gave a fraction of the 
title  compounds  as  an  inseparable  mixture  of  diastereoisomers,  epimeric  at  the 
secondary alcohol centre in the 
13C NMR ratio of 3.1 : 1 (0.026 g, pale yellow oil, 
fraction pure in 89% by GC). 
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1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.270 – 7.162 (10H, m, H
Ar major + minor), 5.613 
– 5.476 (6H, m, 2H
11 + 2H
12 + 2H
6), 5.356 – 5.283 (2H, m, H
5 major + minor), 4.624 – 4.584 
(2H, m, H
3 major + minor), 2.443 – 2.319 (4H, m, H
4 major + minor), 2.197 – 1.960 (10H, m, 
H
major + minor), 1.695 – 1.587 (4H, m, H
major + minor), 1.528 – 1.389 (6H, m, H
major + minor), 
1.359 – 0.964 (18H, m, H
major + minor), 0.813 (6H, br t, J = 7.0 Hz, H
20 major + minor).  
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 143.99 (2C
i-Ph major + minor), 133.62 (2CH
5 
major + minor), 128.33 (4CH
m-Ph major + minor), 127.38 (2CH
11/12), 127.28 (2CH
11/12), 126.37 
(2CH
p-Ph major + minor), 127.04 (2CH
6 major + minor), 125.83 (2CH
o-Ph minor), 125.79 (2CH
o-Ph 
major), 73.58 (CH
3  minor), 73.54 (CH
3  major), 52.09 (CH
8  minor), 52.06 (CH
8  major), 47.08 
(CH
9 minor), 47.03 (CH
9 major), 42.76 (2CH
4 major + minor), 42.25 (CH
16 minor), 42.21 (CH
16 
major), 40.03 (2CH
14 major + minor), 36.92 (2CH2
major + minor), 36.67 (2CH2
major + minor), 36.55 
(CH2
7 minor), 36.49 (CH2
7 major), 32.37 (2CH2
major + minor), 31.50 (2CH2
major + minor), 30.69 
(2CH2
major + minor), 22.91 (2CH2
major + minor), 14.15 (2CH3
20 major + minor). 
LRMS (EI): m/z: 321 ([M – H2O + H]
+, 6%), 320 ([M – H2O]
+, 27%), 192 (5%), 130 
(100%). 
IR (thin film): n ~= 3380 (w, br), 3024 (w), 2956 (m), 2911 (m, br), 1459 (m), 1433 
(m), 1021 (m), 971 (m), 756 (m), 692 (s), 669 (s) cm
–1. 
 
6.5.3.  rac-1-(2-((1S,2R)-4,4-Bis(methoxymethyl)-2-((E)-prop-1-
enyl)cyclopentyl)ethylsulfonyl)benzene  (major  d.r.)  and  rac-1-(2-((1S,2R)-
4,4-bis(methoxymethyl)-2-((E)-prop-1-enyl)cyclopentyl)ethylsulfonyl)-
benzene (minor d.r.) (5.46) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes.  After  25  min  at  the  same  temperature,  a  solution  of  (Z)-4,4-
bis(methoxymethyl)nona-1,6-diene (0.212 g, 1.0 mmol) in dry THF (3 mL) was added 
dropwise, the stirring continued for 30 min at –78 °C before the reaction mixture was 
allowed to warm to RT and stirred for a further 4 h. After cooling the reaction to –78 
°C, a solution of 1-(chloromethylsulfonyl)benzene (0.76 g, 4.0 mmol) in dry THF (3 
mL) was added dropwise followed by dropwise addition of LDA (2.22 mL of a 1.8 M 
solution, 4.0 mmol). The reaction mixture was allowed to warm to RT within 5 h and 
stirred at this temperature for a further 4 h, before addition of MeOH (5 mL) and a 
saturated aqueous solution of NaHCO3
 (6 mL). The mixture left stirring overnight. The 
mixture was poured onto H2O (100 mL), the products extracted with Et2O (3 × 50 mL). 
The combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as a 
dark brown oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with  20  ￿  50%  of  Et2O  in  hexanes  as  the  eluent  gave  the  title  compounds  as  an 
inseparable mixture of E : Z isomers in the ratio of 3.8 : 1 (0.232 g, 45%, pale yellow 
oil). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 7.990 – 7.915 (2H, m, H
o-Ph minor), 7.896 – 
7.866 (2H, m, H
o-Ph major),  7.670 – 7.634 (1H, m, H
p-Ph minor), 7.651 (1H, t, J = 7.5 Hz, 
H
p-Ph minor), 7.597 – 7.543 (2H, m, H
m-Ph minor), 7.562 (2H, t, J = 7.5 Hz, H
m-Ph minor), 5.471 
– 5.326 (1H, m, H
11 minor), 5.368 (1H, dq, J = 15.1, 6.5 Hz, H
11 major), 5.180 – 5.075 (1H, 
m, H
11 minor), 5.150 (1H, fs ddq, J = 15.1, 8.0, 1.0 Hz, H
10 major), 3.319 (6H, s, H
1 minor), 
3.289 (6H, s, H
1major), 3.214 – 3.035 (10H, m, H
2 major + minor + H
9 minor), 3.072 (2H, dd, J 
= 9.0, 7.5 Hz, H
9  major), 2.400 (1H, m, H
7 minor), 2.033 – 1.816 (2H, m, H
7 major + H), 
1.781 – 1.655 (4H, m), 1.609 (3H, dd, J = 6.5, 1.5 Hz, H
12 major), 1.558 (3H, dd, J = 7.0, 
1.7 Hz, H
12 minor), 1.534 – 1.382 (3H, m), 1.318 – 1.117 (4H, m), 1.033 (1H, dd, J = 
13.1, 11.0 Hz, H
minor), 0.974 (1H, dd, J = 13.1, 11.0 Hz, H
major).  
13C NMR (100.5 MHz, CDCl3):  ￿  (ppm)  =  139.27  (C
i-Ph  major),  139.21  (C
i-Ph  minor), 
133.54 (CH
p-Ph/10 major), 133.54 (CH
p-Ph/10 minor), 133.52 (CH
p-Ph/10 major), 133.34 (CH
p-Ph/10 
minor),  129.16 (4CH
m-Ph  major  +  minor),  127.99  (4CH
o-Ph  major  +  minor), 125.81 (CH
11  major),   246 
124.87 (CH
11 minor), 77.75 (CH2
2 minor), 77.71 (CH2
2 major), 77.67 (2CH2
2 major + minor), 59.18 
(4CH3
1 major + minor), 55.32 (CH2
9 minor), 55.24 (CH2
9 major), 49.31 (CH
7  major), 45.73 (C
3 
minor),  45.39  (C
3  major),  44.61  (CH
7  minor),  43.74  (CH
6  major),  43.42  (CH
6  minor),  39.84 
(CH2
4/5 major), 39.75 (CH2
4/5 minor), 38.59 (CH2
4/5 minor), 38.43 (CH2
4/5 major), 26.60 (CH2
8 
minor), 26.25 (CH2
8 major), 17.88 (CH3
12 major), 13.24 (CH3
12 minor). 
HRMS (EI): Found: [M – MeOH]
+, 334.1597. [C19H26O3S]
+ requires: 334.1603. 
LRMS (EI): m/z: 334 ([M – MeOH]
+, 3%), 289 ([M – Ph]
+, 20%), 192 (29%), 160 
(100%). 
IR (thin film): n ~= 2922 (m), 2865 (m), 2824 (m), 1448 (s), 1308 (s), 1138 (s), 1107 
(s), 1085 (s), 968 (s), 729 (s), 684 (s), 533 (s) cm
–1. 
 
6.5.4.  rac-(3R,4R)-3-(Bromomethyl)-1,1-bis(methoxymethyl)-4-
propylcyclopentane (5.50) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes.  After  25  min  at  the  same  temperature,  a  solution  of  (Z)-4,4-
bis(methoxymethyl)nona-1,6-diene (0.212 g, 1.0 mmol) in dry THF (3 mL) was added 
dropwise, the stirring continued for 30 min at –78 °C before the reaction mixture was 
allowed to warm to RT and stirred for a further 2 h. After cooling the reaction to –78 
°C, dropwise addition of n-BuLi (0.44 mL of a 2.5 M solution in hexanes, 1.1 mmol) 
followed.  After  stirring  the  reaction  mixture  at  the  same  temperature  for  5  min,  a 
solution of CBr4 (0.497 g, 1.5 mmol) in dry THF (1 mL) was added dropwise and the 
stirring was continued for 15 min at –78 °C, before addition of MeOH (5 mL) and a 
saturated  aqueous  solution  of  NaHCO3  (6  mL).  The  whole  mixture  was  allowed  to 
warm to RT, left stirring overnight. The mixture was poured onto H2O (100 mL), the 
products extracted with Et2O (3 × 50 mL). The combined organic phases were washed   247 
with  H2O  (3  ×  100  mL)  and  brine  (100  mL),  dried  over  MgSO4,  filtered  and 
concentrated in vacuo to give the crude product as a dark brown oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 10% of Et2O in hexanes as the eluent gave the title compound as a yellow oil in 
yield of 0.223 g (76%). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 3.584 (1H, dd, J = 9.8, 3.3 Hz, H
8), 3.344 (3H, 
s, H
1), 3.341 (3H, s, H
1), 3.318 (1H, dd, J = 10.0, 7.5 Hz, H
8), 3.225 (2H, br d, J = 9.0 
Hz, H
2), 3.195 (1H, d, J = 9.0 Hz, H
2), 3.191 (1H, d, J = 9.0 Hz, H
2), 1.881 – 1.823 (3H, 
m), 1.642 (1H, m), 1.501 (1H, m), 1.417 – 1.179 (3H, m), 1.131 (1H, dd, J = 13.0, 11.0 
Hz), 1.072 (1H, m), 0.892 (3H, t, J = 7.3 Hz, H
11). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 77.76 (CH2
2), 77.56 (CH2
2), 59.25 (2CH3
1), 
47.05 (CH
6), 44.95 (C
3), 42.98 (CH
7), 39.25 (CH2), 38.46 (CH2), 37.84 (CH2), 36.17 
(CH2
8), 21.21 (CH2), 14.35 (CH3
11). 
HRMS (EI): Found: [M + Na]
+, 315.0932. [C13H25NaBrO2]
+ requires: 315.0930. 
LRMS (EI): m/z: 262 ([M – C2H6]
+, 11%), 260 ([M – MeOH]
+, 7%), 230 (58%), 228 
(54 %), 148 (90%), 45 (100%). 
IR (thin film): n ~= 2949 (m), 2922 (m), 2869 (m), 1452 (m), 1198 (m), 1104 (s), 960 
(m), 729 (w), 642 (w) cm
–1. 
 
6.5.5.  rac-(3R,4R)-3-(Bromomethyl)-1,1-bis(methoxymethyl)-4-
methylcyclopentane  (major  d.r.)  and  rac-(3S,4R)-3-(bromomethyl)-1,1-
bis(methoxymethyl)-4-methylcyclopentane (minor d.r.) (5.51) 
O
O
H
H
H
1 3 2
7
6
5
4
H
Br
9
8 O
O
H
H
H
1 3 2
7
6
5
4
H
Br
9
8
94                 :                 6
+
 
To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of bis(methoxymethyl)hepta-
1,6-diene (0.184 g, 1.0 mmol) in dry THF (3 mL) was added dropwise, the stirring 
continued for 30 min at –78 °C before the reaction mixture was allowed to warm to RT   248 
and stirred for a further 2 h. After cooling the reaction to –78 °C, dropwise addition of  
n-BuLi (0.44 mL of a 2.5 M solution in hexanes, 1.1 mmol) followed. After stirring the 
reaction mixture at the same temperature for 5 min, a solution of CBr4 (0.497 g, 1.5 
mmol) in dry THF (1 mL) was added dropwise and the stirring was continued for 15 
min at –78 °C, before addition of MeOH (5 mL) and a saturated aqueous solution of 
NaHCO3 (6 mL). The whole mixture was allowed to warm to RT, left stirring overnight. 
The mixture was poured onto H2O (100 mL), the products extracted with Et2O (3 × 50 
mL). The combined organic phases were washed with H2O (3 × 100 mL) and brine (100 
mL), dried over MgSO4, filtered and concentrated in vacuo to give the crude product as 
a dark brown oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 10% of Et2O in hexanes as the eluent gave the title compounds as an inseparable 
mixture of trans : cis ring junction isomers in the ratio of 94 : 6 (0.186 g, 70%, yellow 
oil). 
 
1H NMR (400 MHz, CDCl3): ￿ (ppm) = 3.562 (1H, dd, J = 9.8, 3.3 Hz, H
8 major), 3.365 
(1H, dd, J = 7.9, 2.1 Hz, H
8 minor), 3.332 (6H, s, H
1major), 3.326 (6H, s, H
1 minor), 3.304 
(1H, dd, J = 9.8, 7.0 Hz, H
8 major), 3.241 – 3.155 (4H, m, H
2 minor), 3.215 (2H, d, J = 8.8 
Hz, H
2 major), 3.186 (2H, d, J = 8.8 Hz, H
2 major), 1.855 (1H, dd, J = 12.8, 7.3 Hz, H
4 
major), 1.819 (1H, dd, J = 12.8, 7.0 Hz, H
5 major), 1.819 – 1.646 (2H, m, H
6 + 7 major), 1.306 
(1H, dd, J = 12.8, 9.8 Hz, H
4 major), 1.146 (1H, dd, J = 12.8, 10.5 Hz, H
5 major), 0.970 
(3H, d, J = 6.3 Hz, H
9 major), 0.906 (3H, d, J = 7.3 Hz, H
9 minor). 
13C NMR (100.5 MHz, CDCl3): ￿ (ppm) = 78.30 (CH2
2 minor), 77.86 (CH2
2 major), 77.55 
(CH2
2 major), 77.35 (CH2
2 minor), 59.21 (4CH3
1 major + minor), 48.43 (CH
6  major), 46.60 (C
3 
minor), 45.16 (CH
6 minor), 44.88 (C
3 major), 41.74 (CH
5 major), 39.68 (CH
5 minor), 38.57 (CH2
8 
major), 38.05 (CH2
7 major), 37.41 (CH2
4 major), 36.40 (CH2
8 minor), 35.57 (CH
7 minor), 35.19 
(CH2
4 minor), 17.87 (CH3
9 major), 15.19 (CH3
9 minor). 
HRMS (EI): Found: [M – MeOH]
+, 232.0462. [C10H17OBr(79)]
+ requires: 232.0463. 
LRMS (EI): m/z: 265 ([M + H]
+, 2%), 234 ([M – 2CH3]
+, 15%), 232 ([M – MeOH]
+, 
13%), 202 (71%), 200 (59%), 107 (97%), 45 (100%). 
IR (thin film): n ~= 2949 (m), 2915 (m), 2865 (m), 2824 (m), 1444 (m), 1194 (m), 1100 
(s), 960 (m), 642 (w) cm
–1. 
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Table 1. Crystal data and structure refinement. 
 
Identification code   2007sot0730     
Empirical formula   C30H36O2 
Formula weight   428.59 
Temperature   120(2) K 
Wavelength   0.71073 Å 
Crystal system   Triclinic 
Space group   P-1  
Unit cell dimensions  a = 9.5488(6) Å  a = 106.772(4)° 
  b = 11.0306(6) Å  b = 110.048(3)° 
  c = 13.4198(9) Å  g  = 95.736(4)° 
Volume  1239.89(13) Å
3 
Z  2 
Density (calculated)  1.148 Mg / m
3 
Absorption coefficient  0.070 mm
- - - -1 
F(000)  464 
Crystal  Block; Colourless 
Crystal size  0.14 ´ 0.12 ´ 0.10 mm
3 
q range for data collection  2.98 - 27.48° 
Index ranges  -12 £ h £ 12, -14 £ k £ 14, -17 £ l £ 17 
Reflections collected  20095 
Independent reflections  5646 [Rint = 0.0537] 
Completeness to q = 27.48°  99.0 %  
Absorption correction  Semi-empirical from equivalents 
Max. and min. transmission  0.9931 and 0.9903 
Refinement method  Full-matrix least-squares on F
2 
Data / restraints / parameters  5646 / 0 / 292 
Goodness-of-fit on F
2  1.071 
Final R indices [F
2 > 2s(F
2)]  R1 = 0.0570, wR2 = 0.1296 
R indices (all data)  R1 = 0.0752, wR2 = 0.1437 
Extinction coefficient  0.020(4) 
Largest diff. peak and hole  0.345 and -0.235 e Å
- - - -3 
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Diffractometer: Nonius KappaCCD area detector (f scans and w scans to fill asymmetric unit sphere). Cell determination: DirAx 
(Duisenberg, A.J.M.(1992). J. Appl. Cryst. 25, 92-96.) Data collection: Collect (Collect: Data collection software, R. Hooft, Nonius 
B.V., 1998). Data reduction and cell refinement: Denzo (Z. Otwinowski & W. Minor, Methods in Enzymology (1997) Vol. 276: 
Macromolecular Crystallography, part A, pp. 307-326; C. W. Carter, Jr. & R. M. Sweet, Eds., Academic Press). Absorption 
correction:  SORTAV  (R.  H.  Blessing,  Acta  Cryst.  A51  (1995)  33-37;  R.  H.  Blessing,  J.  Appl.  Cryst.  30  (1997)  421-426). 
Structure solution: SHELXS97 (G. M. Sheldrick, Acta Cryst. (1990) A46 467-473). Structure refinement: SHELXL97 (G. M. 
Sheldrick (1997), University of Göttingen, Germany). Graphics: Cameron - A Molecular Graphics Package. (D. M. Watkin, L. 
Pearce and C. K. Prout, Chemical Crystallography Laboratory, University of Oxford, 1993). 
 
Special details:  
Table 2. Atomic coordinates [´ 10
4], equivalent isotropic displacement parameters [Å
2 ´ 10
3] and site occupancy 
factors. Ueq is defined as one third of the trace of the orthogonalized U
ij tensor. 
 
Atom   x  y  z  Ueq  S.o.f. 
 
C1  4935(2)  4604(2)  1560(1)  24(1)  1 
C2  3793(2)  3981(2)  1921(2)  26(1)  1 
C3  2601(2)  4797(2)  1742(2)  26(1)  1 
C4  3559(2)  6211(2)  2246(1)  22(1)  1 
C5  4125(2)  6672(2)  3547(1)  22(1)  1 
C6  5646(2)  6934(2)  4057(1)  23(1)  1 
C7  6401(2)  6779(2)  3221(1)  25(1)  1 
C8  5084(2)  6091(2)  2054(1)  23(1)  1 
C9  3023(2)  6728(2)  4106(1)  22(1)  1 
C10  3052(2)  6028(2)  4826(1)  26(1)  1 
C11  2020(2)  6070(2)  5353(2)  30(1)  1 
C12  935(2)  6815(2)  5166(2)  31(1)  1 
C13  894(2)  7519(2)  4456(2)  30(1)  1 
C14  1924(2)  7481(2)  3936(2)  26(1)  1 
C15  2715(2)  7133(2)  1735(1)  24(1)  1 
C16  1210(2)  6827(2)  1145(2)  30(1)  1 
C17  3607(2)  8421(2)  1900(1)  24(1)  1 
C18  4638(2)  9276(2)  2955(2)  27(1)  1 
C19  5414(2)  10481(2)  3071(2)  31(1)  1 
C20  5163(2)  10860(2)  2141(2)  35(1)  1 
C21  4148(2)  10025(2)  1091(2)  38(1)  1 
C22  3379(2)  8822(2)  972(2)  32(1)  1 
C23  6604(2)  7400(2)  5306(1)  26(1)  1 
C24  7800(2)  8660(2)  5729(2)  27(1)  1 
C25  8869(2)  9026(2)  6964(2)  29(1)  1 
C26  10212(2)  10153(2)  7335(2)  29(1)  1 
C27  11366(2)  10496(2)  8537(2)  31(1)  1 
C28  12644(2)  11652(2)  8856(2)  35(1)  1 
C29  7389(2)  4428(2)  1533(1)  26(1)  1 
C30  8790(2)  3942(2)  2015(2)  35(1)  1 
O1  6342(1)  4169(1)  1952(1)  26(1)  1 
O2  7215(2)  4996(1)  873(1)  36(1)  1 
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Table 3. Bond lengths [Å] and angles [°]. 
 
 
 
Symmetry transformations used to generate equivalent atoms: 
 
Table 4. Bond lengths [Å] and angles [°]. 
 
C1-O1  1.4507(19) 
C1-C2  1.516(2) 
C1-C8  1.553(2) 
C1-H1  1.0000 
C2-C3  1.519(2) 
C2-H2A  0.9900 
C2-H2B  0.9900 
C3-C4  1.551(2) 
C3-H3A  0.9900 
C3-H3B  0.9900 
C4-C15  1.530(2) 
C4-C5  1.545(2) 
C4-C8  1.575(2) 
C5-C6  1.335(2) 
C5-C9  1.483(2) 
C6-C23  1.506(2) 
C6-C7  1.510(2) 
C7-C8  1.543(2) 
C7-H7A  0.9900 
C7-H7B  0.9900 
C8-H8  1.0000 
C9-C10  1.395(2) 
C9-C14  1.401(2) 
C10-C11  1.393(2) 
C10-H10  0.9500 
C11-C12  1.387(3) 
C11-H11  0.9500 
C12-C13  1.385(3) 
C12-H12  0.9500 
C13-C14  1.384(2) 
C13-H13  0.9500 
C14-H14  0.9500 
C15-C16  1.332(2) 
C15-C17  1.497(2) 
C16-H16A  0.9500 
C16-H16B  0.9500   264 
C17-C22  1.396(2) 
C17-C18  1.397(2) 
C18-C19  1.394(2) 
C18-H18  0.9500 
C19-C20  1.380(3) 
C19-H19  0.9500 
C20-C21  1.382(3) 
C20-H20  0.9500 
C21-C22  1.388(3) 
C21-H21  0.9500 
C22-H22  0.9500 
C23-C24  1.530(2) 
C23-H23A  0.9900 
C23-H23B  0.9900 
C24-C25  1.524(2) 
C24-H24A  0.9900 
C24-H24B  0.9900 
C25-C26  1.525(2) 
C25-H25A  0.9900 
C25-H25B  0.9900 
C26-C27  1.518(2) 
C26-H26A  0.9900 
C26-H26B  0.9900 
C27-C28  1.521(2) 
C27-H27A  0.9900 
C27-H27B  0.9900 
C28-H28A  0.9800 
C28-H28B  0.9800 
C28-H28C  0.9800 
C29-O2  1.202(2) 
C29-O1  1.348(2) 
C29-C30  1.498(3) 
C30-H30A  0.9800 
C30-H30B  0.9800 
C30-H30C  0.9800 
 
O1-C1-C2  108.43(13) 
O1-C1-C8  114.91(13) 
C2-C1-C8  105.96(13) 
O1-C1-H1  109.1 
C2-C1-H1  109.1 
C8-C1-H1  109.1   265 
C1-C2-C3  101.32(13) 
C1-C2-H2A  111.5 
C3-C2-H2A  111.5 
C1-C2-H2B  111.5 
C3-C2-H2B  111.5 
H2A-C2-H2B  109.3 
C2-C3-C4  103.89(13) 
C2-C3-H3A  111.0 
C4-C3-H3A  111.0 
C2-C3-H3B  111.0 
C4-C3-H3B  111.0 
H3A-C3-H3B  109.0 
C15-C4-C5  113.22(13) 
C15-C4-C3  113.02(13) 
C5-C4-C3  109.01(13) 
C15-C4-C8  113.70(13) 
C5-C4-C8  102.27(13) 
C3-C4-C8  104.77(12) 
C6-C5-C9  126.46(15) 
C6-C5-C4  112.69(14) 
C9-C5-C4  120.79(14) 
C5-C6-C23  127.87(15) 
C5-C6-C7  111.89(15) 
C23-C6-C7  120.17(14) 
C6-C7-C8  104.75(13) 
C6-C7-H7A  110.8 
C8-C7-H7A  110.8 
C6-C7-H7B  110.8 
C8-C7-H7B  110.8 
H7A-C7-H7B  108.9 
C7-C8-C1  114.57(13) 
C7-C8-C4  106.25(13) 
C1-C8-C4  103.88(12) 
C7-C8-H8  110.6 
C1-C8-H8  110.6 
C4-C8-H8  110.6 
C10-C9-C14  117.65(15) 
C10-C9-C5  120.73(15) 
C14-C9-C5  121.62(15) 
C11-C10-C9  121.23(16) 
C11-C10-H10  119.4 
C9-C10-H10  119.4   266 
C12-C11-C10  120.14(16) 
C12-C11-H11  119.9 
C10-C11-H11  119.9 
C13-C12-C11  119.34(17) 
C13-C12-H12  120.3 
C11-C12-H12  120.3 
C14-C13-C12  120.51(16) 
C14-C13-H13  119.7 
C12-C13-H13  119.7 
C13-C14-C9  121.12(16) 
C13-C14-H14  119.4 
C9-C14-H14  119.4 
C16-C15-C17  118.79(15) 
C16-C15-C4  122.17(15) 
C17-C15-C4  119.04(14) 
C15-C16-H16A  120.0 
C15-C16-H16B  120.0 
H16A-C16-H16B  120.0 
C22-C17-C18  117.44(16) 
C22-C17-C15  119.33(15) 
C18-C17-C15  123.19(15) 
C19-C18-C17  121.10(17) 
C19-C18-H18  119.4 
C17-C18-H18  119.4 
C20-C19-C18  120.40(17) 
C20-C19-H19  119.8 
C18-C19-H19  119.8 
C19-C20-C21  119.30(17) 
C19-C20-H20  120.4 
C21-C20-H20  120.4 
C20-C21-C22  120.44(18) 
C20-C21-H21  119.8 
C22-C21-H21  119.8 
C21-C22-C17  121.31(17) 
C21-C22-H22  119.3 
C17-C22-H22  119.3 
C6-C23-C24  113.93(14) 
C6-C23-H23A  108.8 
C24-C23-H23A  108.8 
C6-C23-H23B  108.8 
C24-C23-H23B  108.8 
H23A-C23-H23B  107.7   267 
C25-C24-C23  112.77(14) 
C25-C24-H24A  109.0 
C23-C24-H24A  109.0 
C25-C24-H24B  109.0 
C23-C24-H24B  109.0 
H24A-C24-H24B  107.8 
C24-C25-C26  112.84(15) 
C24-C25-H25A  109.0 
C26-C25-H25A  109.0 
C24-C25-H25B  109.0 
C26-C25-H25B  109.0 
H25A-C25-H25B  107.8 
C27-C26-C25  114.78(15) 
C27-C26-H26A  108.6 
C25-C26-H26A  108.6 
C27-C26-H26B  108.6 
C25-C26-H26B  108.6 
H26A-C26-H26B  107.5 
C26-C27-C28  111.70(15) 
C26-C27-H27A  109.3 
C28-C27-H27A  109.3 
C26-C27-H27B  109.3 
C28-C27-H27B  109.3 
H27A-C27-H27B  107.9 
C27-C28-H28A  109.5 
C27-C28-H28B  109.5 
H28A-C28-H28B  109.5 
C27-C28-H28C  109.5 
H28A-C28-H28C  109.5 
H28B-C28-H28C  109.5 
O2-C29-O1  123.74(16) 
O2-C29-C30  125.01(17) 
O1-C29-C30  111.24(15) 
C29-C30-H30A  109.5 
C29-C30-H30B  109.5 
H30A-C30-H30B  109.5 
C29-C30-H30C  109.5 
H30A-C30-H30C  109.5 
H30B-C30-H30C  109.5 
C29-O1-C1  116.66(13) 
 
Symmetry transformations used to generate equivalent atoms:  
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Table 5. Anisotropic displacement parameters [Å
2´ 10
3]. The anisotropic displacement factor exponent takes the 
form: -2p 
2[h
2a*
2U
11 + ... + 2 h k a* b* U
12 ]. 
 
Atom  U
11  U
22  U
33  U
23  U
13  U
12 
 
C1  24(1)   21(1)  26(1)   9(1)  10(1)   9(1) 
C2  26(1)   20(1)  32(1)   7(1)  11(1)   4(1) 
C3  24(1)   21(1)  29(1)   5(1)  10(1)   3(1) 
C4  23(1)   18(1)  23(1)   6(1)  8(1)   4(1) 
C5  24(1)   16(1)  24(1)   7(1)  9(1)   5(1) 
C6  24(1)   17(1)  25(1)   7(1)  8(1)   5(1) 
C7  22(1)   22(1)  27(1)   6(1)  8(1)   4(1) 
C8  24(1)   19(1)  24(1)   7(1)  8(1)   5(1) 
C9  23(1)   19(1)  23(1)   6(1)  7(1)   3(1) 
C10  26(1)   22(1)  29(1)   11(1)  10(1)   7(1) 
C11  34(1)   29(1)  32(1)   15(1)  15(1)   5(1) 
C12  30(1)   35(1)  34(1)   13(1)  18(1)   7(1) 
C13  29(1)   33(1)  30(1)   12(1)  12(1)   12(1) 
C14  27(1)   26(1)  27(1)   11(1)  11(1)   9(1) 
C15  26(1)   22(1)  21(1)   6(1)  9(1)   7(1) 
C16  27(1)   28(1)  31(1)   9(1)  7(1)   7(1) 
C17  26(1)   23(1)  26(1)   9(1)  10(1)   10(1) 
C18  31(1)   23(1)  27(1)   9(1)  10(1)   8(1) 
C19  33(1)   22(1)  32(1)   7(1)  8(1)   6(1) 
C20  38(1)   25(1)  43(1)   16(1)  14(1)   7(1) 
C21  46(1)   37(1)  37(1)   23(1)  15(1)   11(1) 
C22  37(1)   31(1)  26(1)   12(1)  8(1)   8(1) 
C23  24(1)   24(1)  26(1)   8(1)  6(1)   5(1) 
C24  25(1)   23(1)  28(1)   7(1)  7(1)   5(1) 
C25  29(1)   26(1)  27(1)   7(1)  7(1)   5(1) 
C26  29(1)   24(1)  29(1)   9(1)  6(1)   4(1) 
C27  32(1)   24(1)  30(1)   9(1)  6(1)   3(1) 
C28  35(1)   26(1)  33(1)   9(1)  5(1)   1(1) 
C29  28(1)   23(1)  26(1)   5(1)  11(1)   6(1) 
C30  28(1)   36(1)  39(1)   10(1)  13(1)   10(1) 
O1  25(1)   25(1)  30(1)   12(1)  12(1)   10(1) 
O2  40(1)   40(1)  39(1)   21(1)  21(1)   14(1) 
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Table 6. Hydrogen coordinates [´ 10
4] and isotropic displacement parameters [Å
2 ´ 10
3]. 
 
Atom   x  y  z  Ueq  S.o.f.
 
 
H1  4516  4321  716  28  1 
H2A  4263  4048  2722  32  1 
H2B  3353  3057  1440  32  1 
H3A  1928  4680  2143  31  1 
H3B  1965  4566  928  31  1 
H7A  7173  6246  3362  30  1 
H7B  6907  7635  3270  30  1 
H8  5164  6515  1504  27  1 
H10  3788  5512  4959  31  1 
H11  2060  5588  5841  36  1 
H12  227  6843  5521  38  1 
H13  154  8031  4325  36  1 
H14  1885  7975  3456  31  1 
H16A  722  7422  839  36  1 
H16B  624  6014  1032  36  1 
H18  4813  9033  3604  33  1 
H19  6119  11045  3795  37  1 
H20  5683  11685  2222  42  1 
H21  3976  10276  446  45  1 
H22  2683  8262  244  38  1 
H23A  7132  6714  5482  31  1 
H23B  5922  7534  5722  31  1 
H24A  8413  8561  5259  32  1 
H24B  7272  9372  5638  32  1 
H25A  9266  8261  7081  34  1 
H25B  8282  9265  7445  34  1 
H26A  10747  9934  6814  35  1 
H26B  9809  10929  7260  35  1 
H27A  11810  9737  8612  37  1 
H27B  10840  10700  9064  37  1 
H28A  13170  11451  8336  52  1 
H28B  13373  11837  9630  52  1 
H28C  12211  12412  8805  52  1 
H30A  9273  3729  1468  52  1 
H30B  8503  3164  2176  52  1 
H30C  9510  4617  2715  52  1 
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